

Prolactin: Structure, Function, and Regulation of Secretion

MARC E. FREEMAN, BÉLA KANYICSKA, ANNA LERANT, AND GYÖRGY NAGY*

Department of Biological Science, Florida State University, Tallahassee, Florida; Department of Anatomy, The University of Mississippi Medical Center, Jackson, Mississippi; and Neuroendocrine Research Laboratory, Department of Human Morphology, Semmelweis University School of Medicine, Budapest, Hungary

I. Introduction	1524
II. Prolactin Chemistry and Molecular Biology	1524
A. Prolactin: gene, primary structure, and species specificity	1524
B. Secondary and tertiary structure of prolactin	1524
C. Prolactin variants	1524
III. Sites of Synthesis and Secretion of Prolactin	1525
A. Anterior pituitary gland	1525
B. Brain	1526
C. Placenta, amnion, decidua, and uterus	1527
D. Mammary gland and milk	1527
E. The immune system	1528
F. Prolactin-secreting cell lines	1528
IV. Prolactin Receptors	1529
A. Prolactin receptor: gene, splicing variants, and isoforms	1529
B. Activation of prolactin-R and the associated signal transduction pathways	1529
C. Distribution of prolactin-R	1532
V. Biological Actions of Prolactin	1533
A. Reproduction	1533
B. Homeostasis	1536
VI. Patterns of Pituitary Prolactin Release	1537
A. Circadian rhythm of prolactin secretion	1537
B. Patterns of prolactin secretion in different reproductive states	1538
C. Prolactin release in response to exteroceptive stimuli	1540
VII. Regulation of Pituitary Prolactin Secretion	1542
A. CNS	1542
B. Intrapituitary regulation	1573
C. Peripheral organs	1579
VIII. Epilogue	1585

Freeman, Marc E., Béla Kanyicska, Anna Lerant, and György Nagy. Prolactin: Structure, Function, and Regulation of Secretion. *Physiol Rev* 80: 1523–1631, 2000.—Prolactin is a protein hormone of the anterior pituitary gland that was originally named for its ability to promote lactation in response to the suckling stimulus of hungry young mammals. We now know that prolactin is not as simple as originally described. Indeed, chemically, prolactin appears in a multiplicity of posttranslational forms ranging from size variants to chemical modifications such as phosphorylation or glycosylation. It is not only synthesized in the pituitary gland, as originally described, but also within the central nervous system, the immune system, the uterus and its associated tissues of conception, and even the mammary gland itself. Moreover, its biological actions are not limited solely to reproduction because it has been shown to control a variety of behaviors and even play a role in homeostasis. Prolactin-releasing stimuli not only include the nursing stimulus, but light, audition, olfaction, and stress can serve a stimulatory role. Finally, although

* The sequence of authorship does not imply importance of contribution but is presented alphabetically.

it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. It is the purpose of this review to provide a comprehensive survey of our current understanding of prolactin's function and its regulation and to expose some of the controversies still existing.

I. INTRODUCTION

Prolactin is a polypeptide hormone that is synthesized in and secreted from specialized cells of the anterior pituitary gland, the lactotrophs. The hormone was given its name based on the fact that an extract of bovine pituitary gland would cause growth of the crop sac and stimulate the elaboration of crop milk in pigeons or promote lactation in rabbits (1477). However, we now appreciate that prolactin has over 300 separate biological activities (184) not represented by its name. Indeed, not only does prolactin subserve multiple roles in reproduction other than lactation, but it also plays multiple homeostatic roles in the organism. Furthermore, we are now aware that synthesis and secretion of prolactin is not restricted to the anterior pituitary gland, but other organs and tissues in the body have this capability. Indeed, the multiple roles and sources of prolactin had led Bern and Nicoll (154) to suggest renaming it "omnipotin" or "versatilin."

In this review we integrate the burgeoning information on prolactin's structure (sect. II), synthesis and release from varying sources (sect. III), the intracellular mechanism of its action (sect. IV), its major biological functions (sect. V), and the patterns (sect. VI) and regulation of its secretion (sect. VII).

II. PROLACTIN CHEMISTRY AND MOLECULAR BIOLOGY

A. Prolactin: Gene, Primary Structure, and Species Specificity

Based on its genetic, structural, binding and functional properties, prolactin belongs to the prolactin/growth hormone/placental lactogen family [group I of the helix bundle protein hormones (195, 791)]. Genes encoding prolactin, growth hormone, and placental lactogen evolved from a common ancestral gene by gene duplication (1311). The divergence of the prolactin and growth hormone lineages occurred ~400 million years ago (357, 358). In the human genome, a single gene, found on chromosome 6, encodes prolactin (1363). The prolactin gene is 10 kb in size and is composed of 5 exons and 4 introns (357, 1772). Transcription of the prolactin gene is regulated by two independent promoter regions. The proximal 5,000-bp region directs pituitary-specific expression (160), while a more upstream promoter region is

responsible for extrapituitary expression (159). The human prolactin cDNA is 914 nucleotides long and contains a 681-nucleotide open reading frame encoding the prolactin prohormone of 227 amino acids. The signal peptide contains 28 amino acids; thus the mature human prolactin is composed of 199 amino acids (1640).

The prolactin molecule is arranged in a single chain of amino acids with three intramolecular disulfide bonds between six cysteine residues (Cys⁴-Cys¹¹, Cys⁵⁸-Cys¹⁷⁴, and Cys¹⁹¹-Cys¹⁹⁹ in humans) (357). The sequence homology can vary from the striking 97% among primates to as low as 56% between primates and rodents (1640). In rats (358) and mice (968), pituitary prolactin consists of 197 amino acids, whereas in sheep (1036), pigs (1035), cattle (1851), and humans (1624) it consists of 199 amino acids with a molecular mass of ~23,000 Da.

B. Secondary and Tertiary Structure of Prolactin

Studies on the secondary structure of prolactin have shown that 50% of the amino acid chain is arranged in α -helices, while the rest of it forms loops (169). Although it was predicted earlier (1311), there are still no direct data about the three-dimensional structure of prolactin. The tertiary structure of prolactin was predicted by homology modeling approach (635), based on the structural similarities between prolactin and other helix bundle proteins, especially growth hormone (2, 438). According to the current three-dimensional model, prolactin contains four long α -helices arranged in antiparallel fashion (2, 438).

C. Prolactin Variants

Although the major form of prolactin found in the pituitary gland is 23 kDa, variants of prolactin have been characterized in many mammals, including humans. Prolactin variants can be results of alternative splicing of the primary transcript, proteolytic cleavage and other post-translational modifications of the amino acid chain.

1. Alternative splicing

Alternative splicing of prolactin mRNA has been proposed as one source of the variants (1639, 1640). Indeed, evidence suggestive of the existence of an alternatively spliced prolactin variant of 137 amino acids has been described in the anterior pituitary (501, 1882). In addition,

alternative splicing involving retention of introns is also possible. However, alternative splicing is not considered a major source of prolactin variants.

2. Proteolytic cleavage

Of the cleaved forms that have been characterized, 14-, 16-, and 22-kDa prolactin variants have been most widely studied. The 14-kDa NH₂-terminal fragment is a posttranslational product of the prolactin gene that is processed in the hypothalamus and shares biological activity with the 16-kDa fragment (335, 1765). Both seem to possess a unique biological activity, which will be described later. The 16-kDa fragment [prolactin-(1–148)] was first described in rat pituitary extracts (1207) and has subsequently been found in mouse (1642) and human (1643) pituitary glands as well as in human plasma (1643). The 16-kDa prolactin is a product of kallikrein enzymatic activity. Kallikrein is an estrogen-induced, trypsin-like serine protease that is found in the Golgi cisternae and secretory granules of lactotrophs (1433). This enzyme will cleave rat prolactin in a thiol-dependent manner. Thiol alters the conformation of prolactin such that kallikrein recognizes it as a substrate. Treatment of native prolactin with carboxypeptidase-B results in a 22-kDa prolactin fragment [prolactin-(1–173)]. Surprisingly, this synthetic fragment can be detected in pituitary extracts by Western blot using an antiserum produced specifically against the 22-kDa prolactin fragment (45). It seems that the production and release of these proteolytic fragments from the pituitary gland is specific to female rats and sensitive to inhibition by dopamine (45). Although these and other fragments have been found in pituitary gland and serum, more work is required to determine their physiological significance since the possibility remains that they may be preparative artifacts (1640).

3. Other posttranslational modifications

Besides proteolytic cleavage, the majority of prolactin variants can be the result of other posttranslational processing of the mature molecule in the anterior pituitary gland or the plasma. These include dimerization and polymerization, phosphorylation, glycosylation, sulfation, and deamidation (1702).

A) DIMERIZATION AND POLYMERIZATION: MACROPROLACTINS. Dimerization and polymerization of prolactin or aggregation with binding proteins, such as immunoglobulins, by covalent and noncovalent bonds may result in high-molecular-weight forms. In general, the high-molecular-weight forms have reduced biological activity (1640). The role of prolactin-IgG macromolecular complexes in the detection and differential diagnosis of different prolactinemias is targeted primarily in clinical studies (299).

B) PHOSPHORYLATION. Phosphorylation of prolactin occurs within the secretory vesicle of lactotrophs just be-

fore exocytosis and involves esterification of hydroxyl groups of serine and threonine residues (670). Phosphorylated prolactin isoforms have been isolated from bovine (224) and murine (1337) pituitary glands. Phosphorylated isoforms of prolactin may constitute as much as 80% of total pituitary prolactin in cattle (938). Although phosphoprolactin has been shown to be secreted *in vitro*, it is not known if it is secreted into the plasma *in vivo*. The significance of phosphorylated and nonphosphorylated prolactins has been reviewed in detail (736). Phosphorylated prolactin has much lower biological activity than nonphosphorylated prolactin (1859). However, phosphorylated prolactin may subserve a unique role as an autocrine regulator of prolactin secretion since it suppresses the release of nonphosphorylated prolactin from GH₃ cells (768). Phosphorylation of prolactin as well as the relative ratio of phosphorylated to nonphosphorylated isoforms seems to be regulated throughout the estrous cycle (769), although the physiological relevance of this finding is not yet appreciated. However, novel data indicate that phosphorylated prolactin acts as an antagonist to the signal transduction pathways (362) and proliferative activities initiated by unmodified prolactin on Nb2 lymphoma cells (315). Further investigation is needed to determine the significance of phosphorylated prolactin in primary cells and tissues.

C) GLYCOSYLATION. Glycosylated prolactin has been found in the pituitary glands of a wide variety of mammalian, amphibian, and avian species (1640). The degree of glycosylation varies from 1 to 60% among species and may also vary between reproductive states within species (1640). The linkage of the carbohydrate moiety may be either through nitrogen (*N*-glycosylation) or oxygen (*O*-glycosylation). The carbohydrate residues of the oligosaccharide chain may contain varying ratios of sialic acid, fucose, mannose, and galactose that differ considerably between species, physiological, and pathological states (1640). Like other prolactin variants, glycosylation also lowers biological activity (1127, 1641) as well as receptor binding and immunologic reactivity of prolactins (740). Glycosylation also alters the metabolic clearance rate of prolactin (1641). Taken together, glycosylation of prolactin may play a role either in regulation of the biological activity or clearance of the molecule.

III. SITES OF SYNTHESIS AND SECRETION OF PROLACTIN

A. Anterior Pituitary Gland

1. Morphology of lactotrophs

The cells of the anterior pituitary gland which synthesize and secrete prolactin were initially described by

light microscopy using conventional staining techniques (753). These cells, designated lactotrophs or mammotrophs, comprise 20–50% of the cellular population of the anterior pituitary gland depending on the sex and physiological status of the animal. Lactotrophs were subsequently identified unequivocally by immunocytochemistry in the anterior pituitary gland of the mouse (109), rat (110, 1287), and human (111, 725, 1387) using species-specific prolactin antibodies. Ontogenetically, lactotrophs descend from the Pit-1-dependent lineage of pituitary cells, together with somatotrophs and thyrotrophs (348, 643, 1382, 1599).

The morphology and distribution of lactotrophs have been best described in the rat (1768), where prolactin-containing cells are sparsely distributed in the lateroventral portion of the anterior lobe and are present as a band adjacent to the intermediate lobe (1287). Their shapes are heterogeneous, appearing as either polyhedral or angular but at times rounded or oval (429). With the use of either velocity sedimentation at unit gravity (1650) or discontinuous Percoll gradients (1813) to separate cell populations, it has been shown that lactotrophs vary based on their secretory granule size and content (1650) as well as on the amount of prolactin and prolactin mRNA present (1813).

2. Functional heterogeneity of lactotrophs

Aside from morphological heterogeneity, lactotrophs display functional heterogeneity as well. Development of the reverse hemolytic plaque assay (572, 576, 1300) led to a more precise description of functional heterogeneity in lactotrophs (1090). Although prolactin is largely found and secreted from a distinct cell type in the pituitary gland, the lactotroph, both prolactin and growth hormone can also be secreted from the intermediate cell population called mammosomatotrophs (572, 574, 576, 1300). These bifunctional cells, which predominate in the pituitary of neonatal rats (770), differentiate into lactotrophs in the presence of estrogen (191). Mammosomatotrophs also differentiate into lactotrophs in pups in the presence of a maternal signal that appears in early lactation (1427) and is delivered to the pups through the mother's milk (1429).

There also appears to be functional heterogeneity among lactotrophs with regard to their regional distribution within the anterior lobe (1246) as well as to the nature of their responsiveness to secretagogues (188); that is, lactotrophs from the outer zone of the anterior lobe respond greater to thyrotrophin releasing hormone (TRH) than those of the inner zone, adjacent to the intermediate lobe of the pituitary gland (188). On the other hand, dopamine-responsive lactotrophs (84) are more abundant in the inner than the outer zone of the anterior pituitary. Surprisingly, functional heterogeneity is also reflected in the discordance between prolactin gene transcription and prolactin release in some lactotroph popu-

lations (296, 1562). Taken together, it is clear that lactotrophs are not homogeneous in their morphology, hormonal phenotype, distribution, or function.

B. Brain

The first observation that prolactin is produced in the brain was by Fuxe et al. (594) who found prolactin immunoreactivity in hypothalamic axon terminals. Prolactin immunoreactivity was subsequently found in the telencephalon in the cerebral cortex, hippocampus, amygdala, septum (433), caudate putamen (502, 737), brain stem (433, 737), cerebellum (1589), spinal cord (737, 1630), choroid plexi, and the circumventricular organs (1741).

1. Hypothalamus

Prolactin immunoreactivity is found within numerous hypothalamic areas in a variety of mammals (29, 677, 678, 737, 1321, 1630, 1741). Within the rat hypothalamus, prolactin immunoreactivity is detectable in the dorsomedial, ventromedial (676), supraoptic, and paraventricular (735) nuclei. Several approaches have been taken to prove that prolactin found in the hypothalamus is synthesized locally, independent of prolactin synthesis in the pituitary gland. Indeed, hypophysectomy has no effect on the amount of immunoreactive prolactin in the male hypothalamus and only diminishes but does not abolish the quantity of immunoreactive prolactin in the female rat hypothalamus (433).

With the use of conventional peptide mapping (434) and sequencing of a polymerase chain reaction (PCR) product of hypothalamic cDNA from intact and hypophysectomized rats (1882), it has been established that the primary structure of prolactin of hypothalamic and pituitary origin is identical. Thus it seems that the prolactin gene expressed in the rat hypothalamus is identical to the prolactin gene of the anterior pituitary (501, 1882).

Although the role of prolactin of hypothalamic origin in the central nervous system (CNS) is not apparent, it should be noted that the hypothalamus contains the appropriate proteolytic enzymes to cleave 23-kDa prolactin into 16- and 14-kDa fragments (435). We do not know if prolactin of neural origin exerts its central effect as a neurotransmitter, neuromodulator, or a central cytokine regulating vascular growth and/or glial functions. To ascribe a role for prolactin of neural origin is troublesome, in part, because it is difficult to differentiate between the effects of prolactin of pituitary versus hypothalamic origin in the CNS. One cause of these difficulties is that pituitary prolactin from the circulation bypasses the blood-brain barrier and enters the CNS through the choroid plexi of the brain ventricles. Coincidentally, choroid plexi have a very high density of prolactin receptors (prolactin-Rs) as demonstrated by autoradiography (1113,

1853, 1854), immunocytochemistry (1495), standard receptor binding assays (1242), reverse transcriptase PCR, and ribonuclease protection assay (590). Interestingly, prolactin enhances the expression of its own receptors in the choroid plexus (1113). Aside from passage from the blood to the cerebrospinal fluid by way of the choroid plexus, pituitary prolactin may also reach the brain by retrograde blood flow from the anterior pituitary to the hypothalamus (1192, 1351). Therefore, because the actions of prolactin in the CNS can be due to the hormone of pituitary or hypothalamic origin, in this review we refer to its effects in the CNS without attributing a source.

2. Regulation of hypothalamic prolactin synthesis

Some well-established stimulators of pituitary prolactin secretion also affect hypothalamic prolactin production. For example, ovarian steroids modulate hypothalamic synthesis and release of prolactin (436, 437). Approximately 33% of the prolactin immunoreactive neurons in the medial basal hypothalamus can be labeled with [3 H]estradiol (436), suggesting that these neurons have estrogen receptors. Ovariectomy lowers hypothalamic prolactin content, whereas estrogen replacement elevates it (436, 437). Of the known hypophysiotrophic factors, angiotensin II stimulates release of prolactin from hypothalamic fragments (437), and intracerebroventricular injection of vasoactive intestinal peptide will increase the amount of hypothalamic prolactin mRNA (212). However, other established stimulators of pituitary prolactin secretion such as TRH are without effect (437). Obviously, much more work is needed to establish the control of hypothalamic prolactin synthesis and release.

C. Placenta, Amnion, Decidua, and Uterus

The placenta, in addition to its bidirectional fetomaternal metabolic transport functions, has a wide array of endocrine functions as well. Among its many secretory products are a family of placental lactogens found in the rat (354, 393, 537, 744, 1487–1489, 1491, 1651), mouse (1605, 1896), hamster (874, 1662–1664), cow (46, 1612), pig (568), and human (728). The rat placenta produces a bewildering array of prolactin-like molecules that bear structural similarity to pituitary prolactin (1058, 1652). These placental lactogens (PL) or prolactin-like proteins (PLP) have been variously identified as PL-I, PL-II, PL-Im (mosaic), PL-Iv (variant) (349, 1487, 1490), or PLP-A, -B, -C, -D, -E, -F, and -G (356, 392, 851). In addition, the placenta contains a lactogen known as proliferin (PLF) (1056) and proliferin-related protein (PRP) (1057).

The decidua, on the other hand, produces a prolactin-like molecule, that is indistinguishable from pituitary prolactin in human (35, 342, 1475, 1707), but is somewhat dissimilar in rat (688). A novel member of this family is

prolactin-like protein J (1752), which is produced by the decidua during early pregnancy. Each of these prolactin-like molecules can bind to the prolactin-R (755, 860), and their secretion is regulated by local decidual (638, 689, 729–731, 1745, 1746), but not hypothalamic (637) prolactin-releasing factors (PRF). Progesterone has also been identified as a potent stimulator of decidual prolactin production (1143). In addition to stimulatory factors, a substance with inhibitory activity is found in decidual conditioned media (731). This substance decreases basal decidual prolactin release and competes with the decidual PRF (731). Recently, the N5 endometrial stromal cell line, which expresses the prolactin gene driven by the extrapituitary promoter, has been identified as a possible model system to study decidual prolactin gene expression (210). Ample evidence indicates that decidual prolactin diffuses into the amniotic fluid (1473, 1474, 1476, 1501). Although the function of amniotic prolactin is uncertain, it has been suggested that it may serve an osmoregulatory (1781), maturational (864), or immune (732) role in the embryo/fetus.

Finally, the nonpregnant uterus has been shown to be a source of prolactin as well. Indeed, a decidual-like prolactin, indistinguishable from pituitary prolactin (611), has been identified in the myometrium of nonpregnant rats (1855). Interestingly, although progesterone stimulates the production of decidual prolactin, it appears to be a potent inhibitor of myometrial prolactin production (611). The physiological role for myometrial prolactin has yet to be identified.

D. Mammary Gland and Milk

Prolactin can be detected in epithelial cells of the lactating mammary gland (1326) as well as in the milk itself (680). There is little doubt that a portion of the prolactin found in the milk originates in the pituitary gland and reaches the mammary gland through the circulation. Thus some of the prolactin found in milk is taken up rather than produced by the mammary epithelial cells. Indeed, a significant amount of radiolabeled prolactin introduced into the circulation appears in milk (685, 1253). Apparently, prolactin reaches the milk by first crossing the mammary epithelial cell basement membrane, attaches to a specific prolactin binding protein within the mammary epithelial cell, and is ultimately transported by exocytosis through the apical membrane into the alveolar lumen (1352, 1583).

In addition to uptake of prolactin from the blood, the mammary epithelial cells of lactating animals are capable of synthesizing prolactin. The presence of prolactin mRNA (992, 1682) as well as synthesis of immunoreactive prolactin by mammary epithelial cells of lactating rats has been described (1063, 1064). It is possible that *de novo*

synthesis of mammary prolactin requires a systemic trophic factor since the amount of both prolactin mRNA and immunoreactive prolactin declines over 24–48 h in mammary gland explants (992). The mammary gland may also act as a posttranslational processing site for prolactin. In both human (499) and rat (888, 889) milk, the number of prolactin variants far exceeds that found in serum. Indeed, the mammary gland is the site of formation of the important 16-kDa variant of prolactin mentioned previously (332). Although prolactin, produced locally by mammary epithelial cells promotes proliferation, the 16-kDa cleaved prolactin variant inhibits local angiogenesis, which makes this proteolytic step a possible target of breast cancer research (636).

The physiological role for milk-borne prolactin has only been described in the rat, which is born immature relative to many other mammals. Indeed, during a brief window of neonatal life, the gastrointestinal tract lacks the ability to digest protein and likewise possesses the ability to absorb intact protein. This is particularly important since the rat pituitary gland is relatively quiescent during this period. Approximately 20% of the prolactin ingested in milk passes to the neonatal circulation (686). It has been shown that milk prolactin participates in the maturation of the neuroendocrine (1596, 1629) and immune (687, 702) systems.

E. The Immune System

A great deal of evidence suggests that lymphocytes can be a source of prolactin as well (599, 882, 1214, 1516). Indeed, immune-competent cells from thymus and spleen as well as peripheral lymphocytes contain prolactin mRNA and release a bioactive prolactin that is similar to pituitary prolactin (445, 612, 613, 1214–1216, 1523). Not only is an immunoreactive 22-kDa prolactin found in murine (1214) and human (1886) immune-competent cells, but size variants of prolactin have been described as well (1215, 1398, 1523, 1592).

Although the control of pituitary prolactin secretion differs from that of lymphocytic origin, there is abundant evidence that lymphocytes contain dopamine receptors that may be involved in the regulation of lymphocytic prolactin production/release (432). Pharmacological characterization of lymphocytic dopamine receptors suggests that rather than the classical D_2 type receptors found on lactotrophs, both the D_4 and D_5 predominate on lymphocytes (186, 187, 1361, 1470, 1545, 1824). Moreover, mRNA for the D_1 , D_3 , and D_5 receptors have been identified in rat lymphocytes (283).

The question remains of the role for pituitary and lymphocytic prolactin in the immune response. It is interesting to note that pituitary prolactin gene expression (1601), bioassayable serum prolactin (1601), immunoas-

sayable serum prolactin (1505), and lymphocyte number (1505, 1601) are elevated during acute skin allograft rejection in mice. Administration of bromocryptine, a D_2 receptor agonist, or antilymphocytic serum diminishes circulating levels of prolactin in grafted animals and prolongs graft survival (1294, 1505). Because bromocryptine has little direct effect on lymphocytic prolactin secretion (1294), such data suggest that pituitary prolactin may modulate the elaboration of lymphocytic prolactin and that suppression of pituitary prolactin is thus a requirement for graft survival (1131). Indeed, such a role for prolactin in transplant rejection warrants further investigation.

F. Prolactin-Secreting Cell Lines

To study the synthesis, processing and secretion of prolactin at the cellular and molecular level, cell lines derived from pituitary tumors have been developed. The first cell line was a mammosomatotroph (MtT/W5) isolated from a radiation-induced pituitary tumor produced in a Wistar-Furth rat (1724, 1907). Because these cell lines secreted mostly growth hormone, they were designated as GH cells. It was subsequently found that some of the subclones were pluripotent and heterogeneous (1721, 1722). For example, GH₃ cells may release growth hormone only (somatotrophs), prolactin only (mammatrophs), both hormones (mammosomatotrophs), or neither hormone (189, 192). Similarly, the GH₁ and GH₄C₁ cell lines produce both prolactin and growth hormone but in varying ratios (1721).

The most obvious advantage of using cell lines rather than primary pituitary lactotrophs is that clonal cells are usually immortal, can be easily stored, and thus provide a perpetual supply of cells without sacrificing animals and purifying primary pituitary cultures. To critically use these cells, one should recognize their dissimilarity to primary cultures of pituitary cells. For example, unlike pituitary cells, the vast majority of the prolactin synthesized by GH cell lines is rapidly released and not stored (1722); thus there is no intracellular degradation of prolactin (381). Moreover, GH cells lack functional dopamine receptors, and thus they are resistant to the prolactin-inhibiting actions of dopamine (538). This can be viewed as either an advantage or a disadvantage. Because cell lines lack the complete receptor repertoire of a normal pituitary cell, one must be careful when drawing conclusions that apply to normal lactotrophs on the basis of data collected from cell lines. On the other hand, with knowledge of the defect borne by cell lines, one can study the role of an absent phenotype in control of cellular function. For example, one can transfect GH₄C₁ cells with a dopamine receptor gene, thus isolating and examining the role of that particular dopamine receptor subtype in lactotroph function (22, 244, 249, 491, 666, 1784, 1807, 1924).

Not all clonal lactotroph lines deviate as markedly from primary cells. For example, the MMQ cell line derived from the estrogen-induced rat pituitary tumor 7315a secretes prolactin exclusively, expresses functional dopamine D₂ receptors (881), and behaves in a manner similar to (but not the same as) that of normal lactotrophs (567, 699).

IV. PROLACTIN RECEPTORS

A. Prolactin Receptor: Gene, Splicing Variants, and Isoforms

The prolactin-R is a single membrane-bound protein that belongs to class 1 of the cytokine receptor superfamily (131, 132, 926, 997). Just like their respective ligands, prolactin and growth hormone receptors share several structural and functional features despite their low (30%) sequence homology (632, 633). Each contains an extracellular, transmembrane, and intracellular domain (1899). The gene encoding the human prolactin-R is located on chromosome 5 and contains at least 10 exons (131, 132). Transcriptional regulation of the prolactin-R gene is accomplished by three different, tissue-specific promoter regions. Promoter I is specific for the gonads, promoter II for the liver, and promoter III is "generic," present in both gonadal and nongonadal tissues (812). Numerous prolactin-R isoforms have been described in different tissues (24, 386, 1031). These isoforms are results of transcription starting at alternative initiation sites of the different prolactin-R promoters as well as alternative splicing of non-coding and coding exon transcripts (809, 812). Although the isoforms vary in the length and composition of their cytoplasmic domains, their extracellular domains are identical (184, 926, 1031). The three major prolactin-R isoforms described in rats are the short (291 amino acids), intermediate (393 amino acids), and long (591 amino acids) forms (184). In mice, one long and three short forms have been described (338, 386). In addition to the membrane-bound receptors, soluble prolactin-binding proteins were also described in mammary epithelial cells (158) and milk (1430). These soluble forms contain 206 NH₂-terminal amino acids of the extracellular domain of the prolactin-R (159). The soluble prolactin binding proteins are also products of the same prolactin-R gene, but it is still uncertain whether they are results of alternative splicing of the primary transcript or products of proteolytic cleavage of the mature receptor (or both) (184).

B. Activation of Prolactin-R and the Associated Signal Transduction Pathways

1. Prolactin-R domains and receptor activation

A) EXTRACELLULAR DOMAIN: LIGAND-INDUCED DIMERIZATION. The extracellular domain of all rat and human prolactin-R

isoforms consists of 210 amino acids (196, 197) and shows sequence similarities with other cytokine receptors (cytokine receptor homology domain, CRH) (1872). The extracellular domain can be further divided into NH₂-terminal D1 and membrane-proximal D2 subdomains (926, 1872). Both D1 and D2 show analogies with the fibronectin type III molecule, which drives the receptor-ligand interactions in the majority of cytokine receptors (1872). The most conserved features of the extracellular domain are two pairs of disulfide bonds (between Cys¹²-Cys²² and Cys⁵¹-Cys⁶²) in the D1 domain and a "WS motif" (Trp-Ser-x-Trp-Ser) in the D2 domain (1872). The disulfide bonds and the WS motif are essential for the proper folding and trafficking of the receptor, although they are not responsible for binding the ligand itself (632). Activation of the prolactin-R involves ligand-induced sequential receptor dimerization (184) (Fig. 1). Each prolactin molecule contains two binding sites (site 1 involves helices 1 and 4, while site 2 encompasses helices 1 and 3). First, prolactin's binding site 1 interacts with a prolactin-R molecule (634). The formation of this initial hormone-receptor complex is the prerequisite for the interaction of binding site 2 on the same prolactin molecule with a second prolactin-R (184). Disruptive mutation of prolactin binding site 2 is detrimental to prolactin-R activation, which can be initiated only when a trimeric complex (2 receptors, 1 hormone) is formed (184, 634).

B) INTRACELLULAR DOMAIN: ACTIVATION OF JAK2 AND RECEPTOR PHOSPHORYLATION. I) *Transmembrane and intracellular domains*. The role of the 24-amino acid-long transmembrane domain in the activation of prolactin-R is unknown (184). The intracellular domain, however, is a key player in the initiation of the signal transduction mechanisms associated with the prolactin-R (184). The intracellular domains are different in length and composition among the various prolactin-R isoforms and show little sequence similarities with other cytokine receptors (184). However, there are two relatively conserved regions termed box 1 and box 2 (1260). Box 1 (Fig. 1) is a membrane-proximal, proline-rich motif necessary for the consensus folding of the molecule recognized by the transducing molecules (184). Box 2 is less conserved and is missing in the short isoform of the prolactin receptor (632, 926).

II) *Activation of Jak2*. Although the intracellular domain of the prolactin-R is devoid of any intrinsic enzymatic activity, ligand-mediated activation of prolactin-R results in tyrosine phosphorylation of numerous cellular proteins (1479), including the receptor itself (926, 1267). The membrane proximal region of the intracellular domain is constitutively (i.e., not induced by ligand binding) associated with a tyrosine kinase termed Janus kinase 2 (Jak2) (266, 834, 1013). Phosphorylation of Jak2 occurs within 1 min after prolactin binding, suggesting a major upstream role for Jak2 (1014) (Fig. 1). Experimental data suggest two major prerequisites for Jak2 activation: 1)




FIG. 1. Mechanism of prolactin receptor activation. Activation of prolactin-R involves ligand-induced sequential receptor dimerization (184) driven by the prolactin molecule containing two binding sites. First, prolactin's binding site 1 interacts with a prolactin-R molecule (*step 1*). The extracellular (EC) domain of all prolactin-R isoforms consists of NH₂-terminal D1 and membrane-proximal D2 subdomains (926), both of which show analogies with the fibronectin type III molecule driving the receptor-ligand interactions in cytokine receptors (1872). The formation of the initial hormone-receptor complex induces the interaction of binding site 2 on the same prolactin molecule with a second prolactin-R (184) (*step 2*). Although the intracellular (IC) domains of prolactin-R isoforms differ in length and composition, there are two conserved regions, termed box 1 and box 2 (1260). Both the presence of the proline-rich box 1 (1014) and strict homodimeric stoichiometry of prolactin-R dimers (550) are necessary for the activation of the tyrosine kinase termed Janus kinase2 (Jak2), constitutively associated with the IC domain of the prolactin-R (1013). Jak2 kinases transphosphorylate each other (550) (*step 2*) and phosphorylate (P) the Tyr residues (Y) of the prolactin-R itself (*step 3*) (1514). Although phosphorylation of Jak2 is a key event in the activation of all prolactin-R isoforms, Tyr phosphorylation of the receptor itself does not occur upon activation of the short form of the prolactin-R, despite the presence of four Tyr residues in its intracellular domain (660).

presence of the proline-rich box 1 motif in the intracellular domain of the prolactin-R (1014) and 2) homodimeric stoichiometry of the ligand-induced prolactin-R dimers (307, 549, 550). Although the association of Jak2 with prolactin-R has been undoubtedly proven (266, 1013, 1515), the exact structure of their association is not known. Although box 1 of the intracellular domain adopts the typical SH3 (src kinase homology domain 3) folding (1464), no matching SH3 region is found in the sequence of Jak2, implying either the presence of an adapter protein or a mechanism different from the well-known SH3-SH3 binding (1357a). Activation of Jak2 occurs by transphosphorylation upon receptor dimerization, which brings two Jak2 molecules close to each other (550). Experiments with chimeric receptors suggest that mere juxtaposition of box 1 regions does not guarantee Jak2 activation (306). Exact homology of the rest of the intracellular domain is also required, suggesting the significance of the COOH-terminal residues (550).

III) Phosphorylation of the prolactin-R. Jak2 kinases transphosphorylate each other and are involved in the phosphorylation of Tyr residues of the prolactin-R itself (1514) (Fig. 1). Phosphotyrosines are of interest since they are potential binding/docking sites for transducer molecules containing SH2 domains. Although phosphory-

lation of Jak2 occurs in all active prolactin-R isoforms, Tyr phosphorylation of the receptor itself does not occur upon activation of the short form of the prolactin-R, despite the presence of four Tyr residues in its intracellular domain (660). Certain cellular functions, like proliferation, mediated by the short form of the prolactin-R, can take place without prolactin-R phosphorylation (1906). The long form of the prolactin-R also contains numerous Tyr residues, many of which are phosphorylated upon prolactin-R activation (1412).

2. Signal transduction pathways associated with the prolactin-R

A) STAT PROTEINS. The signal transducer and activator of transcription (STAT) protein family has been shown to be a major transducer in cytokine receptor signaling (834). The STAT family currently consists of eight members. Four of them, STAT1, STAT3, and especially STAT5a and STAT5b, have been identified as transducer molecules of the prolactin-R (631, 852). STAT contain five conserved features: a DNA-binding domain, an SH3-like domain, an SH2-like domain, and an NH₂- and a COOH-terminal transactivating domain (552). According to the consensus model of STAT activation (184, 552), a phos-




FIG. 2. Signal transduction pathways initiated by activation of the prolactin (PRL) receptor. Jak/STAT pathway: members of the signal transducer and activator of transcription (STAT) protein family (834), STAT1, STAT3, STAT5a, and STAT5b are the central transducer molecules of the signal transduction pathways initiated by prolactin-R (PRL-R) activation (631, 852). STAT contain a DNA-binding domain, an SH3-like domain, an SH2-like domain, and an NH₂- and a COOH-terminal transactivating domain (552). A phosphorylated Tyr residue (Y) of the activated long prolactin-R isoform interacts with the SH2 domain of a STAT. STAT, while docked at the receptor, is phosphorylated by the receptor-associated Jak kinase. Then, phosphorylated STAT dissociates from the receptor and hetero- or homodimerizes through its phosphotyrosine residues with the SH2 domain of another phosphorylated STAT molecule. Finally, the STAT dimer translocates to the nucleus and activates a STAT DNA-binding motif in the promoter of a target gene (184), termed GAS (γ -interferon activated sequence) (791). The tyrosine residues of the short form of prolactin receptor are not phosphorylated by Jak2, but the phosphotyrosine of Jak2 can serve as docking site for Stat1 (184). MAPK cascade: activation of the prolactin-R also activates the mitogen-activated protein kinase (MAPK) cascade (1417), which is involved in the activation of a wide range of transcription factors/immediate early genes by phosphorylation. Phosphotyrosine residues of the activated long prolactin-R isoform serve as docking sites for adapter proteins (Shc/Grb2/SOS) connecting the receptor to the Ras/Raf/MAPK cascade (382). Novel data indicate communication between the Jak/STAT and MAPK pathways (698). Ion channels: box 1 of the intracellular domain of prolactin-R is also involved in the activation of a tyrosine kinase-dependent, calcium-sensitive K⁺ channels through Jak2 (1435). The COOH terminal of prolactin-R's intracellular domain is involved in the production of the intracellular messengers [inositol 1,3,4,5-tetrakisphosphate (IP₄) and inositol hexakisphosphate (IP₆)] that open voltage-independent Ca²⁺ channels (1452, 1659). Src kinases: prolactin also induces the activation of members of the Src kinase family, *c-src* (150, 1658) and Fyn (20), which are involved in the Tyr phosphorylation of phosphatidylinositol 3-kinase (PI3K) (152, 1453). Downregulation: Jak/STAT pathways can be inhibited by SOCS (suppressors of cytokine signaling) which inhibit Jak kinases (503, 762, 1289, 1312, 1411, 1672) or CIS (cytokine-inducible SH2-containing protein), which compete with STAT for docking sites on prolactin receptor (1144, 1914).

phorylated Tyr residue of the activated cytokine receptor interacts with the SH2 domain of STAT (Fig. 2). Then STAT, while docked at the receptor, is phosphorylated by the receptor-associated Jak kinase. The phosphorylated STAT dissociates from the receptor and hetero- or homodimerizes through its phosphotyrosine residues with the SH2 domain of another phosphorylated STAT molecule (184) (Fig. 2). Finally, the STAT dimer translocates to the nucleus and activates a STAT DNA-binding motif in the promoter of a target gene (184, 291). The consensus

DNA motif recognized by STAT1, STAT3, and STAT5 homo- or heterodimers is termed GAS (γ -interferon activated sequence) (791) (Fig. 2). GAS consists of a palindromic sequence: TTCxxxGAA (791). Numerous promoters contain the GAS consensus motif, and multiple cytokines have been shown to activate these promoters in vitro (548, 658). It has been proposed that STAT interact with other signal transducers (e.g., glucocorticoid receptor) to initiate a cell- and cytokine-specific response (1687, 1688).

Of the STAT1, STAT3, and STAT5 proteins, STAT5 (earlier known as mammary gland factor, MGF) is recognized as the most important transducer of the long and intermediate isoforms of the prolactin-R (1060). STAT5 has two isoforms, STAT5a and STAT5b, encoded by two different genes, with 95% sequence homology and differences only in the COOH-terminal domain. Both isoforms possess a Tyr-694, which is phosphorylated by Jak2 (659). In addition to Tyr phosphorylation, activation of STAT involves serine/threonine phosphorylation as well. The major difference between STAT5a and -b isoforms lies in their serine/threonine phosphorylation sites (133). Protein kinase C (PKC)- α and casein kinase II have been proposed as serine/threonine kinases activating STAT5 (133). Novel data indicate that STAT5 may fulfill inhibitory roles in regulation of gene transcription (1088).

B) OTHER SIGNALING PATHWAYS. I) *Ras/Raf/MAP kinase pathway*. Although Jak/STAT are the most important pathways initiated by activation of the prolactin-R, a number of reports implicate activation of the mitogen-activated protein (MAP) kinase cascade as well (242, 345, 383, 384, 518, 1307, 1323, 1417). Phosphotyrosine residues of the prolactin-R can serve as docking sites for adapter proteins (Shc/Grb2/SOS) connecting the receptor to the Ras/Raf/MAPK cascade (291, 382) (Fig. 2). Although initially the Jak/Stat and MAPK pathways were regarded as independent or parallel pathways, there are data suggesting that these pathways are interconnected (698).

II) *Other kinases: c-src and Fyn*. Several recent reports indicate prolactin-induced activation of members of the Src kinase family, c-src (150, 267, 1658) and Fyn (31a) (Fig. 2). Recently, prolactin-induced rapid Tyr phosphorylation of insulin receptor substrate-1 (IRS-1) and a subunit of the phosphatidylinositol (PI) 3'-kinase (103, 152, 1453) have been described. Both IRS-1 and PI 3'-kinase seem to be associated with the prolactin-R complex. It has been proposed that prolactin-induced activation of PI 3'-kinase is mediated by Fyn (31a) (Fig. 2).

III) *Intracellular ion concentration*. At least two events and two regions of the prolactin-R are involved in prolactin-induced ionic changes. Box 1 of the intracellular domain of the prolactin-R is involved in the activation of tyrosine kinase-dependent K^+ channels by Jak2 (1435), whereas the COOH terminal of the intracellular domain is involved in the production of the intracellular messengers [inositol 1,3,4,5-tetrakisphosphate [$\text{Ins}(1,3,4,5)\text{P}_4$] and inositol hexakisphosphate (InsP_6)] that open voltage-independent Ca^{2+} channels (351, 1452, 1659) (Fig. 2).

C) DOWNREGULATION OF PROLACTIN-R SIGNAL: TYR PHOSPHATASES AND INHIBITOR PROTEINS. Because activation of prolactin-R results in Tyr phosphorylation of multiple signal molecules, it is expected that inactivation of signaling pathways involves Tyr phosphatases (184). Experimental data indicate that SH2 containing Tyr phosphatases SHP-1 and SHP-2 play less of a role in downregulation of pro-

lactin signaling than in GH or other cytokines (23, 147, 490, 1411, 1445, 1770).

A newly revealed facet of cytokine receptor signaling is identification of SH2-containing protein families inhibiting the Jak/STAT pathways. These protein families are referred to as cytokine-inducible SH2-containing protein (CIS) (1042, 1144, 1914) and suppressors of cytokine signaling (SOCS) (503, 762, 1289, 1312, 1672). Their main mechanism of action in prolactin receptor signaling has been recently characterized (1411). The data indicate that prolactin induces acute and transient expression of SOCS-1 and SOCS-3 (1411). SOCS-1 and SOCS-3 switch off the prolactin receptor-mediated signaling by inhibiting the catalytic activity of Jak2 and activation of STAT proteins (1411). The CIS and SOCS-2 genes respond with prolonged activity to prolactin administration, and SOCS-2 seems to restore the cells' sensitivity to prolactin receptor stimulation probably by suppressing SOCS-1's inhibitory effect (1411).

C. Distribution of Prolactin-R

1. Subcellular distribution: surface targeting, internalization, and nuclear translocation of prolactin-R

For proper surface targeting, glycosylation of the asparagyl residues (Asn^{35} , Asn^{80} , Asn^{108}) of the extracellular domain of the prolactin-R is crucial, although not an absolute requirement for prolactin-R activation (256). Although prolactin-R is mainly a cell-surface receptor, deglycosylated forms of prolactin-R can accumulate in the Golgi apparatus (256). Nitric oxide activates *N*-acetylglucosamine transferase, which is responsible for glycosylation of these intracellular receptors and promotes migration of these newly glycosylated receptors to the cell surface (183).

Earlier, endocytosis of prolactin and prolactin-R had been shown in several cell types (149, 447, 877). Surprisingly, even translocation of prolactin (1451) and prolactin-R to the nucleus has been demonstrated in different cell types (344, 1028, 1450). Nuclear translocation of prolactin-R can be accompanied by nuclear actions like stimulation of PKC (241, 343, 1449). Because activation of "classical" cytokine signaling pathways (Jak/STAT, MAP kinase) (1404) do not require nuclear translocation of prolactin-R, the mechanism and in vivo importance of prolactin-R internalization and nuclear actions still remain to be determined.

2. Distribution of prolactin-R in the mammalian body

It is not surprising that prolactin-R and its message are found in the mammary gland and the ovary, two of the best-characterized sites of prolactin actions in mammals

(1268). What may be truly surprising is that the receptor and its mRNA are also found in numerous parts of the CNS. The distribution of mRNA for the long form of the prolactin-R has been characterized in the rat brain (112). Abundant message is found in the choroid plexus, bed nucleus of the stria terminalis, amygdala, the central gray of the midbrain, thalamus, hypothalamus, cerebral cortex, and olfactory bulb (586, 587). Recently, prolactin binding sites have been described in the area postrema, which is one of the main chemosensitive areas of the brain lacking the blood-brain barrier (1112). Prolactin receptors are also present in a wide range of peripheral organs like the pituitary gland, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus, skeletal muscle, and skin (184, 1268).

V. BIOLOGICAL ACTIONS OF PROLACTIN

Our goal in this section is to summarize the most relevant actions of prolactin in the mammalian body. An extensive summary of prolactin's effects in different vertebrate species and organ systems can be found in the recent review written by Kelly et al. (184).

A. Reproduction

Prolactin is best known for the multiple effects it exerts on the mammary gland. However, it also exerts effects on other targets important to the reproduction of the mammalian species. In some mammals, particularly rodents, prolactin is also important for the maintenance and secretory activity of the corpus luteum. It also affects other actions related to reproduction such as mating and maternal behaviors.

1. Lactation

The varied effects of prolactin on the mammary gland include growth and development of the mammary gland (mammogenesis), synthesis of milk (lactogenesis), and maintenance of milk secretion (galactopoiesis).

Although it has long been accepted that prolactin is involved in the development of the mammary gland (154), recent elegant techniques have confirmed such findings. Indeed, targeted disruption of the prolactin gene (prolactin knockout) (790) or knockout of the prolactin receptor (1358) results in abnormal mammogenesis characterized by complete absence of lobuloalveolar units in adult homozygous females. Prolactin knockout heterozygotes appear to have nearly normal mammogenesis that is indistinguishable from wild type (790). Transplantation of mammary epithelium from prolactin receptor knockouts into mammary fat pads of wild-type mice revealed that prolactin affects mammary morphogenesis in two differ-

ent ways: it controls ductal side branching and terminal end bud regression in virgin animals via indirect mechanisms, but acts directly on the mammary epithelium to produce lobuloalveolar development during pregnancy (223). Lactogenesis clearly requires pituitary prolactin, since hypophysectomy during pregnancy prevents subsequent lactation (1306). Due to impairment of mammogenesis, both prolactin knockout (790) and prolactin receptor knockout (1358) homozygous mice fail to produce milk. Interestingly, although the heterozygous prolactin knockouts have normal mammogenesis (790), the F₁ generation heterozygous prolactin receptor knockouts are unable to lactate for their first litter (1358). However, milk is delivered perfectly normally to the F₁'s second litter (1358). The phenotype of the F₂ generation was similar (1358). With further reproductive cycles, mammogenesis in both the F₁ and F₂ generations proceeds sufficiently to support lactation, indicating that the defect in heterozygotes is one affecting the rate of mammary gland development. These experiments further indicate that two functional alleles of the prolactin receptor are required for full lactation.

Although there are dramatic differences between mammals in the hormonal requirements for galactopoiesis, the common absolute requirement is prolactin. Aqueous extracts of anterior pituitary gland containing prolactin (1093) initiate lactation in pseudopregnant rabbits (1694). Replacement of prolactin to hypophysectomized rabbits will fully restore lactation (364). On the other hand, while hypophysectomy of rats and mice stops lactation (1587), the replacement cocktail should minimally consist of prolactin and glucocorticoid or adrenocorticotrophin to maintain sufficient nurturing of the pups (173). Addition of growth hormone permits the maintenance of maximal lactation (1094).

It should be noted that none of these actions is solely due to prolactin, but the hormone is merely a player in an orchestra of hormones and growth factors that affect the mammary gland. A great deal of evidence from hypophysectomized-ovariectomized-adrenalectomized rodents suggests that the mammary gland's lobuloalveolar growth and development *in vivo* requires prolactin, estrogen, progesterone, and glucocorticoids (837). During pregnancy, the extensive branching of the ducts and development of the alveoli is a function of progesterone and prolactin or placental lactogen (837). There is evidence that insulin, growth hormone, thyroid hormone, parathyroid hormone, calcitonin, several growth factors, and even oxytocin may also play a role in galactopoiesis in various mammals (1779).

In the process of lactogenesis, prolactin stimulates uptake of some amino acids, the synthesis of the milk proteins casein and α -lactalbumin, uptake of glucose, and synthesis of the milk sugar lactose as well as milk fats (118, 1779).

Controlled exclusively by promoter III of the rat prolactin-R gene (812), the mammary gland expresses mainly the long form of prolactin-R (1268). The activation of promoter III involves binding of C/ERB β (CCAAT-enhancer binding protein) and Sp1 (recognizing GC boxes of DNA) transcription factors to their respective binding elements and activation of a downstream sequence element resembling the consensus AP2 binding site (812). As in vitro studies indicate (750) and in vivo studies confirm (854), prolactin-R in the mammary gland is phosphorylated upon prolactin binding (1868) and activates the Jak2/STAT5 pathway responsible for both mammo- and lactogenesis. STAT5 (especially STAT5a) activated by the long form of the prolactin-R induces transcription of milk protein genes (151). Null mutation of the STAT5a or STAT5b gene is detrimental to tubuloalveolar development of the mammary gland and results in inability to lactate in homozygous ($-/-$) females (184). The signal transduction pathways over which prolactin induces mammary gland growth and development have been extensively studied in vitro and reviewed recently (750).

2. Luteal function

Actions of prolactin on luteal function depend on species and the stage of the estrous cycle. In rodents, prolactin can either be luteotrophic after mating or luteolytic in the absence of a mating stimulus.

In most rodents, prolactin acts as a luteotrophic hormone by maintaining the structural and functional integrity of the corpus luteum for 6 days after mating (1232). This "luteotrophic" action of prolactin, which has been best described in the rat, is characterized by enhanced progesterone secretion (580). Progesterone is essential for the implantation of the fertilized ovum (along with estrogen), maintenance of pregnancy, and inhibition of ovulation (580). In the absence of prolactin, the dominant steroid produced by the corpus luteum of the rat is 20α -hydroxyprogesterone, whose synthesis from progesterone is catalyzed by 20α -hydroxysteroid dehydrogenase (1508). This metabolite of progesterone is "inactive" in most progesterone bioassays. Prolactin enhances progesterone secretion two ways: prolactin potentiates the steroidogenic effects of luteinizing hormone (LH) in granulosa-luteal cells (1471) and inhibits the 20α -hydroxysteroid dehydrogenase enzyme, which inactivates progesterone (580). In other rodents such as hamsters, prolactin is part of a "luteotrophic complex" consisting of LH, follicle stimulating hormone (FSH), and prolactin (672). There is some evidence that prolactin may also be part of a luteotrophic complex in dogs (1322) and primates (1472). In humans, high levels of prolactin inhibit granulosa cell luteinization (10, 1170) and steroidogenesis (1017). Further evidence of luteal dependence on prolactin is found in prolactin receptor knockouts who lack

normal luteal function and thus are sterile due to decreased ovulation rate, aberrant oogenesis, and implantation failure (184). Prolactin is essential for progesterone biosynthesis and luteal cell hypertrophy during pregnancy. In addition to luteal function, the prolactin-R mediates numerous functions in granulosa cells and oocytes as well (184).

Aside from its luteotrophic role, there is evidence in the rat that prolactin may be luteolytic as well (1111, 1887) by inducing programmed cell death in the corpora lutea (901, 1156). Prolactin's luteolytic effect seems to be mediated by CD3-positive lymphocytes, which increase the expression of the membrane form of the Fas ligand, known to mediate luteal cell death through the Fas receptor (989). In the rat, as many as three generations of corpora lutea may appear on the ovary. There is evidence that prolactin may perform a "housekeeping function" by inducing the structural regression of the oldest of these. It should be emphasized that the corpora lutea are nonfunctional at the time that prolactin exerts this effect. The mechanism by which prolactin can be both luteotrophic and luteolytic is still uncertain. One suggestion is that at some critical time between periods of exposure to prolactin during the estrous cycle, the corpora lutea of the rat acquire the capacity to express monocyte chemoattractant protein-1, which subsequently interacts with prolactin on proestrus to induce luteal cell death (200, 1773).

Both short and long isoforms of the prolactin-R are present in the ovaries (337, 1621). Transcription of the prolactin-R in the ovaries is controlled by intricate developmental and hormonal regulation (340, 1730). Regulation of transcription of the prolactin-R gene in the ovaries is accomplished by the gonad-specific promoter I and the "generic" promoter III. Essential transcriptional activator of prolactin-R's promoter I is steroidogenic factor-1 (SF-1)-binding consensus element, which is activated by SF-1 (810, 811). SF-1 is a specific zinc finger DNA binding protein, also known as Ad4BP (1089).

Recently, expression of a prolactin-R associated phosphoprotein (PRAP) has been described in luteal cells (468). PRAP binds to the intracellular domain of the long form of the prolactin-R, but not to the short form. Expression of PRAP is upregulated by estrogen and prolactin (469). Structurally, PRAP shows 89% homology with a newly characterized form (type 7) of 17β -hydroxysteroid dehydrogenases/ 17 -ketosteroid reductases (17 -HSD), suggesting that PRAP may be an enzyme catalyzing the conversion of estrone to estradiol (1324).

3. Reproductive behavior

A) FEMALE RECEPTIVITY. There are data suggesting that prolactin influences reproductive behavior (476). In humans, high prolactin levels are associated with psychosomatic reactions including pseudopregnancy (1653). There

are prolactin-R in the ventromedial nucleus of the hypothalamus (375), an area which controls female sexual behavior. Coincidentally, iontophoresis of prolactin to this area increases local neuronal electrical activity (743). However, in rats, prolactin's precise action has been confounded by the multiplicity of experimental designs. For example, when given in the third ventricle of estrogen and progesterone-primed ovariectomized rats, prolactin diminishes lordosis frequency, an index of sexual receptivity (470). Though, when given in the midbrain of estradiol-treated ovariectomized rats, prolactin enhances sexual receptivity (738). Enhancement of endogenous prolactin secretion in response to dopamine antagonism has been reported to have no effect on mating behavior in females (1654), whereas elevation of prolactin secretion in response to the nursing stimulus diminishes sexual behavior (1655). In contrast, when the rat is sexually receptive in the afternoon of proestrus, suppression of the spontaneous release of prolactin with a dopamine agonist dramatically attenuates sexual receptivity (1884). Finally, although a null mutation of the prolactin-R gene in the mouse produces most of the defects associated with a deficiency of prolactin, such receptor-deficient females appear to mate normally with heterozygote or wild-type males (1358, 1680). Thus these data, taken together, do not provide a firm basis for assigning a well-defined role for prolactin in female sexual behavior. In contrast, it is clear that prolactin suppresses stereotypical male sexual behavior in rats (451, 896) and sheep (629).

B) PARENTAL BEHAVIOR. Probably the best-characterized prolactin-driven behaviors are the parental behaviors. In mammals, maternal behavior is the most extensively studied (218, 221, 1086, 1530). These include nest building as well as gathering, grouping, cleaning, crouching over, and nursing of the young by the mother. Although most widely described in rats, there is also an extensive literature on the effects of prolactin on the induction and maintenance of these maternal behaviors in mice, rabbit, hamsters, and sheep (219, 1329). It should be emphasized that prolactin, by itself, does not initiate maternal behavior, but merely decreases the latency to the onset of maternal behavior. Intracerebroventricular infusion of prolactin decreases the latency to initiation of maternal behavior in steroid-primed rats (220). The basic observation was made that nulliparous female rats treated with a pregnancy-like regimen of estrogen and progesterone for 10 days showed maternal behaviors with a mean latency of 5–6 days. Superimposition of prolactin treatment on the ovarian steroid regimen reduces the latency of maternal behavior to 1–2 days (217). In addition, hypophysectomized rats failed to display a facilitation of maternal behavior in response to the sequential steroid treatment. On the other hand, prolactin-hypersecreting pituitary transplants placed beneath the kidney capsule of hypophysectomized female rats kept on a maternal ovarian steroid replace-

ment regimen, dramatically advanced the onset of maternal behaviors (218). Suppression of endogenous prolactin release with bromocryptine prevents the onset of maternal behavior, whereas superimposition of prolactin promotes it (222). Prolactin may be exerting this effect by acting within the medial preoptic area of the hypothalamus (220, 1701).

Pup contact has been shown to induce transcription of the long-form prolactin-R mRNA in the brain of female rats. The effect of pup contact on prolactin-R expression is prevented by ovariectomy and hypophysectomy (1701). It seems that the effect of pup contact is not sex specific; the same induction of brain prolactin-R long-form mRNA expression and maternal behavior can be observed in pup-contacted male rats. Administration of prolactin promotes, while female contact suppresses, the effect of pup contact in males (1530). In mice carrying a germ line null mutation of the prolactin receptor gene, homozygous mutant and heterozygous mutant nulliparous females show a deficiency in pup-induced maternal behavior (1086). Moreover, primiparous heterozygous females exhibit a profound deficit in maternal care when challenged with foster pups. Such data suggest that pup contact is required for transcription of the prolactin receptor whose stimulation by prolactin eventuates in maternal behavior (1086).

Although not as widely studied, prolactin may have a role in paternal care as well. The data for this role are most convincing in fish and birds but somewhat less convincing in mammals (1574). Indeed, because prolactin is an "old" hormone, it could be that this role in our most recent ancestors has become somewhat redundant. This is emphasized by the significant stereotypical paternal role of nonmammalian vertebrates (e.g., the male sea horse is the incubator) and the almost nonexistent role in most mammals.

C) PROLACTIN-R IN THE HYPOTHALAMUS. Although the brain contains mainly the long isoform of the prolactin-R, the hypothalamus contains both the long and short forms (323). Within the hypothalamus, prolactin-R mRNA-containing neurons have been found in the anterior as well as the mediobasal hypothalamus (323–325). Also, the mRNA of the long form of prolactin-R is found within the periventricular, paraventricular, supraoptic, arcuate, and ventromedial nuclei of the hypothalamus as well as the medial preoptic area (112). Immunocytochemical data support these observations by showing that these hypothalamic areas contain prolactin-R protein as well (1028, 1415, 1495). Expression of prolactin-R in the brain increases with age (325, 993, 1241), exposure to estrogens (1264, 1598), elevation in serum prolactin levels, and by pup contact (1700).

Few studies have examined the signal transduction pathways specifically activated upon binding of prolactin to its receptor in the CNS. Preliminary data from our

laboratory indicate that systemic administration of prolactin results in nuclear translocation of STAT5 in neurons of the mediobasal hypothalamus. This suggests that the signal transduction pathways coupled to prolactin-R in CNS neurons are similar to those described in peripheral tissues. Prolactin also increases the expression of NGFI-A, NGFI-B, *c-fos*, and *c-jun* in numerous populations of CNS neurons, among them the tuberoinfundibular (TIDA) neurons of the arcuate nucleus (1524).

B. Homeostasis

Aside from its actions on reproductive processes, prolactin plays a role in maintaining the constancy of the internal environment by regulation of the immune system, osmotic balance, and angiogenesis.

1. Immune response

Prolactin is a common mediator of the immunoneuroendocrine network, where nervous, endocrine, and immune systems communicate with each other (631). Prolactin plays a significant role in regulation of the humoral and cellular immune responses in physiological as well as pathological states, such as autoimmune diseases (253, 1295, 1850).

The earliest evidence that prolactin plays a role in the immune response was the demonstration in 1972 that exogenous prolactin enhanced thymic function in prolactin-deficient dwarf mice (314). Shortly thereafter, Nagy and Berczi (1269) found that hypophysectomy or suppression of prolactin secretion with bromocryptine (1273) led to attenuation of humoral or cell-mediated immunity that could be reversed by treatment with exogenous prolactin. A large number of immune perturbations were found to be associated with prolactin deficiency (148, 1269–1273).

As noted in two recent reviews (1145, 1871), prolactin stimulates mitogenesis in both normal T lymphocytes (1828) and the Nb2 lymphoma cell line (1622). It should not be surprising that prolactin affects lymphocytes since prolactin-R has been detected on human peripheral lymphocytes (1517–1519) and their mRNA expression is regulated by prolactin itself (442). Moreover, effects of prolactin on lymphocytes may involve interleukin (IL)-2 since T-lymphocyte activation by IL-2 requires prolactin (344, 712). Interestingly, prolactin's site of action for modifying the effects of IL-2 on lymphocytes appears to be the nucleus (343). Prolactin is also required for mitogen-stimulated proliferation of lymphocytes (741, 757, 758). Nb2 cells, derived from immature T lymphocytes, are dependent on the mitogenic activity of prolactin (1622, 1713). Indeed, this property has served as the basis for a highly sensitive, specific bioassay for prolactin. However, there is not uniform agreement on the role of prolactin in hematopoiesis. Although targeted disruption of the pro-

lactin gene leads to numerous defects in prolactin-dependent events such as lactation, there is no difference between homozygotes and heterozygotes in the frequency of B- and T-cell antigen expression (790). Such results argue that prolactin does not play an indispensable role in primary lymphocyte differentiation or its absence during development can be compensated by other factors.

The role of prolactin in the immune response of the organism is a matter of continuing concern. It appears that immune responses *in vivo* are enhanced by prolactin. For example, prolactin-secreting pituitary grafts placed beneath the kidney capsule (1270) or administration of prolactin (1272) restores dinitrochlorobenzene-induced contact dermatitis impaired by hypophysectomy. On the other hand, skin allograft transplants elevate serum prolactin (725). During graft rejection, lymphocytic prolactin gene expression is also upregulated (1601). Moreover, elevated serum prolactin levels induced by skin allografts can be suppressed by either bromocryptine or an antilymphocytic serum (1505). However, only antilymphocytic serum prolongs the survival time of the graft (1505). These data suggest that lymphocytic prolactin plays a specific role in skin graft rejection and may play a role in other transplantation responses as well (764).

Immunocytochemical demonstration of prolactin-R on T and B lymphocytes (1769) was followed by detection of mRNA encoding the short and long prolactin-R isoforms in the thymus, spleen, lymph nodes, and bone marrow of both rats and mice (1020). Expression of prolactin-R isoforms was more extensively mapped in rat splenocytes and thymocytes from birth to adulthood (703), as well as during the estrous cycle, pregnancy, and lactation (704). Prolactin's functions are the most extensively described and reviewed in the Nb2 cell line (1920). This cell line also expresses an intermediate (393 amino acid) isoform of prolactin-R (184). In Nb2 lymphocytes, activation of the prolactin-R is associated with (945) 1) rapid tyrosine phosphorylation of STAT5a, STAT5b, STAT1 α , and STAT3; 2) rapid and selective formation of STAT5a/b heterodimers; 3) marked Ser, but not Thr phosphorylation of STAT5a and STAT5b; and 4) the appearance of two qualitatively distinct STAT5 protein complexes that discriminate between oligonucleotides corresponding to the prolactin response elements of the β -casein and interferon regulatory factor-1 gene promoters (945).

2. Osmoregulation

One of the least understood actions of prolactin is regulation of solute and water transport across mammalian cell membranes (1602). Studies in this area were motivated by the finding in lower vertebrates that prolactin stimulates solute transport across cell membranes and thus could be an osmoregulatory hormone (153). Some of

the actions in mammals are easier to envision in a physiological perspective than others. For example, prolactin exerts a host of activities on transport of solute across mammary epithelial cell membranes. In keeping with its lactogenic properties, among the earliest discoveries was the observation that prolactin decreases the transport of sodium and increases the transport of potassium across mammary epithelial cells taken from bromocryptine-treated rabbits (534, 535). Similarly, prolactin stimulates the uptake of amino acids by the rat mammary gland (1825) as well as the uptake of the nonmetabolizable amino acid α -aminoisobutyric acid by mouse mammary explants (1480). The requirement of such prolactin-driven solute movement for lactation has not been described. Prolactin also affects water transport across amniotic membranes. It stimulates water transport across guinea pig and sheep amnion (1114) but inhibits it in human amnion (1026). Prolactin is responsible for fluid (1447), sodium, chloride (1102–1104), and calcium (1365) transport across intestinal epithelial membranes. Correlation between sweat chloride and prolactin concentrations (1492) may implicate prolactin as one of the possible pathogenic factors in cystic fibrosis (968).

Although not examined in a systematic manner, it seems likely that the enhanced solute transport during late pregnancy (205) might be a mechanism whereby prolactin contributes to the preparation by the pregnant mother for subsequent lactation. A similar teleological argument can be made for the observation that prolactin acts on the proximal convoluted tubule of the renal nephron to promote sodium, potassium, and water retention (1685). These data, taken together, argue for the need for systematic studies on the role of prolactin on fluid and solute transport in a physiological context.

3. Angiogenesis

Angiogenesis, the development of blood vessels, is inhibited by proteolytic fragments of native prolactin (333). This antiangiogenic activity is inherent to the 16-kDa fragment (334). In fact, there are specific, high-affinity, saturable binding sites for the 16-kDa fragment of prolactin on capillary endothelial cells (336). The 14-kDa fragment shares the antiangiogenic activity of the 16-kDa fragment (335). In contrast, it has recently been found that intact human prolactin, placental lactogen, and growth hormone have angiogenic activities (1695). Although a physiological significance has not been ascribed to these opposing effects, it seems likely that there may be a therapeutic use for prolactin fragments as local inhibitors of tumorigenesis, or conversely, a role as pathological effector through its antiangiogenic actions.

VI. PATTERNS OF PITUITARY PROLACTIN RELEASE

When the release of prolactin is assessed at the single-cell level, the pattern of prolactin secretion of individual lactotrophs shows sexual dimorphism. In general, slightly more than half the lactotrophs of female rats secrete prolactin in a continuous pattern, whereas those of males secrete in a discontinuous or intermittent pattern (297). In the following sections we summarize the patterns of prolactin secretion at the level of the whole organism under different physiological and experimental conditions.

A. Circadian Rhythm of Prolactin Secretion

Plasma concentrations of prolactin are the highest during sleep and the lowest during the waking hours in humans (1380, 1555). Recent human volunteer experiments prove, however, that this rhythm of prolactin secretion is maintained in a constant environment independent of the rhythm of sleep (1848), although with considerably larger amplitude in women than men. These data indicate that the rhythm of daily prolactin release in humans is a true circadian rhythm that may be generated by the suprachiasmatic nuclei of the hypothalamus (1848).

There is ample chronobiological evidence that the temporal organization of prolactin secretion is controlled by circadian input in rats as well (167, 951). The rhythm of prolactin release is maintained in constant environment and abolished by lesion of the suprachiasmatic nuclei in rats (167, 168). In contrast to humans, there is a tight relationship between sleep patterns and prolactin levels in rats. Experimental data suggest that high prolactin levels may be the cause rather than the result of change in sleep patterns. In rats, using either injection of prolactin (1496) or implantation of anterior pituitary grafts to render the animal hyperprolactinemic (1332), high prolactin levels increase the duration and frequency of rapid-eye-movement sleep (REMS), thus leading to the idea of a functional relationship between nocturnal elevations of prolactin and REMS. There is some evidence that vasoactive intestinal polypeptide (VIP), a potent prolactin-releasing peptide, may also be involved in REMS (863, 1333). Immunoneutralization of circulating prolactin blocks systemically administered VIP-enhanced REMS (981, 1331). However, immunoneutralization of endogenous circulating prolactin only slightly attenuates spontaneous REMS, suggesting that central rather than systemic prolactin may be the physiological effector (981, 1331). Release of prolactin associated with REMS was also described in humans (1556). However, slow-wave sleep (SWS) (1848) also appears to be associated with nocturnal prolactin secretion in humans (1055).

There is ample evidence (see sect. VIIA1A) that dopaminergic tone of hypothalamic origin that exerts inhibitory effect over prolactin secretion (140) also changes throughout the day (420, 1027). It has been shown that dopaminergic activity in the median eminence shows daily changes, strongly suggesting a daily rhythm of dopamine levels in the long portal vessels reaching the anterior lobe of the pituitary gland (1101, 1606, 1903). According to this daily rhythm, the dopaminergic tone of TIDA neurons decreases before the daily elevation in prolactin levels (1101). The presence of this daily rhythm of TIDA neuronal activity in female rats has been verified with various ovarian steroid backgrounds (1606, 1607, 1903). It has been demonstrated that a similar pattern in immediate early gene expression exists in neuroendocrine dopaminergic neurons of female rats in various reproductive states (1027, 1029). These data, as well as experiments conducted in constant environment and manipulations of suprachiasmatic input (1101, 1100, 1606), strongly suggest that the daily rhythm exhibited by neuroendocrine dopaminergic neurons is endogenous in nature and entrained by light.

Hypothalamic oxytocin, which has been identified as a potential PRF, plays an important role in maintaining the endogenous prolactin-stimulatory rhythm (71, 73, 75–77). Indeed, in rats treated with a dopamine antagonist at various times of day to unmask a rhythm of prolactin secretion (71), administration of an oxytocin antagonist abolishes the rhythm (74). Since these initial findings, numerous other candidates of central origin have emerged as possible regulators of circadian release of pituitary prolactin (813, 1858, 1912, 1919).

B. Patterns of Prolactin Secretion in Different Reproductive States

1. Lactation

The best-known physiological stimulus affecting prolactin secretion is the suckling stimulus applied by the nursing young. This has been characterized as a classical neuroendocrine reflex. Just as muscle contraction evoked by an electrochemical stimulus is described as a stimulus-contraction reflex, one can describe the release of prolactin in response to the nursing young as a stimulus-secretion reflex. In rats, blood prolactin concentrations begin to rise within 1–3 min of initiation of nursing, peak within 10 min, are sustained at a constant level as long as nursing continues, and fall when nursing is terminated (684). The expression of prolactin mRNA in the pituitary gland follows the same pattern (1016). Cessation of the suckling stimulus results in termination of prolactin secretion, and the rate of decrease in blood prolactin levels is proportional to the metabolic clearance rate of the hormone (683, 1274). Moreover, the amount of prolactin

released is related to the intensity of the stimulus as it is somewhat commensurate with the number of pups nursing (1182). These parameters appear to be similar in all mammals with only subtle exceptions. For example, in the rhesus monkey, nursing induces a biphasic release of prolactin (575). In humans (443, 1683), cattle (1019), and rodents (78, 887), the prolactin-secretory response to nursing is superimposed by the endogenous circadian rhythm of prolactin secretion; that is, the same intensity of suckling stimulus can elevate prolactin levels more effectively at certain times of day when the circadian input enhances the suckling stimulus-evoked secretory response.

The control of suckling-induced prolactin secretion is somewhat enigmatic. It is certain that the suckling stimulus results in a diminution of the amount of dopamine released into portal blood (404) and arriving at the anterior pituitary gland (1281). Thus the suckling stimulus essentially relieves the lactotroph from tonic inhibition. However, the amount of prolactin released in response to suckling is far greater than that resulting from pharmacological or surgical interference with dopamine input to the pituitary gland. This argues for a prolactin-releasing input superimposed on the diminution of the inhibitory input provided by suckling-induced suppression of dopamine. Indeed, there are many candidates for a PRF stimulated by suckling. For example, passive immunization against TRH inhibits suckling-induced prolactin release (405, 1603). However, the supremacy of TRH in regulating suckling-induced prolactin release is not universally accepted (1481). The intriguing observation that posterior pituitary lobectomy abolishes suckling-induced prolactin secretion has led to the suggestion that the posterior lobe transfers a PRF to the anterior lobe through the short portal vessels (827, 827, 1256). The identity of the posterior pituitary PRF has eluded many investigators. Among the obvious candidates for PRF are vasopressin (1283) and its glycopeptide vasopressin-neurophysin precursor (1276, 1277), oxytocin (76, 78) and even dopamine of posterior pituitary origin (1281). However, there is not universal agreement on the candidacy of the vasopressin-neurophysin glycopeptide (829), and there is some indication that the PRF may be a heretofore unidentified posterior pituitary (27, 766, 1059) or intermediate lobe (27) peptide. It is safe to say at this time that, although we have several plausible candidates, none has emerged as the undisputed suckling-induced PRF.

2. Estrous and menstrual cycles

The secretion of prolactin has been most extensively studied during the estrous cycle of the rat. The secretion of prolactin throughout most of the estrous cycle appears low and unchanging from the evening of estrus through the morning of the next proestrus (254, 608, 1296, 1647).

During the afternoon of proestrus, a preovulatory surge of prolactin secretion occurs, which is similar in timing to that of LH (1647). Although the LH surge on proestrus is symmetrical, the surge of prolactin consists of a rapid, sharp peak followed by a prolonged plateau and an extended termination phase (60, 1259). Although most laboratories have reported a single surge of prolactin on proestrus (608, 1296, 1647), others have reported a secondary surge on estrus (254) or continuously elevated prolactin levels on proestrus, estrus, and metestrus (34). Because these latter results may have been caused by the method and frequency of blood collection, it is generally accepted that the afternoon of proestrus is the only time that a major surge of prolactin secretion occurs.

Because the events of the rodent estrous cycle and those of the primate menstrual cycle share some common controls, it would not be illogical to expect a midcycle surge of prolactin during the menstrual cycle that coincides with that of luteinizing hormone. However, only one study finds a small, late follicular phase rise of prolactin secretion culminating in a midcycle peak that is only 50% greater than prolactin levels of the early follicular phase (1812). Such small changes can easily be overshadowed by pulsatile changes, thus leading to a failure to detect significant variations at midcycle in individual samples.

It is clear that the rising blood levels of estradiol signal the hypothalamo-pituitary axis to release this surge of prolactin on proestrus. Administration of an antiserum to estradiol on the morning of diestrus-2 blocks the proestrous surge of prolactin (1302). A single injection of estradiol given to ovariectomized rats results in daily surges of prolactin that are similar in timing to the proestrous surge of prolactin (1297). These data suggest the existence of a circadian hypothalamic timing mechanism that is enhanced by estradiol. This mechanism by which estradiol induces a proestrous surge of prolactin secretion probably involves actions at the preoptic area of the hypothalamus, since caudal transection of preoptic efferents (939) or lesion of the preoptic area (1369) block the estradiol-stimulated surge of prolactin secretion, while implantation of estradiol in the preoptic area stimulates a surge (1370). Indeed, ample evidence suggests that both forms (α and β) of the estrogen receptor are expressed by the neurons of the preoptic area (161, 195, 358, 995, 1039, 1388, 1869, 1925).

Progesterone administered on diestrus-3 of a 5-day cycle will advance the proestrous surge of prolactin by 1 day (1305). Moreover, progesterone enhances the magnitude of an estrogen-induced proestrus-like surge of prolactin in ovariectomized rats (259, 1911). However, the precise role of progesterone in the secretion of prolactin on proestrus has yet to be described.

Hypothalamic control of the preovulatory proestrous surge of prolactin is far from clear. Although it is clear that dopamine inhibits prolactin secretion and that re-

moval of the tonic dopaminergic inhibition results in enhanced prolactin secretion, the role of dopamine as a regulator of the proestrous surge of prolactin is contradictory. Hypothalamo-hypophysial portal blood concentrations of dopamine (140), the activity of tyrosine hydroxylase (287), the turnover of dopamine in the median eminence (411), and the subsequent concentration of dopamine in the anterior lobe of the pituitary gland (420) have been reported to decline on proestrus before the increase in prolactin secretion. On the other hand, others have reported no change in dopamine turnover at the same time (786, 1448). Similarly, dopamine receptors in the anterior pituitary have been reported to both increase (1384) and decrease (748) during the afternoon of proestrus. The source of dopamine controlling prolactin secretion is believed to be TIDA neurons with cell bodies in the arcuate nucleus of the hypothalamus and axons terminating in the median eminence. However, there is ample evidence that some of the dopamine arrives at the anterior lobe of the pituitary gland from the posterior lobe that contains axon terminals of tuberohypophysial dopaminergic (THDA) neurons whose cell bodies are found in the rostral part of the arcuate nucleus (63). In addition, dopamine may arrive from the intermediate lobe that contains axon terminals of periventricular-hypophysial dopaminergic (PHDA) neurons that reside in the hypothalamic periventricular nucleus (655, 656). The short portal vessels connecting the lobes of the pituitary gland may serve as the vascular pathway through which dopamine is transported to the anterior lobe from the neural and intermediate lobes of the pituitary gland. Indeed, the fact that posterior lobectomy results in a chronic elevation of prolactin secretion (1255) suggests a functional role for THDA neurons. However, data are unavailable to suggest a similar role for PHDA neurons.

Further muddying these waters is the fact that a prolactin-releasing hormone of hypothalamic origin must play a role in the surge of prolactin secretion on proestrus. Numerous candidates abound. TRH is one of the earliest proposed candidates. Passive immunoneutralization of endogenous TRH has been reported to partially inhibit (963) or delay the onset (788) of the proestrous surge of prolactin. Indeed, the concentration of TRH in portal blood is slightly elevated during the afternoon of proestrus (553). However, there is no distinct concomitant elevation in TSH secretion during the afternoon of proestrus (178) which, intuitively, should be expected to accompany the increase in prolactin secretion on proestrus. Similar to TRH, the concentration of oxytocin increases in portal blood during the afternoon of proestrus (1551). Hourly injections of an oxytocin antagonist block the proestrous surge of prolactin (867), and administration of an antiserum to oxytocin attenuates the estrogen-induced proestrus-like surge of prolactin (1537).

3. Mating and pregnancy

As noted earlier, prolactin is a luteotrophic hormone in the rat. Indeed, the unmated rat has an extremely short luteal phase due to the lack of sufficient prolactin to maintain the corpus luteum. However, if mating occurs or a copulomimetic stimulus is applied to the uterine cervix, the corpus luteum is rescued. It was assumed that the mating stimulus eventuated in elevated prolactin secretion. With the availability of the first radioimmunoassay for prolactin (1304), it was shown that mating did not induce constantly elevated prolactin secretion but rather twice daily surges of prolactin. If the rats are kept under 12:12-h dark-light cycles, with lights on at 0600 h, the diurnal surge of prolactin secretion begins in the afternoon (1300–1500 h), reaches peak values during the early evening (1700–1800 h), and returns to basal levels by 2400 h. The other surge, called nocturnal, begins by 0100 h, peaks by 0300–0700 h, and approaches baseline by 1100 h. These surges recur for 10 days if the mating is fertile and results in pregnancy (255, 1648), or persist for 12 days in pseudopregnancy when mating is sterile or copulomimetic (584, 1647). There are abundant data which show that the surges of prolactin cease after *day 10* of pregnancy due to the negative-feedback action of placental lactogen acting at both pituitary and hypothalamic levels (64, 649, 1755, 1756, 1760–1763, 1832–1834, 1838), the details of which are described in section VII C3.

Prolactin secretion stimulated by copulomimetic stimuli can be initiated and maintained independent of ovarian steroids (585). In contrast, the surges of prolactin secretion of pseudopregnancy end after *day 13* due to the diminishing secretion of progesterone from the waning corpora lutea coupled with the rising titers of estradiol from the newly developing ovarian follicles (645). Moreover, the nonpregnant uterus itself secretes an, as yet, uncharacterized factor, which inhibits prolactin secretion by acting directly on the lactotroph (647, 648, 650).

The areas of the hypothalamus upon which the mating stimulus acts to initiate this unique pattern of prolactin secretion have also been characterized (581, 705–707, 710, 920). The primary transduction pathway involves the pelvic nerve (275, 1509, 1874). Presumably, the mating stimulus is carried over spinal afferent pathways and enters the brain. Although the exact pathways in the entire brain have not been mapped, pharmacological and physiological studies have implicated various areas of the hypothalamus. On the basis of classical lesion and stimulation studies, it appears that the preoptic area of the hypothalamus contains two functional neuronal populations controlling prolactin secretion (581). In the unmated rat, one population is tonically active and inhibits the nocturnal surge of prolactin, whereas the other is inactive (581, 706). It appears that the uterine cervical stimulation of mating inactivates the former and activates the latter,

which eventuates in nocturnal and diurnal surges of prolactin secretion. Induction of the surges either by cervical stimulation or manipulation of the preoptic area requires an intact dorsomedial/ventromedial hypothalamic nucleus (707, 710).

The suprachiasmatic nuclei of the hypothalamus are responsible for the faithful timing of the mating-induced surges of prolactin (168), which are under the control of an endogenous circadian rhythm (167). After cervical stimulation, two daily decreases in the activity of neuroendocrine dopaminergic neurons of the hypothalamus occur (1029). It has been suggested that the hypothalamus produces a sex-specific stimulatory rhythm regulating prolactin secretion which is unmasked by the dopamine-lowering actions of the mating stimulus at the uterine cervix (71). It has been proposed that prolactin-releasing quanta of oxytocin are released twice each day into portal blood feeding the sinusoid capillaries of the anterior pituitary gland (73, 76). The timing of these events, the decrease in dopaminergic tone followed by an increase in the concentration of oxytocin in portal blood, corresponds to the release of prolactin in cervically stimulated animals (76). The key neurotransmitters regulating each of these oxytocin-dependent events are different. The early morning (nocturnal) oxytocin-mediated prolactin release is regulated by VIP, whereas the diurnal event seems to be dependent on serotonergic activation (73, 74, 77).

It has been argued that a luteotrophic mechanism, activated by a mating stimulus, is one of the more efficient systems governing reproduction (580). In rodents, it is advantageous for quick turnover of generations to shorten the luteal phase during estrous cycles when an ovulation is not associated with a fertile mating and conception, whereas an active luteal phase, preparing the uterus for implantation of an embryo, is only associated with a mating stimulus.

C. Prolactin Release in Response to Exteroceptive Stimuli

1. Light

A) CIRCADIAN PATTERNS. In photoperiodic mammals such as rats, light is an important regulator of prolactin secretion. Indeed, shifting of the light phase results in a coincidental shift of the proestrous surge (179), the estrogen-induced proestrus-like surge, and the mating-induced surges of prolactin in rats (1418). When placed in constant light, rats become acyclic (772). Complete removal of a photoperiod by placing the animals in constant light or through various means of light deprivation result in free-running proestrus-like surges of prolactin secretion in estrogen-treated ovariectomized rats (1418) and free-running mating-induced surges of prolactin secretion (167,

1418). These effects require an intact suprachiasmatic nucleus (168). These data point to the fact that these events are under the control of an endogenous circadian rhythm and that lighting periodicity entrains that rhythm.

B) SEASONAL PATTERNS. Prolactin secretion is also affected by variations of day length in seasonal mammals. In adult male hamsters, 2 mo of exposure to a short photoperiod (5 h of light, 19 h of darkness) causes testicular regression and a precipitous decline in release of prolactin (98, 170). Although testicular regression is blocked by transections dorsal or ventral to the hypothalamic paraventricular nucleus (845), the fall in prolactin secretion associated with short days is not (99). This may not be unexpected given that the effects of short photoperiod on testicular regression and blunting of prolactin secretion may be dissociated under certain regimens (455), thus suggesting two different levels of control for these two photoperiodic events. Indeed, the effect of shortened photoperiod on prolactin secretion can be reversed by infusion of VIP into the paraventricular nucleus of the hypothalamus (97).

In the ewe, another seasonal mammal, shortened days lead to a diminution of prolactin secretion (927). In rams, the effect presents itself within a week of exposure to the shortened photoperiod (1052). The effect of photoperiod is mediated by melatonin secreted from the pineal gland (385, 1431, 1432), transduced through the suprachiasmatic nucleus (1582), or acting directly on the pituitary gland (1050). Short days also diminish the activity of tyrosine hydroxylase and the content of dopamine in the median eminence (1738, 1816). However, this reduction in dopaminergic activity does not appear to have a direct effect on prolactin secretion (1817). In addition, dopamine does not mediate the suppressing effects of melatonin on prolactin secretion (1051, 1053, 1817).

It has been shown that photoperiodic information regulating postnatal prolactin secretion is transferred from mother to fetus in both sheep (488) and hamsters (1600). Pregnant ewes exposed to short days give birth to lambs that have lower serum prolactin concentrations than those of dams exposed to long days. Prenatal exposure of pregnant hamsters to short days results in male offspring producing higher prolactin concentrations than those from dams exposed to long days. Female hamster neonates are unaffected by altered prenatal photoperiod. These prolactin-secretory responses presumably involve maternal melatonin as affected by the photoperiod (1908, 1909). In fetal sheep, prolactin secretion is also affected by maternal photoperiod or melatonin (124, 1383). However, with increasing gestational age, the fetal hypothalamus appears to mask or suppress these effects (801). The basis for the return of fetal independence from maternal influence is not yet fully appreciated. It is possible that the varying paradigms of photoperiod exposure may have

engendered these seemingly paradoxical sequences of events.

2. Audition

Of the many environmental inputs controlling prolactin secretion, the effect of specific sounds is one of the most responsive and robust but the least studied (682, 1733, 1831). Recordings of ultrasounds of hungry pups stimulate prolactin secretion in lactating and virgin female rats (1733). This response is specific to ultrasounds generated by pups as adult ultrasound or background tape noise does not affect prolactin secretion. Although the basis for this response has not been studied, one can easily imagine its utility. Indeed, ultrasound-induced maternal prolactin secretion may be responsible for preparing the mammary gland for a subsequent suckling bout or the released prolactin is transported to the milk to act as a stimulator of the pups' development.

3. Olfaction

Of the chemical senses, olfactory stimuli play a robust role in prolactin secretion. Pheromones secreted by a male unfamiliar to the pregnant female will result in early loss of pregnancy in mice. This phenomenon is referred to as the Bruce effect, in recognition of its discoverer (229–231). The pheromonal signal is conveyed to the accessory olfactory bulb by the vomeronasal nerves, which synapse on the primary dendrites of mitral cells in glomeruli. The mitral cells, in turn, excite cells of the corticomедial amygdala (1038), which excite cells in the medial preoptic area of the hypothalamus and result in excitation of TIDA neurons of the arcuate nucleus (1037). The implication is that the loss of pregnancy occurs due to the dopamine-induced suppression of prolactin secretion (1503) and consequently its luteotrophic support. Indeed, replacement of prolactin reverses the abortive effect of the unfamiliar male's pheromones (453, 454).

In lactating female rats, the odor of the pups placed beneath the mother's cage stimulates prolactin secretion (1183, 1184) but, interestingly, inhibits milk secretion in late lactation (682). On the other hand, when placed next to the mother, pup odors are stimulatory to both prolactin secretion and milk secretion (682). Thus the prolactin secretory mechanism is more sensitive than the galactopoietic mechanism to pup odor in late lactating rats.

4. Stress

It is clear that prolactin secretion is dramatically affected by "stress." A myriad of stresses have been used to characterize such effects on prolactin secretion. These include, but are not limited to, the following: ether stress (116, 667, 866, 876, 893, 1077, 1105, 1200, 1257, 1296, 1913), restraint stress (416, 590, 598, 883, 923, 944, 1446),

thermal stress (1782a), hemorrhage (274, 883), social conflict (817), and even academic stress in humans (1108).

Because, in most cases, the prolactin-secretory response (i.e., stimulation or inhibition) differs depending on the nature of stress, one cannot describe a unitary mechanism but must define the mechanism associated with each specific stress modality.

The prolactin-secretory response to ether stress has been reported to differ during the reproductive state of the rat. During diestrus of the estrous cycle, ether stress increases prolactin secretion (1296). However, there is no universal agreement as to the nature of the responses at proestrus. For example, ether stress has been reported to increase (855), decrease (1231), or have no effect on (1296) prolactin levels during the afternoon of proestrus.

Restraint stress applied before the surge of prolactin secretion on the afternoon of proestrus enhances the surge while application during the surge attenuates it (1649). Similarly, restraint stress suppresses the proestrus-like estrogen-induced afternoon surge of prolactin in ovariectomized rats (598). It has also been reported that restraint stress suppresses the nocturnal surge of prolactin during pseudopregnancy (1221) or pregnancy (1223). Because dopamine is the hypothalamic neurohormone tonically inhibiting prolactin secretion, it is intuitively obvious that dopamine would also be implicated in the stress-mediated effects on prolactin secretion. Indeed, pimozide, a dopamine antagonist, prevents restraint stress-induced decrease in the estrogen-induced afternoon proestrus-like surge of prolactin (598). Moreover, a modest increase in TIDA neuronal activity accompanies restraint stress in estrogen-treated (1224) but not in cycling or lactating (923) rats. Other hypothalamic substances implicated in the prolactin-secretory stress response include serotonin (865, 876), histamine (953, 956), *N*-methyl-D,L-aspartic acid (214), atrial natriuretic peptide (571), β -endorphin and dynorphin (1407), oxytocin (956), and vasopressin (953).

The physiological importance to the organism of the prolactin-secretory response to stress is rather elusive. It is clear that neither the stress-induced attenuation of the proestrous prolactin surge affects the estrous cycle of the rat (1222) nor reduction of the mating-activated nocturnal surge has any effect on the outcome of a pregnancy or pseudopregnancy in the rat (1223). Given the finding of a role for prolactin in humoral or cell-mediated immunity, it can be argued that the prolactin-secretory response to stress has an immunomodulatory function protecting the organism from the consequences of stress (597). Although there are no experimental data to support this hypothesis, it has been suggested that prolactin secretion, particularly during lactation, acts as a protective factor in stress-induced gastric ulcers (464). Teleology would advise that other roles, probably in maintaining homeostatic balance affected by other stress hormones, exist as well.

VII. REGULATION OF PITUITARY PROLACTIN SECRETION

Prolactin secretion is affected by a large variety of stimuli provided by the environment and the internal milieu (Fig. 3). The most important physiological stimuli that elevate pituitary prolactin secretion are suckling (1298, 1732), stress (1296, 1298), and increased levels of ovarian steroids, primarily estrogen (1298, 1301). Such stimuli are transduced by the hypothalamus which elaborates a host of PRF and prolactin-inhibiting factors (PIF) (Fig. 3). In mammals, the control exerted by the hypothalamus over pituitary prolactin secretion is largely inhibitory (140). On the other hand, the hypothalamus is also involved in the acute stimulatory control of prolactin secretion by removal of the inhibition (disinhibition) and/or superimposition of brief stimulatory input. In addition, prolactin secretion is also influenced by numerous factors released by the lactotrophs themselves (autocrine regulation) or by other cells within the pituitary gland (paracrine regulation) (Fig. 3).

A. CNS

The general and well-accepted view is that lactotrophs have spontaneously high secretory activity. Therefore, pituitary prolactin secretion is under a tonic and predominant inhibitory control exerted by the hypothalamus. This view is based on the following observations: 1) surgical disconnection of the pituitary gland and the medial basal hypothalamus (median eminence lesion or pituitary stalk section) results in gradual increase in plasma prolactin that reaches a plateau within a week after these surgeries (79, 174, 899, 1004), 2) prolactin secretion occurs at a high spontaneous rate when the anterior lobe is transplanted to a site that has no vascular or neural connection to the hypothalamus (e.g., under the kidney capsule) (523, 524), or 3) when pituitary cells are cultured *in vitro* (1298, 1299, 1590). Thus it appears that prolactin secretion is severely restrained *in vivo* by the action of hypothalamic PIF.

The precise characteristics of the regulation of prolactin secretion are fundamentally determined by the physiological status of the animal. Therefore, for the purpose of this review, we will make reference to the animal model used in the studies involved. To narrow the scope of this review, specific attention will be given to animal models with obvious physiological significance, such as the estrous cycle of female rats (proestrous prolactin-secretory surge), pregnant/pseudopregnant female rats (daily nocturnal and diurnal prolactin surges), lactating female rats (suckling-induced prolactin secretion), and male rats (stress-related prolactin secretion). Different experimental models emphasizing particular stages of the




FIG. 3. An overview of the regulation of prolactin secretion. Prolactin secretion is paced by a light-entrained circadian rhythm, which is modified by environmental input, with the internal milieu and reproductive stimuli affecting the inhibitory or stimulatory elements of the hypothalamic regulatory circuit. The final common pathways of the central stimulatory and inhibitory control of prolactin secretion are the neuroendocrine neurons producing prolactin inhibiting factors (PIF), such as dopamine (DA), somatostatin (SST), and γ -aminobutyric acid (GABA), or prolactin releasing factors (PRF), such as thyrotropin releasing hormone (TRH), oxytocin (OT), and neurotensin (NT). PIF and PRF from the neuroendocrine neurons can be released either at the median eminence into the long portal veins or at the neurointermediate lobe, which is connected to the anterior lobe of the pituitary gland by the short portal vessels. Thus lactotrophs are regulated by blood-borne agents of central nervous system or pituitary origin (α -melanocyte stimulating hormone) delivered to the anterior lobe by the long or short portal veins. Lactotrophs are also influenced by PRF and PIF released from neighboring cells (paracrine regulation) or from the lactotrophs themselves (autocrine regulation).

estrous cycle (e.g., ovariectomized females with various ovarian steroid replacement) are also considered.

1. Biogenic amines

A) DOPAMINE. *I) Dopamine is the major PIF.* Observations that drugs affecting catecholamine metabolism also alter prolactin secretion (79, 361) and the fact that dopamine is present in high concentration in both the median eminence (593) and the hypophysial stalk blood (140, 142, 621, 1422) led several investigators to conclude that dopamine is the major physiological hypothalamic PIF. Ample experimental evidence shows that dopamine inhibits prolactin release from pituitary lactotrophs both in vivo and in vitro (1096–1098). Subsequently, dopamine receptors have been detected on pituitary membranes (226, 369, 373, 639). Dopamine receptors located on lactotroph membranes belong to the D_2 subclass of the

dopamine receptor family (279, 280, 1171). Recent evidence emphasizes the physiological importance of hypothalamic dopamine in regulating lactotroph function. Mice with a disrupted D_2 receptor gene have anterior lobe lactotroph hyperplasia and hyperprolactinemia (925, 1526). The hyperplasia ultimately leads to lactotroph adenoma in both male and female D_2 knockout mice (92).

II) Anatomy of the neuroendocrine dopaminergic neurons. Using the Falk and Hillarp amine-fluorescence method (533), Dahlström and Fuxe (379) mapped the catecholaminergic neuron populations and classified them as A1 to A15 according to their rostrocaudal distribution in the CNS (379). The dopaminergic neurons of the periventricular and arcuate nuclei of the medial-basal hypothalamus (termed A14 and A12, respectively) provide dopamine to the pituitary gland (655, 656, 783, 922).

The A14 and A12 dopaminergic neuron populations




FIG. 4. Neuroendocrine dopaminergic neuron populations in the rat hypothalamus. Perikarya of the periventricular hypothalamic dopaminergic (PHDA) neurons (A14 cell group) are located in the periventricular nucleus, and their axons terminate in the intermediate lobe of the pituitary gland (IL). The arcuate nucleus (A12 cell group) contains the perikarya of two distinct neuroendocrine dopaminergic neuron populations. The tuberohypophyseal dopaminergic (THDA) neurons project from the rostral arcuate nucleus both to the neural (NL) and intermediate (IL) lobes of the pituitary gland. From the dorsomedial part of the arcuate nucleus the tuberoinfundibular (TIDA) neurons project to the external zone (EZ) of the median eminence (ME). TIDA terminals release dopamine into the perivascular spaces of the fenestrated capillary loops of the EZ, giving rise to the long portal veins (LP). The long portal veins empty into the sinusoids of the anterior lobe (AL) of pituitary gland. Small short portal (SP) veins connect the fenestrated capillaries of the neural and intermediate lobes with the anterior lobe sinusoids. Thus dopamine of TIDA, THDA, and PHDA origin can reach lactotrophs, located in the anterior lobe of the pituitary gland. III.v, 3rd ventricle; OC, optic chiasma; MB, mammillary body; IZ, internal zone of the median eminence; PS, pituitary stalk. [From Lerant et al. (1029). Copyright The Endocrine Society.]

can be divided into three anatomically and functionally different systems based on the rostrocaudal distribution of the dopaminergic perikarya and their terminal fields in the distinct lobes of the pituitary gland (Fig. 4). TIDA neurons are located mostly in the dorsomedial part of the arcuate nucleus (A12) and project to the external zone of the median eminence (922) where dopamine is released into the perivascular space surrounding the capillary loops of the pituitary portal system. The intermediate and neural lobes of the pituitary gland are innervated by two virtually independent groups of hypothalamic dopaminergic neurons (130, 656). The periventricular hypophyseal dopaminergic (PHDA) neurons (A14) are located in the hypothalamic periventricular nucleus and terminate in the intermediate lobe (655). On the other hand, THDA neurons are found in the rostral arcuate nucleus (A12) between the previous two cell groups and project to both the intermediate and the neural lobe of the pituitary gland (783, 784). The microanatomy and biochemistry, as well as the distinct physiological functions of the TIDA and THDA neurons, were first described by Holzbauer and Racke (783). Subsequent studies provided more detailed morphological and functional characterization of the three neuroendocrine dopaminergic systems of the hypothalamus (419, 657, 759, 922, 1076, 1279, 1281, 1373, 1414).

III) TIDA neurons and their regulatory properties. Dopamine of TIDA origin, delivered through long portal vessels into the sinusoid capillaries of the anterior lobe, is considered the major physiological regulator of prolactin secretion (1024).

TIDA neurons have unique regulatory properties

compared with other dopaminergic neurons of the CNS, like the nigrostriatal (NSDA) and mesolimbic (MLDA) dopaminergic neurons (1368). Moreover, there are significant differences between the regulatory properties of TIDA neurons in males and females (1368). In females, basal TIDA activity (412, 414) and responsiveness to prolactin are higher than in males (414). This may be explained by tonic inhibition of the activity of TIDA neurons in male rats by endogenous opioids, which is not present in female rats (1123). TIDA neuronal activity is decreased by ovariectomy and increased by orchidectomy (708). These effects were reversed by appropriate steroid treatment (709). There are sexual differences in the response to stress, which decreases TIDA activity in females, but not in male rats (415). Because all of the above experiments were performed in vivo, it cannot be firmly concluded that the sexual specificity was directly at the dopaminergic neuron.

Due to the preponderant influence of dopamine on prolactin secretion at the pituitary level and the well-established feedback action of prolactin on these neurons, it is difficult to separate/isolate the central effects of dopamine from its direct influence on prolactin secretion. Therefore, until recently, the role of dopamine as neurotransmitter in regulation of prolactin secretion was poorly documented. Nevertheless, dopamine can affect prolactin secretion by acting centrally, in addition to its direct action on the lactotroph (155, 156, 474, 475, 486, 487). In male rats, specific D_1 antagonists elevate, whereas D_1 agonists (88) decrease dihydroxyphenylacetic acid (DOPAC) content in the median eminence (155, 475),

indicating D₁ receptor-mediated inactivation of TIDA neurons. Because D₁ receptors have been shown to be coupled to G_o or G_s proteins (1401) that stimulate adenylate cyclase activity, these data suggest D₁-mediated decrease in TIDA activity is mediated by activation of an inhibitory neuron innervating TIDA neurons.

Other pharmacological experiments suggest that TIDA neurons receive stimulatory input through D₂ receptors (156, 474, 486). The latter influence is thought to be mediated by inhibiting inhibitory (possibly dynorphinergic) interneurons (1124). In earlier pharmacological experiments, acute administration of less selective dopamine agonists (e.g., apomorphine) or antagonists (e.g., haloperidol) failed to alter the activity of TIDA neurons (413, 539). On the basis of recent observations made by using pharmacological probes more selective at different dopamine receptor subtypes, it has been concluded that a simultaneous activation or inhibition of D₁ and D₂ receptors cancels the actions mediated by these receptors on TIDA neurons (475).

IV) THDA and PHDA neurons. The role of dopamine released from PHDA and THDA axon terminals at the neurointermediate lobe has attracted more attention during the past few years. For example, it has been reported that the activity of both PHDA and THDA neurons, unlike the TIDA system, is independent of circulating gonadal steroids (1279). Moreover, there are no marked differences between male and female rats in the activity of THDA neurons (759). In addition, it has recently been found that TIDA and THDA neurons, but not PHDA neurons, regulate the control of the secretion of prolactin in response to the suckling stimulus (1281). Surgical removal of the neurointermediate lobe results in a three- to fourfold increase in basal plasma prolactin levels in male, as well as cycling and lactating female rats (143, 1406). Consistent with this finding is the report that electrochemically detectable dopamine in the anterior pituitary gland is reduced after surgical removal of the posterior lobe (1248). Moreover, in lactating rats, basal- and suckling-induced pituitary prolactin secretion is suppressed after water deprivation (1279). Because the THDA system is selectively activated by dehydration (30, 785, 1443, 1764), it is conceivable that dopamine, released by nerve terminals in the neurointermediate lobe of the pituitary gland, may travel to the anterior lobe through the short portal vessels to affect prolactin secretion. Indeed, haloperidol (a D₂ dopamine receptor antagonist) pretreatment can block dehydration-induced plasma prolactin depletion (1279). Thus a reduction or an elevation of dopamine level in blood carried by the short portal vessels may provide a mean by which prolactin secretion of lactotrophs can be affected during lactation.

It is well known that dopamine, released from terminals of PHDA neurons in the intermediate lobe (19, 19, 493, 1711), tonically inhibits the secretion of α -melano-

cyte stimulating hormone (α -MSH) from melanotrophs of the intermediate lobe (201, 1054, 1747). Therefore, assuming that PHDA neurons participate in the regulation of prolactin secretion, one can expect parallel changes in plasma levels of prolactin and α -MSH during an acute stimulus like suckling (1811). However, it has been clearly shown that there is no change in plasma α -MSH in response to nursing (933). Therefore, an acute diminution in the activity of PHDA-regulated α -MSH secretion does not occur during the suckling stimulus. However, the observations that the dopamine concentration in the neurointermediate lobe is lower and the basal level of plasma α -MSH is higher in lactating than in cycling female rats (1811) indicate some supporting role for PHDA neurons in the regulation of prolactin secretion during lactation.

V) Is dopamine the sole PIF? The question whether dopamine is the sole PIF mediating tonic hypothalamic inhibition is still unsettled. In early studies of this issue, investigators reported that the amount of dopamine in stalk blood is sufficient to account for only about two-thirds of the prolactin inhibition normally observed (403, 1299). This conclusion was based on quantitative studies in which dopamine was replaced in rats depleted of endogenous dopamine with the tyrosine hydroxylase (TH, the rate-limiting enzyme of dopamine synthesis) inhibitor α -methyl-*para*-tyrosine (α -MpT), and the rate of dopamine infusion was set to mimic the levels measured in stalk blood of intact animals (621, 1024). Although the inhibitory influence of dopamine on pituitary prolactin secretion is established beyond a reasonable doubt, an inverse relationship between hypothalamic secretion of dopamine and pituitary secretion of prolactin does not always exist. For instance, the dopamine level in hypophysial stalk plasma is five to seven times lower in males than in females (140, 142, 696), but plasma levels of prolactin are not much different. Moreover, a mirror-image relationship between dopamine concentrations of the median eminence or the portal blood and plasma prolactin has also not been demonstrated in lactation (404, 1421, 1423). The apparent inconsistency between dopaminergic activity and prolactin secretion could easily be resolved by assuming that additional PIF (e.g., GABA and somatostatin) may also contribute to the negative control of prolactin secretion. These alternative PIF candidates (listed in Table 2) are discussed later in this section.

VI) Prolactin secretion due to dopamine withdrawal. The most plausible mechanism for an increase in prolactin release is disinhibition, i.e., that a given stimulus reduces the tonic inhibitory effect of the hypothalamus thus freeing the pituitary gland to express its inherent capacity to secrete prolactin spontaneously at a very high rate (1024, 1299, 1301). Indeed, treatment of rats with sufficient amounts of α -MpT to completely suppress dopamine secretion into hypophysial stalk blood results in

an increase in prolactin secretion (621, 694) quantitatively similar to those observed after suckling or stress. Similar results can be obtained in vitro when removal of dopamine infusion results in a rapid increase of prolactin release (530). Thus disinhibition is a potential mechanism by which neurogenic stimuli induce release of prolactin. However, conflicting results have been reported about the change in dopaminergic neuronal activity in response to the suckling stimulus. Dopaminergic neuronal activity has been described to increase (595), remain unchanged (1240, 1835), or slightly decrease (322, 1181, 1219, 1585) during a single bout of suckling. Most direct studies have been those in which the mammary nerve was stimulated electrically to simulate suckling and dopamine release was detected in hypophysial stalk blood (404, 1423) or in the median eminence with an electrochemical probe (1421). Using this experimental paradigm, only a brief (3–5 min) 60–70% decline in dopamine release was observed (404, 1421, 1423). This decline was followed by a series of rapid pulses of dopamine above the baseline which lasted for the duration of mammary nerve stimulation (1423). These results have led to the conclusion that a decrease in dopamine outflow from the hypothalamus itself is insufficient to account for the suckling-induced prolactin release. However, recent experiments have clearly demonstrated that dopamine content of the inner zone of the anterior lobe obtained from lactating rats is reduced after a 10-min suckling stimulus (1281). This finding seems to explain the previous controversial results, since the inner zone of the anterior lobe has been shown to be the most responsive to the inhibitory action of dopamine (188, 1280). Moreover, increased responsiveness to prolactin secretagogues (like TRH, ANG II, or forskolin) have been observed in lactotrophs of the inner zone, but not the outer zone of the anterior lobe of the pituitary gland after a 10 min suckling stimulus (1280).

VII) Dopamine as a stimulator of prolactin secretion. Several observations on pituitary cells in vitro indicate that dopamine is also capable of stimulating prolactin secretion, especially at low (pM) concentration (252, 427, 979, 1614). It appears that the in vivo status of the donor animals determines the lactotrophs' responsiveness to dopamine in vitro. For example, lactotrophs obtained from suckled lactating rats (761), or estradiol- and progesterone-treated ovariectomized female rats (346), have a propensity to respond by stimulation when challenged with dopamine in vitro. More than a decade ago, Denef et al. (427) then Shin (1614) first reported that a very low concentration of dopamine (1,000-fold lower than those required for maximal inhibition) could actually stimulate prolactin secretion from male rat pituitary cells in vitro. Kramer and Hopkins (979) and more recently Burris and co-workers (251, 252) have extended these studies using both static and dynamic cultures of pituitary cells from cycling female rats. This latter group has found

that a rapid reduction in dopamine concentration from 10^{-7} M (a dose that maximally inhibits prolactin secretion) to 10^{-10} or 10^{-12} M caused a greater stimulation of prolactin release than that evoked by complete removal of dopamine (251). Arey et al. (72) and Nagy and co-workers (1280, 1282) have published the first reports, which have clearly suggested a possible physiological relevance of these in vitro data. Arey et al. (72) have demonstrated that infusion of $10 \text{ ng} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ dopamine to freely moving rats results in a further increase in the already elevated plasma prolactin when synthesis of endogenous dopamine is blocked by the TH inhibitor α -MPT. The other group has used anterior pituitary cells obtained from nonsuckled (separated from their litters for 4 h) or suckled (for 10 min) lactating rats that were exposed to various concentrations of dopamine in vitro. Prolactin release was measured by reverse hemolytic plaque assay. Surprisingly, pituitary cells from nonsuckled rats exhibited only the prolactin-inhibitory response to dopamine but never actually stimulated prolactin above basal values as has been found for pituitary cells derived from males or cycling females (761, 1282). In striking contrast, a brief suckling stimulus applied immediately before death rendered the prolactin cells responsive to stimulation by 10^{-12} M concentration of dopamine (761).

The case for dopamine enhancement of prolactin secretion both in vitro and in vivo raises the question of the physiological relevance of this phenomenon. Have lactotrophs in situ ever been exposed to dopamine levels low enough to be stimulatory? The suckling stimulus results in a brief and transient reduction in the level of dopamine in long hypophysial portal vessels (404, 1423, 1499). Dopamine concentration in the portal circulation of cycling rats is the lowest during the day of proestrus (140). However, it is doubtful that a 50–70% decrease in portal blood dopamine (140, 404) is sufficient to achieve concentrations capable of stimulating prolactin release. On the other hand, dopamine concentration in stalk blood (140, 142, 621) is in the low nanomolar range (10^{-8} M), which is either ineffective or has only a weak inhibitory effect in vitro (1097), but 100- to 1,000-fold lower doses are required to stimulate prolactin release. One possible explanation is that the diminution in dopamine arriving at the anterior pituitary through the long portal vessels may not accurately reflect the total amount of dopamine the gland "sees." Indeed, a significant portion of the dopamine arriving at the anterior lobe originates from axon terminals in the neurointermediate lobe (1248) and is delivered through short portal vessels (420, 422).

It has been argued that dynamic release of prolactin is partially the consequence of complete withdrawal of dopamine (1133, 1135, 1138). Indeed, many of the transduction events mediating dopaminergic inhibition of prolactin secretion are completely reversed when dopamine is acutely withdrawn (674, 675, 767). Though there is no

doubt that these data support this contention, it is difficult to conceive that the dopaminergic neuron becomes completely quiescent to facilitate prolactin secretion. Indeed, it has been shown that a diminution of dopamine stimulates a far greater amount of prolactin secreted than that in response to complete withdrawal (252).

Another possible explanation for these apparent controversies is the assumption that dopamine may require supplementary agent(s) to effectively inhibit prolactin release and thus properly function as the PIF (1617, 1620). Shin et al. (1617) proposed ascorbic acid, routinely used to protect dopamine from oxidation, as a major candidate for the supplementary factor of dopamine. It is quite clear that ascorbic acid is not a simple antioxidant and can truly potentiate the inhibitory effect of dopamine in vitro by 100 times. Therefore, ascorbic acid may serve as a "responsiveness" agent for potentiating dopamine inhibition of prolactin release. Frawley and co-workers (761) have provided evidence that α -MSH from the intermediate lobe can also function as a responsiveness factor in vitro. In contrast to ascorbic acid, α -MSH decreases the responsiveness of lactotrophs to the inhibitory effect of a high dose of dopamine and enhances their responsiveness to the stimulatory effect of a low dose (761). Ascorbic acid, α -MSH, and possibly other substances as well, produced either in the hypothalamus or in the pituitary gland, may function as a lactotroph responsiveness factor (LRF). These responsiveness factors can be defined as substances with little or no direct influence on prolactin release themselves while they can exert profound effects on prolactin secretion by altering lactotrophs' responsiveness to the classical hypothalamic releasing and/or inhibiting factors.

VIII) Signal transduction pathways in lactotrophs coupled to the dopamine receptor. A number of transduction mechanisms have been described that mediate dopaminergic control of prolactin secretion. Inhibition of prolactin secretion by activation of D_2 receptors has been linked to inhibition of adenylyl cyclase (508, 565) and inositol phosphate metabolism (272, 510, 513, 1635). Moreover, activation of the D_2 receptor modifies at least five different ion channels. Dopamine activates a potassium current that induces plasma membrane hyperpolarization (847) and increases two voltage-activated potassium currents while decreasing two voltage-activated calcium currents (492, 1067–1069, 1070, 1110). It has been shown that the nonhydrolyzable GTP analog guanosine 5'-O-(3-thiotriphosphate) (GTP γ S) potentiates dopaminergic inhibition of voltage-sensitive calcium channels (1066). With the use of varying antibodies raised against specific G proteins (1065) or antisense oligonucleotide technology (100), it has been shown that the excitation of voltage-sensitive potassium channels through D_2 dopamine receptors is a function of $G_{i,3}\alpha$, whereas the inhibition of voltage-activated calcium channels is mediated by

$G_o\alpha$ proteins (1065). Thus inhibition of prolactin secretion in response to dopamine is a function of coupling of D_2 receptors to a $G_{i,3}\alpha$ which inhibits adenylyl cyclase activity and concomitantly excites voltage-sensitive potassium channels while coupled to $G_o\alpha$ and inhibiting voltage-sensitive calcium channels. Although the inhibition of cyclase activity may be unrelated to the inhibition of exocytosis (1002), the net effect on prolactin secretion appears to be mediated by inhibition of the calcium channels and excitation of potassium channels.

In contrast, stimulation of prolactin secretion by dopamine involves binding to a D_2 receptor (252) which is functionally coupled to a G_s (251) and in turn activates voltage-sensitive calcium channels (582) that subsequently increase intracellular calcium (248) to facilitate exocytosis (327, 1740).

IX) Prolactin feedback on neuroendocrine dopaminergic neurons. It is well established that prolactin affects its secretion by regulating its own hypothalamic control through a short-loop feedback mechanism (1194). Elevation of serum levels of prolactin increases hypothalamic dopamine synthesis (412) and the concentration of dopamine in hypothalamo-hypophyseal portal blood (695). The rate of dopamine synthesis is reduced by hypophysectomy or lowering blood levels of prolactin with bromocriptine (418). Recently, the presence of prolactin-R has been described in all subpopulations (TIDA, THDA, PHDA) of the neuroendocrine dopaminergic neurons (69, 1028), providing the anatomical basis for short prolactin feedback. All of these subpopulations are activated by prolactin (419). With the use of an interesting animal model, the prolactin-deficient dwarf mouse, it has been shown that TIDA neurons do not develop in sufficient number in the absence of prolactin (1413, 1414). Prolactin replacement during development (1498), but not when an adult (1414), reverses this deficit.

X) The dopamine transporter as regulator of prolactin secretion. Termination of dopamine action is primarily achieved by its reuptake by the dopamine transporter located on the terminals of dopaminergic neurons. Mice lacking the dopamine transporter gene are incapable of nursing their young and are significantly growth retarded (626). These animals have a marked reduction in the size of the anterior and intermediate lobes but not the posterior lobe of the pituitary gland (193). Accompanying the anterior pituitary hypoplasia is a diminution of prolactin and growth hormone message and an increased amount of extracellular dopamine in the anterior lobe (193, 421). It is not only the dopamine transporter of TIDA neurons that is effective in regulating prolactin secretion, but the transporter in THDA and PHDA neurons as well (421). Activity of the transporter on TIDA, THDA, and PHDA neurons is required to clear dopamine from the respective perivascular spaces and thus allow prolactin secretion.

B) NOREPINEPHRINE AND EPINEPHRINE. Early pharmacolog-

ical data indicated a tonic inhibitory influence of central noradrenergic systems on basal or estradiol-induced prolactin secretion (1012). The tonic inhibitory effect of norepinephrine is likely mediated by α_1 -adrenergic receptors (400). On the other hand, the proestrous surge of prolactin secretion and stress-induced prolactin release is suppressed by surgical or chemical (6-hydroxydopamine) impairment of central noradrenergic pathways (1003). Blockade of central norepinephrine biosynthesis does not alter suckling-induced prolactin release in lactating rats (286).

Data concerning the role of epinephrine in regulating anterior pituitary hormone secretion are scarce. Although the selective blockade of epinephrine biosynthesis in the CNS blocks the estradiol/progesterone-induced LH surge, the secretion of prolactin is not altered by an inhibitor of phenylethanolamine-*N*-methyltransferase (PNMT) (1734). On the basis of these observations, epinephrine does not appear to have a major function in regulation of prolactin secretion (1734). However, other pharmacological (911, 1012, 1818) and morphological data (775) suggest that central adrenergic mechanisms are involved in the regulation of prolactin secretion. More recently, by using light and electron microscopic immunocytochemical techniques, PNMT-immunoreactive axon terminals have been detected terminating on the cell bodies and dendrites of dopaminergic neurons in the arcuate nucleus (805), thus providing a morphological basis for the modulation of TIDA neuronal activity by epinephrine. Taken together, it seems quite conceivable that adrenergic modulation, mediated by either norepinephrine or epinephrine, plays an important role in stress-induced prolactin secretion; the functional context of the immunocytochemical findings (775, 805) is still undefined.

C) SEROTONIN. Although receptors for serotonin are present in the anterior lobe of the pituitary gland (262, 263), serotonin does not stimulate prolactin release in vitro (999, 1000), suggesting that it functions as a neurotransmitter rather than a neurohormone. It seems that the dorsal raphe nucleus is the main source of the ascending serotonergic pathways involved in the regulation of prolactin secretion (Fig. 6) (551, 1788).

Intracerebroventricular or intravenous infusion of serotonin (5-hydroxytryptamine) or its precursor 5-hydroxytryptophan results in an increase of plasma prolactin levels in rats (999, 1085), as well as in humans (919). Moreover, inhibition of serotonin synthesis, while not affecting prolactin secretion in intact rats (972), reduces prolactin release in estrogen-primed rats (260, 313) as well as completely blocks suckling-induced release of prolactin (972). After a block of serotonin synthesis, administration of 5-hydroxytryptophan, the immediate precursor of serotonin, restores the prolactin response to nursing (972). A low dose of the serotonin-receptor blocker methysergide has also been shown to abolish the

prolactin response to suckling (600). Suckling results in a rapid (within 5 min) decrease in the hypothalamic concentration of serotonin and an elevation of its metabolite 5-hydroxyindoleacetic acid, simultaneously with the release of prolactin (1181). Although the studies with serotonin receptor antagonists are not always conclusive (986), it can be safely assumed that serotonin facilitates suckling-induced prolactin release. 5-Hydroxytryptophan-induced prolactin release requires an intact neurointermediate lobe (1200) and is blunted by hypothalamic ablation in rats (1341). An essential role of the hypothalamic paraventricular nucleus (PVN) in the 5-hydroxytryptophan- or serotonin agonist-induced increase of prolactin secretion has also been demonstrated (104, 105, 107, 1200). These data suggest hypothalamic target(s) for the ascending serotonergic pathways. However, the hypothalamic dopaminergic neurons do not seem to be the major site where serotonin exerts its prolactin-releasing activity because serotonin elevates prolactin more or less independently of the concentration of dopamine in the portal circulation (1420). Dopamine infusion cannot prevent serotonin-induced prolactin release, and 5-hydroxytryptophan can further increase plasma prolactin in rats pretreated with either α -MPT, the inhibitor of the biosynthesis of dopamine or reserpine, a dopamine-depleting agent (1152).

Serotonin afferents terminating in the suprachiasmatic region are important in the regulation of prolactin secretion, especially in generating the estrogen-induced prolactin surge of ovariectomized rats (921). However, pharmacological lesion of the serotonin neurons with 5,7-dihydroxytryptamine (5,7-DHT), either at the dorsal raphe or suprachiasmatic regions, does not affect suckling-induced or the high afternoon episodic prolactin bursts in lactating rats (1284).

Within the last decade, several serotonin receptor types have been identified in the CNS, but the specific role of one or the other in the mediation of the prolactin response to serotonin is still superficially understood. 5HT_{1A}, 5HT_{2A}, and 5HT_{2C} serotonin receptor agonists increase plasma prolactin in vivo (108, 1040). More recently, the pivotal role of the paraventricular hypothalamic nucleus in the mediation of serotonin-induced prolactin release has been confirmed (104, 105). It has been shown that after a selective lesion of the PVN, prolactin release induced by a 5HT_{2C} receptor agonist is completely prevented, and the stimulatory effect of the 5HT_{2A} agonist is significantly reduced, whereas there is no change in prolactin response induced by the 5HT_{1A} receptor agonist (106, 107). The latter observation suggests that other structures may also have a role in the mediation of the serotonin-induced prolactin response.

D) HISTAMINE. Early pharmacological experiments indicated clearly that endogenous histamine has a stimulatory influence on prolactin secretion (1780). For instance,

intracerebroventricular injection of histamine increases prolactin secretion from male or ovariectomized estradiol-primed rats (59, 456, 458, 460, 1044, 1484), whereas H1 histamine receptor antagonists block suckling- or stress-induced prolactin release (59, 644, 1044). On the other hand, H2 histamine antagonists rather than H1 block exogenous histamine-induced prolactin secretion (58, 457, 460, 1468). Although the precise pharmacological profile of the receptor(s) mediating histamine effects on prolactin secretion is not clear, it seems that histamine may affect prolactin secretion predominantly through H2 receptor activation (58) and that the effects of H1 antagonists on prolactin secretion observed earlier are likely due to a heretofore uncharacterized nonspecific effect of these compounds (1780).

There is little doubt that the effect of histamine on prolactin secretion is mediated through the CNS (960, 962, 1580). Indeed, a wide variety of histaminergic compounds show little direct effect on the pituitary gland (58, 1780, 1879). Because the histamine-induced rise in prolactin secretion coincides with a decrease in dopamine concentration in portal blood (622), it seems likely that the neuroendocrine dopaminergic neurons in the hypothalamus, especially the TIDA system, are the primary targets for a central histaminergic influence. On the other hand, histamine-stimulated prolactin secretion may not be mediated by an inhibition of TIDA systems after all, since intracerebroventricular injection of histamine, while producing a dose-dependent increase of prolactin secretion, does not affect the biochemical indexes of dopaminergic neuronal activity (DOPAC concentration or L-DOPA accumulation) in the median eminence (557). Although the latter results cast some doubt on the direct histaminergic influence on TIDA neurons, it still seems likely that a histamine-dopamine interaction at the hypothalamic level is part of the neural mechanism by which histamine modulates prolactin secretion (558). In addition, histamine, through a presynaptic H3 histamine receptor (1571), is capable of modulating the release of vasopressin (953, 955), norepinephrine (554), serotonin (555, 875), endogenous opioids (958), and dopamine (1571), all of which are involved in the regulation of prolactin secretion.

The role of the central histaminergic system in regulating prolactin secretion was corroborated by the finding that bilateral lesion of the posterior hypothalamus (1317), which destroys histaminergic neurons exclusively localized in the mammillary nuclei (16, 838, 1376), inhibits stress-induced prolactin secretion in male rats (961). In addition, inhibition of histamine synthesis and release by activation of central presynaptic H3 receptors (90, 603) diminishes stress-induced prolactin secretion (961, 1656).

2. *Acetylcholine*

In GH₃ cells, muscarinic acetylcholine receptor activation decreases prolactin secretion (1885). With the consideration of the rapid deactivation of acetylcholine by the omnipresent cholinesterases, it seems unlikely that acetylcholine of hypothalamic origin subserves a neuroendocrine role as a regulator of prolactin secretion (276).

Cholinergic stimulation by systemic or intracerebroventricular administration of cholinergic agonists causes a decrease in serum prolactin concentration (662, 665, 1043). Moreover, cholinergic agonists (nicotinic and, to a lesser extent, muscarinic) prevent suckling- or estradiol-induced prolactin secretion (58, 180, 1696). It is generally assumed that the inhibitory effect of acetylcholine and its agonist is mediated through the stimulation of TIDA neurons (504, 665, 1696, 1885). This assumption is further supported by the finding that acetylcholine agonists prevent the morphine-induced increase of prolactin secretion (1261), since morphine is known to affect prolactin secretion by decreasing TIDA activity (472, 742, 1836). Acetylcholine administered intracerebroventricularly decreases the concentration of dopamine in portal blood (622), which is obviously inconsistent with the acetylcholine-induced decrease of prolactin secretion (662, 665, 1043). The latter observation indicates that in addition to the hypothalamic neuroendocrine dopaminergic systems, there are other targets of cholinergic modulation of prolactin secretion.

3. *Neuropeptides*

A) TRH. TRH was originally isolated as a hypophysiotrophic factor that stimulates thyroid-stimulating hormone (TSH) secretion from pituitary cells (1566). Subsequently, TRH has been shown to stimulate prolactin release from lactotrophs in a dose-dependent manner both in vitro and in vivo (178, 202, 1723).

TRH-like immunoreactivity is widely distributed in the CNS (774, 1186). Most of the TRH-immunopositive perikarya projecting to the median eminence are in the parvicellular subdivision of the paraventricular nucleus of the hypothalamus (227, 724, 774, 1015, 1186). TRH is secreted into hypophyseal stalk blood (520, 553), and its receptor is present on pituitary cells (1129), specifically on lactotrophs (763). These data would suggest that almost all of the requirements for considering TRH as a PRF in a physiological context are satisfied.

TRH can efficiently stimulate pituitary prolactin secretion in vivo in estrogen-primed male rats (1419) but not in normal male or lactating female rats (681, 1419, 1481). However, the release of prolactin and TSH is dissociated. TSH secretion is found to be only modestly affected (1481) or unaffected (1615) by stress or suckling, whereas

prolactin responses to the same stimuli are quite significant (1481, 1615).

Injection of specific antibodies to immunoneutralize hypophysiotrophic factors (passive immunization) is widely used to confirm the physiological relevance of a given factor. TRH antiserum can suppress the proestrous prolactin surge (963) and attenuate the suckling-induced prolactin response (405). However, TRH antiserum only weakly reduces prolactin-releasing activity of the hypothalamic extract (203, 1704), suggesting that TRH is not the only authentic PRF.

In addition to its well-established role as a prolactin-releasing hormone, TRH may also affect prolactin secretion by acting within the CNS. It has been reported that central administration of TRH inhibits prolactin secretion (1342), most likely through stimulation of TIDA neurons (836, 1342). Because TRH-immunopositive neural projections from the paraventricular nucleus to the arcuate nucleus have been detected (227), there is a morphological basis for a direct TRH/dopamine interaction at the hypothalamic level.

Many studies at the cellular level argue for a role for TRH in the control of prolactin secretion. TRH receptors in lactotrophs have been detected by Hinkle and Tashjian (763). With the use of modern immunocytochemical approaches, TRH receptors have been found on the plasma membrane as well as intracellularly in rat lactotrophs (1917). Primary cultures of rat pituitary cells were stained with an antibody to the native TRH receptor and with a bioactive, fluorescent analog of TRH, rhodamine-TRH. Rhodamine-TRH specifically stained 86% of lactotrophs and 21% of nonlactotrophs from primary pituitary cell cultures. Lactotrophs and thyrotrophs accounted for 90% of cells that were labeled with rhodamine-conjugated TRH, but there were occasional lactotrophs and thyrotrophs that did not show detectable staining with antireceptor antibodies or with rhodamine-TRH (1917). These data imply that some of the functional heterogeneity among lactotrophs (190, 298, 773, 830, 1625, 1708, 1814, 1921) may result from a differential expression of the TRH receptor. With the use of TRH receptor immunocytochemistry and rhodamine-labeled TRH, it has been demonstrated convincingly that the TRH receptor undergoes ligand-directed endocytosis in normal cells (1917). TRH receptors were localized on the surface of cells before TRH exposure, and rhodamine-TRH fluorescence was confined to the plasma membrane when TRH binding was performed at 0°C, where endocytosis is blocked. When cells were incubated with TRH at 37°C, receptors were found in intracellular vesicles in both lactotrophs and thyrotrophs, and rhodamine-TRH was rapidly internalized into endosomes at elevated temperatures (1917).

Once bound to the receptor, TRH activates GTP-binding proteins (1002), which have been characterized as either G_s (943), G_q or G_{11} (807). Activation of G_q or G_{11} , in

turn, activates membrane-bound phospholipase C that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate to yield inositol trisphosphate and diacylglycerol (57, 529, 807, 1684). Inositol trisphosphate mediates the mobilization of nonmitochondrial calcium in lactotrophs (617). Diacylglycerol, in turn, activates calcium-dependent protein kinase C (467) which phosphorylates voltage-sensitive calcium channels resulting in increased Ca^{2+} influx, and thus enhances prolactin exocytosis (563, 564, 747).

TRH was originally depicted as rapidly stimulating a biphasic pattern of prolactin secretion characterized by a first phase fast elevation within 30 s followed by a lower amplitude sustained secondary phase (17, 924). On the basis of studies in tumorous cell lines, it has been suggested that this pattern of prolactin secretion parallels and is the result of similar changes in intracellular calcium. More specifically, it has been suggested that inositol trisphosphate induces an initial rapid release of calcium from intracellular stores that mediates the first phase of prolactin secretion while the second phase is the consequence of diacylglycerol-induced activation of protein kinase C, phosphorylation of a voltage-gated calcium channel, and ultimately entrance of calcium from extracellular sources (215, 614–616, 722, 971). However, using selective pharmacological depletion of intracellular calcium stores or blockade of voltage-sensitive calcium channels, it was suggested that in normal pituitary cells, calcium influx and/or transduction pathways linked to calcium influx are more important to prolactin secretion in response to TRH than is liberation of Ca^{2+} from cytoplasmic stores (1558).

Newer data have revealed more of the spatiotemporal complexity of the cytoplasmic Ca^{2+} changes. For instance, using membrane capacitance measurements to study TRH-induced modulation of exocytosis by metabolically intact perforated patch-clamped rat lactotrophs, it was found that TRH promotes exocytosis through three distinct stages (563). First, within 30 s, TRH transiently evokes exocytosis that is independent of membrane depolarization and extracellular calcium influx, but is likely driven by Ca^{2+} released from inositol trisphosphate-sensitive intracellular pools. Second, within 3 min of exposure, TRH facilitates depolarization-evoked exocytosis while inhibiting the voltage-gated calcium current. Finally, after 8 min, TRH further enhances depolarization-evoked exocytosis by increasing high voltage-activated calcium channel current through a protein kinase C-dependent mechanism (564).

Finally, there is a large amount of literature showing that transient dopamine antagonism (716–721) or transient dopamine withdrawal (1132–1134, 1136–1138) magnifies the stimulatory effect of TRH on prolactin secretion. Although the data are convincing, the interpretation must be approached with caution, since it is unlikely that,

under physiological conditions, dopaminergic neurons become totally quiescent. It seems more likely that the lactotroph is exposed to diminishing concentrations of dopamine rather than a complete absence of dopamine. The effect of a reduction of dopamine exposure on TRH-stimulated prolactin secretion has yet to be determined.

B) OXYTOCIN. Oxytocin is synthesized in the PVN and supraoptic nucleus (SON) and axonally transported to the neural lobe where it is briefly stored until release from terminals. Axons of the oxytocin neurons passing through the median eminence already form synaptic boutons, which contact the capillary loops of the median eminence. Indeed, oxytocin release into the long portal vessels has been well-established (620, 1320). Moreover, short portal vessels connecting neural lobe and the inner zone of the anterior lobe also provide a potential route for delivering oxytocin to the adenohypophysis.

The stimulatory effect of neurointermediate lobe extracts on prolactin release has been thought to be partially due to the influence of oxytocin in the extracts (1537). Oxytocin is secreted into the hypophysial portal blood in 10–15 times higher concentrations than found in the peripheral circulation (620), and high-affinity receptors resembling the uterine oxytocin receptors are present in the anterior lobe. However, the prolactin-releasing potency and efficacy of oxytocin *in vitro* are rather low (827, 1537), and the definitive role of oxytocin as a neurohypophysial PRF requires further attention.

Several studies have previously indicated that, at least in certain experimental situations, oxytocin may be involved in the stimulatory regulation of prolactin secretion (1372, 1542). Although a large dose of oxytocin induces a rise in plasma prolactin in male or ovariectomized female rats (1087), it fails to affect prolactin secretion in lactating rats. In contrast, subcutaneous administration of a low dose of oxytocin induces a reduction in basal as well as stress-induced secretion of prolactin in male rats (1087, 1235, 1243). Attempts to antagonize the action of endogenous oxytocin *in vivo* have also resulted in conflicting data. Passive immunization with oxytocin antisera delays and reduces prolactin surges induced by suckling or by estrogen (1537). On the other hand, injection of a specific oxytocin antagonist, which blocks suckling-induced milk ejection, does not alter concomitant prolactin release (867). However, treatment with an oxytocin antagonist prevents the proestrous surge of prolactin (867). Moreover, oxytocin antagonism blocks the endogenous stimulatory rhythm (73, 74, 76) that governs prolactin secretion in female rats (71). Similarly, oxytocin antagonism blocks mating-induced prolactin secretion (74). Therefore, it seems likely that oxytocin may act as a PRF under some (but not all) physiological states.

In addition to its role as neurohormone, the possibility of central effects of oxytocin should also be taken into consideration (1309, 1310). For instance, oxytocin as neu-

rotransmitter may play a stimulatory role in regulating TIDA neurons (1919), which, in turn, would convey an inhibitory influence on prolactin secretion.

C) VASOPRESSIN. Similar to oxytocin, vasopressin is synthesized by the magnocellular neurons located mainly in the posterior division of the paraventricular and the supraoptic nuclei (1657). In addition, vasopressin immunoreactivity is also found in the parvicellular neurons of the medial division of the paraventricular neurons (1657). The axons of the magnocellular neurons pass through the median eminence en route to the posterior lobe of the pituitary gland (782), whereas the parvicellular neurons project directly to the external zone of the median eminence to terminate on the primary capillary bed from which the long portal vessels arise (1657). Therefore, vasopressin can reach the anterior lobe of the pituitary gland from both sources, through the long or the short portal systems (673).

Previous studies have clearly indicated that disturbances in the water and electrolyte regulation at the level of the neural lobe severely alters adenohypophysial prolactin secretion (450, 829, 1283). Bilateral anterior hypothalamic deafferentation behind the optic chiasm or lesion of the PVN interrupting the paraventriculo-, and supraoptico-hypophysial tract (948), or denervation of the neural lobe (1811) result in diabetes insipidus (145) and prevent suckling-induced prolactin release in oxytocin-substituted lactating animals. In addition, there is no suckling-induced hormone response in homozygous Brattleboro mothers suffering diabetes insipidus due to the genetic failure of the biosynthesis of arginine vasopressin (829, 1283, 1283). Moreover, passive immunizations against arginine vasopressin (1283), or the glycopeptide moiety of the vasopressin-neurophysin-glycopeptide precursor, with a highly specific antiserum attenuates the suckling-induced rise of plasma prolactin (1276). Taken together, these data suggest that vasopressin and related peptides play a significant role in regulating prolactin secretion.

Although arginine vasopressin induces prolactin release *in vivo* (1372, 1785, 1809), it does not effectively release prolactin *in vitro* (734, 1616). There are arginine vasopressin receptors in the rat anterior pituitary (47, 957), and arginine vasopressin is present in high concentration in portal blood (1926). In addition, neurophysin II, the midportion of the prepro-vasopressin molecule, can stimulate prolactin release from the anterior lobe but not through a direct effect on the pituitary gland (1618). The 39-amino acid glycopeptide comprising the COOH terminus of the vasopressin precursor has been reported to stimulate (1276), inhibit (1567), or have no effect (829) on prolactin release from cultured pituitary cells. Passive immunization studies support the stimulatory role of this peptide in the control of prolactin secretion (1276). Despite some controversial and inexplicable results, vaso-

pressin, its precursor, its specific neurophysin, or other factors associated with diabetes insipidus may affect pituitary prolactin secretion (50, 952).

Vasopressin exerts its physiological effects by activating at least two different receptors: the V_1 ("vascular") vasopressin receptor is most abundant in vascular smooth muscle cells and hepatocytes, whereas the V_2 receptors were originally found in the renal tubular epithelial cells (857). The V_1 couples to the phosphoinositide signaling pathway, whereas the V_2 receptors activate adenylate cyclase (857). The arginine vasopressin-induced increase in prolactin secretion is mediated mainly through V_1 (50, 952), although other vasopressin receptor(s) may also play a role (954, 955).

D) THE SECRETIN/VIP FAMILY. Several biologically active peptides of the secretin/VIP family, such as VIP, peptide histidine-isoleucine (PHI) and the recently discovered pituitary adenylyl cyclase-activating polypeptide (PACAP) have been shown to significantly affect pituitary prolactin secretion.

VIP was originally isolated from porcine small intestine (1527). Its presence was then demonstrated in the hypothalamic paraventricular nuclei and the median eminence (162, 380, 1010, 1191, 1399, 1638). PHI and VIP are synthesized from a common precursor (848) and are homologous to each other (1709, 1727). Both peptides are secreted in equimolar amounts into hypophyseal portal blood (1608). The new relative in this family is PACAP (1208). PACAP is a VIP-like hypothalamic peptide occurring in two forms, PACAP-27 and the COOH-terminally extended PACAP-38. These peptides share strong sequence homology (68%) with the NH_2 -terminal portion of VIP and can induce a very strong accumulation of cAMP in cultured anterior pituitary cells (1208) by binding to high-affinity receptor sites (1623).

VIP can stimulate prolactin release both in vivo and in vitro (917, 1512, 1591, 1823) through a direct action on VIP receptors found in anterior pituitary cells (125). VIP stimulates prolactin release in vitro between 10^{-7} and 10^{-10} M concentrations in a dose-related manner (1608–1610). Moreover, it is detected in the portal blood in a concentration ~ 10 times higher than that found in the general circulation (1528), which is sufficient to stimulate prolactin release from pituitary cells in vitro. These findings suggest that VIP may be an important mediator of prolactin release in different physiological situations. Moreover, when passive immunization is performed to neutralize VIP in the plasma (891, 1611), stimulation of prolactin release by ether stress is completely blocked (1611), whereas suckling-induced prolactin response is only partially inhibited (4). Simultaneous administration of VIP and PHI antisera completely blocks 5-hydroxytryptophan-induced prolactin release (891), while passive immunization with antisera to either VIP or PHI results in only a minimal effect (891). Taken together, these data

suggest that endogenous VIP-like peptides likely play a role as hypothalamic neurohormones (i.e., PRF) by transducing central stimulatory influences on the pituitary lactotrophs (1313, 1506), particularly those which are conveyed by serotonergic mechanisms (891). VIP also plays a role as an autocrine regulator of prolactin secretion (715, 1275), and as such, can be released by the lactotrophs themselves. Therefore, the source of VIP affected by in vivo immunoneutralization is not clear. As to what proportion of the reduction of prolactin release by VIP antiserum is due to the neutralization of VIP of hypothalamic origin remains to be established.

Similar to VIP, PHI can stimulate prolactin release in the freely moving rat (892, 1343, 1873) as well as from dispersed pituitary cells (1538). The relative contribution of PHI and VIP to the control of prolactin secretion requires further investigation.

Systemic injection of PACAP-38 significantly and dose-dependently stimulates pituitary prolactin in both male (1025) and nonsuckled lactating female rats (67). This effect of PACAP on prolactin secretion is likely related to its stimulation of prolactin gene expression (212, 352, 1815) through a protein kinase A-mediated pathway (353). Surprisingly, PACAP-38 dose-dependently inhibits prolactin release in both monolayer cultures (858) and reverse hemolytic plaque assay (858) of rat pituitary cells. Thus in vitro and in vivo experiments provide contrasting effects of PACAP-38 on pituitary prolactin release.

Early observations already indicated that, in addition to their direct action on lactotrophs, there is a hypothalamic site of action for some of these peptides (849, 917, 1823). However, there is no consensus as yet concerning the central effects of the secretin/VIP peptide family on prolactin secretion. For instance, preoptic injection of VIP, but not of secretin or PHI, stimulates prolactin secretion (123), suggesting specific actions of VIP on the preoptic mechanisms governing prolactin secretion in ovariectomized rats (123).

Both PACAP and VIP, when administered intracerebroventricularly to conscious ovariectomized estradiol-implanted female rats, stimulate TIDA activity (813). However, the effects of these peptides on prolactin secretion are opposite: whereas PACAP inhibits, VIP stimulates prolactin secretion (813). The inhibitory effect of PACAP on prolactin secretion is consistent with its stimulation of hypothalamic dopaminergic activity. It seems, however, that in the case of VIP, an additional unknown mechanism comes into play [perhaps an increase of PRF from hypothalamic sources (74, 1547)] that would override the consequence of TIDA activation. Interestingly, in sheep, PACAP also inhibits prolactin secretion (1560) by acting within the medial basal hypothalamus (40). However, in anesthetized male rats, central administration of

PACAP-27 or PACAP-38 elicits a dose-related increase in plasma prolactin level (1900).

E) OPIOIDS. The discovery of opiate receptors in the CNS in the early 1970s (1405, 1636, 1731) initiated the search for endogenous ligands for these receptors. The first two endogenous opioid peptides (EOP) were soon discovered (815, 816) and termed enkephalins (Met-enkephalin, H-Tyr-Gly-Gly-Phe-Met-OH; and Leu-enkephalin, H-Tyr-Gly-Gly-Phe-Leu-OH). Later studies revealed that endogenous opioids consist of three separate peptide families, enkephalins, dynorphins, and endorphins, encoded by three separate genes (19). Based on pharmacological characteristics and the biological response they initiate, three major types of opiate receptors have been identified (1130), and later cloned (μ , δ , and κ) (245, 935, 1119, 1196). They all belong to the seven transmembrane G protein-coupled receptor superfamily (934, 1119).

The enkephalin immunopositive neurons are the most widely distributed among the EOP expressing neurons (931). In the hypothalamus the paraventricular and supraoptic nuclei are abundant in enkephalin-immunopositive neurons that project to the posterior lobe of the pituitary gland. The endorphin/ACTH immunopositive neurons are distributed almost exclusively in the medial basal hypothalamus (arcuate nucleus, extended rostrally into the retrochiasmatic area, caudally into the submamillary region, and dorsally into the zone between the ventricular surface and the ventromedial hypothalamic nucleus) and in the brain stem (nucleus intercommissuralis of the tractus solitarius) (1316).

Distribution of the opiate receptors in the hypothalamus was studied extensively, first by receptor autoradiography (1034) and, following the molecular cloning of various types of opiate receptors (522, 935, 1041), by *in situ* hybridization (1119). These studies revealed an abundant expression of κ -receptors in the magnocellular neurons (PVN, SON), arcuate nucleus, and medial preoptic area (1119). However, with the exception of the medial preoptic area, expression of the μ -receptor is modest in these areas (1119), which seems somewhat discordant with the previous pharmacological characterization of the opiate receptors affecting TIDA neurons and/or prolactin secretion (965). It is important to add, however, that by immunohistochemical methods, strong staining for a μ -receptor-like protein is found in the external zone of the median eminence (1119). Because little μ -opiate receptor mRNA was found in the median eminence, it is assumed that the μ -receptor protein is synthesized elsewhere and transported to the median eminence along the axons of the phenotypically uncharacterized neurons. The latter findings strongly indicate a presynaptic inhibitory function of μ -receptors at the median eminence level. It has been reported that endogenous opioids can antagonize the effect of dopamine at the pituitary level (1511), al-

though this conclusion was later contested by others (448).

A considerable amount of data obtained with a wide variety of opiate agonists indicate that endogenous opioids indeed play an important role in regulating prolactin secretion (1346). The opiate receptor subtypes mediating the effect of opiate agonists on prolactin secretion are predominantly μ and κ (984, 985). Opioid receptor blockade by a single intravenous injection of naloxone completely suppresses the proestrous prolactin surge (833), indicating that some endogenous opioid activity is required to generate the prolactin secretory surge during proestrus in the rat. In addition, endogenous opioid peptides play an important role in the hypothalamic control of the menstrual cycle (545, 546).

Recent investigations reinforced the notion that endogenous opioids contribute to suckling-induced prolactin secretion by inhibiting neuroendocrine dopaminergic neurons in the hypothalamus (70). Sustained naloxone infusion (12 h) decreases prolactin concentration in the serum of nursing lactating dams. In the absence of suckling stimuli, the infusion of naloxone does not influence the already low prolactin concentration. However, it robustly diminishes suckling-induced prolactin secretion following pup deprivation. Consistent with the effects on prolactin secretion, TH activity in the median eminence is elevated, and TH mRNA level is increased in the arcuate nucleus by sustained naloxone infusion (70). In addition, endogenous opioids also mediate the nocturnal surge of prolactin secretion in pseudopregnant rats (1525).

Most stressful stimuli activate inhibitory neuronal pathways that decrease the activity of TIDA neurons resulting in an increase of prolactin secretion (415, 415, 866, 868, 1076). Endogenous opioids (83, 440, 547, 693, 1806) and opiate agonists (31, 86, 440, 693, 908, 1121, 1123, 1467, 1806) suppress the activity of TIDA neurons, presumably by activation of μ and/or κ type of opiate receptors (261), while increasing prolactin secretion (742, 1804, 1805). Because specific opiate antagonists suppress stress-induced prolactin secretion in most cases (473, 866, 1504, 1540, 1634, 1789, 1891), it seems likely that endogenous opioids contribute to the stress-induced increase of prolactin secretion via inhibition of the TIDA system. The responsiveness of TIDA neurons to stress is not influenced by the stage of the estrous cycle, indicating that the level of ovarian steroids in the circulation may not be the primary feedback signal affecting the responsiveness of TIDA neurons to endogenous opioids (415). However, sustained elevation of adrenal glucocorticoids, resulting from chronic activation of the hypothalamo-pituitary-adrenal axis, decreases the efficacy of opioid agonists to affect TIDA activity and/or prolactin secretion (540, 541, 908, 937). These latter observations indicate that the regulation of prolactin secretion by endogenous opioids is

well integrated into the overall neurohumoral mechanisms of adaptation (homeostasis).

Hyperprolactinemia, brought about by pregnancy, pseudopregnancy, lactation, or experimental manipulations (e.g., pituitary grafts under the kidney capsule, chronic D_2 dopamine antagonist administration), invariably results in elevated enkephalin gene expression in TIDA neurons (1185, 1187). The latter effect of heightened prolactin secretion is augmented by progesterone, whereas estradiol has little or no effect (1187). Although enkephalins might serve as a negative-feedback signal that regulates TIDA activity during pregnancy in an autocrine manner (1187), the physiological significance of these intriguing observations is still uncertain.

It is well established that certain elements of the neural circuitry regulating prolactin secretion are especially sensitive to ovarian and/or adrenal steroids. The actual hormonal milieu and the previous history of the animal seems equally important to determine the characteristics of the regulation of prolactin secretion by endogenous opioids. For instance, long-term application of estradiol to the arcuate nucleus reverses the role of endogenous opioids and serotonin in the regulation of prolactin secretion, whereas opioid antagonism with naloxone or serotonin synthesis inhibition by *para*-chlorophenylalanine both elevate prolactin secretion (281, 282). Moreover, the prolactin response to an enkephalin analog is dependent on the presence or absence of the suckling stimulus (1278).

Although extrahypothalamic site(s) whereby endogenous opioids alter prolactin secretion cannot be excluded, the prevailing view of the locus of endogenous opioids' action asserts that it takes place at the hypothalamic level (1485, 1836, 1880). Indeed, chemical lesions within the arcuate nucleus by neonatal administration of monosodium glutamate impairs the ability of morphine to induce prolactin secretion (49) while the opiate antagonist naloxone diminishes the release of prolactin evoked by electrical stimulation of the medial basal hypothalamus (48). A number of functional studies indicate that opioids directly affect the activity of the TIDA neurons (472, 742, 1836). Recently described neuroanatomical studies support this assertion (1119).

Prolactin at a concentration of 100 nM stimulates the release of β -endorphin from hypothalamic organ culture while decreasing the secretion of gonadotrophic hormone-releasing hormone (GnRH) (265). The latter effect of prolactin is blocked by naloxone, indicating that hyperprolactinemia-induced depression of gonadotropin secretion is mediated by endogenous opioids (265). The connection between hyperprolactinemia and the suppression of GnRH secretion by persistent activation of an endogenous opioid system is supported by several other observations. For instance, the polycystic ovarian condition induced by estradiol valerate (which induces hyperpro-

lactinemia) can be relieved by chronic treatment with an opiate antagonist (290).

F) ANG II. The octapeptide angiotensin II is the main effector of the renin-angiotensin system (194, 1521). The final steps of its biosynthesis involve consecutive proteolytic cleavages of its inactive precursors, angiotensinogen and angiotensin I, by renin and angiotensin converting enzyme (ACE), respectively (194, 544). Angiotensin II is produced both systemically and locally in various tissues, such as the vascular endothelium, heart, brain, pituitary, ovary, and adrenal gland (194, 544, 1521). It is important in regulation of blood pressure, vascular tone, and salt and water homeostasis, and it can influence cell growth, migration, differentiation, and apoptosis in many different target tissues (194, 544, 1521).

Pharmacologically, angiotensin receptors have been classified into two subtypes: AT_1 and AT_2 receptors (194, 243, 1751). Although both AT_1 and AT_2 receptors have been detected in the brain (869, 870, 1021, 1023, 1778), it appears that AT_1 is the dominant receptor subtype in adults (1022, 1364, 1778). In addition to the AT_2 receptor (832), two isoforms of the AT_1 receptor, AT_{1A} and AT_{1B} , have been isolated in rodents by molecular cloning (711, 850, 894, 1710). The AT_{1B} is the predominant ANG II receptor expressed in the pituitary gland (1022) while AT_{1A} is present in areas of the hypothalamus pertinent to the regulation of pituitary function (869, 871, 871a, 1022, 1777).

Numerous observations indicate clearly that ANG II could contribute to the physiological regulation of prolactin secretion, both at hypothalamic (1265, 1266, 1521, 1673, 1675, 1678, 1777) and pituitary (14, 14, 36, 409, 746, 1575) levels. When applied directly to pituitary cells in vitro, ANG II seems more specific than TRH, the leading contender among the PRF candidates, as it releases prolactin while it has little or no effects on other pituitary hormones (14). Moreover, the in vitro efficacy of ANG II on prolactin secretion is greater than TRH (14).

Centrally administered ANG II appears to be inhibitory to prolactin secretion in male (1266) as well as female (1265, 1521, 1675, 1678) rats, regardless of the endocrine status of the animal. On the other hand, the endogenous angiotensin system in the hypothalamus does not seem to be involved in maintaining the low level of basal prolactin secretion, since centrally administered angiotensin receptor antagonist or angiotensin convertase inhibitor do not increase prolactin secretion of ovariectomized female (1265) or male (1266) rats. However, the blockade of the central angiotensin system by these compounds greatly facilitates stress- or estradiol-induced prolactin secretion (1265, 1266, 1521). On the basis of these data, it has been proposed that a possible function of the endogenous angiotensin system in the hypothalamus is to limit the magnitude of prolactin secretion in response to environmental or endogenous stimuli (1521, 1673).

Several studies support the hypothesis that hypothalamic AT₁ receptors participate in the ovarian steroid feedback on prolactin secretion (1521, 1673). The number of AT₁ receptors in the arcuate nucleus is inversely related to prolactin secretion: low during proestrus and highest at estrus and confined to the dorsomedial portion of the arcuate nucleus (1586) where the cell bodies of the TIDA system are located (527). In subsequent studies, it has been demonstrated that a combined treatment of estradiol and progesterone induces ANG II AT_{1A} receptor mRNA expression specifically in dopaminergic neurons in the dorsomedial arcuate nucleus (871a). As demonstrated earlier, these dopaminergic neurons also express estradiol and/or progesterone receptors (967, 1548, 1549, 1626, 1861). It appears, therefore, that the ovarian steroid-induced regulation of ANG II receptors in TIDA neurons exemplifies the generally accepted concept that a wide array of central peptidergic and peripheral hormonal signals converge on and are integrated by the TIDA neurons (Fig. 5).

Signaling events coupled to AT₁ receptors include elevation of phosphatidylinositol hydrolysis through phospholipase C activation and intracellular Ca²⁺ mobilization, increase of cAMP formation, activation of multiple protein kinases (protein kinase C, several protein tyrosine kinases, mitogen-activated protein kinases), and protooncogene expression (506, 513, 610, 1075, 1572, 1902). There is ample evidence that an increase in phosphatidylinositol hydrolysis through phospholipase C activation is the major initial signaling event elicited by ANG II receptor activation in lactotrophs (269, 270). In addition, ANG II causes an elevation in cAMP formation in lactotroph-enriched pituitary cell preparations in parallel with its stimulatory effect on prolactin secretion (93). The effect of ANG II on adenylyl cyclase seems to be phospholipase C-mediated since it is sensitive to inhibition of the phospholipase C/protein kinase C pathway (93). Dopamine inhibits angiotensin-induced phosphatidylinositol turnover and cAMP formation in a pertussis toxin-sensitive manner (513). Peripheral hormones such as ovarian steroids or glucocorticoids seem to modulate the sensitivity of adenohypophysial cells to the dopaminergic inhibition of ANG II effects (513, 1265, 1675).

G) SUBSTANCE P. Substance P and related peptides (neurokinin A and neurokinin B) are members of the mammalian tachykinin peptide family, currently referred to as neurokinins (1456). These peptides result from processing two preprotachykinin (PPT) gene products. Substance P and neurokinin A originate from PPT-A, whereas neurokinin B originates from PPT-B. The physiology and pharmacology of these peptides and their receptors have been reviewed (1359, 1456). Although these peptides have been found in many different tissues, they are mainly expressed in neurons (932, 1359). It appears that their




FIG. 5. Direct effects of neurotransmitters, neuromodulators, and peripheral hormones on the activity of tuberoinfundibular dopaminergic system (TIDA). The inhibitory agents (*left*) will promote an increase of prolactin secretion as a result of diminishing TIDA activity. On the other hand, the stimulatory neurotransmitters and progesterone (*right*) will tend to decrease prolactin secretion as a result of increasing output of TIDA neurons. It should be noted, however, that many of these agents have multiple levels of action, often with opposing biological effect. Therefore, in some cases (*), effects on PRF and/or directly at the lactotrophs will prevail over the influence on TIDA activity. See text for references and further details. 5-HT, serotonin; NE, norepinephrine; HA, histamine; EOP, endogenous opioid peptides (endorphin, enkephalin, dynorphin, nociceptin/orphanin); GAL, galanin; SST, somatostatin; CCK₈, cholecystokinin-8; GABA, γ -aminobutyric acid; NO, nitric oxide; ACh, acetylcholine; TRH, thyrotropin releasing hormone; OT, oxytocin; VP, vasopressin; VIP, vasoactive intestinal polypeptide; PACAP, pituitary adenylyl cyclase-activating peptide; ANG II, angiotensin II; NT, neurotensin; NPY, neuropeptide Y; CT, calcitonin; BOM, bombesin-like peptides (gastrin-releasing peptide, neuromedin B, neuromedin C); ANP, atrial natriuretic peptides.

main physiological function is related to neurotransmission (932, 1359).

High immunoreactive substance P concentration is found in the median eminence-arcuate region in primates (777, 1005, 1500), while it is less abundant in rodents (228, 376, 1062). However, in rats receiving colchicine intravenicularly, numerous substance P immunoreactive cell bodies and fibers are found in the arcuate nucleus, the ventral portion of the ventromedial nucleus, the dorsomedial nucleus, and the periventricular area (1776). Abundant immunoreactive fibers are also found in the median eminence surrounding capillaries in the subependymal layer, as well as in the palisade structure in the external

layer of the median eminence (1776). In the arcuate nucleus, synapses of substance P fibers are readily detectable by immunoelectron microscopy. In the median eminence, substance P immunoreactive fibers are frequently seen in the subependymal, internal, and external zones (1776). In the median eminence, immunoreactive substance P fibers do not form synapses but appear terminate on the basal lamina covering the pericapillary space (1776). In some cases, extrusions of substance P immunoreactive fibers into the perivascular space are also observed. Moreover, a high level of expression of substance P receptors has been detected in all of these areas of the hypothalamus (1120). Taken together, these neuroanatomical attributes indicate strongly that substance P acts as a neurotransmitter in the arcuate nucleus and other parts of the hypothalamus and, as such, is likely involved in the regulation of prolactin secretion. In addition, substance P may modulate the release of PRF/PIF neurohormones presynaptically in the median eminence. Finally, the rather conspicuous presence of immunoreactive substance P fibers in the external zone of the median eminence indicates that substance P could have a role as a neurohormone and might reach the lactotrophs in the pituitary gland through the long portal vessels (1776).

Specific substance P binding sites have been detected in the pituitary (930, 1006, 1007), and by the combined application of receptor autoradiography and immunocytochemistry, specifically in lactotrophs (1008). Prolactin secretion is enhanced when pituitaries are incubated in the presence of substance P (1819, 1820). Moreover, prolactin secretion increases following intravenous administration of substance P (1482), indicating that substance P probably has a direct action on lactotrophs.

Substance P injected intraventricularly induces an increase in prolactin secretion in primates (489) as well as rats (1820). Microinjection of substance P into the medial preoptic area of conscious, freely moving animals increases prolactin secretion both in normal and orchidectomized rats (1416). Conversely, substance P antagonist or substance P antiserum injection in the same area decreases prolactin secretion, indicating that endogenous substance P in the medial preoptic area exerts a stimulatory influence over prolactin secretion (1416). However, negative results with centrally injected substance P antiserum or substance P antagonist have also been reported. For instance, in castrated male rats, substance P antagonists or substance P antiserum failed to influence prolactin secretion (402). It appears that the actual effect of substance P on prolactin secretion depends on the dose and route of administration: intracerebroventricularly injected substance P stimulates prolactin secretion, whereas at lower doses it is inhibitory (80, 81, 701). Similar paradoxical effects of substance P have been observed with intravenous administration (1482, 1739, 1820).

On the basis of pharmacological and neuroanatomical evidence, there is little doubt that substance P is an important factor in the regulation of prolactin secretion (861). However, the neural mechanism by which substance P or other members of the tachykinin/neurokinin family exert their action on prolactin secretion is not yet understood. The fact that these peptides have multiple sites of action, together with the possibility that biologically opposing effects can be elicited by these peptides at different loci, makes it difficult to explore their physiological role in regulating pituitary hormone secretions. Local administration of recently developed specific neurokinin receptor agonists and antagonists (932) would help to elucidate the precise physiological role of substance P and other tachykinins/neurokinins in regulating prolactin secretion.

There are some observations suggesting that tachykinins in the CNS and the pituitary are involved in prolactin feedback regulation. For instance, antiserum to substance P reduces the increase of GABA content in the hypothalamus induced by hyperprolactinemia (11). More information is available on substance P concerning the gonadal steroid-mediated feedback on prolactin secretion. Estradiol increases substance P content in medial basal hypothalamus, dorsomedial hypothalamus, and mammillary bodies in guinea pig (166). In female rats, pituitary content of substance P and substance P mRNA levels decrease dramatically after estradiol treatment (1338). Because the hypothalamic level of substance P mRNA was unchanged in these experiments, the regulation of substance P gene expression by estradiol in female rats seems to be confined to the pituitary (1338).

Three receptors subtypes of the mammalian neurokinins have been identified (NK-1, NK-2, and NK-3) and sequenced by molecular cloning. All belong to the G protein-coupled receptor superfamily (for references, see Refs. 932, 1456). Neurokinin receptor activation leads to an increase of intracellular free Ca^{2+} , an effect mediated through G_q -activated phospholipase C (932). In lactotroph-enriched anterior pituitary cell cultures, substance P caused a translocation of certain protein kinase C isozymes (1158).

H) GALANIN. The peptide galanin consists of 29 amino acids, originally isolated from porcine intestine and named after its NH_2 - and COOH -terminal residues, glycine and alanine (1728). The rat galanin amino acid sequence was first deduced from an estrogen-induced prolactinoma cDNA library (1839).

Galanin has a widespread distribution throughout the CNS and peripheral nervous system. The patterns of galanin-containing neurons in the CNS and their possible physiological functions have been reviewed (136, 1188). The heavy presence and specific distribution of galanin-positive neurons in the hypothalamus suggested an important function for this peptide in the neuroendocrine

regulation of anterior pituitary hormone secretion. Indeed, the incidence of galanin-immunoreactive cells is the highest in the hypothalamus, and the galanin immunopositive fibers are most abundant in the external zone of the median eminence. Most of the fibers in the median eminence originate from the ventrolateral portion of the arcuate nucleus (for references see Ref. 1188). The concentration of galanin in the portal blood is 4- to 10-fold higher than in the peripheral blood (1078). It appears that galanin meets all criteria to be considered as a hypothalamic-hypophysiotrophic hormone (1080). However, galanin is also abundantly expressed in the anterior lobe of the pituitary gland (909). A sex difference in galanin expression is detectable in the median eminence, neurointermediate lobe, and the anterior pituitary where the concentration of immunoreactive galanin is significantly higher in females (596). Interestingly, a few galanin-positive nerve fibers have been also detected in the anterior lobe of the rat (1061).

It appears that the anterior pituitary expresses a unique high-affinity galanin receptor that differs in its ligand structure-affinity requirements from galanin receptors previously characterized in the brain (1890). Only the hypothalamus has the capacity to express both types of galanin receptors (1890). It is clear that the galanin receptors belong to the G protein-coupled receptor superfamily (136, 914, 1188, 1842); however, the intracellular signaling mechanism coupled to these receptors in lactotrophs has not yet been elucidated. Information provided by nonpituitary cell types offers little clue to the mechanism of galanin's action in lactotrophs (914). For example, it has been reported that galanin is inhibitory on muscarinic acetylcholine receptor-mediated stimulation of phosphoinositide turnover in the hippocampus (1366) and activates ATP-dependent K^+ channels in pancreatic tumor cells (471) as well as insulinoma (996) and pheochromocytoma (439) cell lines in a pertussis toxin-sensitive manner. All these signaling events would be inconsistent with a direct prolactin-releasing effect of galanin in lactotrophs. Investigations on a clonal pituitary cell line implicate phospholipase C activation as a key event leading to sustained elevation of prolactin secretion by galanin (727).

Galanin is capable of stimulating prolactin secretion in a pituitary cell line, GH₃/B6, predicting the possibility of a direct pituitary action (697). Indeed, it has been shown that galanin is capable of stimulating prolactin secretion in a cultured pituitary cell preparation (465, 1890, 1890) and that specific galanin antiserum inhibits basal prolactin secretion (1890). The latter observation strongly suggests a paracrine and/or autocrine regulation by galanin (discussed in sect. VII B1AII). Moreover, galanin also has been shown to directly regulate lactotroph proliferation (1889). On the basis of the fact that galanin is secreted into peripheral blood (909, 1078), and its secretion is

regulated by hypothalamic factors such as dopamine and somatostatin (inhibition), as well as by TRH (stimulation) (824), it has been suggested that galanin might be a novel anterior pituitary hormone (1188, 1842).

Centrally administered galanin increases prolactin secretion, whereas it has a weak or no effect when given peripherally (973, 1177, 1360). These observations indicate that the prolactin-releasing effect of galanin likely results from its hypothalamic action, possibly by altering the balance between stimulatory and inhibitory outputs of the prolactin release-regulating circuitry. This latter hypothesis is supported by observations that galanin-containing axons synapse on dopaminergic neurons in the arcuate nucleus (806) and that galanin reduces [3 H]dopamine release from the median eminence (1327) and stimulates VIP release from the hypothalamus (844, 844). Moreover, the central action of galanin on prolactin secretion requires serotonin (975), α_2 -noradrenergic, and opioid elements (793, 976). Passive immunization experiments with specific galanin antiserum indicate that endogenous galanin may not play a significant role regulating prolactin secretion in male rats (1360). On the other hand, galanin presumably plays an important role in regulating prolactin secretion during proestrus in female rats (1079, 1188). Because passive immunization against galanin blunts the preovulatory prolactin surge, it is assumed that the contribution of endogenous galanin to neural events leading to the proestrous prolactin surge is stimulatory (1079, 1188).

Hyperprolactinemia, induced by implanting anterior pituitaries under the renal capsule, reduces galanin content in the pituitary (726). Chronically high prolactin concentration in the blood also suppresses estradiol-induced galanin expression in the pituitary (726). How hyperprolactinemia affects galanin in the CNS is not yet known.

It has been shown that the gene encoding rat galanin contains a functional estrogen response element in its regulatory region (1842). The galanin mRNA-inducing effect of estradiol is most impressive in the pituitary (see sect. VII B1AII). Although less robust than in the pituitary, estrogens clearly have a positive effect on galanin gene expression in the hypothalamus (910, 1033).

1) NEUROTENSIN. Neurotensin, a peptide of 13 amino acids, was originally isolated from bovine hypothalamus (288). The potential role of neurotensin in neuroendocrine regulation has been reviewed by Aronin et al. (89) and more recently by Rostene and Alexander (1507).

It is intriguing that there is extensive coexistence of neurotensin and dopamine in hypothalamic arcuate and periventricular neurons (831). Neurotensin is present in the median eminence (946) and in the anterior lobe of the pituitary gland (630). The major, but not exclusive, source of neurotensin immunoreactivity in the external layer of the median eminence is the neuronal somata located in the hypothalamic arcuate nuclei (946).

Several observations indicate that neurotensin is capable of affecting lactotrophs *in vitro* (505). For example, neurotensin dose-dependently increases prolactin secretion ($ED_{50} = 0.6$ nM), an action additive with TRH and VIP (505). Because neurotensin is present in a high concentration in the median eminence (946), it seems reasonable to assume that neurotensin is a potential PRF distinct from TRH or VIP (505).

Neurotensin has opposite effects on prolactin secretion, depending on the site of administration. Intracerebroventricular administration of neurotensin decreases, whereas peripheral administration of neurotensin increases prolactin secretion (964, 1166, 1167, 1482), indicating that neurotensin can affect the neuroendocrine regulation of prolactin secretion at multiple levels (1166). It seems likely that neurotensin causes stimulation of prolactin secretion by acting at a site(s) which is outside of the blood-brain barrier (1166). As for the locus of central inhibition of prolactin secretion, the stimulation of TIDA neurons by neurotensin offers a plausible mechanism (964, 1167). Indeed, several observations indicate that neurotensin enhances the activity of TIDA neurons (692, 964, 1167, 1373). In addition, centrally administered neurotensin can prevent prolactin secretion elicited by stress or serotonergic or opioid agonists (1166, 1167, 1753). The effect of neurotensin on the TIDA system likely results from a direct action on these neurons (964).

Data provided by passive immunization with a highly specific neurotensin antiserum conversely reflect the effects of exogenous peptide administration and further emphasize the physiological importance of neurotensin in regulating prolactin secretion (1166). For instance, intraventricular injection of a neurotensin antiserum results in an increase in prolactin secretion, whereas intravenous injection of the same antiserum leads to a decrease in prolactin secretion (1166). These experiments reveal a central (possibly hypothalamic) inhibitory and a peripheral (possibly pituitary) stimulatory influence of endogenous neurotensin on prolactin secretion. The changes in neurotensin concentration in the median eminence (followed over time by push-pull perfusion technique) correlate well with the surge of prolactin secretion induced by estradiol priming (1866).

Lactation increases neurotensin immunoreactivity in the hypothalamus, particularly in the TIDA neurons (1126). That a physiological hyperprolactinemia coincides with an enhancement of neurotensin expression, especially in neurons which are responsible for hypothalamic inhibition of prolactin secretion, indicate, albeit indirectly, that neurotensin might play a role in mediating prolactin feedback signaling. Indeed, recent pharmacological experiments using a specific neurotensin antagonist, SR-48692, provide direct evidence that neurotensin mediates the hyperprolactinemia-induced activation of TIDA neurons in both male and female rats (751).

The expression of the neurotensin gene is intricately regulated by steroid hormones as well as second messenger signals at the promoter level. A synergistic regulation of neurotensin gene expression by cAMP and glucocorticoids has been reported (1315). Sexually dimorphic neurotensin neurons in the preoptic area possess estradiol receptors (752), and female rats have a larger number of neurons bearing both neurotensin and estradiol receptors (752). Interestingly, neonatal masculinization with testosterone propionate selectively increases neurotensin content in the medial basal hypothalamus but not in the medial preoptic area (444).

It appears that neurotensin does not affect adenylyl cyclase in lactotrophs (1179), and its stimulatory influence on prolactin secretion results from activation of the intracellular Ca^{2+} -mobilizing cascade as well as by increasing Ca^{2+} influx through voltage-dependent calcium channels (1179). In addition, arachidonic acid release and activation of the lipoxygenase pathways may also contribute to the prolactin-releasing effect of neurotensin (271, 1179). In the CNS, neurotensin activates dopaminergic neurons via a non-pertussis toxin-sensitive G protein, likely $G_{\alpha_{q/11}}$ (1856).

J) NEUROPEPTIDE Y. Neuropeptide Y is a member of the pancreatic polypeptide family isolated by Tatemoto et al. in 1982 (1725, 1726). Neuropeptide Y has a multifaceted role in a wide variety of physiological functions (897), and its physiological role in modulating LH secretion is especially well established (579, 897).

With the use of specific neuropeptide Y antisera, detailed maps of the neuropeptide Y systems in the CNS have been provided (for references, see Ref. 897). High-density neuropeptide Y-positive terminals are found throughout the medial preoptic and anterior hypothalamic areas, as well as the periventricular, suprachiasmatic, paraventricular, and supraoptic nuclei (328, 430, 1286, 1336). The medial basal hypothalamus is particularly rich in neuropeptide Y-positive nerve endings, especially the arcuate nucleus and the median eminence. The majority of the neuropeptide Y terminals have been found in the internal and the subependymal zone, although fibers in the external zone in close proximity to the portal capillaries are detected (1169, 1172). Many neuropeptide Y-positive fibers lie in close proximity to the cell bodies and dendrites of luteinizing hormone releasing hormone (LHRH), CRH, oxytocin, vasopressin, and TRH neurons (1800). Neuropeptide Y and norepinephrine are frequently found colocalized in many areas in the CNS and in the peripheral sympathetic system (525, 526, 776, 781, 1561). It appears that, in many cases, neuropeptide Y and norepinephrine act in concert to modulate target cell function (897). However, neuropeptide Y is not confined to the norepinephrinergic system in the CNS because several neuropeptide Y-positive perikarya have been detected in

the hypothalamus, especially in the ventromedial portion of the arcuate nucleus (28, 328, 430, 1286).

Expression of neuropeptide Y in the mediobasal hypothalamus is increased during lactation (330, 331, 1107, 1400, 1646). The appearance of immunoreactive neuropeptide Y in TIDA neurons is especially striking since these neurons do not normally express detectable levels of neuropeptide Y in other physiological situations. The appearance of neuropeptide Y positive terminals around the loops of the hypothalamo-hypophyseal portal capillaries shows a remarkable plasticity since these terminals largely disappear within 24 h followed by the cessation of nursing (330, 331, 1857).

Neuropeptide Y stimulates prolactin secretion in cultured pituitary cells obtained from random cycling female rats (302). On the other hand, in primary cultures of anterior pituitary cells obtained from lactating or ovariectomized estradiol-treated animals, neuropeptide Y causes a concentration-dependent decrease in prolactin secretion (1857). The inhibitory effect of the peptide is additive to the inhibition of prolactin secretion caused by dopamine (1857). Withdrawal of the peptide from the culture medium results in a quick rebound of prolactin secretion, similar to that of dopamine withdrawal (1857). In addition, neuropeptide Y, alone or in combination with dopamine, decreases TRH-induced prolactin release (1857); the presence of neuropeptide Y markedly augments the inhibitory effect of dopamine (1857).

The presence of neuropeptide Y in TIDA neurons and in periportal nerve terminals in the median eminence indicates that the peptide can affect prolactin secretion either by modulating dopamine release presynaptically and/or by affecting dopamine's action in the pituitary (1857). It has been hypothesized that a possible function of the neuropeptide Y expressed in TIDA neurons during lactation is to amplify the inhibitory action of dopamine on prolactin secretion (1857).

In the male rat, intracerebroventricular administration of neuropeptide Y decreases prolactin secretion (592, 1466). The central inhibitory effect of neuropeptide Y on prolactin secretion is probably mediated by stimulating TIDA neurons, since the activity of these dopaminergic neurons increases upon neuropeptide Y administration (592). Moreover, neuroanatomical observations at the electron microscopic level reveal synaptic connections between TH-positive cells and neuropeptide Y-positive fibers (714). These observations undoubtedly reveal the potential of neuropeptide Y as a regulator of prolactin secretion and suggest a central site of action. It is still uncertain, however, whether endogenous neuropeptide Y significantly contributes to the tonic inhibition of prolactin secretion in male rats since previous reports on the effects of centrally administered neuropeptide Y antiserum on prolactin secretion are conflicting (618, 1465, 1466). Neuropeptide Y antiserum increases plasma pro-

lactin level only in intact males, suggesting that the central inhibitory action of neuropeptide Y probably depends on sex steroids (618).

It has been noted that stimulation of central neuropeptide Y Y2 receptors by injection of neuropeptide Y or a Y2 agonist in the lateral ventricle increases prolactin gene expression in the pituitary (604). The mechanism by which central neuropeptide Y affects prolactin mRNA levels in the anterior pituitary gland and its physiological significance is unclear.

Expression of neuropeptide Y in the mediobasal hypothalamus increases dramatically during lactation (330, 331, 1107, 1646). However, although the elevated neuropeptide Y expression is a lactation-dependent phenomenon, it does not require high plasma prolactin levels (1400). Therefore, it appears that neuropeptide Y in the hypothalamus does not mediate prolactin feedback *per se*. The increased expression of neuropeptide Y gene in the arcuate nucleus is likely related to feeding behavior and/or adaptive changes in energy balance necessary to sustain lactation (1107, 1379).

In the medial basal hypothalamus, neuropeptide Y Y2 receptors are upregulated by estradiol and decreased by progesterone cotreatment in ovariectomized rats (1381). However, the functional significance of these changes in regulating prolactin secretion during the estrous cycle is unclear.

On the basis of ligand binding and pharmacological studies, at least two neuropeptide Y receptors might exist in the CNS (897). The Y1 receptor is coupled to phospholipase C and inositol phosphate metabolism and enhances intracellular Ca^{2+} mobilization upon activation, while the Y2 receptor decreases Ca^{2+} influx resulting in an inhibition of the target cell's secretory activity (528, 1849). Both Y1 and Y2 couple negatively to adenylyl cyclase (897). All of the effects of neuropeptide Y on these signaling events can be prevented by pertussis toxin, which indicates G_o/G_i mediation (528, 897). Moreover, it seems that neuropeptide Y, similar to the effects of dopamine, reduces Ca^{2+} entry through voltage-dependent Ca^{2+} channels in lactotrophs (1857). In cultured lactotrophs obtained from lactating animals, neuropeptide Y reduces the intracellular Ca^{2+} elevation caused by TRH (1857). The latter effect of neuropeptide Y is more robust on the sustained phase of TRH-induced intracellular Ca^{2+} concentration elevation, which is consistent with the notion that neuropeptide Y mainly affects Ca^{2+} influx (1857). It is interesting to note that a similar cooperativity between LHRH and neuropeptide Y on gonadotrophs has been reported earlier (374). In the latter case, however, neuropeptide Y augments stimulatory signaling elicited by LHRH, and it was suggested that neuropeptide Y facilitates Ca^{2+} influx through voltage-sensitive Ca^{2+} channels (374). Although the precise mechanisms for these actions of neuropeptide Y have not been elucidated, it is intriguing that the same

peptide receptor might be coupled to different intracellular signaling pathways exerting biologically opposing cellular events.

K) SOMATOSTATIN. The presence of growth hormone release-inhibiting factor in the hypothalamus was first discovered in 1968 (982), and the active tetradecapeptide, named somatostatin, was later purified by Guillemin et al. (211). It became apparent from the beginning that somatostatin not only inhibits GH, but the secretion of prolactin, TSH, and ACTH as well (1394, 1460, 1783). Two biologically active forms of somatostatin (somatostatin-14 and somatostatin-28) have been identified as the product of the same gene (519, 1434, 1568). The molecular biology and physiology of somatostatin have been reviewed (1251, 1390, 1863).

Somatostatin immunoreactive neurons are widespread throughout the CNS and peripheral nervous system (556). In the hypothalamus, somatostatin neurons that project to the external zone of the median eminence are mainly concentrated in the medial preoptic and the anterior periventricular area, as well as in the paraventricular nucleus (724). These "neuroendocrine" somatostatin neurons receive abundant afferent connections from galanin, neurotensin, neuropeptide Y, GABA, serotonin, enkephalin, substance P, TRH, and catecholaminergic systems (3, 157, 318, 724, 895).

Somatostatin inhibits basal as well as TRH- or VIP-induced prolactin secretion in vitro in prolactin-producing cell lines or hemipituitaries (461, 462, 466, 509, 733, 941). Although somatostatin and its analogs are capable of inhibiting prolactin secretion in vivo, somatostatin inhibits prolactin secretion with lower efficacy compared with its effect on growth hormone secretion (1394). However, the concentration of immunoreactive somatostatin in the portal blood is high enough to be biologically relevant to the regulation of prolactin secretion (3, 319). Injection of somatostatin antisera intravenously causes a marked increase in plasma prolactin concentration, indicating that endogenous somatostatin may indeed exert an inhibitory influence over prolactin secretion in vivo (507).

Similar to many other prolactin secretagogues, estradiol can profoundly alter the responsiveness of lactotrophs to somatostatin (942, 994). Indeed, although somatostatin causes a robust inhibition of prolactin secretion in male or ovariectomized female estradiol-primed rats, its effect in normal or pimozide-treated animals is much less robust (359, 651, 913, 1018). Interestingly, although long-term exposure to estradiol gradually diminishes the dopaminergic control of prolactin secretion (1001) and eventually leads to an uncoupling of inhibitory signaling to D₂ dopamine receptors (1454), the sensitivity of lactotrophs to somatostatin increases with estradiol treatment (1001). The significance of these observations as related to the mechanism of estradiol-induced tumorigenesis of lactotrophs is not yet clear. In

anterior pituitary cells and tumorous MtTW-10 cells of pituitary origin, somatostatin inhibits estradiol-induced prolactin, galanin, and growth hormone secretion and synthesis (824, 826). Galanin is characterized as a potent auto- and paracrine PRF (258, 825, 1888). Thus somatostatin might affect prolactin secretion, in part, by inhibiting galanin release/synthesis from lactotrophs. Because the synthesis and release of galanin in the lactotroph is strongly estradiol dependent (258, 803), the suggested galanin-mediated mechanism for somatostatin's action on prolactin secretion would be consistent with its sensitivity to estradiol (359, 651, 1018).

The pharmacological characterization of somatostatin receptors in lactotrophs, somatotrophs, and thyrotrophs indicates a single class of somatostatin binding sites in these cell types (515). Interestingly, in prolactin-producing tumorous cells, specific somatostatin binding is always found, although usually in lower density than in growth hormone-producing cells, whereas nonprolactin producing chromophobe adenomas are devoid of ¹²⁵I-somatostatin binding sites (507). The fact that normal lactotrophs as well as tumorous cells of "mammosomatotroph" origin are capable of expressing somatostatin receptors emphasizes the potential of somatostatin and its analogs in regulating lactotroph function under varying physiological or pathological conditions.

The advances made in the molecular biology and pharmacology of the somatostatin receptor family have been reviewed recently (1251, 1393, 1463). Molecular cloning has revealed six somatostatin receptors (SST1–5, two splice-variants for SST2) encoded by five separate genes, all belonging to the G protein-coupled receptor superfamily (1391, 1392, 1463). All somatostatin receptor subtypes (proteins and/or mRNA) have been detected in the hypothalamus and the pituitary (390, 463, 671, 1190, 1195, 1334, 1375, 1744). The SST2A and SST5 receptors are rather abundant in the anterior lobe of the pituitary gland (390, 1190, 1334). Lactotrophs as well as tumorous cells in the mammosomatotroph lineage preferentially (but not exclusively) express the SST5 receptor subtype (671, 1190, 1195, 1613). Although previous pharmacological studies indicate that more than one somatostatin receptor exists (1394, 1462), such multiplicity of SST receptors revealed by molecular cloning is somewhat unexpected (625, 1391, 1462, 1463). With respect to anterior pituitary hormone secretion, the functional significance of the molecular diversity of somatostatin receptors has not been clarified as yet. Recent developments in the synthesis of potent subtype-selective peptidomimetics (both agonists and antagonists) will undoubtedly help the functional characterization of the different somatostatin receptor subtypes (1494, 1904).

Somatostatin receptor expression in the pituitary gland is sensitive to ovarian and adrenal steroid hormones. For instance, estradiol upregulates SST2 receptor

gene expression in rat prolactinoma cells (1829, 1830). Short-term exposure to glucocorticoids upregulates, whereas a prolonged exposure downregulates the expression of somatostatin receptors in pituitary cells (1573), as well as in a rat prolactinoma-derived cell line (1829, 1892). These observations indicate that responsiveness of lactotrophs and somatotrophs to somatostatin is regulated through the expression of somatostatin receptors, and such regulation by these steroids is consistent with their effects in vivo on somatostatin-induced modulation of prolactin and growth hormone secretion.

The widespread distribution of somatostatin and somatostatin receptors throughout the entire CNS indicates clearly that somatostatin subserves a role as neurotransmitter as well (556, 1462). The possibility that somatostatin might affect prolactin secretion through affecting the TIDA system has been suggested earlier (898). With respect to prolactin secretion, it is noteworthy that estradiol-induced regulation of somatostatin receptors in the brain is restricted to the arcuate nucleus of the hypothalamus. In ovariectomized rats, estradiol treatment significantly increases the number of ^{125}I -somatostatin binding sites in the ventrolateral part of the arcuate nucleus (1645). In the same region, somatostatin binding is higher in proestrus compared with other stages of the estrous cycle (1645). The expression of somatostatin receptors, SST2 receptor subtype in particular, is upregulated by estradiol (135, 1588). However, to what extent these changes in the expression of somatostatin receptors within the arcuate nucleus reflect on the regulation of prolactin secretion is not clear.

The affinity of ^{125}I -somatostatin binding and the in vitro potency of different somatostatin analogs on adenylyl cyclase and intracellular free Ca^{2+} are well correlated, suggesting a possible causal relationship between biological effects of somatostatin and the inhibition of adenylyl cyclase and/or intracellular free Ca^{2+} (941, 1715). However, the inhibition of hormone secretion by somatostatin cannot be explained solely through adenylyl cyclase and/or Ca^{2+} entry inhibition. Thus it has been suggested that another mechanism of transduction may be involved in the inhibitory actions of somatostatin on prolactin, growth hormone, and TSH secretion (941, 1715).

L) CALCITONIN. Calcitonin, a polypeptide originally described as a plasma Ca^{2+} -lowering hormone (360) secreted by the parafollicular cells (C cells) in the thyroid gland (570), has been shown to inhibit prolactin secretion (reviewed in Ref. 1631). Calcitonin and calcitonin gene-related peptide (CGRP) are apparently encoded by the same gene (853), but the processing pathway is tissue specific; whereas the parathyroid gland is the major source of calcitonin, in the CNS the CGRP is the dominant form (33, 570, 1502).

Calcitonin-like immunoreactivity is present in the

CNS and in lactotrophs of the anterior lobe of the pituitary gland (1225). Calcitonin is most abundant in the inner portion of the anterior lobe (1595). In accordance with the latter observation, salmon calcitonin antiserum causes more robust prolactin secretion when applied to lactotrophs obtained from the inner region of the anterior lobe (1595).

Calcitonin peptides are capable of inhibiting basal as well as TRH-stimulated prolactin secretion by acting directly on dispersed pituitary cells in culture (514, 880, 1225, 1593–1595, 1597, 1631, 1894). The effects of calcitonin-like peptides on prolactin secretion seem specific since these peptides do not influence GH, LH, FSH, and TSH secretion (880, 1593, 1597, 1894). The inhibitory effect of calcitonin on prolactin secretion is dependent on the thyroid status of the animal, since in pituitaries obtained from thyroidectomized animals, calcitonin stimulates prolactin secretion (1905). Endogenous calcitonin release by pituitary cells in culture is sufficient to inhibit prolactin secretion since anti-salmon calcitonin antiserum increases prolactin secretion (1595, 1660) even in the presence of dopamine (1595). Cell immunoblot assay and RIA reveal that anterior pituitary cells are capable of releasing calcitonin-like peptides (1660), indicating a paracrine regulation of prolactin secretion by these peptides (discussed further in sect. VII B 1 A VII). These data suggest that calcitonin is a physiologically important inhibitor of prolactin secretion and likely acts in concert with dopamine and other PIF to provide a tonic inhibition of prolactin secretion (1595).

Several investigations have concluded that calcitonin-like peptides are effective in inhibiting prolactin secretion when administered in vivo (495, 531). That calcitonin is a physiological regulator of prolactin secretion has gained further support by recent evidence showing that passive immunization with salmon calcitonin antiserum increases plasma prolactin concentration within 30 min of antiserum administration (1595). Calcitonin-like peptides lower prolactin secretion induced by stress in prepubertal female rats or by the suckling stimulus in lactating animals (495, 1348). Intracerebroventricular administration of a calcitonin analog lowers basal as well as stress- or morphine-induced prolactin secretion (1633). These data suggest that, in addition to its direct effects in the pituitary, calcitonin has central inhibitory activity on prolactin secretion as well, probably through enhancement of hypothalamic inhibitory pathways controlling prolactin secretion (1308, 1633). It has been suggested that calcitonin has a potential role as neuromodulator in the CNS (1679) and it may decrease prolactin secretion by activating the TIDA system (341). Taken together, it seems very likely that endogenous calcitonin plays a role in tonic inhibition of prolactin secretion (1595). However, in spite of the numerous observations concerning the effects of calcitonin on prolactin secretion in a wide

variety of *in vivo* situations (119, 370–372, 495, 531, 1347, 1348, 1633, 1905), the precise physiological role of calcitonin in the regulation of prolactin secretion is not yet understood.

The signaling mechanism coupled to calcitonin receptors in lactotrophs is not clear. However, interactions of calcitonin with well-known prolactin secretagogues provide some clue (880, 1593, 1597, 1894). The inhibition of TRH-induced prolactin secretion by calcitonin seems rather selective, since prolactin release induced by other Ca^{2+} -mobilizing secretagogues such as ANG II or neurotensin, or by a Ca^{2+} ionophore A23187 or maitotoxin (an activator of voltage-dependent Ca^{2+} channels), is unaffected by calcitonin (880, 1593, 1597, 1894). Likewise, prolactin secretion elicited by adenylyl cyclase-activating secretagogue VIP or forskolin (a direct activator of adenylyl cyclase) was unaffected by the presence of calcitonin (880, 1593, 1597, 1894). It seems likely that calcitonin receptor activation on lactotrophs interferes with the phospholipase C-related signaling cascade, including Ca^{2+} mobilization from intracellular stores, decrease in inositol phosphate production, as well as a subsequent reduction in cytosolic free Ca^{2+} concentration and arachidonate liberation (514, 880, 1661). Extended exposure to calcitonin inhibits phosphatidylinositol turnover (1660), although in some cases the effect of calcitonin on phosphatidylinositol hydrolysis seems bimodal, consisting of a quick increase followed by a sustained inhibition (1660, 1661).

M) BOMBESIN-LIKE PEPTIDES (GASTRIN-RELEASING PEPTIDE, NEUROMEDINS B AND C). The first representatives of this peptide family, bombesin and ranatensin, were isolated from amphibian skin (516, 517), followed by their mammalian counterparts, gastrin-releasing peptide (GRP), and neuromedins B and C (1199, 1852). These peptides are localized to hypothalamic neurons (928, 1377, 1671, 1792). Given intracerebroventricularly, they are potent inhibitors of basal as well as stimulated prolactin secretion in rats (929).

GRP-positive perikarya are found in the paraventricular part of the paraventricular nucleus and in the periventricular nucleus in close proximity of the third ventricle (928, 1377, 1792). Beaded terminals and fibers are found in the suprachiasmatic nucleus as well as the area dorsal and lateral to the suprachiasmatic nucleus in the region of the periventricular nucleus, while the median eminence displays no immunoreactivity for GRP (928, 1377, 1792). The differential and region specific expression of the two bombesin-like peptides neuromedin B and GRP (1288, 1377, 1844) and their corresponding receptor subtypes (126, 1217, 1671, 1845) suggests that these structurally closely related peptides may have distinct physiological functions in the CNS.

Bombesin and its analogs are capable of stimulating prolactin secretion from GH_4C_1 cells *in vitro* (1876). More-

over, the bombesin-like peptide neuromedin C stimulates prolactin secretion from anterior pituitary cell aggregates cultured in serum-free medium supplemented with thyroxine and dexamethasone (797, 799). The presence of estradiol in the culture medium augments this effect of neuromedin C that can be blocked by specific bombesin receptor antagonists (798, 799). These observations clearly suggest that bombesin-like peptides can exert a direct stimulatory influence on prolactin secretion at the pituitary level. The influence of these peptides on pituitary hormone secretion seems to be specific for lactotrophs since the effectiveness of these peptides on the rest of the anterior pituitary hormones is rather unremarkable (797, 799, 1876).

The lactotroph has the intrinsic capacity to synthesize GRP/bombesin-like peptides (798). However, the participation of GRP-like peptides in local control of hormone release is suspect since a potent receptor antagonist of GRP does not affect basal, stimulated (by VIP, TRH, or ANG II), or suppressed (by dopamine) prolactin secretion from perfused microaggregates of pituitary cells (798).

When given intravenously, bombesin-like peptides increase prolactin secretion in anesthetized steroid-primed rats (700, 1483). However, contrary to the effects of systemic administration, centrally administered bombesin has a very potent and long-lasting inhibitory effect on prolactin release induced by acute stress in conscious male rats (1705). Similarly, synthetic porcine GRP, given intracerebroventricularly, suppresses basal as well as opiate-stimulated prolactin secretion, whereas it does not suppress domperidone-induced elevation of prolactin secretion (1153). Bombesin injected into the third ventricle of ovariectomized conscious rats suppresses prolactin levels in the plasma, concomitant with an increase in tyrosine hydroxylase activity in the hypothalamus (95). In addition, bombesin suppresses basal as well as PGE_2 -induced prolactin secretion when given intracerebroventricularly to rats under urethane anesthesia (912). Moreover, intracerebroventricular bombesin lowers basal prolactin levels in conscious male rats and prevents morphine-, bremazocine-, and stress-induced prolactin secretion. The same dose of bombesin has no effect on prolactin secretion following α -MPT or haloperidol treatment. These results indicate that bombesin acts as an inhibitor of prolactin release, not on the lactotroph itself, but rather by an increase of inhibitory dopaminergic tone (257, 929). Indeed, GRP stimulates spontaneous release of dopamine from perfused rat hypothalamic fragments *in vitro* (886).

It seems that bombesin/GRP peptides exert an overall inhibitory influence over prolactin secretion since central administration of bombesin also prevents the estradiol-induced afternoon prolactin surge. Applied in a smaller dose, bombesin delays the surge but does not prevent it from occurring (1099). The effect of bombesin

seems specific since it can be prevented by administering bombesin together with a specific bombesin antagonist. Interestingly, temporarily lowering endogenous dopaminergic tone dominating the lactotrophs by a single injection of sulpiride at 1400 h reinstates the prolactin surge (1099). The latter observation indicates that bombesin suppresses the estradiol-induced prolactin surge through activating the hypothalamic neuroendocrine dopaminergic systems.

Bombesin not only blocks the prolactin surge but also the circadian changes in TIDA activity (1100). In suprachiasmatic nuclei-lesioned animals, these rhythms are absent and bombesin treatment is without effect. Microinjection of bombesin into the suprachiasmatic nuclei blocks the diurnal changes in TIDA activity and prolactin secretion, whereas injection into the arcuate nucleus does not disturb the rhythmic changes in TIDA and prolactin secretion. It has been suggested that bombesin may act on the rhythm generation center, the suprachiasmatic nucleus, to disrupt TIDA neuron activity associated with the prolactin surge (1100).

Bombesin given intraventricularly decreases prolactin secretion both in male and female rats, but only in males was this effect of bombesin associated with an increase of TIDA activity (1757). The loss of gonadal hormones after ovariectomy renders TIDA neurons responsive to the stimulatory effects of bombesin, whereas immunoneutralization of prolactin does not affect the ability of bombesin to alter the activity of TIDA neurons (1757). Intracerebroventricular injection of bombesin causes a dose- and time-related increase in the activity of TIDA and PHDA neurons and a corresponding decrease in prolactin and α -MSH concentrations in the plasma (1122). Bombesin fails to alter the activity of dopaminergic neurons terminating in the striatum, nucleus accumbens, or in the neural lobe of the pituitary gland (THDA). Because equimolar doses of bombesin and GRP cause similar activation of the TIDA and PHDA systems (1122), it seems likely that a "GRP-preferring" receptor subtype (126, 1671) mediates these effects. A highly specific antiserum against GRP injected into the third ventricle to immunoneutralize endogenous GRP-like peptides in the hypothalamic area increases prolactin secretion (928), underlining the physiological significance of the endogenous GRP-related peptides in regulating prolactin secretion.

The effects of these peptides on prolactin secretion in humans seem less impressive. For instance, bombesin given intravenously ($5 \text{ ng} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ for 2.5 h) does not alter basal but attenuates TRH-induced prolactin secretion in healthy male volunteers (1426). One group (1234) found no effect of bombesin infusion ($200\text{--}600 \text{ pmol} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$) on pituitary hormone secretion, while the biological activity of the bombesin used in this study was confirmed by observing a brisk increase in serum gastrin concentrations and in gastric acid secretion (1234). On

the other hand, it has been reported that bombesin ($10 \text{ ng} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ for 60 min) elicited prolactin release in six of eight subjects (1425). One study found GRP ($0.12 \text{ pmol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ for 30 min and $1.5 \text{ pmol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ for an additional 30 min) ineffective on prolactin secretion while it increased ACTH and cortisol in the serum (959).

Application of microaggregate culture in combination with GRP/bombesin receptor autoradiography and immunocytochemistry for pituitary hormones reveals that the bombesin receptor is expressed mainly in lactotrophs (796). Without estradiol supplement, the proportion of bombesin receptor expressing cells are very low, usually $<1\%$. The presence of 1 nM estradiol in the tissue culture medium robustly increases the number of cells expressing bombesin receptors while dexamethasone has an opposite effect. It seems, therefore, that bombesin receptor expression in the pituitary is estradiol inducible, whereas glucocorticoids have a suppressive effect (796). These data are in good agreement with the effects of estradiol and dexamethasone on the responsiveness of the lactotroph to GRP/bombesin-like peptides observed in a similar experimental settings (798, 799).

Specific, high-affinity bombesin binding sites have been characterized in a pituitary cell line (GH_4C_1) using [^{125}I -Tyr 4]bombesin (1877). Scatchard analysis reveals one class of bombesin binding sites, and the estimated value of the equilibrium dissociation constant [K_d] $\sim 1.2 \text{ nM}$] agrees closely with the half-maximal concentration ($\text{ED}_{50} \sim 0.5 \text{ nM}$) for bombesin stimulation of prolactin release. Subsequent studies have shown that mammalian bombesin-like peptides exert their effects via different receptors (126, 1671, 1845).

Both bombesin and TRH stimulate prolactin secretion from GH_4C_1 cells ($\text{ED}_{50} \sim 2 \text{ nM}$, $\text{E}_{\text{max}} \sim 100 \text{ nM}$). No additional stimulation of prolactin secretion can be seen when bombesin is combined with TRH, while the effects of bombesin and VIP are additive (177). The additive nature of the interaction with VIP confirms a previous suggestion that bombesin-like peptides do not act through adenylyl cyclase stimulation (461). Both bombesin and TRH elicit rapid inositol trisphosphate formation (within 2–4 s). Bombesin causes the same biphasic changes in membrane potential as TRH, and both peptides cause a rapid and sustained increase in intracellular free Ca^{2+} (177, 461, 462, 1766). These results suggest that bombesin stimulates prolactin secretion via an immediate formation of inositol trisphosphate similar to the action of TRH (177, 467, 1703).

Taken together, although a great many pharmacological studies suggest that the GRP/bombesin family of peptides exert effects on prolactin secretion, various uncertainties/inconsistencies among the data cited above postpone their assignment as physiologically relevant controllers of prolactin secretion.

N) CHOLECYSTOKININ. The cholecystokinin (CCK) and

gastrin family of peptides, originally described as gastrointestinal hormones (368), share a common COOH-terminal pentapeptide amide sequence (1691). The COOH-terminal tetrapeptide represents the bioactive core of these molecules (1860). Although gastrin is present in very small concentrations, CCK (in its tyrosine-sulfated form) is predominant in the CNS (1457, 1796, 1797), where it likely functions as a neurotransmitter (366, 1795).

Immunoreactive CCK and its COOH-terminal octapeptide (CCK-8) are found in the CNS of various mammalian species (449, 1252, 1692, 1693, 1797). The observation that CCK and dopamine colocalize in the mesencephalic dopaminergic system spurred further interest in this peptide family (13, 367, 778–780, 1402). CCK-like peptides have been found in hypothalamic regions relevant to the regulation of pituitary function (43, 137, 138, 204, 300, 431, 879, 947, 949, 1128, 1193, 1367). The pharmacology and molecular structure of the CCK receptor family have been reviewed (1860). In the hypothalamus and in most areas in the CNS, the vast majority of the receptors are CCK_B type, although CCK_A is also present and the two receptors often colocalize (1860). A large body of pharmacological and physiological studies support the notion that gastrin/CCK-like peptides play a role in the regulation of anterior pituitary function, including prolactin secretion.

Early experiments did not suggest a significant biological effect for CCK-like peptides at the pituitary level, since no effect on prolactin secretion was detected following an incubation of various concentrations of CCK-8 in vitro with hemipituitaries obtained from ovariectomized rats (1822). It was later found that CCK-8 and to a lesser extent CCK-33 can stimulate pituitary prolactin secretion in vitro (1109). Because the effective concentration range of CCK-8 in these experiments was rather high (10^{-6} to 10^{-5} M), it seems unlikely that CCK is present in the portal blood in a biologically effective concentration (1109). It has been reported that CCK-8 elicits a dose-dependent stimulation of prolactin secretion from dispersed rat anterior pituitary cells (1150). The effective concentration range of CCK-8 in these experiments seems physiologically more relevant (10^{-11} to 10^{-7} M) (1150). With the assumption that the sensitivities of lactotrophs in culture and in vivo are comparable, the latter observation indicates that CCK-8 may, after all, act directly on anterior pituitary cells to stimulate prolactin release.

The less than dramatic effects observed in vitro (1109, 1822) correlate well with the relative ineffectiveness of CCK-like peptides to alter prolactin secretion after peripheral administration. For instance, intravenous injection of CCK-8 does not affect basal prolactin secretion of freely moving male rats, even in a dose as high as 5 μ g/rat (1714). In addition, systemic injection of the non-selective agonists of CCK-8 (caerulein), CCK_B selective agonists (CCK-4 and pentagastrin), CCK_A antagonist

(devazepide), or CCK_B antagonist (L-365,260) does not affect prolactin secretion in male rats (1116). In one early experiment, however, intravenous injection of CCK-8 to female rats causes a short-lived dose-dependent increase in prolactin secretion (1822).

The remarkable difference in terms of efficiency when a CCK-like peptide is given intracerebroventricularly (912, 1822) instead of intravenously indicates clearly that these peptides likely affect prolactin secretion at hypothalamic sites, presumably by altering the activity of prolactin-releasing and/or inhibiting hormone-producing neurons. Indeed, central administration of CCK-8 increases prolactin secretion in freely moving male rats, an effect prevented by the specific CCK antagonists proglumide or benzotript (1714). The enhancement of prolactin secretion by dopamine D₂ antagonists (haloperidol, sulpiride, domperidone) is not altered by central CCK administration. However, when endogenous dopamine is depleted by α -MPT or reserpine, CCK-8 increases plasma prolactin levels. In addition, the decrease of prolactin secretion induced by the dopamine agonist apomorphine can be antagonized by centrally administered CCK. These data indicate that the central effect of CCK-8 is mediated, at least in part, by modulating the output of the neuroendocrine dopaminergic neurons of the hypothalamus (1714). In addition, the elevation in prolactin secretion by CCK-8 can be prevented by intracerebroventricularly administered VIP antiserum (1714). Therefore, one possible route through which CCK-8 increases prolactin secretion in male rats is by stimulating VIP through a central CCK receptor (1714).

Interestingly, when injected into the third ventricle of the brain of conscious ovariectomized rats, 4 or 400 ng CCK-8 does not change prolactin secretion, whereas an intermediate dose (40 ng) of CCK-8 increases plasma prolactin levels within 15 min (1822). Injection of a specific CCK antagonist, proglumide, into the third ventricle of intact male rats causes a robust decrease of prolactin secretion, indicating a tonic central action of CCK on prolactin secretion (1821). On the other hand, ovariectomized female rats respond to central CCK antagonism with stimulation of prolactin secretion (1821). Taken together, the fact that CCK antagonism alters prolactin concentrations in both sexes underlines the physiological importance of endogenous CCK-like peptides in the regulation of prolactin secretion. However, an explanation for the observed sexual differences is not yet available (1821). It is noteworthy that both CCK_A and CCK_B receptors are present in the hypothalamus and are likely involved in the regulation of anterior pituitary hormone secretion in vivo (1410). Because opposite biological effects can be mediated by CCK_A and CCK_B receptors (1115), some of the ambiguity surrounding the effects of CCK on prolactin secretion in female rats may be related to the fact that the sulfated CCK-8 applied in these exper-

iments is not a subtype selective agonist on these receptors.

Anesthesia, not surprisingly, interferes with the central effects of CCK-like peptides. For instance, intravenicularly administered CCK-8 to urethane-anesthetized rats suppresses prolactin secretion (912), whereas in conscious animals CCK-8 is stimulatory (see above).

Electrophysiological data strongly support the view that CCK is an important neurotransmitter in regulating neuroendocrine function of the hypothalamus. For instance, when extracellular single-unit activity is recorded in vitro using brain tissue slice preparation, CCK-8 elicits a robust activation in the majority of neurons within the area of the arcuate nucleus (1049, 1371). CCK-8 is found even more effective in stimulating neuronal activity than glutamate, a well-recognized stimulatory neurotransmitter in the CNS. Estrogen replacement to ovariectomized animals significantly increases the proportion of cells which respond to CCK by excitation (1371). The dorso-medial portion of the arcuate nucleus, where most of the TIDA neurons reside, was included, although not specifically targeted in these experiments. Nevertheless, it is difficult to reconcile the overall excitatory effect of CCK on arcuate neurons (1049, 1371) with its stimulatory effect on prolactin secretion in vivo (1822).

Taken together, CCK-like peptides, acting as neurotransmitters or neuromodulators in the hypothalamus, play an important role in the regulation of prolactin secretion. The most likely locus of the action of these peptides is the arcuate nucleus-median eminence region. The latter conclusion is supported by the observation that local injections of gastrin or CCK-8 in the preoptic region do not change prolactin concentration in the serum (940), while these peptides stimulate prolactin secretion when injected into the third ventricle (see above).

Human pituitary tumors often contain CCK-like immunoreactivities, although the role of CCK peptides and/or their receptors in pituitary tumorigenesis is not known (1459). In healthy males and females, continuous intravenous injection of pentagastrin does not affect prolactin secretion (32). Caerulein (an amphibian peptide, which mimics the biological actions of CCK) does not change basal prolactin secretion but accentuates TRH-induced prolactin release in normal men (1563). Similarly, CCK-8 administered to normal men has no effect on basal prolactin secretion (1285). Intravenous infusion of CCK-8 (140 ng/kg) stimulates prolactin secretion in a dose-dependent fashion (264).

The intracellular signaling pathways coupled to CCK receptors have not yet been fully elucidated (182). All CCK receptors cloned to date apparently belong to the G protein-coupled receptor superfamily (1860). However, the G protein(s) mediating the ionic effects of CCK are not pertussis toxin sensitive (182), indicating that the response to CCK does not involve a G_i or a G_o . The direct

prolactin-releasing effect of CCK is dependent on extracellular Ca^{2+} (1150). In the CNS, the predominant action of CCK is excitatory because it causes depolarization of the neuronal membrane that leads to an increased firing rate. These effects of CCK result from an inhibition of K^+ conductance and increasing Ca^{2+} influx through a calcium-dependent nonselective monovalent cation channel (182).

O) ATRIAL NATRIURETIC PEPTIDES. Atrial natriuretic peptide was first isolated from mammalian heart tissue (900). Three members of the atrial natriuretic peptide family have been isolated and designated A-type (ANP), B-type (BNP), and C-type (CNP) natriuretic peptide (1697, 1698). The biologically active forms consist of 28, 32, and 22 amino acids, and all contain a 17-amino acid ring structure formed by a disulfide bond between two cysteine residues. The ring structure seems essential for their biological activities (1151).

Atrial natriuretic peptide positive cell bodies are detected in the rostral hypothalamus (mostly in the preoptic and periventricular nuclei, median preoptic nucleus, anterior wall of the third ventricle, organum vasculosum laminae terminalis) that project to the median eminence and the neural lobe of the pituitary (713). Atrial natriuretic peptide is detected in the hypophysial portal blood of both male and female rats in a concentration higher than that of the peripheral plasma (1604). The distribution of atrial natriuretic peptide throughout the hypothalamus and the pituitary suggests that both neuromodulator and neuroendocrine effects of these peptides should be considered.

Although most of the data suggest hypothalamic targets for atrial natriuretic peptides in regulating prolactin secretion (see below), a direct hypophysial component of atrial natriuretic peptide's action cannot be excluded, since in some experiments atrial natriuretic peptide is capable of inhibiting prolactin secretion in vitro (482).

Atrial natriuretic peptide administered into the third ventricle decreases basal as well as stress-induced prolactin secretion in male rats, indicating that atrial natriuretic peptide can act centrally to alter neuronal activities responsible for the hypothalamic control of prolactin secretion (1531, 1533). These effects of atrial natriuretic peptide are sensitive to dopamine antagonism; therefore, it seems conceivable that atrial natriuretic peptide exerts its effects through stimulation of hypothalamic dopaminergic neurons (566, 1534). The influence of endogenous atrial natriuretic peptides on prolactin secretion is less well understood because the results obtained by passive immunization with an antiserum to atrial natriuretic peptides are somewhat equivocal (571). Much of the ambiguity could result from the fact that the two major forms of atrial natriuretic peptide in the CNS have opposing neuroendocrine effects by affecting different subsets of neurons (1536). Selective lesions of CNP and atrial natriuretic

peptide targets in the hypothalamus reveal that the two peptides do not act directly on TIDA neurons (1536).

Estradiol injection to ovariectomized animals 24 h before the blood collection resulted in a significant decrease of atrial natriuretic peptide concentrations in the portal plasma (1604). Because the direct pituitary effect of atrial natriuretic peptide is inhibitory to prolactin secretion, the latter finding is consistent with the overall stimulatory influence of estradiol on prolactin secretion. However, this finding is contradicted by the fact that the concentration of atrial natriuretic peptide in the portal plasma remains unchanged throughout the day of proestrus, indicating that atrial natriuretic peptide may not play a role in the spontaneous prolactin surge (1604).

It seems likely that the major role of the hypothalamic atrial natriuretic peptides is the modulation of stress-induced hormone secretion from the anterior pituitary (571). A complementary function of prolactin and atrial natriuretic peptide in maintaining water and ion (especially sodium) homeostasis has been suggested (713, 1685). However, the physiological relevance of atrial natriuretic peptide-mediated regulation of prolactin secretion is not yet clear.

The signal transduction mechanism for atrial natriuretic peptide in the brain and the pituitary has recently been reviewed (713). Although the field is still controversial, it seems that activation of guanylyl cyclase is the major signaling event elicited by atrial natriuretic peptide-like peptides (305, 321, 1345). The increased cGMP was utilized to detect atrial natriuretic peptide-responsive cells within the brain. Cells within the paraventricular nuclei of the hypothalamus are among the responsive cellular elements in the brain (for references, see Ref. 713).

P) ENDOTHELINS. Vasoactive peptides produced by the endothelial cells were discovered based on their strong and long-lasting vasoconstrictor activity (591, 624, 756, 1510). Three peptides were later identified as products of three different genes and named endothelin (ET)-1, ET-2, and ET-3 (843, 1901). It has been thought that the physiological role of these peptides is to serve as paracrine regulatory signals emanating from the endothelium to affect vascular smooth muscle tone (839, 1141, 1142). It is now quite apparent that these peptides have a wide array of physiological functions (814, 1291, 1790) and can modulate secretory functions in many endocrine tissues (1140, 1291, 1689).

The distribution of ET receptors in the CNS has been investigated, first with *in situ* hybridization (787) and more recently with immunocytochemical methods (990). In the hypothalamus and especially in the pituitary, ET_A is the predominant receptor subtype, while the ET_B receptors are most abundant in the cerebellum (787). Recent studies with an ET_A receptor specific antibody revealed a strikingly matching topography of ET_A receptor immuno-

reactivity with catecholaminergic neurons throughout the brain (990, 1895). For instance, in the hypothalamus, the arcuate and the periventricular nuclei, the parvocellular regions of the paraventricular nucleus, and the zona incerta contain strongly immunopositive cell bodies for ET_A receptors (990, 1895). Although this finding is suggestive of a specific functional relationship between endothelin and catecholaminergic systems in the brain, it needs to be reinvestigated with double-label techniques to establish the proposed synaptic connections and demonstrate colocalization of ET_A receptor and tyrosine hydroxylase in the same neuron unequivocally.

There is ample evidence that endothelin-like peptides are involved in the regulation of prolactin secretion (485, 902–905, 1544). Endothelins act directly on the lactotroph to decrease (902, 903, 1544) or increase (485, 906) prolactin secretion dependent on the physiological environment. These data suggest an important role for endothelins in the intrinsic regulatory mechanisms of the pituitary gland (905, 1577), which are discussed in section VII B1AIV.

Recent observations, however, indicate that endothelin-like peptides may also subserve a role as neuromodulators or neurotransmitters. For instance, immunocytochemical studies indicate that ET-1-containing axon collaterals of the hypothalamic magnocellular neurons can reach the area of dopaminergic cell bodies in the periventricular and arcuate nuclei (1895). Because high levels of ET_A receptor immunoreactivity have been detected in these dopaminergic neurons (990), it seems conceivable that endothelins affect prolactin secretion by influencing the activity of the hypothalamic neuroendocrine dopaminergic neurons.

The hypothalamic magnocellular neurons in the supraoptic and paraventricular nuclei were the first neural system where endothelin-like immunoreactivity was detected in the brain (1915). The physiological role of endothelins in the hypothalamo-posterior pituitary system is not well understood. It is interesting to note, however, that physiological conditions exacting profound demand on magnocellular neurons (e.g., water deprivation, lactation) robustly decrease the endothelin-like immunoreactivity in these neurons (1915). On the other hand, expression of ET-1 increases significantly in the supraoptic and paraventricular nuclei from early to late gestation (794). These, admittedly scarce, observations suggest an inhibitory function for endothelins in regulating oxytocin and/or vasopressin secretion and, perhaps indirectly, prolactin secretion.

The hypothalamic magnocellular system has been considered as a potential source of endothelin-like peptides for the anterior lobe of the pituitary gland (1690, 1915). It is conceivable that these neurons provide endothelins to the anterior lobe through their axon collaterals to the median eminence, in a way similar to oxytocin and vasopressin (50, 620, 782). Alternatively, endothelins re-

leased at the posterior lobe of the pituitary gland can reach the anterior lobe through the short portal system. Because endothelins likely influence the blood flow through the portal vascularizations in both cases, until recently, there was limited enthusiasm to consider endothelins as target cell-specific neurohumoral signaling molecules (905). However, recent observations of the magnocellular neurons reveal that part of the ET-1 precursor is not converted to the biologically active mature peptide but is packed in vesicles, transported to the axon terminals, and presumably released by regulated exocytosis (1520) as big ET-1 (1895). Because big ET-1 is practically inactive, it can theoretically reach the anterior lobe through the long portal vessels without affecting the blood flow of the portal vasculature. Assuming that the target cells express endothelin convertase enzyme and endothelin receptors, the big ET-1 will be converted to bioactive ET-1 on the cell surface. The locally generated mature ET-1 will then affect the cell and possibly its neighbors as well (1895). It is noteworthy that, *in vitro*, a non-cell-permeable endothelin convertase enzyme inhibitory peptide (1233) increases prolactin secretion (905), thus indicating that signaling through big ET-1 might be feasible for lactotrophs.

Taken together, the anatomical distribution of ET-like peptides and precursors, as well as endothelin receptors in the hypothalamus and the pituitary, indicate that endothelins of hypothalamic origin may act as neurotransmitter/neuromodulator or neurohormone to regulate prolactin secretion. However, none of these modes of action for endothelin has yet been proven experimentally.

Q) "NEW" PROLACTIN-RELEASING PEPTIDES. Although many of the peptides described above are all "candidates" for the physiological prolactin-releasing hormone of hypothalamic origin, none has definitively been assigned that role. A novel approach has recently been taken to describe another prolactin-releasing peptide of neural origin. With the use of the PCR, a seven-transmembrane-domain receptor, designated hGR3, was isolated from the human pituitary gland and identified as an "orphan receptor" on the basis that an endogenous ligand had not been identified (765). Chinese hamster ovary cells transfected with hGR3 receptor were used to isolate the endogenous ligand from crude bovine hypothalamic extract. The detection of the endogenous ligand relied on the fact that in these cells, activation of hGR3 receptors evokes the release of arachidonic acid, one of the signal transduction cascades known to control pituitary prolactin secretion from pituitary cells. Three bioactive peptides were subsequently isolated from the extract and purified by standard HPLC methodology (765). The cDNA encoding two of the peptide sequences of 20 and 31 amino acids were isolated from bovine, human, and rat brain and found to be highly conserved. The prolactin-releasing peptide mRNA for each is most abundant in the medulla oblongata (589,

1197), whereas only moderate amounts are found in the hypothalamus and the anterior lobe of the pituitary gland (589, 1147).

The synthetic peptides (1319) stimulate release of prolactin from a rat pituitary cell line as well as normal pituitary cells from lactating rats but does not affect the secretion of any other pituitary hormones (765). However, compared with equimolar quantities of some of the other well-described prolactin-releasing peptides, the 31-amino acid peptide is the only substance that potently stimulates prolactin secretion from cells obtained from lactating rats (765). Unfortunately, the claims of bioactivity as an authentic prolactin-releasing peptide have not been fully confirmed. When anterior pituitary cells obtained from male rats are exposed to the peptides, neither the 20- or 31-amino acid peptide stimulates prolactin secretion, whereas only the highest doses of either peptide stimulate prolactin secretion from pituitary cells obtained from random cycling female rats (1541). On the other hand, when administered intravenously to male rats or female rats during proestrus, estrus, or metestrus, the 31-amino acid peptide stimulates prolactin secretion in a dose-dependent manner during each stage of the estrous cycle (most effective during proestrus) as well as in male rats (1148). However, the effective dose is 10-fold greater in male than female rats. Such data suggest that the steroid milieu may determine the response of the lactotroph to these newly discovered peptides.

Immunocytochemical approaches reveal prolactin-releasing peptide-positive fibers in the paraventricular and supraoptic nuclei of the hypothalamus and in the neural lobe of the pituitary gland, whereas cell bodies are found in the dorsomedial and ventromedial nuclei of the hypothalamus (835, 1139). Within the paraventricular nucleus, double-label immunocytochemistry reveals synaptic contact with oxytocin-positive neurons. However, no prolactin-releasing peptide-positive cells or fibers are found in the external layer of the median eminence (835, 1139, 1897), the site at which one would expect to find neurohumoral terminals. On the other hand, immunoreactive processes in the hypothalamus often make contact with ependymal cells lining the third ventricle (835). In other parts of the brain, prolactin-releasing peptide-positive neurons (310, 835) and its message (1197) are noted mainly in two areas of the caudal medulla: ventrolateral reticular formation and commissural organ of the nucleus of the solitary tract, corresponding to the A1 and A2 noradrenergic areas. The distribution of the peptides in the CNS and intestine as well as the receptor throughout the CNS, anterior pituitary gland, and adrenal medulla has suggested an additional role for prolactin-releasing peptides in the central feedback control of neuroendocrine and autonomic homeostasis (1497).

The identification of immunopositive fibers in the neural lobe suggests that the peptide may arrive from the

neural lobe to the anterior lobe through short portal vessels connecting the two lobes. However, establishment of the physiological significance of these prolactin-releasing peptides awaits their identification in hypothalamo-hypophysial portal blood to be considered a neurohormone or in the anterior pituitary gland to be considered a paracrine or autocrine factor.

4. Amino acids

The group of amino acids that includes glutamate, aspartate, glycine, and GABA, and perhaps homocysteic acid and taurine, constitute the most widespread neurotransmitter family in the mammalian CNS (446). Because the vast majority of the excitatory neurotransmission is glutamatergic, and likewise, most of the inhibitory neurotransmission is GABA mediated, the focus is on these two amino acid neurotransmitters in this review.

A) AMINO ACID RECEPTORS. Most of the amino acid receptors belong to the ligand-gated ion channel superfamily of proteins (so-called ionotropic receptors), whereas others are members of the G protein-coupled receptor superfamily (metabotropic receptors). Although the cloned subunits of the ligand-gated ion channels are usually capable of forming a functional homomeric channel, these channels usually lack several features of the native channel complexes. Indeed, the native amino acid receptors are heteromeric structures, made up of several different subunits and auxiliary subunits. The differences in receptor composition likely confer varying modulatory capacity on the channel (446).

Ionotropic glutamate receptors consist of three subclasses: α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate, and *N*-methyl-D-aspartate (NMDA) receptors. These receptors respond to glutamate or glutamate analogs by activating a cation channel that is part of the receptor complex (for references, see Ref. 1409). Through different combinations of subunits and/or by alternative splicing of their mRNA, a large variety of these channels can exist. The glutamate receptor subunits are large ($\sim 100,000$ Da) compared with other ligand-gated ion channels such as GABA_A, glycine, or ACh_N receptors. The functional AMPA and kainate receptors are permeable to monovalent cations (Na^+ and K^+) only, and they usually mediate rapid excitatory events. The NMDA receptor comprises a glutamate binding site, a strychnine-insensitive glycine binding site, a polyamine binding site, and a phencyclidine (MK-801) binding site. It seems that glycine is a necessary coagonist for NMDA receptors. Unlike the AMPA and kainate receptors, the ion channel of NMDA receptors is also permeable to calcium, and this permeability has been linked to many of the long-term effects of NMDA receptors (1409).

Metabotropic glutamate receptors are members of the G protein-coupled receptor superfamily with a char-

acteristic seven transmembrane topology. Several metabotropic glutamate receptors have been identified with differing amino acid homologies, agonist preferences, and signal transduction pathways. The mGluR1 and mGluR5 receptors are linked to the phosphoinositol signal transduction pathway (sensitive to quisqualate), while mGluR2 and mGluR3 receptors are linked to the inhibition of cAMP cascade (the best agonist is glutamate); mGluR4, mGluR6, and mGluR7 are also linked to the inhibition of the cAMP cascade, but prefer L-(+)-2-amino-4-phosphonobutyrate (L-AP4) as an agonist (reviewed by Petralia and Wenthold, Ref. 1409).

As predicted (446), the surprisingly large variety of molecular forms of GABA, glutamate, and other amino acid receptors revealed by molecular cloning approaches present a daunting challenge for physiologists to establish the functional implications of these amino acid receptors.

B) EXCITATORY AMINO ACIDS. The excitatory amino acid (EAA) neurotransmission in the neuroendocrine hypothalamus has recently been reviewed (1793). On the basis of a great many morphological and electrophysiological (1791) studies, glutamate mediates most if not all fast excitatory inputs to the neurons in the arcuate nucleus (1793). Application of receptor autoradiography, *in situ* hybridization, and immunocytochemistry have provided detailed information concerning the distribution of binding sites, mRNA, and channel proteins for the large variety of glutamate receptors (for references, see Ref. 1409). Compared with the rest of the CNS, excitatory amino acid receptors in the hypothalamus are present in light to moderate density (1409). Most of the kainate receptors are in the arcuate nucleus-median eminence (1160, 1782), while NMDA binding sites were found in the preoptic area (1125). It is important to this review that several subtypes of AMPA, kainate, and NMDA receptors are detectable in all three lobes of the pituitary gland (1409). The latter observation indicates that, in addition to the CNS, glutamate receptors may play a direct role at the pituitary level (1409).

It is generally assumed that EAA exert their effects on prolactin secretion by acting at hypothalamic targets (208, 209). It has been reported, however, that glutamate increases prolactin secretion when applied in monolayer culture of dispersed pituitary cells of adult female rats (1074). Pharmacological characterization indicates that the receptor involved in the direct effect of glutamate on lactotrophs likely belongs to the NMDA subclass of the glutamate receptors (1074).

In neonatal rats, many neurons in the medial basal hypothalamus and the retina are vulnerable to systemically administered monosodium glutamate (MSG). Consequently, neonatally administered MSG causes severe disturbances in the regulation of anterior pituitary functions of the adult animal (21, 144, 350, 652, 1408, 1461, 1493, 1735, 1774). It is interesting to note that acute systemic

administration of MSG to the adult animal elicits a rapid and transient release of prolactin (1735). The latter result indicates that components of the regulatory circuitry of prolactin secretion not protected by the blood-brain barrier are sensitive to a glutamatergic stimulus (1735). Excitatory amino acids acting at the NMDA receptor likely play a role in modulating the activity of neuronal systems that regulate the release of both PRF and PIF (91). The effects of excitatory amino acids on prolactin secretion are largely determined by the relative activity of these two regulatory systems. Indeed, in a physiological situation with PRF dominance over PIF (lactation), EAA or EAA agonist administration decreases prolactin secretion (91) through activation of PIF (TIDA). In the case of male rats, where inhibition is the predominant central influence on prolactin secretion, EAA increase prolactin secretion presumably through activating PRF secretion into hypophyseal portal blood (91).

The effects of excitatory amino acids on prolactin secretion change with the reproductive state of the animal and the site of administration (208, 209). As with CNS administration, the predominant effects of these agonists are through stimulation of PRF and/or inhibitory interneurons affecting TIDA/PHDA. On the other hand, in the case of systemic administration, these agonists can reach only the arcuate nucleus-median eminence region, which includes the TIDA/PHDA neurons (208, 209). Central administration of agonists to kainate or NMDA receptors stimulates prolactin release in both cycling and lactating animals (1). Peripheral administration of NMDA agonists stimulates prolactin secretion, whereas kainate has no effect (1). In contrast, systemic injection of either agonist to lactating animals inhibits prolactin secretion, indicating that lactation qualitatively alters the responsiveness of the neural circuitry involved in the regulation of prolactin secretion (1). Interestingly, changes in responsiveness to EAA of those neuronal circuits regulating either prolactin or LH secretion are opposite in nature (1). Nevertheless, the effects of lactation (and the suckling stimulus *per se*) at the level of the pituitary gland should also be considered, since lactation fundamentally alters the responsiveness of the lactotroph to both releasing and inhibiting factors, possibly by remodeling signaling mechanisms coupled to the receptors of these factors (1048).

Hyperprolactinemia (induced by pituitary grafts under the kidney capsule) significantly reduces glutamate concentration in the mediocortical amygdala (1117). It seems likely, however, that this effect of chronically elevated prolactin concentration in the plasma is related to the behavioral changes associated with hyperprolactinemia rather than the regulation of pituitary prolactin secretion *per se* (1117).

C) INHIBITORY AMINO ACIDS (GABA). It has been reported that GABA is partially responsible for the nondopaminergic PIF activity within hypothalamic extracts (1569).

GABA neurons have been visualized by immunohistochemistry using an antibody against glutamate decarboxylase (GAD), an enzyme of GABA biosynthesis (1718, 1827). Cells of the anterior lobe contain specific receptors for GABA (664). Therefore, it is not surprising that GABA directly inhibits the release of prolactin (511, 1441, 1569). However, the effective molar concentration of GABA is ~100 times higher than that of dopamine tested in an *in vitro* superfusion system (1155). GABA concentrations in hypophyseal stalk blood have been equivocally reported to be either higher than (1206) or lower than (1247) that of peripheral plasma.

Initial observations concerning the effects of GABA on prolactin secretion detected both stimulatory and inhibitory influences (1357, 1386). Although in the mid 1970s evidence in favor of dopamine as the major PIF had already been strong (1299), efforts to isolate a nondopaminergic (potentially peptidergic) PIF from the hypothalamus continued. One of these endeavors pointed toward GABA as a potential hypothalamic PIF (1569) and provided impetus for further studies on the role of GABA in regulating pituitary function (292, 511, 1441).

The early results concerning the involvement of GABA in the regulation of prolactin secretion were reviewed by Cocchi *et al.* (347), Racagni *et al.* (1440), Muller *et al.* (1250), and later by Apud *et al.* (52). On the basis of biochemical and immunocytochemical studies, it has been concluded that there are two different GABAergic systems affecting pituitary function: one is intrinsic to the mediobasal hypothalamus (tuberoinfundibular GABAergic system), whereas the other is extrinsic with cell bodies located outside the hypothalamus that project to the mediobasal hypothalamus and establish synaptic contacts with aminergic and peptidergic neurons involved in endocrine functions (52, 1173, 1546, 1570, 1716, 1718, 1719). On the basis of numerous biochemical and immunocytochemical studies (52, 54, 56, 1442), it seems that GABA is not synthesized in the anterior pituitary but rather originates from the CNS and is transported to the anterior lobe of the pituitary gland via the hypophyseal portal system. Indeed, immunochemical and electron microscopic studies detect an abundant GAD-positive (GABAergic) nerve plexus in the external zone of the median eminence (1716, 1827) and nerve endings adjacent to the perivascular space of the fenestrated portal capillaries (1719). In addition, morphological evidence suggests a strong GABAergic innervation of the paraventricular and supraoptic hypothalamic nuclei (1174, 1737), areas thought to be important in PRF-mediated effects on prolactin secretion (1303).

The GABAergic neurons in the medial basal hypothalamus receive multiple intrahypothalamic and extrahypothalamic inputs. A direct stimulation of hypothalamic GABAergic neurons by serotonin (12) and substance P (11) has been demonstrated. Because these latter trans-

mitters have a stimulatory influence on prolactin secretion, it seems reasonable to assume that the GABAergic neurons stimulated by serotonin and substance P function as inhibitory interneurons affecting TIDA activity (1049, 1173, 1717).

The turnover of dopamine in the medial preoptic/anterior hypothalamic area, nucleus accumbens, anterior mediobasal hypothalamus is decreased, whereas dopamine turnover in the mediocortical amygdala is increased by the GABA_A agonist muscimol (588). The effect of muscimol on the mediobasal hypothalamic dopaminergic neurons could be related to the elevated prolactin level caused by the same treatment (588).

In dispersed anterior pituitary cells in a cell-perfusion apparatus, GABA and the GABA agonist muscimol dose-dependently inhibit the release of prolactin (679). GABA antagonists (bicuculline and picrotoxin) block the action of GABA or muscimol, indicating the presence of specific GABA_A receptors on pituitary lactotrophs (679).

The relatively low potency and efficacy of GABA and GABA mimetics on prolactin secretion in vitro makes it difficult to assess the true regulatory and/or clinical potential of GABA at the pituitary level (54, 55, 1168). Although both the brain and anterior pituitary GABA receptors have similar affinity for GABA in Scatchard analysis, in displacement studies pituitary GABA receptors show significantly less affinity for the GABA_A agonist muscimol or the antagonist bicuculline (54). In addition, in male rat anterior pituitary slices, 10^{-6} M GABA is effective in decreasing prolactin release only in the presence of ethanolamine-*O*-sulfate, a potent GABA-transaminase (GABA-T) inhibitor (54). The low affinity of GABA mimetics and the rapid degradation of GABA in vitro could, at least in part, explain the relatively weak direct effects of these compounds on lactotrophs. It is also conceivable that there are two distinct GABA receptors and/or signaling pathways that elicit opposing biological effects on lactotrophs. Indeed, the GABA_A receptor agonist muscimol has a biphasic effect on prolactin secretion in vitro, since at low concentrations it stimulates whereas at high concentrations it inhibits prolactin secretion (38, 39). In addition to its effects on secretion, GABA (through GABA_A receptors) inhibits prolactin gene expression by acting directly on lactotrophs (1072, 1073).

The GABA receptors in the anterior pituitary have been thoroughly characterized (for references, see Ref. 52). From functional studies, it seems likely that the predominant receptor in lactotrophs is GABA_A. Indeed, the ability of GABA_A agonists to displace [³H]GABA binding from anterior pituitary membranes correlates well with their potency to inhibit prolactin secretion under stimulated conditions (e.g., hyperprolactinemia induced by dopamine antagonists). It has been recognized that GABA_A receptors in the CNS are part of a multimolecular complex consisting of a chloride ionophore and its associated

regulatory protein, a bicuculline-sensitive GABA binding site, a benzodiazepine recognition site, and a membrane-bound protein that can alter GABA and benzodiazepine sensitivity (363). GABA_A receptor in the anterior pituitary and the CNS present similar affinity constants when evaluated by Scatchard analysis (54). However, in displacement studies, muscimol (a GABA_A agonist) and bicuculline (a GABA_A antagonist) show 10–100 times less affinity in the anterior pituitary (54). Interestingly, benzodiazepines and barbiturates potentiate the stimulatory effect of muscimol on prolactin secretion, whereas the inhibitory phase is not affected by these drugs (39). These results indicate that the effect of GABA on lactotrophs is complex and that at least one component of the GABA_A receptor-mediated effects is modulated by benzodiazepines and barbiturates, similar to that described in the CNS (39, 661, 1826).

Although the majority of the studies have described GABA_A receptor-mediated regulation of prolactin secretion at the pituitary level, several observations indicate that prolactin secretion can also be modulated through GABA_B receptors. The GABA_B agonist baclofen (β -*p*-chlorophenyl- γ -aminobutyric acid) decreases basal and TRH-stimulated prolactin secretion in a concentration-dependent manner when applied in monolayer culture of dispersed anterior pituitary cells (1091).

In many cases, the effects of systematically administered GABA agonists on basal prolactin secretion in vivo are less than impressive (55, 394–396, 459, 1168). It should be considered, however, that under basal condition, prolactin secretion is tonically suppressed by dopamine of hypothalamic origin; therefore, a further decrease in prolactin secretion by any putative PIF is likely to be modest. However, after relieving the dopaminergic inhibition of prolactin secretion by haloperidol (D₂ dopamine antagonist), GABA_A agonists are capable of significantly decreasing prolactin secretion (55, 397). In addition, the stimulation of prolactin release by histamine is prevented, and the proestrous prolactin surge is significantly blunted by systemic treatment with GABA mimetics or GABA-T inhibitors (459, 1632). It has been reported that in male rats, the GABA_B agonist baclofen blocks prolactin secretion induced by a variety of stressful conditions (430a, 1092). In addition, the same agonist also decreases the elevation of prolactin elicited by serotonin or a suckling stimulus. On the other hand, baclofen is ineffective in changing prolactin secretion following the blockade of dopaminergic neurotransmission by haloperidol or α -MPT (1092). It has therefore been suggested that baclofen inhibits prolactin secretion through a PRF component of the neuroendocrine responses evoked by stress or suckling (1092, 1881).

Centrally administered GABA or the GABA_A agonist muscimol (5 nmol) in most cases reduces hypothalamic dopamine turnover while resulting in increased prolactin

concentration in the plasma (588, 998, 1249, 1356, 1378). However, in some studies carried out in ovariectomized female rats, GABA implanted directly into the arcuate nucleus fails to increase prolactin secretion (1318). Because the peripheral blood contains a significant amount of GABA, the question arose whether the GABA that affects the pituitary lactotrophs is of central or peripheral origin. Intracerebroventricular injection of anesthetized male rats with ethanolamine-*O*-sulfate, the specific inhibitor of GABA catabolism, causes a marked reduction in serum prolactin level and a three- to fourfold rise in the concentration of GABA in the pituitary stalk and in the hypothalamus (56). This demonstrates that GABA in the pituitary stalk plasma is derived from the CNS and that an abrupt increase in the concentration of GABA in hypophyseal portal blood is associated with a suppression of prolactin secretion (56, 691). The effects of ethanolamine-*O*-sulfate on the hypothalamic and anterior pituitary GABA concentration and prolactin secretion occur much earlier than the increase of GABA concentration in the peripheral plasma, indicating that circulating GABA does not play a functional role in the control of prolactin secretion (56). It should be mentioned, however, that the physiological importance of GABA in the hypophyseal portal blood has been subsequently challenged by others (1247, 1619). Nevertheless, the physiological role of GABA in regulating prolactin secretion is further supported by a close temporal relation between daily fluctuations in the activity of the tuberoinfundibular GABAergic system and the circadian prolactin surges (293). It has been suggested that changes in GABAergic activity might occur as a delayed response to prolactin circadian surges (293).

Treatment of ovariectomized rats with aminooxyacetic acid, a GABA-T inhibitor which elevates GABA levels in the CNS, leads to an increase in hypothalamic TH activity and a concomitant decrease in plasma prolactin concentration (96). Muscimol inhibits [^3H]dopamine release from the median eminence *in vitro* in a bicuculline-sensitive, strychnine-insensitive manner, indicating a pre-synaptic inhibition of dopamine release by GABA_A receptors (37). When single-unit activity of neurons in the dorsomedial/ventrolateral part of the arcuate nucleus was examined, over 90% of these cells were inhibited by baclofen, a GABA_B agonist (1049), suggesting a robust, functional inhibitory GABAergic input to the TIDA neurons. Studies in male rats indicate that although acute pharmacological activation of GABA_B receptors inhibits TIDA neurons (1881), these neurons are under tonic inhibition mediated by GABA_A but not GABA_B receptors (1881). Taken together, these observations provide further evidence that the major central effect of GABA on prolactin secretion is exerted by inhibiting the neuroendocrine dopaminergic cells of the hypothalamus. Because the sensitivity of these dopaminergic neurons to neural inputs is

sexually differentiated, that would explain the previously observed gender-related differences in the effects of GABA on prolactin secretion observed in most (1106, 1210, 1846), but not all (1469), laboratories.

Lactating female rats represent a unique model for the regulation of prolactin secretion (for references, see Ref. 1303) where the hypothalamo-pituitary GABAergic system seems to play an important role. Indeed, in lactating rats separated from their pups, reinstitution of suckling results in an increase in GAD activity in the medial basal hypothalamus and an increase in GABA content in the anterior pituitary (1439).

It was suggested that the major function of GABAergic neurons is negative-feedback regulation of prolactin secretion to prevent an exaggerated prolactin output during specific physiological situations (52, 477, 479). Indeed, hyperprolactinemia elevates central GABAergic activity as evidenced by an increase in hypothalamic GABA concentration and GAD activity (543). The effects of prolactin on GABAergic activity *in vivo* are mainly indirect and mediated by substance P and/or serotonin (11, 12, 1706). Immunoneutralization of endogenous substance P prevents prolactin-induced elevation of GABA in the anterior pituitary and diminishes the depolarization-induced GABA release from hypothalamic fragments *in vitro* (11). There are some indications that prolactin can affect tuberoinfundibular GABAergic neurons directly, suggesting that prolactin may influence its own secretion by stimulating the release of hypothalamic GABA, both through an increase of GABA synthesis and modification of GABA reuptake (478, 480). An activation of GABAergic neurons by prolactin in the hypothalamus is supported by the observations that prolactin induces a rapid elevation in intracellular free Ca^{2+} applied in primary cultures of rat embryonic diencephalon (970).

Hyperprolactinemia induced by pituitary grafts under the kidney capsule significantly reduces GABA concentration in the nucleus accumbens and the mediocortical amygdala (1117). In the case of sustained hyperprolactinemia, GABA turnover is reduced in the nucleus accumbens, whereas it is increased in the medial preoptic area (1117). Thus GABAergic systems in these brain areas might not be involved in regulating prolactin secretion *per se*, but rather mediate the prolactin-induced suppression of LH secretion, and/or elicit behavioral effects associated with hyperprolactinemia (1117, 1118). Centrally administered prolactin causes a delayed increase in GABAergic activity in the hypothalamus and GABA concentration in the hypophyseal portal plasma (1071). This indicates that the activity of the tuberoinfundibular GABAergic neurons is regulated by circulating prolactin. Taken together, these results strongly support the notion that prolactin is capable of activating GABAergic neurons in the medio-basal hypothalamus, constituting a short-loop feedback

system by which prolactin regulates its own secretion (1071).

The activity of hypothalamic GABAergic neurons as well as the responsiveness of lactotrophs to GABA are both strongly affected by gonadal steroids, especially estradiol (53, 423, 441, 477, 859) and testosterone (669). The existence of a large number of estradiol-receptive, GABAergic neurons in the mediobasal hypothalamus suggests that these neurons are targets for the positive feedback action of estradiol on prolactin secretion (562). Indeed, estrogens induce hyperprolactinemia concomitantly with an increase of hypothalamic GAD and GABA-T activity, as well as GABA concentration (441). A single injection of estradiol does not change the activity of the tuberoinfundibular GABA neurons as assessed by the rate of GABA accumulation in the median eminence and the anterior pituitary following the blockade of GABA catabolism by ethanolamine-*O*-sulfate (53). However, a single injection of estradiol causes a shift of pituitary GABA receptors from low- to high-affinity state and results in a modest elevation of prolactin secretion. After the single estradiol administration, the GABA agonist muscimol causes a significant decrease in serum prolactin concentration. Chronic estradiol administration reduces the activity of the tuberoinfundibular GABA neurons and drastically decreases the number of high-affinity GABA receptors in the anterior pituitary, resulting in a robust elevation in plasma prolactin concentration. Under these circumstances, muscimol is ineffective in reducing plasma prolactin concentration (53), suggesting that the high-affinity population of anterior pituitary GABA receptors (presumably expressed by the lactotrophs themselves) are involved in the mechanisms whereby GABA inhibits prolactin release from the lactotrophs (53).

It is interesting to note that lactotrophs, as a result of an extended exposure to estradiol, tend to lose their responsiveness to inhibition by GABA (53), dopamine (1024), or endothelins (Kanyicska and Freeman, unpublished data) and became prone to malignant transformation. The precise molecular mechanisms underlying these changes in responsiveness toward endogenous PIF brought about by long-term exposure to estradiol is not yet understood. It seems likely that downregulation of a subset of G_i/G_o proteins is, at least in part, responsible for the estradiol-induced changes in lactotrophs' function (198, 199, 308, 1178, 1397).

The effects of GABA through $GABA_A$ receptors are thought to be initiated by an increase in conductance of cell membrane to chloride ions through activation of chloride channels, which leads to a hyperpolarization of the plasma membrane causing a decrease of Ca^{2+} influx through voltage-dependent Ca^{2+} channels. Patch-clamp studies on rat and bovine lactotrophs indicate that the main effect of GABA on lactotrophs is indeed mediated through modulation of chloride ion conductance. The

chloride channel involved in lactotrophs is voltage insensitive and has a slope conductance of 20 pS (840, 841, 846). Muscimol mimics the effect of GABA on these channels, whereas baclofen is without effect, indicating a $GABA_A$ receptor-mediated activation of these channels (841). The $GABA_B$ receptors couple to potassium channels through GTP-binding proteins (41). Therefore, $GABA_B$ receptor activation also leads to membrane hyperpolarization by increasing membrane conductance to potassium ions. It has been suggested that GABA acting at $GABA_A$ and $GABA_B$ receptors might originate from distinct sets of GABAergic neurons (1699).

Isolated lactotrophs in primary culture respond to GABA or GABA mimetics with a transient increase of cytosolic free Ca^{2+} and depolarization of the plasma membrane (1082). The pharmacology of the latter effect of GABA is consistent with $GABA_A$ receptor involvement (1082). However, these effects of GABA seem inconsistent with the inhibition of prolactin secretion.

The role for GABA as the most important fast inhibitory neurotransmitter in the brain is so well established that the presence of the GABA-synthesizing enzyme GAD in axon terminals is usually interpreted as a sure sign of their inhibitory function (401, 1719). However, there are several observations that can challenge the view that GABA is always inhibitory (1362, 1403). For example, during early postnatal life, GABA is markedly stimulatory on GH and, to a lesser extent, on prolactin secretion when applied directly on pituitary slices or dispersed pituitary cells (6, 7). A similar observation has been made on cultured hypothalamic neurons using electrophysiological techniques (1847). Because GABA exerts its fast inhibitory action through activation of Cl^- channels, it can be assumed that in neonatal cells, the equilibrium potential for Cl^- is higher than the resting potential compared with that of adult cells. Therefore, activation of Cl^- channels will cause a depolarization of the cell membrane, an observation which offers a plausible explanation for the observed stimulation of Ca^{2+} influx by GABA or $GABA_A$ agonists on neonatal anterior pituitary cells (8, 9) and neurons as well (311, 1847). More recently, it has been reported that in mature neurons of the suprachiasmatic nucleus of the hypothalamus, GABA acts as an excitatory neurotransmitter during the day and as an inhibitory neurotransmitter at night (1847). Taken together, although the inhibitory function of GABA seems prevalent, under certain conditions, activation of $GABA_A$ receptors can result in stimulation of the target cell (355).

5. Gaseous transmitters

A) NITRIC OXIDE. Nitric oxide and, more recently, carbon monoxide have been shown to play a regulatory role in neuroendocrine function and prolactin secretion (207).

Among the gaseous neurotransmitters, nitric oxide is the most widely described as controlling prolactin secretion.

Unlike the classical neurotransmitters, nitric oxide is not stored in synaptic vesicles, is not limited to actions at synapses, and does not interact with classical receptor proteins, but it merely diffuses to nearby cells where it modulates the function of postreceptor transduction cascades (388, 389, 1083, 1213, 1254, 1293, 1576). Nitric oxide is synthesized from L-arginine by nitric oxide synthase (389, 1212). Although there are three major isoforms of the enzyme identified to date, only one, neuronal nitric oxide synthase (389), has been shown to play a role in control of prolactin secretion (171, 207).

Because nitric oxide synthase is identical to neuronal NADPH-diaphorase (387), cytochemical detection of NADPH-diaphorase activity is frequently used to study the distribution of nitric oxide synthase. Nitric oxide synthase is found throughout the CNS (1922). In the rat, nitric oxide synthase is present in the anterior pituitary (301), throughout the hypothalamus (51, 172), and colocalized in the locus coeruleus with norepinephrine (1893). Within the hypothalamus, nitric oxide synthase (NADPH-diaphorase) activity is found in the paraventricular and supraoptic nuclei as well as in the lamina terminalis (51, 172, 213, 1767). Moderate activity is found in the medial preoptic nucleus, ventromedial nucleus, suprachiasmatic nucleus, and median eminence (172).

Most of the studies examining a role for nitric oxide on the hypothalamo-pituitary axis focus on LH secretion (207). There is, however, some evidence that nitric oxide may play a role in the control of prolactin secretion as well. Administration of the nitric oxide synthase inhibitor *N*^ω-nitro-L-arginine blocks the preovulatory release of prolactin on proestrus (185). Likewise, administration of the nitric oxide synthase inhibitor *N*^ω-nitro-L-arginine methyl ester blocks the steroid-induced proestrus-like release of prolactin in ovariectomized rats (185). Similar pharmacological blockade of nitric oxide synthase inhibits stress-induced prolactin secretion in male rats, while potentiating morphine-induced increase of prolactin secretion (1157). The latter results are somewhat unexpected, since stress is thought to affect prolactin secretion via activation of the endogenous opioid system (239, 1540, 1634, 1808). It should be considered, however, that systemic nitric oxide synthase inhibition likely affects several different pathways of neurotransmission mediating stress-induced prolactin secretion in addition to endogenous opioids. It is also conceivable that blocking of nitric oxide synthesis has differential effects on morphine-induced (activating a μ -type opioid receptor) versus an endogenous opioid-induced (perhaps activating a κ -opioid receptor) signaling (120).

Administration of the nitric oxide donor sodium nitroprusside to conscious male rats stimulates prolactin secretion (641). All in all, these data indicate that nitric

oxide plays a stimulatory role in the control of prolactin secretion. In support of the former assertion, it has been shown recently that sodium nitroprusside enhances prolactin secretion by inhibiting tyrosine hydroxylase activity in the median eminence of male rats (642), while administration of the nitric oxide synthase inhibitor *N*^G-nitro-L-arginine blocks the estrogen-induced increase of prolactin secretion of ovariectomized rats by increasing dopaminergic activity in the median eminence (1912). These data, therefore, suggest that nitric oxide enhances prolactin secretion by diminishing the activity of TIDA neurons.

At the pituitary level, it seems that nitric oxide, formed either by inducible or constitutive isoforms of nitric oxide synthase (1803), may mediate the inhibitory effect of cytokines on prolactin secretion (1163–1165). Moreover, recent observations suggested that nitric oxide inhibits prolactin secretion by activating guanylyl cyclase-cGMP pathway and that this mechanism may be involved in the GABA-induced inhibition of prolactin secretion (481, 1161, 1162). In addition, incubation of male rat hemipituitaries with sodium nitroprusside inhibits basal prolactin secretion from these glands (482). Interestingly, when applied on dispersed cells from male rat pituitary glands, molsidomine, also a nitric oxide donor (1455), stimulates basal prolactin secretion (238). The opposing biological effects of nitric oxide observed in intact tissue (482) and dispersed cell (238) preparations indicate that cell-to-cell interactions may be important in determining the effects of nitric oxide on prolactin secretion.

Taken together, these data indicate clearly that nitric oxide plays a role in regulating prolactin secretion and argue for a stimulatory role of nitric oxide within the hypothalamus and a predominantly inhibitory effect within the anterior pituitary gland.

B. Intrapituitary Regulation

In addition to the intricate regulation by the hypothalamus and peripheral endocrine glands (reviewed in sect. VII, A and C), the secretion of prolactin is also influenced by local regulatory mechanisms (Fig. 3). It is now widely accepted that the anterior lobe of the pituitary gland has an intrinsic regulatory capacity through paracrine and autocrine signals and that this type of regulation can robustly affect lactotroph function (141, 1577). Because these local regulatory mechanisms of the pituitary gland have recently been extensively reviewed (141, 1577–1579), we will provide only a brief survey of local control of prolactin secretion and elaborate on recent developments in this quickly expanding research area.

1. Anterior lobe

A) AUTOCRINE AND PARACRINE REGULATION: AN OVERVIEW. Modes of local regulation of cellular functions, brought

about by the secretion of diffusible molecules, can be further divided based on the positional relation of the participating cells. The regulation is called autocrine when the secretory product of the cell regulates its own secretion. In the case of paracrine communication, the secretory product is transported by extracellular fluid and exerts a biological effect on target cells at some distance. Juxtacrine regulation is distinguished as a special case of paracrine regulation when the source and target cells are adjacent (juxtaposed) to each other. In addition, when the lactotroph lies in intimate physical contact with another anterior pituitary cell (which could be another lactotroph as well), interactions are also possible without diffusible messenger molecules, through gap junctions or extracellular matrix proteins (164, 165, 424, 494). Because gap junctions, to some extent, are permeable to intracellular messengers such as Ca^{2+} , inositol trisphosphate, or cAMP, it seems conceivable that a larger cell population can be synchronized through these intercellular channels (424). It appears that certain physiological situations promote the formation of reversible supracellular functional units within the pituitary gland. For instance, it has been reported that during lactation, lactotrophs and folliculostellate cells are functionally coupled through gap junctions (25, 26, 991, 1325). Although these types of communication between pituitary cells are extremely important (especially from a pathophysiological point of view), a detailed discussion is beyond the scope of this review. As for the rest, we discuss cell-to-cell communications through secreted diffusible messenger molecules pertaining to prolactin secretion.

A direct contact occurring between lactotrophs and other pituitary cell types in vivo (792, 1287, 1559) is suggestive of juxtacrine regulation. However, such intimate contact between cells does not seem to be required for a more general paracrine regulation of prolactin secretion (426). Paracrine interactions between different pituitary cell types have been studied extensively by Denef et al. (426). Four different cell types have been established as potential sources of paracrine signals affecting lactotroph function: lactotrophs, gonadotrophs, corticotrophs, and folliculostellate cells (101, 425, 1577).

To consider a factor as a potential intrapituitary messenger, proof of its local synthesis should be provided. For peptides and proteins, demonstration of the presence of immunoreactive material together with the respective mRNA through the combined application of immunocytochemical and in situ hybridization techniques is usually accepted as proof of local synthesis. To establish small nonpeptide molecules, such as acetylcholine, ATP or nitric oxide as autocrine/paracrine agents could be more complicated, and usually requires in vitro biochemical/pharmacological experimentation in addition to the demonstration of the synthesis enzyme(s) with immunocytochemistry and in situ hybridization.

Numerous peptides and other molecules have been detected in the pituitary gland that are known to be capable of modulating prolactin secretion (800), including VIP (1275), galanin (596, 909), endothelin (452, 905), prolactin (146, 890, 795), ANG II (426), substance P (89), neurotensin (89, 630), GnRH (129, 1227), TRH (320), corticotrophin releasing factor (1228), growth hormone releasing factor (1230), somatostatin (1229), gastrin (1458), secretin (1335), enkephalins (950, 1771, 1870), vasopressin (828), and acetylcholine (276, 276, 277, 1245, 1564, 1729). There is reason to believe that these messenger molecules are synthesized locally rather than being taken up after delivery through the portal circulation. Considering the high "spontaneous" rate of prolactin secretion, it probably is significant that most of these peptides are potent stimulators of prolactin secretion by acting directly on the lactotrophs (505, 512, 663, 734, 916, 918, 1046, 1154, 1754, 1820).

There is an ever-growing list of peptides with the potential to act as local regulators of prolactin secretion. However, establishing the precise mode of their actions in a physiological context presents a significant challenge. It is probably the most difficult to produce unambiguous data in support of autocrine control of prolactin secretion, since the presence of a biologically active molecule and its mRNA in the lactotroph is not sufficient to verify an autocrine role. Furthermore, demonstration of the biological effect of the putative autocrine agent by antagonism or immunoneutralization in most of the in vitro test systems still would not support such a role convincingly, since these methods are usually applied to a heterogeneous cell population in which a wide variety of cell-to-cell interactions can occur. It seems that the best methodological approach currently available to characterize autocrine regulation is a carefully designed reverse hemolytic plaque assay (572, 576, 1211, 1300). With the use of this method, the secretory activity of a single cell can be assessed quantitatively without interference from neighboring cells (190, 250, 573, 771, 862, 1030, 1090, 1275, 1282).

B) AUTOCRINE AND PARACRINE REGULATORS OF PROLACTIN SECRETION. *I) VIP.* VIP, a known hypothalamic stimulator of prolactin release (4, 1528, 1609), is also synthesized within the anterior lobe of the pituitary gland (87), more specifically, by the lactotrophs (978). Specific VIP antiserum, but not other hyperimmune sera, decreases basal secretion of prolactin in vitro, thus suggesting a paracrine and/or autocrine stimulation of prolactin secretion by locally produced VIP (715). An autocrine control of prolactin secretion by VIP has been demonstrated unequivocally using reverse hemolytic plaque assay (1275), by showing that under conditions in which the pituitary cells are plated at sufficiently low density to preclude paracrine interactions, VIP antiserum or a VIP antagonist suppresses prolactin secretion (1275). These findings likely

have far-reaching physiological and pathological relevance, albeit none has been firmly established yet. For instance, it seems conceivable that the peculiar ability of lactotrophs to secrete prolactin vigorously without any exogenous stimulant may be due to a positive feedback exerted by its own VIP secretion. With some stretch of imagination, it can be envisioned that VIP is a common autocrine mediator of all other PRF or PIF. In support of this notion, it has been found that the presence of a VIP antagonist attenuates TRH-stimulated prolactin secretion in vitro (113). Similarly, the stimulatory effects of serotonin on prolactin secretion from cocultures of anterior lobe and neurointermediate lobe cells can be blocked by simultaneous incubation with a VIP antagonist (115). In addition, it is also conceivable that dopamine may suppress prolactin secretion, at least in part, by antagonizing the stimulatory effect of VIP through an activation of inhibitory signaling or by inhibiting VIP secretion per se, or both (114). Taken together, it appears that VIP has a multifaceted role in the regulation of prolactin secretion that may involve an autocrine, paracrine, or neuroendocrine route of delivery (1275).

II) Galanin. Several lines of evidence indicate that galanin regulates prolactin secretion in a auto- and/or paracrine manner. Galanin-like immunoreactivities have been found in the anterior lobe of rat and human pituitary glands (803, 808, 818, 819, 909, 1840), and it appears that galanin is an estrogen-inducible secretory product of the anterior lobe of the pituitary gland (909, 1339, 1843). Specifically, galanin mRNA and peptide have been detected in lactotrophs (823, 1339). Interestingly, galanin secretion is also affected by prolactin secretagogues, in accordance with galanin's stimulatory effect on prolactin secretion. For instance, galanin secretion from the rat anterior lobe is inhibited by dopamine and somatostatin and stimulated by TRH (824) and estrogen (726, 749, 823, 1843). Exogenous galanin stimulates basal as well as TRH-induced prolactin release and lactotroph proliferation in rats (1360, 1889) and humans (628). Immunoneutralization of endogenous galanin attenuates the preovulatory release of prolactin on proestrus (1081). Although receptor autoradiography fails to detect specific galanin binding sites in the pituitary (820), data obtained by the more sensitive receptor-binding assay clearly indicate that high-affinity galanin receptors are indeed present in the anterior lobe (1890). Moreover, the recently cloned galanin receptor, GALR2, has been shown to be expressed in the anterior lobe of the pituitary gland (532).

Recent experiments provided direct evidence for a tonic autocrine and paracrine stimulatory action for intrapituitary galanin on prolactin secretion (1841, 1843, 1888). In an elegant study, Cai et al. (258) have shown that in estrogen-treated Fischer 344 female rats, more than 90% of the galanin-expressing cells are lactotrophs. Furthermore, with the use of the combination of reverse

hemolytic plaque assay and in situ hybridization, it was found that galanin-positive lactotrophs secrete significantly greater amounts of prolactin compared with galanin-negative lactotrophs. The autocrine function of pituitary galanin has been further supported by in vitro immunoneutralization experiments showing that galanin antiserum significantly attenuates prolactin secretion from galanin-positive cells (258).

III) Endothelins. Endothelin-like peptides (especially ET-1) are potent inhibitors of prolactin release in vitro (452, 902, 903, 1140, 1543, 1544, 1689, 1689). Because endothelin-like peptides are present in all three lobes of the pituitary gland (452, 905) as well as in spent media from rat anterior pituitary cell cultures (1149), it seems plausible that these peptides contribute to the local regulation of prolactin secretion. Endothelin-like immunoreactivity is detectable in lactotrophs (905) as well as other cells of the anterior lobe (1292). Moreover, by using endothelin-specific reverse hemolytic plaque assay, it has been shown that endothelin is indeed secreted from lactotrophs. Interestingly, lactotrophs obtained from cycling female rats show signs of more vigorous endothelin secretion compared with lactotrophs from males (905). The amount of endothelin secreted by the lactotrophs is biologically significant, since it is sufficient to inhibit prolactin secretion, as attested by the fact that the presence of ET_A receptor antagonists markedly enhance prolactin secretion as detected by reverse hemolytic plaque assay (905). Because lactotrophs bear ET_A receptors (904, 1532), it is not surprising that ET_B antagonists were ineffective on prolactin secretion (905). Because in these experiments the reverse hemolytic plaque assay was performed under conditions that preclude paracrine interactions, the argument has been made that prolactin secretion is under autocrine control by endothelins (905). We should add, however, that these data, while strongly supporting the possibility of autocrine regulation by endothelins, by no means exclude paracrine control of prolactin secretion by endothelins.

IV) Prolactin. It is well established that prolactin can inhibit its own secretion by activating neuroendocrine dopaminergic neurons in the hypothalamus (65, 82, 773a, 1353, 1584). However, there is evidence that prolactin can also act directly at the lactotroph and inhibit its own secretion in an autocrine/paracrine manner, in both human and rat pituitary glands (146, 890, 795). Prolactin receptor is detected on the membrane of lactotrophs (323). Moreover, by using electron microscopy and autoradiography, it has been found that prolactin is bound to the plasma membrane and subsequently internalized and found in the Golgi apparatus, secretory granules, nucleus, and mitochondria of the lactotroph (627).

These data demonstrate clearly that lactotrophs have the capacity to perceive and respond to prolactin in their environment. It is interesting to note that in certain phys-

iological or pathological conditions, such as lactation or prolactinoma, lactotrophs apparently lose their autoinhibitory response to prolactin. It appears that the autoinhibitory function of prolactin is related to a particular isoform of the hormone (768) and that an impairment of the synthesis and secretion of this isoform is responsible for the lack of prolactin-induced autoinhibition (768). On the other hand, another isoform of prolactin can act as an autocrine growth factor in tumorous cells (980), resulting in unrestrained cell proliferation (980).

It seems well established that prolactin, together with VIP, galanin, and endothelin, can regulate lactotrophs' function in an autocrine manner, and there is a high probability that such regulation is indeed operational *in vivo*. However, by confirming the autocrine regulatory function of these agents does not exclude the possibility that they also subserve a role as paracrine modulators of prolactin secretion as well. Indeed, simply by considering that a large proportion of the cells in the anterior lobe is lactotroph and many lactotrophs are actively secreting VIP, galanin, endothelin, and prolactin, there is reason to believe that paracrine type of interactions among lactotrophs through these peptides may also exist.

V) ANG II. There is abundant evidence that ANG II is formed in the anterior lobe of the pituitary gland (601, 602, 1290, 1674, 1677), specifically in the lactotrophs (1529, 1674). Moreover, ANG II receptors have been found in the pituitary (1244), presumably in lactotrophs (14, 273, 746, 1244). Because ANG II is a potent stimulator of prolactin release (14, 426, 1575), it seems quite likely that angiotensin stimulates prolactin secretion in a paracrine and/or autocrine manner (987, 1265, 1676, 1678).

VI) Substance P. Although substance P affects prolactin secretion through a neuroendocrine or neurotransmitter role (reviewed in sect. VIIA), there is some evidence that it may also originate from a pituitary source. The preprotachykinin gene has been found in the anterior pituitary, and its expression is regulated by thyroid hormone (872) and estrogen (225). Moreover, substance P and other preprotachykinin gene products are also found in the anterior lobe (428, 1226). Finally, with a cell immunoblot assay, it has been shown that anterior pituitary cells actually secrete substance P (85). Unfortunately, in none of these studies was the endocrine phenotype of the anterior pituitary cell determined, nor was a substance P antagonist applied. Consequently, there is no direct proof to differentiate substance P as either an autocrine or paracrine regulator of pituitary prolactin secretion.

VII) Growth factors. There is strong evidence for an autocrine/paracrine role for transforming growth factor- β (TGF- β), epidermal growth factor (EGF), and nerve growth factor (NGF) in the control of prolactin secretion.

A) TGF- β . TGF- β is a polypeptide of 25 kDa and exists as three isoforms (TGF- β 1, TGF- β 2, and TGF- β 3). The anterior pituitary contains TGF- β 1 and TGF- β 3 (247,

1389, 1552). In lactotrophs, the presence of TGF- β 1 protein as well as TGF- β receptor and its mRNA have been demonstrated (247, 391, 1552). The lactotroph expresses both forms of the TGF- β receptor, designated type I and type II (1389). Most of the biological activity of TGF- β 1 can be attributed to the type I receptor, whereas the growth-inhibitory response is due to type II receptor activation (1553). Intrapituitary administration of TGF- β 1 suppresses pituitary cell proliferation and decreases pituitary prolactin content and plasma prolactin concentration (1198). Moreover, TGF- β inhibits basal secretion of prolactin in a pituitary monolayer culture system (1262) as well as prolactin gene expression in GH₃ cells (408) and normal anterior pituitary cells (5, 1712), likely by a paracrine route (5). It is interesting to note that in rats in which pituitary tumors are induced by estrogen, the proteins and mRNA for TGF- β 1 and the type II receptor are reduced (1389). This finding raises the possibility that pituitary tumorigenesis may be the result of suppression of TGF- β activity.

B) EGF. EGF is a single-chain polypeptide originally extracted from the mouse submaxillary gland. In the anterior pituitary gland, the presence of prepro-EGF mRNA (1444) and the secretion of EGF peptide has been demonstrated (988). Within the pituitary gland, EGF binding sites are restricted to lactotrophs (303, 536). Functionally, EGF promotes differentiation of lactotrophs at the expense of somatotrophs in neonatal rats (542) and stimulates prolactin gene transcription in and prolactin secretion from lactotrophs (1263). EGF also induces expression of functional D₂ dopamine receptors in lactotroph-like cell lines lacking the receptor (1204). Approximately 20% of the cells in the anterior pituitary gland of lactating rats secrete EGF, with 27% of those being lactotrophs (1239). Without reference to cell of origin, it has been suggested that EGF exerts its effects through autocrine and paracrine routes (1237). It is interesting to note that anterior pituitary cells from proestrous rats secrete the greatest amount of EGF and that estradiol is a potent stimulator of EGF secretion from rat pituitary cells (1238). With this in mind, it is tempting to speculate that estrogen induces the proestrous surge of prolactin secretion (1302) partly by stimulating intrapituitary EGF secretion, hence priming the lactotrophs for the massive hormone secretion brought about by hypothalamic factors.

C) NGF. The 26-kDa peptide NGF and its receptor are found in all three lobes of the pituitary gland, with greatest abundance in somatotrophs and lactotrophs (1202, 1395). Stimulation of these cells with VIP (1201) or interleukin-1 β (1396) results in secretion of NGF. Much like EGF, NGF promotes differentiation of lactotrophs at the expense of somatotrophs in GH₃ cells (1203) and anterior pituitary cells from early postnatal rats (1201). NGF also promotes mitogenesis of immature pituitary cells (1437). Unlike EGF, NGF does not appear to be involved directly

in the control of prolactin secretion. It has been proposed that NGF plays a dual role in the pituitary gland: a local one as a stimulator of differentiation and proliferation of lactotrophs during pituitary development and a systemic one as a neurohormone that is cosecreted with prolactin into the bloodstream (1205). Furthermore, NGF is an autocrine differentiation factor for prolactin-secreting cells. Escape from NGF control appears to be one of the mechanisms involved in the development and progression of prolactinomas. Exposure of prolactinomas refractory to dopaminergic therapy to exogenous NGF results in their differentiation into lactotroph-like cells reexpressing the D₂ receptor protein (1205). This observation may open the way to a sequential therapy with NGF and bromocryptine for patients refractory to the conventional therapy (1205).

VIII) Calcitonin. Calcitonin-like immunoreactivity is present and released from rat anterior pituitary cells (514, 880, 1225, 1593–1595, 1597, 1631). Moreover, exogenous salmon calcitonin inhibits basal and TRH-stimulated prolactin release as well as prolactin gene transcription in cultured rat pituitary cells (514, 880, 1225, 1593–1595, 1597, 1631, 1894). Therefore, it has been suggested that calcitonin affects prolactin secretion by a paracrine mechanism (514, 880, 1225, 1593–1595, 1597, 1631). Administration of an antiserum to salmon calcitonin to ovariectomized rats enhances prolactin secretion (1595). Similarly, addition of the antiserum to cultures of rat pituitary cells enhances prolactin secretion in the presence or absence of dopamine (1595). Immunocytochemical studies reveal a nonuniform distribution of calcitonin-like immunoreactivity in the anterior lobe because the cells of the inner zone adjacent to the intermediate lobe contain the greatest salmon calcitonin-like immunoreactivity (1595). Although they are clearly not lactotrophs, the phenotype of these cells has not been determined unequivocally. Nevertheless, it has been suggested that they may be gonadotrophs that affect prolactin secretion by a paracrine and/or juxtacrine pathway (329). There may also be a feedback relationship between prolactin and calcitonin, since the circulating levels of calcitonin in male rats are enhanced by hyperprolactinemia produced by homotransplant of pituitaries to the kidney capsule (1084).

IX) TRH. Earlier we reviewed the extensive literature that TRH of hypothalamic origin is a potent stimulator of pituitary prolactin secretion. It is now apparent that some of the TRH may originate within the anterior pituitary gland. However, it is not clear if this is a source for TRH-stimulated prolactin secretion. Indeed, pro-TRH-derived peptides have been characterized in long-term cultures of anterior pituitary cells (232), while pro-TRH mRNA has been found in a subpopulation of somatotrophs (234) in which the gene expression is regulated coordinately with the growth hormone gene by glucocorticoids (233) and thyroid hormone (235). TRH appears to

be most abundant in anterior pituitary glands obtained from 15-day-old female rats (235, 236). Although TRH is found in pituitary cell cultures, the peptide from this source apparently does not affect prolactin synthesis or secretion (237).

X) Cytokines. IL-6 is a cytokine found in the anterior pituitary gland (1669), likely produced by folliculostellate cells (1801). IL-6 has been shown to stimulate prolactin secretion, both in vitro (1095, 1667) and in vivo (1095). In addition to VIP (1665), IL-1 can also stimulate the release of IL-6 from anterior pituitary cells (1666, 1668). Taken together, these data imply that VIP-induced prolactin secretion may involve a VIP→IL-1→IL-6 cascade within the pituitary gland. However, further studies are required to confirm the role of this cascade in the intrapituitary regulation of prolactin secretion.

XI) GnRH. Perhaps the first example for paracrine modulation of lactotrophs described (425), is the stimulation of prolactin release by GnRH. The most prominent prolactin-releasing activity of GnRH could be detected during the early postnatal life when the relative proportion of gonadotrophs is much higher than in adults (425). Moreover, GnRH will only stimulate prolactin secretion when lactotrophs are cocultured with gonadotrophs (425), indicating that not GnRH itself but other gonadotroph-related products may be responsible for the GnRH-induced stimulation of prolactin secretion. Because all components of the renin-angiotensin system had been described previously to be present in gonadotrophs, the agent mediating this effect was thought to be ANG II (426). However, other experimental data (1486) do not support the role of ANG II in the GnRH-induced and gonadotroph-mediated paracrine influence on prolactin release. The physiological significance of the paracrine regulation of prolactin secretion by gonadotrophs is unknown. However, it probably operates in vivo, since GnRH has been reported to release prolactin in monkeys (609, 1350) and in women during the menstrual cycle (295, 1910).

In addition to the effect of GnRH on the secretory function of lactotrophs, it also affects cell mitosis and cytodifferentiation within the anterior lobe. Treatment of reaggregate pituitary cell cultures with GnRH enhances the total number of lactotrophs replicating DNA (1748) and containing prolactin mRNA (1787). These effects are mediated by growth factors present in the medium conditioned by gonadotroph-enriched cell population obtained from 14-day-old rats. This recruitment of lactotrophs may not be restricted to the early postnatal period of life. During the period of cytodifferentiation as well as in certain physiological situations such as pregnancy or lactation, recruitment seems to be due to the differentiation of progenitor or immature cells, rather than to a mitogenic action on preexisting lactotrophs alone (42, 1787).

Search for paracrine factor(s) mediating lactotroph recruitment by gonadotrophs has continued and yielded a number of candidates, such as the common α -subunit of the pituitary glycoprotein hormones (1478, 1686, 1786, 1787, 1862, 1883), the NH₂-terminal fragment of proopiomelanocortin [POMC-(1–74), isolated from conditioned medium of gonadotroph cell culture] (1749, 1750). Ongoing studies using transgenic animals targeting gonadotrophs likely will help to clarify the precise mechanism and physiological significance of the paracrine communication between lactotrophs and gonadotrophs (1802).

XII) Acetylcholine. An intrapituitary cholinergic system, acting through muscarinic receptors, exerts a tonic inhibitory influence on prolactin release (1245, 1564, 1729). Acetylcholine is produced within the anterior lobe, most likely in corticotrophs (276, 277). Although immunoreactivity for choline acetyltransferase (1637), the enzyme catalyzing the biosynthesis of acetylcholine, and cholinesterase activity (121) can be predominantly localized in corticotrophs, atropine, a potent muscarinic receptor antagonist, dose-dependently increases prolactin release in reaggregate cells of anterior lobe (276). Addition of cholinergic agonists to the cultures inhibits prolactin secretion (278, 1513). Both effects require the presence of glucocorticoids in the culture medium (278). Taken together, it appears that corticotrophs exert a tonic inhibitory influence on prolactin release that is mediated by acetylcholine acting through a muscarinic receptor (276). However, although the interaction between corticotrophs and lactotrophs and the role of acetylcholine in its mediation is one of the best-characterized paracrine mechanisms in the anterior lobe, it is still difficult to place in a physiological perspective. In addition to acetylcholine, galanin and TRH have also been detected in corticotrophs (808), indicating that, at least in certain species, corticotrophs might affect lactotrophs by these two potent prolactin regulatory peptides (905, 1577).

XIII) Factor(s) from folliculostellate cells. Folliculostellate cells (immunocytochemically identified as containing S-100 protein) suppress prolactin-secretory response to ANG II and TRH when they are cultured with lactotrophs as cell aggregates (101). As with paracrine interactions between gonadotrophs and lactotrophs (426), intimate contacts between lactotrophs and folliculostellate cells are not required for this inhibition, since it is still observed after dispersion of the coaggregates into single cells (101). These observations indicate that a diffusible inhibitory factor is secreted by the folliculostellate cells. However, the identity of this putative paracrine factor is unknown. It is also difficult to reconcile the observed inhibitory influence of the folliculostellate cells with the assumption that these cells are also the source of the prolactin-releasing IL-6 as we discussed above.

C) CONCLUSION. Several paracrine interactions between lactotrophs and other cellular phenotypes are now well

established and likely more will soon be discovered. We are only beginning to place intrapituitary regulative networks into a physiological perspective. In general, it seems unlikely that paracrine interactions are responsible for acute regulation of the release of prolactin, since the dynamic regulation of prolactin secretion more likely relies on hypothalamic factors. Indeed, paracrine interactions seem more likely to be responsible for changes occurring within a much slower time domain, pertaining to cellular development and differentiation. In addition, autocrine and/or paracrine regulation likely play an essential role in changing of responsiveness to hypothalamic factors during the estrous cycle, pregnancy, or lactation.

2. Neural and intermediate lobes

There is abundant evidence in the literature that the lactotroph is influenced by the neural and intermediate lobes of the pituitary gland (141). Secretory products of the neural and intermediate lobes of the pituitary gland can reach the anterior lobe through the short portal vessels, which represents a vascular communication between these lobes and the anterior lobe of the pituitary gland. Thus the communication between the neurointermediate lobe and the anterior lobe of the pituitary gland is both neuroendocrine and endocrine. Several observations suggest that dopamine, oxytocin, vasopressin, α -MSH, and possibly other less well-characterized compounds as well, after being released at the posterior and/or intermediate lobes of the pituitary gland, can reach the anterior lobe and participate in the control of prolactin secretion.

A) NEUROINTERMEDIATE LOBE PROLACTIN-RELEASING FACTOR. Posterior pituitary lobectomy elevates prolactin levels in the blood of cycling and lactating rats (143, 1255, 1406). Because dopamine is found emanating from THDA axon terminals in the posterior lobe (176), the response might be due to the removal of dopamine of posterior lobe origin (420, 605–607, 1258), which is transported to the anterior lobe through short portal vessels. In the course of performing these studies, Ben-Jonathan and colleagues (1256) made the serendipitous observation that the suckling-induced release of prolactin was blocked when the neural and intermediate lobes were removed. The absence of a prolactin-secretory response is not due to the removal of oxytocin, since replacement of oxytocin failed to overcome the effects of removal of the neurointermediate lobe (1256). They therefore concluded that the neurointermediate lobe of the pituitary gland contains a non-oxytocinergic prolactin-releasing activity. Indeed, rat neurointermediate lobe extracts stimulate prolactin secretion in vivo (822) and in vitro (821, 827, 827). Bovine intermediate lobe extracts share the same property (1539). Similarly, cocultures of neurointermediate and anterior lobes enhance basal (483) as well as secreta-

gogue-induced (484) prolactin secretion. The prolactin-releasing activity has subsequently been localized to the intermediate lobe of the pituitary gland of the rat (1011, 1681).

Attempts have been made to chemically characterize the activity. It seems clear that the activity is due to a small peptide that is distinct from TRH, ANG II, VIP, arginine vasopressin, and oxytocin (821, 827, 1059). An interesting approach has been taken to produce a model for further purification of the intermediate lobe prolactin-releasing activity. Transgenic mice were generated with large tumors localized to the intermediate lobe (27). These animals were hyperprolactinemic. Inoculation of nude mice with the tumor cells resulted in large secondary tumors. Crude extracts of both primary and secondary tumors stimulated prolactin secretion from GH₃ cells in culture. With chromatography, the activity was found in two size classes: a large 70- to 80-kDa bioactive peak and two very small hydrophobic peaks. None of the elution profiles coincided with β -endorphin, α - or β -melanocyte-stimulating hormone, ACTH, TRH, oxytocin, ANG II, and VIP. Although these data suggest that the prolactin-releasing activity indeed arises from melanotrophs in the intermediate lobe, care should be taken when equating data derived from tumorous tissue to that obtained from normal cells.

B) α -MELANOCYTE-STIMULATING HORMONE. α -Melanocyte-stimulating hormone of intermediate lobe origin appears to play a unique role in the function of the lactotrophs within the anterior lobe. Among the cells of the anterior pituitary, the lactotroph possesses the greatest number of α -melanocyte-stimulating hormone binding sites (1923). Rather than act as a pure PRF, α -melanocyte-stimulating hormone appears to act as a lactotroph-responsiveness factor that plays two roles. With the use of the reverse hemolytic plaque assay it was shown that α -melanocyte-stimulating hormone is responsible for the "recruitment" of lactotrophs from a nonsecretory to a secretory pool as well as enhancement of the sensitivity of lactotrophs to known secretagogues for prolactin (497, 760, 761). The enhanced responsiveness of lactotrophs is due to stimulation, by α -melanocyte-stimulating hormone, of calcium entry from extracellular sources (1330). These effects require *N*-acetylation of α -melanocyte-stimulating hormone for full biological activity (498). It has been suggested that the enhanced prolactin-secretory responsiveness of the pituitary gland of suckled dams to secretagogues (760, 761) and the estrogen-induced release of prolactin (497) are both mediated by α -melanocyte-stimulating hormone.

C. Peripheral Organs

1. The ovaries

A) ESTRADIOL. Ovariectomy has a dramatic effect on the lactotroph (reviewed in Ref. 1768). Removal of the

ovaries is followed by a decrease in lactotroph size and number as well as the intracellular abundance of prolactin-secretory granules (429). Estradiol is the dominant ovarian hormone that reverses these effects and subsequently stimulates prolactin secretion (309). Indeed, in the rat, immunoneutralization of the rising blood levels of estradiol on diestrus through early proestrus blocks the preovulatory release of prolactin on proestrus (1302). Moreover, administration of estradiol to ovariectomized rats results in proestrus-like prolactin-secretory release daily for a number of days (1297, 1305).

Estradiol affects the secretion of prolactin at two levels. Directly at the pituitary lactotroph, estradiol controls prolactin gene expression and modifies its sensitivity to physiological stimulators and inhibitors of prolactin secretion. Within the hypothalamus, estradiol modifies the activity of the neuroendocrine neurons known to control prolactin secretion.

It has been suggested that estradiol is responsible for the differentiation of lactotrophs from a pluripotent pool of somatotrophs and mammosomatotrophs (191), an effect which requires the presence of the neurointermediate lobe of the pituitary gland (496). Estrogen regulates prolactin gene expression within the anterior pituitary gland (1045, 1159, 1627, 1628) by binding to its nuclear receptor and subsequently conferring DNA binding and transcriptional activation of the gene (1867). Progesterone (326) or androgens (1759) in turn inhibit estrogen-induced prolactin gene expression. The transcription of the prolactin gene results in increased synthesis of prolactin, and the increased prolactin secretion may be a reflection of spillover of newly synthesized hormone from the estrogen-stimulated lactotrophs. Although estrogen increases the percent of prolactin-releasing cells in the anterior pituitary, it does not increase the percent of total pituitary cells expressing prolactin mRNA (1562). This would suggest, in contrast to earlier observation (191), that lactotrophs are not differentiated from a pluripotent pool by estrogen. However, other studies have shown that differentiation occurs posttranscriptionally (1428) and thus resolves this discrepancy. Nevertheless, there is a direct relationship between the amount of prolactin secreted by and the amount of prolactin mRNA in lactotrophs obtained from estrogen-treated rats (1009). Moreover, estradiol enhances the secretion of prolactin through a constitutive pathway since nifedipine, a blocker of voltage-sensitive calcium channels which are required for secretion, does not interfere with the estradiol-induced enhancement of prolactin mRNA/lactotroph (1009).

Estrogens modify the response of the rat lactotroph to physiological inhibitors and stimulators of prolactin secretion. Estradiol is antidopaminergic at the lactotroph (1024, 1454, 1454, 1875); that is, dopamine is less potent as an inhibitor of prolactin secretion when lactotrophs are exposed to estradiol in vitro (1454, 1454, 1875) or in vivo

TABLE 1. *Neurotransmitters regulating prolactin secretion*

Neurotransmitter	Receptor in the CNS	CNS Target	Effect on PRL Secretion*
<i>Biogenic amines</i>			
Dopamine	D ₁ (155, 475) D ₂ (156, 474, 486, 1124)	↓ TIDA (155, 475) ↑ TIDA (156, 474, 486, 1124)	↑ Basal (155, 475) ↓ Basal (474)
Norepinephrine and epinephrine	α ₁ (400) α ₂ (1047, 1436, 1780) ‡(884, 885, 983) β (974)	PVN (? TRH) (1780) TIDA (775, 805)	↓ Basal (400, 1012) ↑ Basal (1047, 1436, 1736) ↑ Ovx+E ₂ (1012) ↑ Proestrus (1003) ↑ Suckling (1436) ‡(286) ↑ Stress (1003) ↑ Basal (392) ‡(102, 392, 393) ∅ Ovx+E ₂ (1734)
Serotonin (5-HT)	5HT _{2A} , 5HT _{2C} (108, 1040) 5HT _{1C} (108, 1040)	PVN (104–107, 1200) SCN (921) TIDA (1152, 1420)	↑ Basal (551, 999, 1085, 1788) ↑ E ₂ /proestrus (260, 313) ↑ Suckling (600, 972, 1181)
Histamine	H1 (59, 644, 1044, 1780) H2 (58, 457, 460, 1468, 1780)	TIDA (558, 622, 1571)	↑ Basal (1780) ↑ Stress (961, 1656)
Acetylcholine (ACh)	ACh _N (58, 180, 1696) ACh _M (58, 180, 1696)	TIDA (504, 665, 1261, 1696, 1885) ‡(622)	↓ Basal (662, 665, 1043) ↓ E ₂ /proestrus (58, 180, 1696) ↓ Suckling (180)
<i>Peptides</i>			
Thyrotropin releasing hormone	TRH-R (836)	↑ TIDA (227, 836, 1342)	↓ Basal (836, 1342)
Oxytocin and vasopressin	(246)	↑ TIDA (1919) ‡(1209) SCN (842)	↓ Basal (1087, 1235) ↓ Stress (1235)
VIP/PHI	(163)	Hypothalamus (849, 917, 977, 1823) SCN (123) ↑ TIDA (813)	↑ Basal (813) ↑ E ₂ /proestrus (74, 1547, 1794)
PACAP	(653, 654, 1344, 1623)	↑ TIDA (40, 813)	↓ Basal (40, 813) ↑ Basal (anesthetized) (858, 1900)
Opioids (OPI)	μ, κ (245, 261, 934, 984, 985) κ (937) ORL1, opioid receptor-like receptor (240, 1189)	PVN, SON, MBH (1119) ARC (48, 49) ↓ TIDA (31, 70, 83, 86, 440, 472, 547, 693, 742, 908, 965, 1121, 1123, 1467, 1806, 1836)	↑ Basal (240, 742, 1175, 1804, 1805) ↑ E ₂ /proestrus/PSP (18, 833, 1525, 1554) ↑ Lactating (70, 473) ↑ Nonsuckled (1278) ↓ Suckled (1278) ↑ Stress (473, 540, 541, 866, 908, 1504, 1540, 1634, 1789, 1891)
Angiotensin II	AT-R (194, 1751) AT _{1A} (869, 871, 1022, 1521, 1673, 1777)	TIDA (871a, 1586, 1916)	(↓) Basal (1265, 1266, 1521, 1675, 1678) ↓ Ovx+E ₂ (1265, 1266, 1521, 1673) ↓ Stress (1265, 1266, 1521, 1673)
Substance P (SP)	Tachykinin receptors (932, 1120, 1456)	mPOA (1120, 1416) ARC (1775) SON/PVN (175)	↑ Basal (489, 1416, 1820) (80, 81, 701) ‡(402) ↓ Basal (low dose) (80, 81, 701)
Galanin (GAL)	GAL-R (136, 915, 1890)	MBH (136, 1188) TIDA (806) ↓ DA release/ME (1327) ↑ VIP release/MBH (844)	↑ Basal (973, 975, 976, 1177) ‡(1360) ↑ Proestrus (1079, 1188)
Neurotensin (NT)	NT-R (1328, 1507)	PVN/ARC-ME (831) ↑ TIDA (692, 751, 964, 1167, 1373, 1856)	↓ (964, 1166, 1167, 1482) ↓ E ₂ /proestrus (1166) ↓ Stress (1166, 1167, 1753)
Neuropeptide Y (NPY)	Y ₁ , Y ₂ (897, 1381)	↑ TIDA (592, 714)	↓ Basal (592, 618, 1466)
Somatostatin (SST)	SSTR1-5 (390, 463, 671, 1190, 1195, 1334, 1375, 1744) SSTR2 (135, 1588)	CNS (556, 1462) ↓ TIDA (135, 898, 1588, 1645)	↑ Basal (898)
Calcitonin (CT) and calcitonin gene-related peptide (CGRP)	CT and CGRP receptors (1644)	CNS (1679) ↑ TIDA (341)	∅ Basal (341, 1347, 1348, 1679) ‡(531) ∅ E ₂ /proestrus (371, 372) ↓ Suckling (495, 1348) ↓ Stress (370, 1633)

TABLE 1—*Continued*

Neurotransmitter	Receptor in the CNS	CNS Target	Effect on PRL Secretion*
Bombesin-like peptides (gastrin-releasing peptide and neuromedin B and C)	(126, 1671)	↑ TIDA (95, 257, 886, 929, 1099, 1100, 1122, 1757)	↓ Basal (912, 928, 929, 1705, 1757) ↓ Ovx (95) ↓ E ₂ (1099) †(700, 1483) ↓ Stress (1705)
Cholecystokinin (CCK)	CCK-R (1115, 1410) CCK _B > CCK _A (hypothalamus) (1860)	ARC/TIDA (1049, 1371) ↑ VIP (1714)	↑ Basal (1714, 1821, 1822) †(912)
Atrial natriuretic peptide (ANP)	ANP-R (713, 1522)	TIDA (566, 1534) †(1536) PVN (713)	↓ Basal (1531, 1533) ∅ Proestrus (1604) ↓ Stress (571, 1531, 1533)
<i>Amino acids and nitric oxide</i>			
Glutamate/aspartate	NMDA (91)	PIF (TIDA) and/or PRF (PVN) (91)	↓ Basal (91) ↓ Cycling (1, 208, 209) ↓ Suckling (91) ↑ ↓ (1)
γ-Aminobutyric acid (GABA)	GABA _A (39, 588, 661, 1826, 1881) GABA _B (1049)	↓ TIDA (37, 1049, 1881) SON/PVN (1174, 1737) TIDA (643, 1912)	↑ Basal (588, 998, 1106, 1210, 1249, 1356, 1378, 1846) †(1318) ↑ Suckling (1439)
Nitric oxide (NO)		SON/PVN (51, 172, 213, 1767)	↑ Basal (641, 642) ↑ E ₂ /proestrus (185, 1912) ↑ Stress (1157)

Arrows indicate the nature of the effects of the neurotransmitters: ↑ increase/facilitation, ↓ decrease/inhibition (arrows in parentheses indicate a less than robust effect); ∅, no effect. ARC, arcuate nucleus; MBH, medial basal hypothalamus; mPOA, medial preoptic area; PVN, paraventricular nucleus; TIDA, tuberoinfundibular dopaminergic system; SON, supraoptic nucleus. Reference numbers are given in parentheses. * Only those data are considered where the experimental paradigm indicates that the observed effects on prolactin secretion are probably mediated within the central nervous system (CNS). These experimental approaches usually involve intracerebroventricular administration of a neurotransmitter, its precursor, its selective agonists and/or antagonists, as well as specific antibodies developed against the endogenous transmitter or modulator. The effects of these manipulations were evaluated on nonstimulated (basal) as well as stimulated prolactin secretion. The latter group is further divided according to the cause of elevated prolactin secretion: estradiol and/or proestrus (E₂/proestrus), pseudopregnancy (PSP), suckling stimulus in lactating animals (suckling), or stress. † Conflicting observations.

(346, 1024). Apparently, estradiol exerts this effect by decreasing the number of dopamine receptors (1454). In contrast, estradiol enhances the sensitivity of the lactotroph to TRH (623). It does so by increasing the number of TRH receptors (406). Estradiol depresses the inhibitory input the hypothalamus exerts over pituitary prolactin secretion. Long-term treatment with estradiol lowers the concentration of dopamine in hypothalamo-hypophyseal portal plasma bathing the anterior pituitary gland (365). Similarly, the concentration of dopamine in portal blood is diminished coincident with the beginning of the preovulatory release of prolactin on proestrus (140). In addition, treatment with estradiol decreases the activity of TH, the rate-limiting enzyme of dopamine biosynthesis, in TIDA axons terminating in the median eminence (181, 873, 1027, 1236, 1385). Likewise, the activity of these neurons decreases concomitant with the release of prolactin on proestrus (287, 1027). The surge of prolactin released in response to estradiol increases the activity of these dopaminergic neurons that subsequently terminates prolactin secretion (44, 416, 417, 1218, 1220, 1758).

B) PROGESTERONE. A direct role for progesterone in the synthesis and release of prolactin is not as well described

as that of estradiol. Some studies report no effect (309, 1550), whereas others report inhibition (623, 745) or enhancement (1911) of prolactin secretion in response to progesterone. On the other hand, progesterone is capable of advancing the time of day in which an estrogen-induced surge of prolactin occurs (259, 1911). It appears to exert this effect by actions within the hypothalamus. Progesterone stimulates dopamine release into hypophyseal portal blood (365). However, progesterone has a dual effect on TH activity in TIDA neurons. Acutely, progesterone negatively modulates TH activity (61, 62, 68, 134, 1911). Such observations are consistent with the advancement of the estradiol-induced surge of prolactin by progesterone. Subsequently, progesterone enhances TH activity (66), a finding which is consistent with the inhibition of prolactin secretion by progesterone.

C) CHANGING RATIO OF OVARIAN STEROIDS: ESTROUS CYCLE. We can now place all of these observations in a physiological context. During the afternoon of diestrus-2 of the rat's estrous cycle, the rising titers of ovarian estradiol (1647) stimulate the hypothalamo-pituitary axis to release a "surge" quantity of luteinizing hormone and prolactin on proestrus (1302). The surge of luteinizing hormone stimulates an increase in ovarian progesterone secretion (583)

that initially participates with estrogen in decreasing the activity of TIDA neurons (61, 62, 68, 134, 1911). The resulting estradiol-induced surge of prolactin (1758) along with progesterone (66) activates TIDA neurons which, in turn, extinguishes the surge of prolactin.

2. The adrenal cortex

A rarely discussed aspect of the inhibitory influences on adenohipophysial prolactin secretion is the potential role of the adrenal gland. It is well known that in rats, plasma levels of prolactin increase significantly after adrenalectomy, whereas the effect of adrenalectomy can be reversed by administration of corticosteroids (94, 94, 139, 206, 312, 1032, 1438, 1798). Similar effects of adrenalectomy and the synthetic glucocorticoid dexamethasone have been shown in estrogen-induced (284, 285), stress-induced (521, 739, 1504), and TRH-induced (1581) prolactin responses. Moreover, consistently high levels of plasma prolactin have been found throughout the entire lactation period in adrenalectomized dams (1798). Significantly higher plasma prolactin response to the dopamine receptor blocker haloperidol could be detected in adrenalectomized lactating mothers (936). Dexamethasone pretreatment of lactating rats completely blocks suckling-induced prolactin release (122). This effect is transient, since it cannot be detected 24 h later. In contrast to the dramatic effect on the suckling-induced prolactin response, dexamethasone does not inhibit domperidone-induced pituitary prolactin release, indicating that dexamethasone cannot interfere with the antagonist binding and its effect at the level of dopamine receptor of lactotrophs. Dexamethasone also suppresses prolactin release induced by the suckling stimulus when it is implanted into the medial basal hypothalamus (122). Blockade of glucocorticoid receptors by the administration of RU486 (mifepristone) enhances prolactin secretion (1799). RU486 is also a progesterone antagonist. However, immunoneutralization of circulating progesterone does not affect prolactin secretion (284). Long-term elevation of the serum glucocorticoid level by chronic administration of ACTH (541, 908) or hydrocortisone (937) or by prolonged stress (540) decrease opioid-induced prolactin secretion. These effects of glucocorticoids are taking place predominantly within the CNS. It is assumed that the decreased responsiveness of the TIDA neurons to inhibitory inputs brought about by the elevated glucocorticoid levels (908) may be responsible for the blunted responses of prolactin secretion. Thus the regulatory pathway mediating neurogenic stimuli (suckling or stress)-induced prolactin release is extremely sensitive to glucocorticoid feedback mechanisms, and the adrenal glands of an animal provide a physiologically important signal to the hypothalamo-hypophysial mechanisms regulating prolactin secretion.

Aside from the regulation of prolactin secretion, glucocorticoids also influence the differentiation (1557) and morphology (289) of lactotrophs. Indeed, glucocorticoids stimulate the differentiation of somatotrophs but suppress that of lactotrophs in the fetal rat pituitary gland (1557). Adrenalectomy increases the cellular and nuclear areas of prolactin-immunoreactive cells. Glucocorticoid replacement *in vivo* reverses these effects (289). In cultured cells, exposure to glucocorticoids reduces numerical density and cellular, cytoplasmic, and nuclear areas of prolactin-immunoreactive cells (289). These actions of glucocorticoids may merely be a reflection of another site at which the steroid regulates the immune system: inhibition of secretion of the immunomodulatory hormone prolactin.

3. The placenta

As noted earlier, there is abundant evidence that the rat placenta secretes a lactogen that is similar in biological activity to pituitary prolactin. Aside from maintaining pregnancy and preparing the mammary gland for subsequent lactation, this lactogen also plays a major role in regulating pituitary prolactin secretion (64, 561, 649, 1755, 1756, 1760–1763, 1832–1834, 1838). For example, it is well known that the two surges of pituitary prolactin secretion last appear on *day 10* of a 21-day pregnancy (1648). Coincident with this is the increase in the concentration of placental lactogen in the blood of the pregnant rat at mid-pregnancy (1760–1763). Although rat placental lactogen (1834), spent placental culture media, or maternal serum (649) will inhibit prolactin secretion from pituitary cells in culture, injection of rat placental lactogen will not inhibit prolactin secretion *in vivo* (1837). On the other hand, injection of spent incubation media (1832) or surgical implantation of a lactogen-secreting choriocarcinoma (1146, 1756) will effectively inhibit prolactin surges *in vivo*. Although placental lactogen will diminish the surges of prolactin in pregnant or pseudopregnant rats as well as suckling-induced prolactin secretion (560, 561), it will not inhibit the ante-partum secretion of prolactin (561, 668). This implies some alteration that occurs within the hypothalamo-pituitary axis to change its response to placental lactogen.

Aside from the pituitary gland as the obvious site at which placental lactogen exerts its effect on prolactin secretion, there is ample evidence that the effect may also be exerted within the hypothalamus. Indeed, human placental lactogen is quite effective in activating TH in TIDA neurons (410) and consequently suppressing the surges of prolactin during early pregnancy (668) when injected into the cerebral ventricles. Similarly, transplantation of lactogen-secreting rat choriocarcinoma cells also increases TH activity in TIDA neurons and suppresses prolactin

TABLE 2. *Neurohormones regulating prolactin secretion*

Neurohormone	Receptor/G Protein in the Lactotrophs	Signal Transduction	Direct Effect on PRL Secretion
<i>Established prolactin releasing and release-inhibiting neurohormones</i>			
Dopamine (DA) as PIF *(140, 142, 621)	D ₂ (279, 280, 1171) G _{i3α} , G _{oα} (100, 1065)	↑ I _K (492, 847) ↓ I _{Ca} (407, 754, 847) ↓ AC/cAMP (398, 508, 565, 619, 1002, 1355) ↓ PLC (272, 510, 513, 1002, 1635)	↓ In vitro (140, 1096–1098) ↓ In vivo (140, 395, 1281, 1421, 1423)
Thyrotropin releasing hormone (TRH) *(520, 553)	TRH-R (763, 1129, 1917) G _{q/11} (807) G _s (943)	↑ PLC/Ca ²⁺ (57, 529, 563, 564, 747, 807, 1002, 1558, 1684) ↓ I _{Kir} (127, 128, 1565)	↑ In vitro (17, 924, 1723) ↑ In vivo (178, 405, 963, 1419)
Oxytocin *(620)	OT-R	↑ PLC/Ca ²⁺ (246)	↑ In vitro (827, 1537) ↑ In vivo (867, 1087, 1235, 1243, 1537, 1542) †(1371)
Vasoactive intestinal polypeptide (VIP) *(1313)	VIP-R (125)	↑ AC/cAMP (1314, 1349, 1354, 1355) ↑ I _{Ca} (856)	↑ In vitro (1535, 1538, 1608–1610) ↑ in vivo (4, 891, 892, 1313, 1343, 1506, 1611, 1873)
<i>Putative prolactin releasing and release-inhibiting neurohormones</i>			
Somatostatin (SST) *(3, 319, 724)	SST-R ₁₋₅ (390, 463, 671, 1190, 1195, 1334, 1375, 1391, 1392, 1463, 1613, 1744)	↓ AC/cAMP (941, 1715) ↓ I _{Ca} (941, 1715) ↑ I _{K(Ca)} (1878)	↓ In vitro (461, 462, 466, 509, 733, 824, 826, 941, 1783) †(1394, 1460) ↓ In vivo (359, 507, 651, 913, 1001, 1018)
γ-Aminobutyric acid (GABA) *(1206, 1716, 1719, 1827) †(1247, 1619)	GABA _A (52, 54, 679, 841) GABA _B (378, 1091, 1092) ↓ In vivo (55, 96, 378, 394–396, 459, 1092, 1168, 1632, 1881)	↑ I _{Cl} (841, 846) ↑ I _{K(GTP)} (41)	↓ In vitro (56, 511, 679, 691, 1441, 1569) †(38, 39)
Atrial natriuretic hormones (ANH) *(1604)	ANH-R (713)	↑ GC/cGMP (305, 321, 713, 1345)	↓ In vitro (482) ↑ In vivo †(571)
Vasopressin (VP) *(782, 789, 966, 1424)	VP-R (47, 957) V ₁ (50, 952) V ₂ (954, 955)	↑ PLC/Ca ²⁺ (246) ↑ AC/cAMP (246)	↑ In vitro (734, 1616) ↑ In vivo (829, 1276, 1283, 1372, 1616, 1785, 1809)
Calcitonin (CT)		↓ PLC/PLA ₂ (514, 880, 1660, 1661) ↑ Fast [Ca ²⁺] _i (1660, 1661) ↓ In vivo (495, 531, 1348, 1595, 1633, 1660) ↓ Sustained [Ca ²⁺] _i (1660, 1661)	↓ In vitro (514, 880, 1225, 1593–1595, 1597, 1631, 1894) ↑ In vivo [in the absence of T ₃] (1905)
Neuropeptide Y	Y ₁ , Y ₂ (897)	↑ PLC/Ca ²⁺ [Y1] (528, 1849) ↓ I _{Ca} [Y2] (528, 1849, 1857) ↓ AC/cAMP [Y1, Y2] (897)	↑ In vitro [cycling female] (302) ↓ In vitro [ovx or lactating] (1857)
Angiotensin II	AT _{1B} (1022) G _i /G _o (513)	↑ PLC/Ca ²⁺ (269, 270, 506, 513, 610, 1075, 1572, 1902) ↑ AC/cAMP (93)	↑ In vitro (14, 36, 409, 746, 1575)
Galanin (GAL) *(1078)	GAL-R (136, 915, 1890)	↑ PLC/Ca ²⁺ (727)	↑ In vitro (465, 697, 1890)
Substance P (SP)	SP-R (930, 1006–1008)	↑ PLC/Ca ²⁺ (932, 1158)	↑ In vitro (1819, 1820) ↑ In vivo (1482)
Bombesin-like peptides (gastrin-releasing peptide, neuromedin B and C)	(126, 796, 1671, 1845, 1877)	↑ PLC/Ca ²⁺ (177, 461, 462, 1766)	↑ In vitro (797–799, 1876)
Neurotensin (NT) *(946, 1866)	NT-R (1180)	↑ PLC/Ca ²⁺ (1179) ↑ I _{Ca} (1179) ↑ PLA ₂ (271, 1179)	↑ In vitro (505) ↑ In vivo (964, 1166, 1167, 1482)
Dopamine as PRF	D ₂ (252) G _s (251)	↑ I _{Ca} (248, 582)	↑ In vitro (252, 346, 427, 761, 979, 1614) ↑ Ex vivo (761, 1280, 1282) ↑ In vivo (72)

Neuroendocrine regulators of prolactin secretion were selected based on the following (pharmacological, neuroanatomical, and physiological) criteria. 1) They are capable of affecting prolactin secretion by acting directly at the lactotrophs; 2) produced by neurons, usually residing within the so-called “neuroendocrine hypothalamus,” which project to the external zone of the median eminence; and 3) their concentration in the pituitary portal blood is significantly higher than in the peripheral circulation. Putative releasing and release-inhibiting hormones only partially fulfill these criteria. Arrows indicate the nature of the effects of the neurohormones: ↑ increase/facilitation, ↓ decrease/inhibition. AC, adenylyl cyclase; GC, guanylyl cyclase; PLA₂, phospholipase A₂; PLC, phospholipase C; I_K, potassium current/channel; I_{K(Ca)}, Ca²⁺-dependent potassium current/channel; I_{K(GTP)}, G protein-gated potassium channel; I_{Kir}, inward rectifying potassium channel; I_{Ca}, calcium current/channel; I_{Cl}, chloride current/channel. Reference numbers are given in parentheses. * Detected in the portal blood and/or in the external zone of the median eminence. † Conflicting observations.

It has long been recognized that nutritional status and reproductive capacity are related (377, 569). Leptin, the product of the obese (*ob*) gene, is a humoral signal secreted by adipose tissue to act in the CNS to regulate

food intake and body weight (15, 268, 294, 802, 1685). It seems that leptin provides the link between nutritional and reproductive function (117, 316, 339, 377, 569, 1742).

Leptin stimulates prolactin secretion from cells isolated from the anterior lobe of the pituitary gland (1918). Given intracerebroventricularly, leptin-(116–130) stimulates prolactin (and LH) secretion in fasted adult male rats (640). In addition, leptin restores the starvation-eliminated prolactin (and LH) surges in estradiol/progesterone-implanted ovariectomized animals (969). Restoring circulating leptin concentration of starved animals to the physiological level by administering leptin subcutaneously with osmotic minipumps also restores the estradiol/progesterone-induced prolactin (and LH) surge (1865). In addition, antileptin serum significantly delays the onset of the secretory surge of prolactin in normally fed animals (969). These observations indicate that physiological concentrations of leptin in the peripheral circulation can exert a stimulatory effect on steroid-induced (1865) or spontaneous (969) prolactin (and LH) secretion.

Increased serum prolactin concentrations, induced by pituitary graft or exogenous ovine prolactin injection, stimulate leptin secretion (690). Moreover, prolactin is able to increase leptin mRNA in white adipose tissue (690). These recent observations indicate that both prolactin and leptin are intricately involved in the complex regulation of energy balance and reproduction.

Taken together, these data indicate that leptin plays an important permissive role in the generation of steroid-induced prolactin (and LH) surges in female rats. However, the mechanism whereby leptin alters prolactin secretion is not yet known. Several hypothalamic neuronal systems (e.g., oxytocin/vasopressin, NPY, POMC, Agouti-related peptide) express leptin receptors and are affected by leptin in the peripheral circulation and/or in the cerebrospinal fluid (500, 559, 1743, 1898). Recent evidence indicates that the effects of leptin on prolactin secretion are mediated by melanocortins, possibly through MC4 melanocortin receptors (1864).

There is little information on the intracellular signaling mechanisms activated by leptin. However, because the leptin receptor (Ob-R) is a member of the cytokine receptor family (1720), the Jak/STAT pathway (for further details, see sect. IV) presumably plays an important role in this respect (723). In glucose-sensitive neurons of the lateral hypothalamus, leptin induces a long-lasting hyperpolarization by activating ATP-sensitive potassium (K_{ATP}) channels (1670). It has been suggested by the authors (1670) that the K_{ATP} channel may function as an end point of the intracellular pathway(s) elicited by leptin.

VIII. EPILOGUE

It has been well recognized that prolactin ensures survival of the species through its reproductive role and

survival of the individuals of the species in its homeostatic roles. While we know a great deal about the chemistry, biological actions, and controls in its reproductive role, there is a paucity of similar information in its homeostatic roles. Hopefully these voids articulated in this review will be filled in the near future.

Most of the active endogenous substances regulating prolactin secretion have multiple sites of action: they can act at the hypothalamic level as neurotransmitter (Table 1) and also at the pituitary as a neurohormone (Table 2).

At the hypothalamic level, many of these substances can directly affect the activity of neuroendocrine dopaminergic and PRF neurons and/or presynaptically regulate neural inputs to these neuroendocrine cells (summarized in Figs. 5 and 6). The precise mode of communication between different modules of the regulative circuitry and the integration of the multifarious neuronal and humoral inputs is still not well understood. Ongoing research with insightful combinations of electrophysiological techniques, tract tracing, and immunocytochemical identification (both light and electron microscopic levels) hold much promise for further advance in this field.

At the pituitary level, only a few substances play a role as primary neurohormones by robustly affecting hormone secretion (e.g., dopamine, TRH), while many others can act as modulators by amplifying or diminishing the effect of a primary neurohormone (e.g., neuropeptide Y, galanin, enkephalin). The distinction between the two modes of action is rather intuitive, and the possibility to shift from one mode to another remains open; under different physiological circumstances (e.g., proestrus, pregnancy, lactation, long-term exposure to a noxious stimulus, aging), a modulator can become a principal factor in regulating hormone secretion.

Address for reprint requests and other correspondence: M. E. Freeman, Dept. of Biological Science, Florida State University, Tallahassee, FL 32306–4340 (E-mail: freeman@neuro.fsu.edu).

REFERENCES

1. ABBUD R AND SMITH MS. Altered luteinizing hormone and prolactin responses to excitatory amino acids during lactation. *Neuroendocrinology* 58: 454–464, 1993.
2. ABDEL-MEGUID SS, SHIEH HS, SMITH WW, DAYRINGER HE, VIOLAND BN, AND BENTLE LA. Three-dimensional structure of a genetically engineered variant of porcine growth hormone. *Proc Natl Acad Sci USA* 84: 6434–6437, 1987.
3. ABE H, CHIHARA K, CHIBA T, MATSUKARA S, AND FUJITA T. Effect of intraventricular injection of neurotensin and various other bioactive peptides on plasma immunoreactive somatostatin levels in rat hypophyseal portal blood. *Endocrinology* 108: 1939–1943, 1981.
4. ABE H, ENGLER D, MOLITCH ME, BOLLINGER-GRUBER J, AND REICHLIN S. Vasoactive intestinal peptide is a physiological mediator of prolactin release in the rat. *Endocrinology* 116: 1383–1390, 1985.
5. ABRAHAM EJ, FAUGHT WJ, AND FRAWLEY LS. Transforming growth factor β 1 is a paracrine inhibitor of prolactin gene expression. *Endocrinology* 139: 5174–5181, 1998.
6. ACS Z, MAKARA GB, AND STARK E. Growth hormone secretion of the

- neonatal rat pituitaries is stimulated by gamma-aminobutyric acid in vitro. *Life Sci* 34: 1505–1511, 1984.
7. ACS Z, SZABO B, KAPOCS G, AND MAKARA GB. gamma-Aminobutyric acid stimulates pituitary growth hormone secretion in the neonatal rat. A superfusion study. *Endocrinology* 120: 1790–1798, 1987.
 8. ACS Z, ZSOM L, AND MAKARA GB. Possible mediation of GABA induced growth hormone secretion by increased calcium-flux in neonatal pituitaries. *Life Sci* 50: 273–279, 1992.
 9. ACS Z, ZSOM L, MERGL Z, AND MAKARA GB. Significance of chloride channel activation in the gamma-aminobutyric acid induced growth hormone secretion in the neonatal rat pituitary. *Life Sci* 52: 1733–1739, 1993.
 10. ADASHI EY AND RESNICK CE. Prolactin as an inhibitor of granulosa cell luteinization: implications for hyperprolactinemia-associated luteal phase dysfunction. *Fertil Steril* 48: 131–139, 1987.
 11. AFIONE S, DEBELJUK L, SEILICOVICH A, PISERA D, LASAGA M, DIAZ MC, AND DUVILANSKI B. Substance P affects the GABAergic system in the hypothalamo-pituitary axis. *Peptides* 11: 1065–1068, 1990.
 12. AFIONE S, DUVILANSKI B, SEILICOVICH A, LASAGA M, DIAZ MC, AND DEBELJUK L. Effects of serotonin on the hypothalamic-pituitary GABAergic system. *Brain Res Bull* 25: 245–249, 1990.
 13. AGNATI LF, FUXE K, GIARDINO L, CALZA L, ZOLI M, BATTISTINI N, BENFENATI F, J VANDERHAEGHEN-J, GUIDOLIN D, RUGGERI M, AND GOLDSTEIN M. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. *Ann NY Acad Sci* 448: 315–333, 1985.
 14. AGUILERA G, HYDE CL, AND CATT KJ. Angiotensin II receptors and prolactin release in pituitary lactotrophs. *Endocrinology* 111: 1045–1050, 1982.
 15. AHIMA RS, PRABAKARAN D, MANTZOROS C, QU D, LOWELL B, MARATOS-FLIER E, AND FLIER JS. Role of leptin in the neuroendocrine response to fasting. *Nature* 382: 250–252, 1996.
 16. AIRAKSINEN MS, ALANEN S, SZABAT E, VISSER TJ, AND PANULA P. Multiple neurotransmitters in the tuberomammillary nucleus: comparison of rat, mouse, and guinea pig. *J Comp Neurol* 323: 103–116, 1992.
 17. AIZAWA T AND HINKLE PM. Thyrotropin-releasing hormone rapidly stimulates a biphasic secretion of prolactin and growth hormone in GH₄C₁ rat pituitary tumor cells. *Endocrinology* 116: 73–82, 1985.
 18. AKABORI A AND BARRACLOUGH CA. Effects of morphine on luteinizing hormone secretion and catecholamine turnover in the hypothalamus of estrogen-treated rats. *Brain Res* 362: 221–227, 1986.
 19. AKIL H, WATSON SJ, YOUNG E, LEWIS ME, KHACHATURIAN H, AND WALKER JM. Endogenous opioids: biology and function. *Annu Rev Neurosci* 7: 223–255, 1984.
 20. ALBERS N, HART CS, KAPLAN SL, AND GRUMBACH MM. Hormone ontogeny in the ovine fetus. XXIV. Porcine follicular fluid “inhibins” selectively suppress plasma follicle-stimulating hormone in the ovine fetus. *Endocrinology* 125: 675–679, 1989.
 21. ALBERT PR, NEVE KA, BUNZOW JR, AND CIVELLI O. Coupling of a cloned rat dopamine-D₂ receptor to inhibition of adenylyl cyclase and prolactin secretion. *J Biol Chem* 265: 2098–2104, 1990.
 22. ALI S, CHEN Z, LEBRUN JJ, VOGEL W, KHARITONENKOV A, KELLY PA, AND ULLRICH A. PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation. *EMBO J* 15: 135–142, 1996.
 23. ALI S, PELLEGRINI I, AND KELLY PA. A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. *J Biol Chem* 266: 20110–20117, 1991.
 24. ALLAERTS W, CARMELIET P, AND DENEFF C. New perspectives in the function of pituitary folliculostellate cells. *Mol Cell Endocrinol* 71: 73–81, 1990.
 25. ALLAERTS W AND DENEFF C. Regulatory activity and topological distribution of folliculostellate cells in rat pituitary aggregates. *Neuroendocrinology* 49: 409–418, 1989.
 26. ALLEN DL, LOW MJ, ALLEN RG, AND BEN-JONATHAN N. Identification of two classes of prolactin-releasing factors in intermediate lobe tumors from transgenic mice. *Endocrinology* 136: 3093–3112, 1995.
 27. ALLEN YC, ADRIAN TE, AND ALLEN JM. Neuropeptide distribution in the rat brain. *Science* 221: 877–879, 1983.
 28. ALONSO G, SIAUD P, FAIVRE SARRAILH C, GROUSELLE D, BARBANEL G, AND ASSENMACHER I. Axons containing a prolactin-like peptide project into the perivascular layer of the median eminence: an immunocytochemical light and electron microscope study in adult and infant rats. *Neuroendocrinology* 48: 39–44, 1988.
 29. ALPER RH, DEMAREST KT, AND MOORE KE. Dehydration selectively increases dopamine synthesis in tuberohypophyseal dopaminergic neurons. *Neuroendocrinology* 31: 112–115, 1980.
 30. ALPER RH, DEMAREST KT, AND MOORE KE. Morphine differentially alters synthesis and turnover of dopamine in central neuronal systems. *J Neural Transm* 48: 157–165, 1980.
 31. AL-SAKKAF KH, DOBSON PR, AND BROWN BL. Prolactin induced tyrosine phosphorylation of p59^{lyn} may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. *J Mol Endocrinol* 19: 347–350, 1997.
 32. ALTOMONTE L, ZOLI A, MIRONE L, GHIRLANDA G, BERTOLI A, MANNA R, AND GRECO AV. Stimulatory effect of pentagastrin on growth hormone and prolactin secretion in normal subjects. *Exp Clin Endocrinol* 88: 334–338, 1986.
 33. AMARA SG, JONAS V, ROSENFELD MG, ONG E, AND EVANS RM. Alternate RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptides. *Nature* 298: 240–244, 1982.
 34. AMENOMORI Y, CHEN CL, AND MEITES J. Serum prolactin levels in rats during different reproductive states. *Endocrinology* 86: 506–510, 1970.
 35. ANDERSEN JR. Decidual prolactin. Studies of decidual and amniotic prolactin in normal and pathological pregnancy. *Dan Med Bull* 37: 154–165, 1990.
 36. ANDERSON JM AND CRONIN MJ. Single lactotroph responses to dopamine, angiotensin II, and culture duration. *Am J Physiol Endocrinol Metab* 258: E24–E31, 1990.
 37. ANDERSON R AND MITCHELL R. Effects of GABA receptor agonists on [³H]dopamine release from median eminence and pituitary neurointermediate lobe. *Eur J Pharmacol* 115: 109–112, 1985.
 38. ANDERSON R AND MITCHELL R. Biphasic effect of GABA_A receptor agonists on prolactin secretion: evidence for two types of GABA_A receptor complex on lactotrophs. *Eur J Pharmacol* 124: 1–9, 1986.
 39. ANDERSON RA AND MITCHELL R. Benzodiazepine- and barbiturate-interactions with GABA_A receptor responses on lactotrophs. *Brain Res* 371: 287–292, 1986.
 40. ANDERSON ST, SAWANGJAROEN K, AND CURLEWIS JD. Pituitary adenylyl cyclase-activating polypeptide acts within the medial basal hypothalamus to inhibit prolactin and luteinizing hormone secretion. *Endocrinology* 137: 3424–3429, 1996.
 41. ANDRADE R, MALENKA RC, AND NICOLL RA. A G protein couples serotonin and GABA-B receptors to the same channels in hippocampus. *Science* 234: 1261–1265, 1986.
 42. ANDRIES M AND DENEFF C. Gonadotropin-releasing hormone influences the release of prolactin and growth hormone from intact rat pituitary in vitro during a limited period in neonatal life. *Peptides* 16: 527–532, 1995.
 43. ANHUT H, MEYER DK, AND NEPEL WK. Cholecystokinin-like immunoreactivity of rat medial basal hypothalamus: investigations on a possible hypophysiotropic function. *Neuroendocrinology* 36: 119–124, 1983.
 44. ANNUNZIATO L AND MOORE KE. Prolactin in CSF selectively increases dopamine turnover in the median eminence. *Life Sci* 22: 2037–2041, 1978.
 45. ANTHONY PK, STOLTZ RA, PUCCI ML, AND POWERS CA. The 22K variant of rat prolactin: evidence for identity to prolactin (1–173), storage in secretory granules, and regulated release. *Endocrinology* 132: 806–814, 1993.
 46. ANTHONY RV, LIANG R, KAYL EP, AND PRATT SL. The growth hormone/prolactin gene family in ruminant placentae. *J Reprod Fertil Suppl* 49: 83–95, 1995.
 47. ANTONI FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. *Neuroendocrinology* 39: 186–188, 1984.
 48. ANTONI FA, KANYICKA B, AND MAKARA GB. Effects of naloxone and neonatal treatment with monosodium-L-glutamate on growth hormone and prolactin release induced by electrical stimulation of the medial-basal hypothalamus in rats. *J Endocrinol* 96: 427–432, 1983.

49. ANTONI FA, KANYICSKA B, MEZEY E, AND MAKARA GB. Neonatal treatment with monosodium-L-glutamate: differential effects on growth hormone and prolactin release induced by morphine. *Neuroendocrinology* 35: 231–235, 1982.
50. ANTONI FA, KOVACS KJ, DOHANICS J, MAKARA GB, HOLMES MC, AND MAZUREK MF. Hypophysiotrophic function of vasopressin and oxytocin. *Brain Res Bull* 20: 729–736, 1988.
51. AOKI E, TAKEUCHI IK, AND SHOJI R. Nitric oxide: an attractive signaling molecule. *Acta Histochem Cytochem* 28: 97–106, 1995.
52. APUD JA, COCCHI D, LOCATELLI V, MASOTTO C, MULLER EE, AND RACAGNI G. Biochemical and functional aspects on the control of prolactin release by the hypothalamo-pituitary GABAergic system. *Psychoneuroendocrinology* 14: 3–17, 1989.
53. APUD JA, COCCHI D, MASOTTO C, PENALVA A, MULLER EE, AND RACAGNI G. Effect of single or repeated estrogen administration on tuberoinfundibular GABA neurons and anterior pituitary GABA receptors: biochemical and functional studies. *Brain Res* 361: 146–153, 1985.
54. APUD JA, MASOTTO C, COCCHI D, LOCATELLI V, MULLER EE, AND RACAGNI G. Prolactin control by the tubero-infundibular GABAergic system: role of anterior pituitary GABA receptors. *Psychoneuroendocrinology* 9: 125–133, 1984.
55. APUD JA, MASOTTO C, AND RACAGNI G. Effect of THIP and SL 76002, two clinically experimented GABA-mimetic compounds, on anterior pituitary GABA receptors and prolactin secretion in the rat. *Life Sci* 40: 871–881, 1987.
56. APUD JA, RACAGNI G, IULIANO E, COCCHI D, CASANUEVA F, AND MULLER EE. Role of central nervous system-derived or circulating gamma-aminobutyric acid on prolactin secretion in the rat. *Endocrinology* 108: 1505–1510, 1981.
57. ARAGAY AM, KATZ A, AND SIMON MI. The $G\alpha_q$ and $G\alpha_{11}$ proteins couple the thyrotropin-releasing hormone receptor to phospholipase C in GH₃ rat pituitary cells. *J Biol Chem* 267: 24983–24988, 1992.
58. ARAKELIAN MC, FOGLIA VG, AND LIBERTUN C. Further studies on the effect of cimetidine and other neurotropic drugs on rat serum prolactin. *Horm Metab Res* 14: 147–150, 1982.
59. ARAKELIAN MC AND LIBERTUN C. H1 and H2 histamine receptor participation in the brain control of prolactin secretion in lactating rats. *Endocrinology* 100: 890–895, 1977.
60. ARBOGAST LA AND BEN-JONATHAN N. The preovulatory prolactin surge: an evaluation of the role of dopamine. *Endocrinology* 123: 2690–2695, 1988.
61. ARBOGAST LA AND BEN-JONATHAN N. Tyrosine hydroxylase in the stalk-median eminence and posterior pituitary is inactivated only during the plateau phase of the preovulatory prolactin surge. *Endocrinology* 125: 667–674, 1989.
62. ARBOGAST LA AND BEN-JONATHAN N. The preovulatory prolactin surge is prolonged by a progesterone-dependent dopaminergic mechanism. *Endocrinology* 126: 246–252, 1990.
63. ARBOGAST LA, MURAI I, AND BEN-JONATHAN N. Differential alterations in dopamine turnover rates in the stalk-median eminence and posterior pituitary during the preovulatory prolactin surge. *Neuroendocrinology* 49: 525–530, 1989.
64. ARBOGAST LA, SOARES MJ, TOMOGANE H, AND VOOGT JL. A trophoblast-specific factor(s) suppresses circulating prolactin levels and increases tyrosine hydroxylase activity in tuberoinfundibular dopaminergic neurons. *Endocrinology* 131: 105–113, 1992.
65. ARBOGAST LA AND VOOGT JL. Hyperprolactinemia increases and hypoprolactinemia decreases tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nuclei, but not the substantia nigra or zona incerta. *Endocrinology* 128: 997–1005, 1991.
66. ARBOGAST LA AND VOOGT JL. Progesterone reverses the estradiol-induced decrease in tyrosine hydroxylase mRNA levels in the arcuate nucleus. *Neuroendocrinology* 58: 501–510, 1993.
67. ARBOGAST LA AND VOOGT JL. Pituitary adenylate cyclase-activating polypeptide (PACAP) increases prolactin release and tuberoinfundibular dopaminergic neuronal activity. *Brain Res* 655: 17–24, 1994.
68. ARBOGAST LA AND VOOGT JL. Progesterone suppresses tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nucleus on proestrus. *Endocrinology* 135: 343–350, 1994.
69. ARBOGAST LA AND VOOGT JL. Prolactin (PRL) receptors are colocalized in dopaminergic neurons in fetal hypothalamic cell cultures: effect of PRL on tyrosine hydroxylase activity. *Endocrinology* 138: 3016–3023, 1997.
70. ARBOGAST LA AND VOOGT JL. Endogenous opioid peptides contribute to suckling-induced prolactin release by suppressing tyrosine hydroxylase activity and messenger ribonucleic acid levels in tuberoinfundibular dopaminergic neurons. *Endocrinology* 139: 2857–2862, 1998.
71. AREY BJ, AVERILL RL, AND FREEMAN ME. A sex-specific endogenous stimulatory rhythm regulating prolactin secretion. *Endocrinology* 124: 119–123, 1989.
72. AREY BJ, BURRIS TP, BASCO P, AND FREEMAN ME. Infusion of dopamine at low concentrations stimulates the release of prolactin from α -methyl-para-tyrosine treated rats. *Proc Soc Exp Biol Med* 203: 60–63, 1993.
73. AREY BJ AND FREEMAN ME. Hypothalamic factors involved in the endogenous stimulatory rhythm regulating prolactin secretion. *Endocrinology* 124: 878–883, 1989.
74. AREY BJ AND FREEMAN ME. Oxytocin, vasoactive intestinal peptide and serotonin regulate the mating-induced surges of prolactin secretion in the rat. *Endocrinology* 126: 279–284, 1990.
75. AREY BJ AND FREEMAN ME. Ontogeny of the endogenous stimulatory rhythm regulating prolactin secretion in immature female rats. *Endocrinology* 128: 1481–1484, 1991.
76. AREY BJ AND FREEMAN ME. Activity of oxytocinergic neurons in the paraventricular nucleus mirrors the periodicity of the endogenous stimulatory rhythm regulating prolactin secretion. *Endocrinology* 130: 126–132, 1992.
77. AREY BJ AND FREEMAN ME. Activity of vasoactive intestinal peptide and serotonin in the paraventricular nucleus reflects the periodicity of the endogenous stimulatory rhythm regulating prolactin secretion. *Endocrinology* 131: 736–742, 1992.
78. AREY BJ, KANYICSKA B, AND FREEMAN ME. The endogenous stimulatory rhythm regulating prolactin secretion is present in the lactating rat. *Neuroendocrinology* 53: 35–40, 1991.
79. ARIMURA A, DUNN JD, AND SCHALLY AV. Effect of infusion of hypothalamic extracts on serum prolactin levels in rats treated with Nembutal, CNS depressant or bearing hypothalamic lesions. *Endocrinology* 90: 378–383, 1972.
80. ARISAWA M, SNYDER GD, AND MCCANN SM. Effect of substance P on thyrotropin secretion from the pituitary gland in the rat. *Peptides* 10: 763–766, 1989.
81. ARISAWA M, SNYDER GD, YU WH, DE PALATIS LR, HO RH, AND MCCANN SM. Physiologically significant inhibitory hypothalamic action of substance P on prolactin release in the male rat. *Neuroendocrinology* 52: 22–27, 1990.
82. ARITA J AND KIMURA F. Characterization of in vitro dopamine synthesis in the median eminence of rats with haloperidol-induced hyperprolactinemia and bromocriptine-induced hypoprolactinemia. *Endocrinology* 119: 1666–1672, 1986.
83. ARITA J AND KIMURA F. Enkephalin inhibits dopamine synthesis in vitro in the median eminence portion of rat hypothalamic slices. *Endocrinology* 123: 694–699, 1988.
84. ARITA J, KOJIMA Y, AND KIMURA F. Identification by the sequential cell immunoblot assay of a subpopulation of rat dopamine-unresponsive lactotrophs. *Endocrinology* 128: 1887–1894, 1991.
85. ARITA J, KOJIMA Y, AND KIMURA F. Measurement of the secretion of a small peptide at the single cell level by the cell immunoblot assay: thyroidectomy increases the number of substance P-secreting anterior pituitary cells. *Endocrinology* 132: 2682–2688, 1993.
86. ARITA J AND PORTER JC. Relationship between dopamine release into hypophyseal portal blood and prolactin release after morphine treatments in rats. *Neuroendocrinology* 38: 62–67, 1984.
87. ARNAOUT MA, GARTHWAITE TL, MARTINSON DR, AND HAGEN TC. Vasoactive intestinal polypeptide is synthesized in anterior pituitary tissue. *Endocrinology* 119: 2052–2057, 1986.
88. ARNT J, HYTTTEL J, AND SANCHEZ C. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. *Eur J Pharmacol* 213: 259–267, 1992.
89. ARONIN N, COSLOVSKY R, AND LEEMAN SE. Substance P and neurotensin: their roles in the regulation of anterior pituitary function. *Annu Rev Physiol* 48: 537, 1986.

90. ARRANG JM, GARBARG M, AND SCHWARTZ JC. Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. *Nature* 302: 832–837, 1983.
91. ARSLAN M, POHL CR, SMITH MS, AND PLANT TM. Studies of the role of the *N*-methyl-D-aspartate (NMDA) receptor in the hypothalamic control of prolactin secretion. *Life Sci* 50: 295–300, 1992.
92. ASA SL, KELLY MA, GRANDY DK, AND LOW MJ. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D₂ receptor-deficient mice. *Endocrinology* 140: 5348–5355, 1999.
93. AUDINOT V, RASOLONJANAHARY R, BERTRAND P, PRIAM M, KORDON C, AND ENJALBERT A. Involvement of protein kinase-C in the effect of angiotensin-II on adenosine 3',5'-monophosphate production in lactotroph cells. *Endocrinology* 129: 2231–2239, 1991.
94. AYLSWORTH CF, HODSON CA, BERG G, KLEDZIK G, AND METTES J. Role of adrenals and estrogen in regression of mammary tumors during postpartum lactation in the rat. *Cancer Res* 39: 2436–2439, 1979.
95. BABU GN AND VIJAYAN E. Plasma gonadotropin, prolactin levels and hypothalamic tyrosine hydroxylase activity following intraventricular bombesin and secretin in ovariectomized conscious rats. *Brain Res Bull* 11: 25–29, 1983.
96. BABU GN AND VIJAYAN E. Hypothalamic tyrosine hydroxylase activity, plasma gonadotropin and prolactin levels after aminooxyacetic acid in ovariectomized rats. *Experientia* 40: 1422–1423, 1984.
97. BADURA LL. Hypothalamic administration of vasoactive intestinal peptide modulates photoperiod-dependent basal prolactin secretion in female Siberian hamsters. *Endocr J* 1: 299–305, 1993.
98. BADURA LL AND GOLDMAN BD. Anterior pituitary release of prolactin is inhibited by exposure to short photoperiod. *J Neuroendocrinol* 9: 341–345, 1997.
99. BADURA LL, SISK CL, AND NUNEZ AA. Photoperiodic regulation of prolactin release in male hamsters with hypothalamic knife cuts. *Brain Res Bull* 29: 231–237, 1992.
100. BAERTSCH AJ, AUDIGIER Y, LLEDO P-M, ISRAEL J-M, BOCKAERT J, AND VINCENT J-D. Antisense oligonucleotides assign guanine nucleotide binding protein subtypes to their channel effectors. *Mol Endocrinol* 6: 2257–2265, 1992.
101. BAES M, ALLAERTS W, AND DENEFF C. Evidence for functional communication between folliculostellate cells and hormone-secreting cells in perfused anterior pituitary cell aggregates. *Endocrinology* 120: 685–691, 1987.
102. BAES M AND DENEFF C. Beta 2-receptors in the rat anterior pituitary mediate adrenergic stimulation of prolactin release. *Life Sci* 34: 1447–1454, 1984.
103. BAEUERLE PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle. *Curr Biol* 8: R19–R22, 1998.
104. BAGDY G. Role of the hypothalamic paraventricular nucleus in 5-HT_{1A}, 5-HT_{2A} and 5-HT_{2C} receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. *Behav Brain Res* 73: 277–280, 1996.
105. BAGDY G. Studies on the sites and mechanisms of 5-HT_{1A} receptor-mediated in vivo actions. *Acta Physiol Hung* 84: 399–401, 1996.
106. BAGDY G AND MAKARA GB. Hypothalamic paraventricular nucleus lesions differentially affect serotonin-1A (5-HT_{1A}) and 5-HT₂ receptor agonist-induced oxytocin, prolactin, and corticosterone responses. *Endocrinology* 134: 1127–1131, 1994.
107. BAGDY G AND MAKARA GB. Paraventricular nucleus controls 5-HT_{2C} receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses. *Eur J Pharmacol* 275: 301–305, 1995.
108. BAGDY G, SZEMEREDI K, KANYICKA B, AND MURPHY DL. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine, and prolactin response to *m*-chlorophenylpiperazine in conscious rats. *J Pharmacol Exp Ther* 250: 72–78, 1989.
109. BAKER BL AND GROSS DS. Cytology and distribution of secretory cell types in mouse hypophysis as demonstrated with immunocytochemistry. *Am J Anat* 153: 193–215, 1978.
110. BAKER BL, MIDDLEY AR JR, GERSTEN BE, AND YU YY. Differentiation of growth hormone and prolactin containing acidophils with peroxidase-labeled antibody. *Anat Rec* 164: 163–171, 1969.
111. BAKER BL AND YU YY. An immunocytochemical study of human pituitary mammatropes from fetal life to old age. *Am J Anat* 148: 217–240, 1977.
112. BAKOWSKA JC AND MORRELL JI. Atlas of the neurons that express mRNA for the long form of the prolactin receptor in the forebrain of the female rat. *J Comp Neurol* 386: 161–177, 1997.
113. BALS JA, CACICEDO L, LARA JI, LORENZO MJ, PAZOS F, AND SÁNCHEZ-FRANCO F. Autocrine and/or paracrine action of vasoactive intestinal peptide on thyrotropin-releasing hormone-induced prolactin release. *Endocrinology* 137: 144–150, 1996.
114. BALS JA, SÁNCHEZ-FRANCO F, LORENZO MJ, PAZOS F, LARA JI, AND CACICEDO L. Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion. *Endocrinology* 137: 508–513, 1996.
115. BALS JA, SÁNCHEZ-FRANCO F, PAZOS F, LARA JI, LORENZO MJ, MALDONADO G, AND CACICEDO L. Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: autocrine and/or paracrine action of vasoactive intestinal peptide. *Neuroendocrinology* 68: 326–333, 1998.
116. BANKY Z, NAGY GM, AND HALÁSZ B. Analysis of pituitary prolactin and adrenocortical response to ether, formalin or restraint in lactating rats: rise in corticosterone, but no increase in plasma prolactin levels after exposure to stress. *Neuroendocrinology* 59: 63–71, 1994.
117. BARB CR. The brain-pituitary-adipocyte axis: role of leptin in modulating neuroendocrine function. *J Anim Sci* 77: 1249–1257, 1999.
118. BARBER MC, CLEGG RA, FINLEY E, VERNON RG, AND FLINT DJ. The role of growth hormone, prolactin and insulin-like growth factors in the regulation of rat mammary gland and adipose tissue metabolism during lactation. *J Endocrinol* 135: 195–202, 1992.
119. BARLET JP AND RAVAUULT JP. Calcitonin treatment and plasma prolactin levels in pregnant and lactating ewes. *Reprod Nutr Dev* 24: 63–69, 1984.
120. BARNES PJ, HADDAD EB, AND ROUSELL J. Regulation of muscarinic M₂ receptors. *Life Sci* 60: 1015–1021, 1997.
121. BARRON SE AND HOOVER DB. Localization of acetylcholinesterase and choline acetyltransferase in the rat pituitary cells. *Histochem J* 15: 1087–1098, 1983.
122. BARTHA L, NAGY GM, KIEM DT, FEKETE MIK, AND MAKARA GB. Inhibition of suckling-induced prolactin release by dexamethasone. *Endocrinology* 129: 635–640, 1991.
123. BARTON AC, LAHTI RA, PIERCEY MF, AND MOORE KE. Autoradiographic identification of prolactin binding sites in rat median eminence. *Neuroendocrinology* 49: 649–653, 1989.
124. BASSETT JM, CURTIS N, HANSON C, AND WEEDING CM. Effects of altered photoperiod or maternal melatonin administration on plasma prolactin concentrations in fetal lambs. *J Endocrinol* 122: 633–643, 1989.
125. BATAILLE D, PEILLON F, BESSON J, AND ROSSELIN G. Vasoactive intestinal peptide (VIP): recepteurs spécifiques et activation de l'adenylate cyclase dans une tumeur hypophysaire humaine a prolactine. *C R Seances Acad Sci (III)* 228: 1315–1317, 1979.
126. BATTEY J AND WADA E. Two distinct receptor subtypes for mammalian bombesin-like peptides. *Trends Neurosci* 14: 524–528, 1991.
127. BAUER CK. The erg inwardly rectifying K⁺ current and its modulation by thyrotropin-releasing hormone in giant clonal rat anterior pituitary cells. *J Physiol (Lond)* 510: 63–70, 1998.
128. BAUER CK, MEYERHOF W, AND SCHWARZ JR. An inward-rectifying K⁺ current in clonal rat pituitary cells and its modulation by thyrotropin-releasing hormone. *J Physiol (Lond)* 429: 169–189, 1990.
129. BAUER TW, MORIARTY CM, AND CHILDS GV. Studies of immunoreactive gonadotropin releasing hormone (GnRH) in the rat anterior pituitary. *J Histochem Cytochem* 29: 1171–1178, 1981.
130. BAUMGARTEN HG, BJORKLUND A, HOLSTEIN AF, AND NOBIN A. Organization and ultrastructural identification of the catecholamine nerve terminals in neural lobe and pars intermedia of the rat pituitary. *Z Zellforsch Mikrosk Anat* 126: 483–517, 1972.
131. BAZAN JF. Haemopoietic receptors and helical cytokines. *Immunol Today* 11: 350–354, 1990.
132. BAZAN JF. Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci USA* 87: 6934–6938, 1990.

133. BEADLING C, BABBAGE JW, AND CANTRELL DA. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. *EMBO J* 15: 1902–1913, 1996.
134. BEATTIE CW, RODGERS CH, AND SOYKA LF. Influence of ovariectomy and ovarian steroids on hypothalamic tyrosine hydroxylase activity in the rat. *Endocrinology* 91: 276–279, 1972.
135. BEAUDET A, GREENSPUN D, RAELESON J, AND TANNENBAUM GS. Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function. *Neuroscience* 65: 551–561, 1995.
136. BEDECS K, BERTHOLD M, AND BARTFAI T. Galanin: 10 years with a neuroendocrine peptide. *Int J Biochem Cell Biol* 27: 337–349, 1995.
137. BEINFELD MC, MEYER DK, AND BROWNSTEIN MJ. Cholecystokinin octapeptide in the rat hypothalamo-neurohypophyseal system. *Nature* 288: 376–378, 1980.
138. BEINFELD MC, MEYER DK, ESKAY RL, JENSEN RT, AND BROWNSTEIN MJ. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. *Brain Res* 212: 51–57, 1981.
139. BEN-DAVID M, DANON A, BENVENISTE R, WELLER CP, AND SULMAN FG. Results of radioimmunoassays of rat pituitary and serum prolactin after adrenalectomy and perphenazine treatment in rats. *J Endocrinol* 50: 599–606, 1971.
140. BEN-JONATHAN N. Dopamine: a prolactin-inhibiting hormone. *Endocr Rev* 6: 564–589, 1985.
141. BEN-JONATHAN N AND LIU J-W. Pituitary lactotrophs: endocrine, paracrine, juxtacrine, and autocrine interactions. *Trends Endocrinol Metab* 3: 254–258, 1992.
142. BEN-JONATHAN N, OLIVER C, WINER HJ, MICAL RS, AND PORTER JC. Dopamine in hypophyseal portal plasma of the rat during the estrous cycle and throughout pregnancy. *Endocrinology* 100: 452–480, 1977.
143. BEN-JONATHAN N AND PETERS LL. Posterior pituitary lobectomy: differential elevation of plasma prolactin and luteinizing hormone in estrous and lactating rats. *Endocrinology* 110: 1861–1865, 1982.
144. BENNETT BA AND MORRIS M. An immunohistochemical and biochemical study of catecholaminergic activity in dissociated hypothalamic cultures. *Brain Res* 491: 109–115, 1989.
145. BENSON GK AND COWIE AT. Lactation in the rat after hypophyseal posterior lobectomy. *J Endocrinol* 14: 54–65, 1956.
146. BENTLEY AM AND WALLIS M. In vitro evidence for the autoregulation of prolactin secretion at the level of the pituitary gland in the rat. *J Endocrinol* 115: 13–18, 1987.
147. BERCHTOLD S, VOLAREVIC S, MORIGGI R, MERCEP M, AND GRONER B. Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. *Mol Endocrinol* 12: 556–567, 1998.
148. BERCZI I AND NAGY E. Placental lactogen is a haemopoietic hormone. *Br J Haematol* 79: 355–358, 1991.
149. BERGERON JJM, RESCH L, RACHUBINSKI R, PATEL BA, AND POSTER BI. Effect of colchicine on internalization of prolactin in the female rat liver: an in vivo autoradiographic study. *J Cell Biol* 96: 875–886, 1983.
150. BERLANGA JJ, FRESNO VARA JA, MARTIN-PEREZ J, AND GARCIA-RUIZ JP. Prolactin receptor associated with c-src kinase in rat liver. *Mol Endocrinol* 9: 1461–1467, 1995.
151. BERLANGA JJ, GARCIA-RUIZ JP, PERROT-APPLANAT M, KELLY PA, AND EDERY M. The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter. *Mol Endocrinol* 11: 1449–1457, 1997.
152. BERLANGA JJ, GUALILLO O, BUTEAU H, APPLANAT M, KELLY PA, AND EDERY M. Prolactin activates tyrosyl phosphorylation of insulin receptor substrate 1 and phosphatidylinositol-3-OH kinase. *J Biol Chem* 272: 2050–2052, 1997.
153. BERN HA. Prolactin and osmoregulation. *Am Zool* 15: 937–949, 1975.
154. BERN HA AND NICOLL CA. The comparative endocrinology of prolactin. *Rec Prog Horm Res* 24: 681–720, 1968.
155. BERRY SA AND GUDELSKY GA. D₁ receptors function to inhibit the activation of tuberoinfundibular dopamine neurons. *J Pharmacol Exp Ther* 254: 677–682, 1990.
156. BERRY SA AND GUDELSKY GA. Effect of D₂ dopamine agonists on tuberoinfundibular dopamine neurons. *Neuropharmacology* 30: 961–965, 1991.
157. BERTHERAT J, BLUET-PAJOT MT, AND EPELBAUM J. Neuroendocrine regulation of growth hormone. *Eur J Endocrinol* 132: 12–24, 1995.
158. BERTHON P, KELLY PA, AND JIANE JD. Water-soluble prolactin receptors from porcine mammary gland. *Proc Soc Exp Biol Med* 184: 300–306, 1987.
159. BERWAER M, MARTIAL JA, AND DAVIS JR. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. *Mol Endocrinol* 8: 635–642, 1994.
160. BERWAER M, MONGET P, PEERS B, MATHY-HARTERT M, BELLEFROID E, DAVIS JR, BELAYEW A, AND MARTIAL JA. Multihormonal regulation of the human prolactin gene expression from 5000 bp of its upstream sequence. *Mol Cell Endocrinol* 80: 53–64, 1991.
161. BERWAER M, PEERS B, NALDA AM, MONGET P, DAVIS JR, BELAYEW A, AND MARTIAL JA. Thyrotropin-releasing hormone and epidermal growth factor induce human prolactin expression via identical multiple cis elements. *Mol Cell Endocrinol* 92: 1–7, 1993.
162. BESSON J, ROTSZTEIN W, LABURTHE M, EPELBAUM J, BEAUDET A, KORDON C, AND ROSSELIN G. Vasoactive intestinal peptide (VIP): brain distribution, subcellular localization and effect of deafferentation of the hypothalamus in male rats. *Brain Res* 165: 79–85, 1979.
163. BESSON J, SARRIEAU A, VIAL M, MARIE JC, ROSSELIN G, AND ROSTENE W. Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. *Brain Res* 398: 329–336, 1986.
164. BETHEA CL. Stimulatory effect of estrogen on prolactin secretion from primate pituitary cells cultured on extracellular matrix and in serum-free medium. *Endocrinology* 115: 443–451, 1984.
165. BETHEA CL. Characterization of dopamine and estrogen interaction on primate prolactin secretion with pituitary cells cultured on extracellular matrix and with pituitary stalk-transected monkeys. *Endocrinology* 116: 863–872, 1985.
166. BETHEA CL, HESS DL, WIDMANN AA, AND HENNINGFELD JM. Effects of progesterone on prolactin, hypothalamic beta-endorphin, hypothalamic substance P, and midbrain serotonin in guinea pigs. *Neuroendocrinology* 61: 695–703, 1995.
167. BETHEA CL AND NEILL JD. Prolactin secretion after cervical stimulation of rats maintained in constant dark or constant light. *Endocrinology* 104: 870–876, 1979.
168. BETHEA CL AND NEILL JD. Lesions of the suprachiasmatic nuclei abolish the cervically stimulated prolactin surges in the rat. *Endocrinology* 107: 1–5, 1980.
169. BEWLEY TA AND LI CH. Circular dichroism studies on human pituitary growth hormone and ovine pituitary lactogenic hormone. *Biochemistry* 11: 884–888, 1972.
170. BEX F, BARTKE A, GOLDMAN BD, AND ALTERIO SD. Prolactin, growth hormone, luteinizing hormone receptors, and seasonal changes in testicular activity in the golden hamster. *Endocrinology* 103: 2069–2080, 1978.
171. BHAT G, MAHESH VB, AGUAN K, AND BRANN DW. Evidence that brain nitric oxide synthase is the major nitric oxide synthase isoform in the hypothalamus of the adult female rat and that nitric oxide potentially regulates hypothalamic cGMP levels. *Neuroendocrinology* 64: 93–102, 1996.
172. BHAT GK, MAHESH VB, LAMAR CA, PING L, AGUAN K, AND BRANN DW. Histochemical localization of nitric oxide neurons in the hypothalamus: association with gonadotropin-releasing hormone neurons and co-localization with N-methyl-D-aspartate receptors. *Neuroendocrinology* 62: 187–197, 1995.
173. BINTARNIGSIH J, LYONS WR, JOHNSON RE, AND LI CH. Hormonally-induced lactation in hypophysectomized rats. *Endocrinology* 63: 540–548, 1958.
174. BISHOP N, FAWCETT CP, KRULICH L, AND MCCANN SM. Acute and chronic effects of hypothalamic lesions on the release of FSH, LH and prolactin in intact and castrated rats. *Endocrinology* 91: 643–656, 1972.
175. BITTENCOURT J, BENOIT R, AND SAWCHENKO P. Distribution and origins of substance P-immunoreactive projections to the paraven-

- tricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections. *J Chem Neuroanat* 4: 63–78, 1991.
176. BJORKLUND A, MOORE RY, NOBIN A, AND STENEVI U. The organization of tubero-hypophysial and reticulo-infundibular catecholamine neuron systems in the rat brain. *Brain Res* 51: 171–191, 1973.
177. BJORO T, TORJENSEN PA, OSTBERG BC, SAND O, IVERSEN JG, GAUTVIK KM, AND HAUG E. Bombesin stimulates prolactin secretion from cultured rat pituitary tumour cells (GH₄C₁) via activation of phospholipase C. *Regul Pept* 19: 169–182, 1987.
178. BLAKE CA. Stimulation of pituitary prolactin and TSH release in lactating and proestrous rats. *Endocrinology* 94: 503–508, 1974.
179. BLAKE CA. Effects of pinealectomy on the rat oestrous cycle and pituitary gonadotrophin release. *J Endocrinol* 69: 67–75, 1976.
180. BLAKE CA AND SAWYER CH. Nicotine blocks the suckling-induced rise in circulating prolactin in lactating rats. *Science* 177: 619–621, 1972.
181. BLUM M, McEWEN BS, AND ROBERTS JL. Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. *J Biol Chem* 262: 817–821, 1987.
182. BODEN P AND WOODRUFF GN. Ionic mechanisms underlying cholecystokinin action in rat brain. *Ann NY Acad Sci* 713: 129–137, 1994.
183. BOLANDER FF JR. Regulation of prolactin receptor glycosylation and its role in receptor location. *Mol Cell Endocrinol* 149: 85–92, 1999.
184. BOLE-FEYSOT C, GOFFIN V, EDERY M, BINART N, AND KELLY PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. *Endocr Rev* 19: 225–268, 1998.
185. BONAVERA JJ, SAHU A, KALRA PS, AND KALRA SP. Evidence in support of nitric oxide (NO) involvement in the cyclic release of prolactin and LH surges. *Brain Res* 660: 175–179, 1994.
186. BONDY B, ACKENHEIL M, AND RUPPERT T. Spiperone binding in lymphocytes: part of a dopamine uptake system. *Ann NY Acad Sci* 650: 221–225, 1992.
187. BONDY B, DE JONGE S, PANDER S, PRIMBS J, AND ACKENHEIL M. Identification of dopamine D₄ receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. *J Neuroimmunol* 71: 139–144, 1996.
188. BOOCKFOR FR AND FRAWLEY LS. Functional variations among prolactin cells from different pituitary regions. *Endocrinology* 120: 874–879, 1987.
189. BOOCKFOR FR, HOFFLER JP, AND FRAWLEY LS. Cultures of GH₃ cells are functionally heterogeneous: thyrotropin-releasing hormone, estradiol, and cortisol cause reciprocal shifts in the proportions of growth hormone and prolactin secretors. *Endocrinology* 117: 418–420, 1985.
190. BOOCKFOR FR, HOFFLER JP, AND FRAWLEY LS. Analysis by plaque assays of GH and prolactin release from individual cells in cultures of male pituitaries. Evidence for functional heterogeneity within rat mammatrope and somatotrope populations. *Neuroendocrinology* 42: 64–71, 1986.
191. BOOCKFOR FR, HOFFLER JP, AND FRAWLEY LS. Estradiol induces a shift in cultured cells that release prolactin or growth hormone. *Am J Physiol Endocrinol Metab* 250: E100–E103, 1986.
192. BOOCKFOR FR AND SCHWARZ LK. Cultures of GH₃ cells contain both single and dual hormone secretors. *Endocrinology* 122: 762–764, 1988.
193. BOSSÉ R, FUMAGALLI F, JABER M, GIROS B, GAINETDINOV RR, WETSEL WC, MISSALE C, AND CARON MG. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. *Neuron* 19: 127–138, 1997.
194. BOTTARI SP, DE GASPARO M, STECKELINGS UM, AND LEVENS NR. Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications. *Front Neuroendocrinol* 14: 123–171, 1993.
195. BOULAY JL AND PAUL WE. The interleukin-4-related lymphokines and their binding to hematopoietin receptors. *J Biol Chem* 267: 20525–20528, 1992.
196. BOUTIN J-M, EDERY M, SHIROTA M, JOLICOEUR C, LESUEUR L, ALI S, GOULD D, DJIANE J, AND KELLY PA. Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. *Mol Endocrinol* 3: 1455–1461, 1989.
197. BOUTIN JM, JOLICOEUR C, OKAMURA H, GAGNON J, EDERY M, SHIROTA M, BANVILLE D, DUSANTER-FOURT I, DJIANE J, AND KELLY PA. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. *Cell* 53: 69–77, 1988.
198. BOUVIER C, FORGET H, LAGACÉ G, DREWS R, SINNETT D, LABUDA D, AND COLLU R. G proteins in normal rat pituitaries and in prolactin-secreting rat pituitary tumors. *Mol Cell Endocrinol* 78: 33–44, 1991.
199. BOUVIER C, LAGACE G, AND COLLU R. G protein modulation by estrogens. *Mol Cell Endocrinol* 79: 65–73, 1991.
200. BOWEN JM, KEYES PL, WARREN JS, AND TOWNSON DH. Prolactin-induced regression of the rat corpus luteum: expression of monocyte chemoattractant protein-1 and invasion of macrophages. *Biol Reprod* 54: 1120–1127, 1996.
201. BOWER A, HADLEY ME, AND HRUBY VJ. Biogenic amines and control of melanophore stimulating hormone release. *Science* 184: 70–72, 1974.
202. BOWERS CY, FRIESEN HG, HWANG P, GUYDA HJ, AND FOLKERS K. Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide. *Biochem Biophys Res Commun* 45: 1033–1041, 1971.
203. BOYD AE. Prolactin-releasing factor (PRF) in porcine hypothalamic extract distinct from TRH. *Endocrinology* 99: 861–871, 1976.
204. BRADWEIN J AND KOSZYCKI D. The cholecystokinin hypothesis of anxiety and panic disorder. *Ann NY Acad Sci* 713: 273–282, 1994.
205. BRAITHWAITE GD, GLASCOCK RF, AND RIAZUDDIN S. Studies on the transfer of calcium across the ovine placenta and incorporation into the foetal skeleton. *Br J Nutr* 27: 417–424, 1972.
206. BRANN CW, PUTNAM CD, AND MAHESH VB. Corticosteroid regulation of gonadotropin and prolactin secretion in the rat. *Endocrinology* 126: 159–166, 1990.
207. BRANN DW, BHAT GK, LAMAR CA, AND MAHESH VB. Gaseous transmitters and neuroendocrine regulation. *Neuroendocrinology* 65: 385–395, 1997.
208. BRANN DW AND MAHESH VB. Excitatory amino acids: evidence for a role in the control of reproduction and anterior pituitary hormone secretion. *Endocr Rev* 18: 678–700, 1997.
209. BRANN DW, PING L, AND ZAMORANO P. Role of excitatory amino acids in reproduction. In: *Excitatory Amino Acids: Their Role in Neuroendocrine Function*, edited by Brann DW and Mahesh VB. Boca Raton, FL: CRC, 1996, p. 133–166.
210. BRAR AK, KANDA Y, KESSLER CA, CEDARS MI, AND HANDWERGER S. N5 endometrial stromal cell line: a model system to study decidual prolactin gene expression. *In Vitro Cell Dev Biol Anim* 35: 150–154, 1999.
211. BRAZEAU P, VALE W, BURGUS R, LING N, BUTCHER M, RIVIER J, AND GUILLEMIN R. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 179: 77–79, 1973.
212. BREDOW S, KACSÓH B, OBÁL F JR, FANG J, AND KRUEGER JM. Increase of prolactin mRNA in the rat hypothalamus after intracerebroventricular injection of VIP or PACAP. *Brain Res* 660: 301–308, 1994.
213. BREDT DS, GLATT CE, HWANG PM, FOTUHI M, DAWSON TM, AND SNYDER SH. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. *Neuron* 7: 615–624, 1991.
214. BREGONZIO C, NAVARRO CE, AND DONOSO AO. NMDA receptor antagonists block stress-induced prolactin release in female rats at estrus. *Eur J Pharmacol* 350: 259–265, 1998.
215. BRENNER-GATI L AND GERSHENGORN MC. Effects of thyrotropin-releasing hormone on phosphoinositides and cytoplasmic free calcium in thyrotropic pituitary cells. *Endocrinology* 118: 163–170, 1986.
216. BRETON C, PECHOUX C, MOREL G, AND ZINGG HH. Oxytocin receptor messenger ribonucleic acid: characterization, regulation, and cellular localization in the rat pituitary gland. *Endocrinology* 136: 2928–2936, 1995.
217. BRIDGES RS. A quantitative analysis of the roles of dosage, sequence, and duration of estradiol and progesterone exposure in

- the regulation of maternal behavior in the rat. *Endocrinology* 114: 930–940, 1984.
218. BRIDGES RS. Prolactin stimulation of maternal behavior in female rats. *Science* 227: 782–784, 1985.
 219. BRIDGES RS. The role of lactogenic hormones in maternal behavior in female rats. *Acta Paediatr* 83 Suppl 397: 33–39, 1994.
 220. BRIDGES RS, NUMAN M, RONSHEIM PM, MANN PE, AND LUPINI CE. Central prolactin infusions stimulate maternal behavior in steroid-treated, nulliparous female rats. *Proc Natl Acad Sci USA* 87: 8003–8007, 1990.
 221. BRIDGES RS, ROBERTSON MC, SHIU RPC, FRIESEN HG, STUER AM, AND MANN PE. Endocrine communication between conceptus and mother: placental lactogen stimulation of maternal behavior. *Neuroendocrinology* 64: 57–64, 1996.
 222. BRIDGES RS AND RONSHEIM PM. Prolactin (PRL) regulation of maternal behavior in rats: bromocriptine treatment delays and PRL promotes the rapid onset of behavior. *Endocrinology* 126: 837–848, 1990.
 223. BRISKEN C, KAUR S, CHAVARRIA TE, BINART N, SUTHERLAND RL, WEINBERG RA, KELLY PA, AND ORMANDY CJ. Prolactin controls mammary gland development via direct and indirect mechanisms. *Dev Biol* 210: 96–106, 1999.
 224. BROOKS CL, KIM BG, APHALE P, KLEEMAN BE, AND JOHNSON GC. Phosphorylated variant of bovine prolactin. *Mol Cell Endocrinol* 71: 117–123, 1990.
 225. BROWN ER, HARLAN RE, AND KRAUSE JE. Gonadal steroid regulation of substance P (SP) and SP-encoding messenger ribonucleic acids in the rat anterior pituitary and hypothalamus. *Endocrinology* 126: 330–340, 1990.
 226. BROWN GM, SEEMAN P, AND LEE T. Dopamine/neuroleptic receptors in basal hypothalamus and pituitary. *Endocrinology* 99: 1407–1410, 1976.
 227. BROWNSTEIN MJ, ESKAY RL, AND PALKOVITS M. Thyrotropin releasing hormone in the median eminence is in processes of paraventricular nucleus neurons. *Neuropeptides* 2: 197–201, 1982.
 228. BROWNSTEIN MJ, MROZ EA, KIZER JS, PALKOVITS M, AND LEEMAN SE. Regional distribution of substance P in the brain of the rat. *Brain Res* 116: 299–305, 1976.
 229. BRUCE HM. Smell as an exteroceptive factor. *J Anim Sci* 25 Suppl: 83–89, 1966.
 230. BRUCE HM. Pheromones. *Br Med Bull* 26: 10–13, 1970.
 231. BRUCE HM. Olfaction. *J. Reprod Fertil Suppl* 19: 403–404, 1973.
 232. BRUHN TO, BOLDUC TG, MACLEAN DB, AND JACKSON IMD. ProTRH peptides are synthesized and secreted by anterior pituitary cells in long-term culture. *Endocrinology* 129: 556–558, 1991.
 233. BRUHN TO, BOLDUC TG, RONDEEL JMM, AND JACKSON IMD. Thyrotropin-releasing hormone gene expression in the anterior pituitary. II. Stimulation by glucocorticoids. *Endocrinology* 134: 821–825, 1994.
 234. BRUHN TO, RONDEEL JMM, BOLDUC TG, AND JACKSON IMD. Thyrotropin-releasing hormone (TRH) gene expression in the anterior pituitary. I. Presence of pro-TRH messenger ribonucleic acid and pro-TRH-derived peptide in a subpopulation of somatotrophs. *Endocrinology* 134: 815–820, 1994.
 235. BRUHN TO, RONDEEL JMM, BOLDUC TG, AND JACKSON IMD. Thyrotropin-releasing hormone gene expression in the anterior pituitary. III. Stimulation by thyroid hormone: potentiation by glucocorticoids. *Endocrinology* 134: 826–830, 1994.
 236. BRUHN TO, RONDEEL JMM, BOLDUC TG, AND JACKSON IMD. Thyrotropin-releasing hormone gene expression in cultured anterior pituitary cells: role of gender. *Neuroendocrinology* 61: 77–84, 1995.
 237. BRUHN TO, RONDEEL JMM, AND JACKSON IMD. Thyrotropin-releasing hormone gene expression in the anterior pituitary. IV. Evidence for paracrine and autocrine regulation. *Endocrinology* 139: 3416–3422, 1998.
 238. BRUNETTI L, RAGAZZONI E, PREZIOSI P, AND VACCA M. A possible role for nitric oxide but not for prostaglandin E_2 in basal and interleukin-1 β -induced PRL release in vitro. *Life Sci* 56: PL277–PL283, 1995.
 239. BRUNI JF, VAN VUGT D, MARSHALL S, AND MEITES J. Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. *Life Sci* 21: 461–466, 1977.
 240. BRYANT W, JANIK J, AND CALLAHAN P. Orphanin FQ stimulates prolactin and growth hormone release in male and female rat. *Brain Res* 807: 228–233, 1998.
 241. BUCKLEY AR, CROWE PD, AND RUSSELL DH. Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen. *Proc Natl Acad Sci USA* 85: 8649–8653, 1988.
 242. BUCKLEY AR, RAO Y-P, BUCKLEY DJ, AND GOUT PW. Prolactin-induced phosphorylation and nuclear translocation of MAP kinase in Nb2 lymphoma cells. *Biochem Biophys Res Commun* 204: 1158–1164, 1994.
 243. BUMPUS FM, CATT KJ, CHIU AT, DEGASPARO M, GOODFRIEND T, HUSAIN A, PEACH MJ, TAYLOR DGJ, AND TIMMERMAN PB. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. *Hypertension* 17: 720–721, 1991.
 244. BUNZOW JR, VAN TOL HHM, GRANDY DK, ALBERT P, SALON J, CHRISTIE M, MACHICLA GA, NEVE KA, AND CIVELLI O. Cloning and expression of a rat D2 dopamine receptor cDNA. *Nature* 336: 783–787, 1988.
 245. BUNZOW JR, ZHANG G, BOUVIER C, SAEZ C, RONNEKLEIV OK, KELLY MJ, AND GRANDY DK. Characterization and distribution of a cloned rat μ -opioid receptor. *J Neurochem* 64: 14–24, 1995.
 246. BURBACH JPH, ADAN RAH, LOLAIT SJ, VAN LEEUWEN FW, MEZEY E, PALKOVITS M, AND BARBERIS C. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. *Cell Mol Neurobiol* 15: 573–595, 1995.
 247. BURNS G AND SARKAR DK. Transforming growth factor- β_1 -like immunoreactivity in the pituitary gland of the rat: effect of estrogen. *Endocrinology* 133: 1444–1449, 1993.
 248. BURRIS TP AND FREEMAN ME. Low concentrations of dopamine increase cytosolic calcium in lactotrophs. *Endocrinology* 133: 63–68, 1993.
 249. BURRIS TP AND FREEMAN ME. Comparison of the forms of the dopamine D_2 receptor expressed in GH $_4$ C $_1$ cells. *Proc Soc Exp Biol Med* 205: 226–235, 1994.
 250. BURRIS TP AND FREEMAN ME. Identification of subpopulations of anterior pituitary cells responsive to secretagogues using the reverse hemolytic plaque assay: subpopulation of lactotrophs is responsive to stimulatory doses of dopamine. *Neuroprotocols* 5: 188–197, 1994.
 251. BURRIS TP, NGUYEN DN, SMITH SG, AND FREEMAN ME. The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins. *Endocrinology* 130: 926–932, 1992.
 252. BURRIS TP, STRINGER LC, AND FREEMAN ME. Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. *Neuroendocrinology* 54: 175–183, 1991.
 253. BUSKILA D AND SHOENFELD Y. Prolactin, bromocriptine and autoimmune diseases. *Isr J Med Sci* 32: 23–27, 1996.
 254. BUTCHER RL, COLLINS WE, AND FUGO NW. Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17 β throughout the 4-day estrous cycle of the rat. *Endocrinology* 94: 1704–1708, 1974.
 255. BUTCHER RL, FUGO NW, AND COLLINS WC. Semicircadian rhythm in plasma levels of prolactin during early gestation in the rat. *Endocrinology* 90: 1125–1127, 1972.
 256. BUTEAU H, PEZET A, FERRAG F, PERROT-APPLANAT M, KELLY PA, AND EDERY M. N-glycosylation of the prolactin receptor is not required for activation of gene transcription but is crucial for its cell surface targeting. *Mol Endocrinol* 12: 544–555, 1998.
 257. BUYDENS P, GOVAERTS J, VELKENIERS B, FINNE E, AND VANHAELST L. The effect of bombesin on basal, alpha-methyl-p-tyrosine, haloperidol, morphine, bromazocine and stress-induced prolactin secretion. *Life Sci* 43: 1755–1760, 1988.
 258. CAI A, BOWERS RC, MOORE JP JR, AND HYDE JF. Function of galanin in the anterior pituitary of estrogen-treated Fischer 344 rats: autocrine and paracrine regulation of prolactin secretion. *Endocrinology* 139: 2452–2458, 1998.
 259. CALIGARIS L, ASTRADA JJ, AND TALEISNIK S. Oestrogen and progesterone influence on the release of prolactin in ovariectomized rats. *J Endocrinol* 60: 205–215, 1974.
 260. CALIGARIS L AND TALEISNIK S. Involvement of neurons containing

- 5-hydroxytryptamine in the mechanism of prolactin release induced by estrogen. *J Endocrinol* 62: 25–32, 1974.
261. CALLAHAN P, BAUMANN MH, AND RABII J. Inhibition of tuberoinfundibular dopaminergic neural activity during suckling: involvement of mu and kappa opiate receptor subtypes. *J Neuroendocrinol* 8: 771–776, 1996.
262. CALOGERO AE, BAGDY G, BURRELLO N, POLOSA P, AND D'AGATA R. Role for serotonin₃ receptors in the control of adrenocorticotrophic hormone release from rat pituitary cell cultures. *Eur J Endocrinol* 133: 251–254, 1995.
263. CALOGERO AE, GAGLIARDI M, MONCADA ML, AND D'AGATA R. Effect of selective serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells. *J Endocrinol* 136: 381–387, 1993.
264. CALOGERO AE, NICOLSI AM, MONCADA ML, CONIGLIONE F, VICARI E, POLOSA P, AND D'AGATA R. Effects of cholecystokinin octapeptide on the hypothalamic-pituitary-adrenal axis function and on vasopressin, prolactin and growth hormone release in humans. *Neuroendocrinology* 58: 71–76, 1993.
265. CALOGERO AE, WEBER RF, RAITI F, BURRELLO N, MONCADA ML, MONGIOI A, AND D'AGATA R. Involvement of corticotropin-releasing hormone and endogenous opioid peptides in prolactin-suppressed gonadotropin-releasing hormone release in vitro. *Neuroendocrinology* 60: 291–296, 1994.
266. CAMPBELL GS, ARGETSINGER LS, IHLE JN, KELLY PA, RILLEMA JA, AND CARTER-SU C. Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. *Proc Natl Acad Sci USA* 91: 5232–5236, 1994.
267. CAMPBELL-BURK S AND CARPENTER JW. Refolding and purification of Ras proteins. *Methods Enzymol* 255: 3–13, 1995.
268. CAMPFIELD LA, SMITH FJ, AND BURN P. The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. *Horm Metab Res* 28: 619–632, 1996.
269. CANONICO PL AND MACLEOD RM. Angiotensin increases inositol phosphate content in anterior pituitary cells in culture: a relationship with its prolactin-stimulating activity. *Regul Pept Suppl* 4: 221–223, 1985.
270. CANONICO PL AND MACLEOD RM. Angiotensin peptides stimulate phosphoinositide breakdown and prolactin release in anterior pituitary cells in culture. *Endocrinology* 118: 233–238, 1986.
271. CANONICO PL, SPECIALE C, SORTINO MA, AND CAPAGNINI US. Involvement of arachidonate metabolism in neurotensin-induced prolactin release in vitro. *Am J Physiol Endocrinol Metab* 249: E257–E263, 1985.
272. CANONICO PL, VALDENEGRO CA, OF WITA, MACLEOD RM, AND O'DELL ANH. The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine. *Endocrinology* 113: 7–14, 1983.
273. CAPPONI AM, FACROD-COUNE CA, GAILLARD RC, AND MULLER AF. Binding and activation properties of angiotensin II in dispersed rat anterior pituitary cells. *Endocrinology* 110: 1043, 1982.
274. CARLSON DE, KLEMCKE HG, AND GANN DS. Response of prolactin to hemorrhage is similar to that of adrenocorticotropin in swine. *Am J Physiol Regulatory Integrative Comp Physiol* 258: R645–R649, 1990.
275. CARLSON RR AND DEFEO VJ. Role of the pelvic nerve versus the abdominal sympathetic nerves in the reproductive function of the female rat. *Endocrinology* 77: 1022, 1965.
276. CARMELIET P AND DENEFF C. Immunocytochemical and pharmacological evidence for an intrinsic cholinomimetic system modulating prolactin and growth hormone release in rat pituitary. *Endocrinology* 123: 1128–1139, 1988.
277. CARMELIET P AND DENEFF C. Synthesis and release of acetylcholine by normal and tumoral pituitary corticotrophs. *Endocrinology* 124: 2218–2227, 1989.
278. CARMELIET P, MAERTENS P, AND DENEFF C. Stimulation and inhibition of prolactin release from rat pituitary lactotrophs by the cholinomimetic carbachol in vitro. Influence of hormonal environment and intercellular contacts. *Mol Cell Endocrinol* 63: 121–131, 1989.
279. CARON MC, BEAULIEU M, RAYMOND V, GANGE B, DROUIN J, LEFKOWITZ J, AND LABRIE F. Dopaminergic receptors in the anterior pituitary gland. *J Biol Chem* 253: 2244, 1978.
280. CARON MG. Dopaminergic receptors in the anterior pituitary gland. Correlation of [³H]dihydroergocryptine binding with the dopaminergic control of prolactin release. *J Biol Chem* 253: 2244–2253, 1978.
281. CARON RW AND DEIS RP. Participation of opioid and serotonergic systems in prolactin secretion induced by hypothalamic action of estradiol. *Neuroendocrinology* 64: 124–130, 1996.
282. CARON RW, SALICIONI AM, AND DEIS RP. Regulation of prolactin secretion by adrenal steroids in oestrogen-treated ovariectomized rats: participation of endogenous opioid peptides. *Neuropharmacology* 36: 1433–1438, 1997.
283. CARONTI B, CALDERARO C, PASSARELLI F, PALLADINI G, AND PONTIERI FE. Dopamine receptor mRNAs in the rat lymphocytes. *Life Sci* 62: 1919–1925, 1998.
284. CARON RW, SALICIONI AM, AND DEIS RP. Mifepristone treatment demonstrates the participation of adrenal glucocorticoids in the regulation of oestrogen-induced prolactin secretion in ovariectomized rats. *J Steroid Biochem Mol Biol* 48: 385–389, 1994.
285. CARON RW, SALICIONI AM, AND DEIS RP. Regulation of prolactin secretion by adrenal steroids in oestrogen-treated ovariectomized rats: participation of endogenous opioid peptides. *Neuropharmacology* 36: 1433–1438, 1997.
286. CARR LA, CONWAY PM, AND VOOGT JL. Role of norepinephrine in the release of prolactin induced by suckling and estrogen. *Brain Res* 133: 305–314, 1977.
287. CARR LA AND VOOGT JL. Catecholamine synthesizing enzymes in the hypothalamus during the estrous cycle. *Brain Res* 196: 437–445, 1980.
288. CARRAWAY RE AND LEEMAN SE. Isolation of a new hypotensive peptide, neurotensin, from bovine hypothalamus. *J Biol Chem* 248: 6854–6861, 1973.
289. CARRETERO J, RUBIO M, SÁNCHEZ F, CABO JJ, VÁZQUEZ G, SANTOS M, PÉREZ RM, AND VÁZQUEZ R. Corticosterone induces hypoactivity of prolactin-immunoreactive cells. *Acta Anat* 160: 15–20, 1997.
290. CARRIÈRE PD, FAROOKHI R, AND BRAWER JR. The role of aberrant hypothalamic opiate function in generating polycystic ovaries in the rat. *Can J Physiol Pharmacol* 67: 896–901, 1989.
291. CARTER-SU C AND SMIT LS. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. *Recent Prog Horm Res* 53: 61–82, 1998.
292. CASANUEVA F, APUD J, LOCATELLI V, MARTINEZ-CAMPOS A, CIVATI C, RACAGNI G, COCCHI D, AND MULLER EE. Mechanisms subserving the stimulatory and inhibitory components of gamma-aminobutyric acid-ergic control of prolactin secretion in the rat. *Endocrinology* 109: 567–575, 1981.
293. CASANUEVA F, APUD JA, MASOTTO C, COCCHI D, LOCATELLI V, RACAGNI G, AND MULLER E. Daily fluctuations in the activity of the tuberoinfundibular GABAergic system and plasma prolactin levels. *Neuroendocrinology* 39: 367–370, 1984.
294. CASANUEVA FF AND DIEGUEZ C. Neuroendocrine regulation and actions of leptin. *Front Neuroendocrinol* 20: 317–363, 1999.
295. CASPER RF AND YEN SS. Simultaneous pulsatile release of prolactin and luteinizing hormone induced by luteinizing hormone-releasing factor agonist. *J Clin Endocrinol Metab* 52: 934–936, 1981.
296. CASTAÑO JP, FAUGHT WJ, GLAVÉ EE, RUSSELL BS, AND FRAWLEY LS. Discordance of prolactin gene transcription, mRNA storage, and hormone release in individual mammotropes. *Am J Physiol Endocrinol Metab* 272: E390–E396, 1997.
297. CASTAÑO JP AND FRAWLEY LS. Individual lactotrophs release prolactin in a temporally divergent and sexually dimorphic pattern. *Am J Physiol Endocrinol Metab* 269: E814–E819, 1995.
298. CASTANO JP, KINEMAN RD, AND FRAWLEY LS. Dynamic monitoring and quantification of gene expression in single, living cells: a molecular basis for secretory cell heterogeneity. *Mol Endocrinol* 10: 599–605, 1996.
299. CAVACO B, LEITE V, SANTOS MA, ARRANHADO E, AND SOBRINHO LG. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. *J Clin Endocrinol Metab* 80: 2342–2346, 1995.
300. CECCATELLI S, ERIKSSON M, AND HOKFELT T. Distribution and coexistence of corticotropin-releasing factor-, neurotensin-, enkephalin-, cholecystokinin-, galanin- and vasoactive intestinal polypeptide/histidine isoleucine-like peptides in the parvocellular

- part of the paraventricular nucleus. *Neuroendocrinology* 49: 309–323, 1989.
301. CECCATELLI S, HULTING A-L, ZHANG X, GUSTAFSSON L, VILLAR M, AND HÖKFELT T. Nitric oxide synthase in the rat anterior pituitary gland and the role of nitric oxide in regulation of luteinizing hormone secretion. *Proc Natl Acad Sci USA* 90: 11292–11296, 1993.
 302. CHABOT JG, ENJALBERT A, PELLETIER G, DUBOIS PM, AND MOREL G. Evidence for a direct action of neuropeptide Y in the rat pituitary gland. *Neuroendocrinology* 47: 511–517, 1988.
 303. CHABOT JG, WALKER P, AND PELLETIER G. Distribution of epidermal growth factor binding sites in the adult rat anterior pituitary gland. *Peptides* 7: 45–50, 1986.
 304. CHADIO SE AND ANTONI FA. Specific oxytocin agonist stimulates prolactin release but has no effect on inositol phosphate accumulation in isolated rat anterior pituitary cells. *J Mol Endocrinol* 10: 107–114, 1993.
 305. CHANG MS, LOWE DG, AND LEWIS M. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. *Nature* 341: 68–72, 1989.
 306. CHANG WP AND CLEVINGER CV. Modulation of growth factor receptor function by isoform heterodimerization. *Proc Natl Acad Sci USA* 93: 5947–5952, 1996.
 307. CHANG WP, YE Y, AND CLEVINGER CV. Stoichiometric structure-function analysis of the prolactin receptor signaling domain by receptor chimeras. *Mol Cell Biol* 18: 896–905, 1998.
 308. CHAO CC AND MALVEN PV. Immunoreactive dynorphin-A in bovine anterior pituitary and its in vitro release. *Peptides* 8: 361–366, 1987.
 309. CHEN CL AND MEITES J. Effects of estrogen and progesterone on serum and pituitary prolactin levels in ovariectomized rats. *Endocrinology* 86: 503–505, 1970.
 310. CHEN CT, DUN SL, DUN NJ, AND CHANG JK. Prolactin-releasing peptide-immunoreactivity in A1 and A2 noradrenergic neurons of the rat medulla. *Brain Res* 822: 276–279, 1999.
 311. CHEN G, TROMBLEY PQ, AND VAN DEN POL AN. Excitatory actions of GABA in developing rat hypothalamic neurones. *J Physiol (Lond)* 494: 451–464, 1996.
 312. CHEN HJ, BRADLEY CJ, AND MEITES J. Stimulation of carcinogen-induced mammary tumor growth in rats by adrenalectomy. *Cancer Res* 36: 1414–1417, 1976.
 313. CHEN HJ AND MEITES J. Effects of biogenic amines and TRH on release of prolactin and TSH in the rat. *Endocrinology* 96: 10–14, 1975.
 314. CHEN HW, WEIER H, HEINIGER HJ, AND HUEBNER RI. Tumorigenesis in strain DW/J mice and induction by prolactin of the group-specific antigen of endogenous C-type RNA tumor virus. *J Natl Cancer Inst* 49: 1145–1153, 1972.
 315. CHEN TJ, KUO CB, TSAI KF, LIU JW, CHEN DY, AND WALKER AM. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. *Endocrinology* 139: 609–616, 1998.
 316. CHEUNG CC, THORNTON JE, KULPER JL, WEIGLE DS, CLIFTON DK, AND STEINER RA. Leptin is a metabolic gate for the onset of puberty in the female rat. *Endocrinology* 138: 855–858, 1997.
 317. CHEW LJ, SEAH V, MURPHY D, AND CARTER D. Anterior pituitary vasoactive intestinal peptide mRNA is colocalised with prolactin mRNA in hyperoestrogenised rats. *J Mol Endocrinol* 16: 211–220, 1996.
 318. CHIHARA K, ARIMURA A, AND SCHALLY AV. Effect of intraventricular injection of dopamine, norepinephrine, acetylcholine, and 5-hydroxytryptamine on immunoreactive somatostatin release into rat hypophyseal portal blood. *Endocrinology* 104: 1656–1662, 1979.
 319. CHIHARA K, ARIMURA A, AND SCHALLY AV. Immunoreactive somatostatin in rat hypophyseal portal blood: effects of anesthetics. *Endocrinology* 104: 1434–1441, 1979.
 320. CHILDS GV, COLE DE, KUBEK M, TOBIN RB, AND WILBER JF. Endogenous thyrotropin-releasing hormone in the anterior pituitary: sites of activity as identified by immunocytochemical staining. *J Histochem Cytochem* 26: 901–908, 1978.
 321. CHINKERS M, GARBERS DL, AND CHANG MS. A membrane form of a guanylate cyclase is an atrial natriuretic peptide receptor. *Nature* 338: 78–83, 1989.
 322. CHIOCCIO SR, CANNATA MA, CORDERO FUNES JR, AND TRAMEZZANI JH. Involvement of adenohipophysial dopamine in the regulation of prolactin release during suckling. *Endocrinology* 105: 544–547, 1979.
 323. CHIU S, KOOS RD, AND WISE PM. Detection of prolactin receptor (PRL-R) mRNA in the rat hypothalamus and pituitary gland. *Endocrinology* 130: 1747–1749, 1992.
 324. CHIU S AND WISE PM. Prolactin receptor mRNA localization in the hypothalamus by in situ hybridization. *J Neuroendocrinol* 6: 191–199, 1994.
 325. CHIU S AND WISE PM. Prolactin receptor gene expression in specific hypothalamic nuclei increases with age. *J Gerontol A Biol Sci Med Sci* 51: B220–B224, 1996.
 326. CHO BN, SUH YH, YOON YD, LEE CC, AND KIM K. Progesterone inhibits the estrogen-induced prolactin gene expression in the rat pituitary. *Mol Cell Endocrinol* 93: 47–52, 1993.
 327. CHOW RH, KLINGAUF J, AND NEHER E. Time course of Ca^{2+} concentration triggering exocytosis in neuroendocrine cells. *Proc Natl Acad Sci USA* 91: 12765–12769, 1994.
 328. CHRONWALL BM, DIMAGGIO DA, MASSARI VJ, PICKEL VM, RUGGIERO DA, AND O'DONOHUE TL. The anatomy of neuropeptide Y-containing neurons in rat brain. *Neuroscience* 15: 1159–1181, 1985.
 329. CHRONWALL BM, SANDS SA, LI Z, AND SHAH GV. Calcitonin-like peptide containing gonadotrophs are juxtaposed to cup-shaped lactotrophs. *Endocrine* 4: 27–33, 1996.
 330. CIOFI P, CROWLEY WR, PILLEZ A, SCHMUELL LL, TRAMU G, AND MAZZUCA M. Plasticity in expression of immunoreactivity for neuropeptide Y, enkephalins and neurotensin in the hypothalamic tubero-infundibular dopaminergic system during lactation in mice. *J Neuroendocrinol* 5: 599–602, 1993.
 331. CIOFI P, FALLON JH, CROIX D, POLAK JM, AND RAMU GT. Expression of neuropeptide Y precursor-immunoreactivity in the hypothalamic dopaminergic tubero-infundibular system during lactation in rodents. *Endocrinology* 128: 823–834, 1991.
 332. CLAPP C. Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms. *Endocrinology* 121: 2055–2064, 1987.
 333. CLAPP C AND DE LA ESCALERA GM. Prolactins: novel regulators of angiogenesis. *News Physiol Sci* 12: 231–237, 1997.
 334. CLAPP C, MARTIAL JA, GUZMAN RC, RENTIER-DEL RUE F, AND WEINER RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. *Endocrinology* 133: 1292–1299, 1993.
 335. CLAPP C, TORNER L, GUTIÉRREZ-OSPINA G, ALCÁNTARA E, LÓPEZ-GÓMEZ FJ, NAGANO M, KELLY PA, MEJÍA S, MORALES MA, AND MARTÍNEZ DE LA ESCALERA G. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. *Proc Natl Acad Sci USA* 91: 10384–10388, 1994.
 336. CLAPP C AND WEINER RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. *Endocrinology* 130: 1380–1386, 1992.
 337. CLARKE DL, AREY BJ, AND LINZER DIH. Prolactin receptor messenger ribonucleic acid expression in the ovary during the rat estrous cycle. *Endocrinology* 133: 2594–2603, 1993.
 338. CLARKE DL AND LINZER DIH. Changes in prolactin receptor expression during pregnancy in the mouse ovary. *Endocrinology* 133: 224–232, 1993.
 339. CLARKE IJ AND HENRY BA. Leptin and reproduction. *Rev Reprod* 4: 48–55, 1999.
 340. CLARKE LA, WATHES DC, AND JABBOUR HN. Expression and localization of prolactin receptor messenger ribonucleic acid in red deer ovary during the estrous cycle and pregnancy. *Biol Reprod* 57: 865–872, 1997.
 341. CLEMENTI G, NICOLETTI F, PATACCHIOLI F, PRATO A, PATTI F, FIORE CE, MATERA M, AND SCAPAGNINI U. Hypoprolactinemic action of calcitonin and the tuberoinfundibular dopaminergic system. *J Neurochem* 40: 885–886, 1983.
 342. CLEMENTS J, WHITFIELD P, COOKE N, HEALY D, MATHESON B, SHINE J, AND FUNDER J. Expression of the prolactin gene in human decidua-chorion. *Endocrinology* 112: 1133–1134, 1983.
 343. CLEVINGER CV, ALTMANN SW, AND PRYSTOWSKY MB. Requirement of nuclear prolactin for interleukin-2-stimulated proliferation of T lymphocytes. *Science* 253: 77–79, 1991.

344. CLEVINGER CV, RUSSELL DH, APPASAMY PM, AND PRYSTOWSKY MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. *Proc Natl Acad Sci USA* 87: 6460–6464, 1990.
345. CLEVINGER CV, TORIGOE T, AND REED JC. Prolactin induces rapid phosphorylation and activation of prolactin receptor-associated RAF-1 kinase in a T-cell line. *J Biol Chem* 269: 5559–5565, 1994.
346. CLOSE FT AND FREEMAN ME. Effects of ovarian steroid hormones on dopamine-controlled prolactin secretory responses in vitro. *Neuroendocrinology* 65: 430–435, 1997.
347. COCCHI D, CASANUEVA F, LOCATELLI V, APUD J, MARTINEZ-CAMPOS A, CIVATI C, RACAGNI G, AND MULLER EE. GABAergic mechanisms in the control of PRL and GH release. *Adv Biochem Psychopharmacol* 26: 247–259, 1981.
348. COHEN LE, WONDISFORD FE, AND RADOVICK S. Role of Pit-1 in the gene expression of growth hormone, prolactin, and thyrotropin. *Endocrinol Metab Clin North Am* 25: 523–540, 1996.
349. COHICK CB, DAI GL, XU L, DEB S, KAMEI T, LEVAN G, SZPIRER C, SZPIRER J, KWOK SCM, AND SOARES MJ. Placental lactogen-I variant utilizes the prolactin receptor signaling pathway. *Mol Cell Endocrinol* 116: 49–58, 1996.
350. COIRINI H, JOHNSON AE, AND MCEWEN BS. Estradiol modulation of oxytocin binding in the ventromedial hypothalamic nucleus of male and female rats. *Neuroendocrinology* 50: 193–198, 1989.
351. COLBRAN RJ AND SODERLING TR. Calcium/calmodulin-independent autophosphorylation sites of calcium/calmodulin-dependent protein kinase II: studies on the effect of phosphorylation of threonine 305/306 and serine 314 on calmodulin binding using synthetic peptides. *J Biol Chem* 265: 11213–11219, 1990.
352. COLEMAN DT AND BANCROFT C. Pituitary adenylate cyclase-activating polypeptide stimulates prolactin gene expression in a rat pituitary cell line. *Endocrinology* 133: 2736–2742, 1993.
353. COLEMAN DT, CHEN XH, SASSAROLI M, AND BANCROFT C. Pituitary adenylate cyclase-activating polypeptide regulates prolactin promoter activity via a protein kinase A-mediated pathway that is independent of the transcriptional pathway employed by thyrotropin-releasing hormone. *Endocrinology* 137: 1276–1285, 1996.
354. COLOSI P, OGREN L, SOUTHAARD JN, THORDARSON G, LINZER DIH, AND TALAMANTES F. Biological, immunological, and binding properties of recombinant mouse placental lactogen-I. *Endocrinology* 123: 2662–2667, 1988.
355. COLWELL CS. Time to get excited by GABA. *Nature* 384: 554–555, 1997.
356. CONLIFFE PR, FARMERIE WG, CHARLES GD, BUHI WC, KELLY PA, SIMMEN RCM, AND SHIVERICK KT. Expression and characterization of recombinant rat placental prolactin-like protein C. *Mol Cell Endocrinol* 106: 121–130, 1994.
357. COOKE NE, COIT D, SHINE J, BAXTER JD, AND MARTIAL JA. Human prolactin cDNA structural analysis and evolutionary comparisons. *J Biol Chem* 256: 4007–4016, 1981.
358. COOKE NE, COIT D, WEINER RI, BAXTER JD, AND MARTIAL JA. Structure of cloned DNA complementary to rat prolactin messenger RNA. *J Biol Chem* 255: 6502–6510, 1980.
359. COOPER GR AND SHIN SH. Somatostatin inhibits prolactin secretion in the estradiol primed male rat. *Can J Physiol Pharmacol* 59: 1082–1088, 1981.
360. COPP DH AND CAMERON EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. *Science* 134: 2038–2039, 1962.
361. COPPOLA JA, LEONARDI RG, LIPPMAN W, PERRINE JW, AND RINGLER I. Induction of pseudopregnancy in rats by depletors of endogenous catecholamines. *Endocrinology* 77: 485, 1965.
362. COSS D, KUO CB, YANG L, INGLETON P, LUBEN R, AND WALKER AM. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. *Endocrinology* 140: 5087–5094, 1999.
363. COSTA E AND GUIDOTTI A. Molecular mechanism in the receptor action of benzodiazepines. *Annu Rev Pharmacol Toxicol* 19: 531–546, 1979.
364. COWIE AT, HARTMANN PT, AND TURVEY A. The maintenance of lactation in the rabbit after hypophysectomy. *J Endocrinol* 43: 651–662, 1969.
365. CRAMER CR, PARKER OM JR, AND PORTER JC. Estrogen inhibition of dopamine release into hypophysial portal blood. *Endocrinology* 104: 419–422, 1979.
366. CRAWLEY JN. Comparative distribution of cholecystokinin and other neuropeptides. *Ann NY Acad Sci* 448: 1–8, 1985.
367. CRAWLEY JN. Cholecystokinin-dopamine interactions. *Trends Pharmacol Sci* 12: 232–236, 1991.
368. CRAWLEY JN AND CORWIN RL. Biological actions of cholecystokinin. *Peptides* 15: 731–755, 1994.
369. CREESE I, SCHNEIDER R, AND SNYDER SH. ³H spiperone labels dopamine receptors in pituitary and brain. *Eur J Pharmacol* 46: 377, 1977.
370. CRESSENT M, ELIE C, AND MILHAUD G. The effect of calcitonin on prolactin secretion during gestation. *Life Sci* 34: 1621–1626, 1984.
371. CRESSENT M, ELIE C, AND MILHAUD G. Effect of calcitonin on the prolactin surge of proestrus. *Horm Metab Res* 19: 364–366, 1987.
372. CRESSENT M, ELIE C, TABOULET J, MOUKHTAR MS, AND MILHAUD G. Calcium regulating hormones during the estrous cycle of the rat. *Proc Soc Exp Biol Med* 172: 158–162, 1983.
373. CRONIN MJ AND WEINER RI. [³H]spiroperidol binding to a putative dopamine receptor in sheep and steer pituitary and stalk median eminence. *Endocrinology* 104: 307, 1979.
374. CROWLEY WR, SHAH GV, CARROLL BL, KENNEDY D, DOCKTER ME, AND KALRA SP. Neuropeptide-Y enhances luteinizing hormone (LH)-releasing hormone-induced LH release and elevations in cytosolic Ca²⁺ in rat anterior pituitary cells: evidence for involvement of extracellular Ca²⁺ influx through voltage-sensitive channels. *Endocrinology* 127: 1487–1494, 1990.
375. CRUMEYROLLE-ARIAS M, LATOUCHE J, JAMMES H, DJIANE J, KELLY PA, REYMOND MJ, AND HAOUR F. Prolactin receptors in the rat hypothalamus: autoradiographic localization and characterization. *Neuroendocrinology* 57: 457–466, 1993.
376. CUELLO AC AND KANAZAWA I. The distribution of substance P immunoreactive fibers in the rat central nervous system. *J Comp Neurol* 178: 129–156, 1978.
377. CUNNINGHAM MJ, CLIFTON DK, AND STEINER RA. Leptin's actions on the reproductive axis: perspectives and mechanisms. *Biol Reprod* 60: 216–222, 1999.
379. DAHLSTROM A AND FUXE K. Evidence for the existence of monoaminergic containing neurons in the central nervous system. I. Demonstration of monoamines in cell bodies of brain stem neurons. *Acta Physiol Scand* 62 Suppl 232: 1–55, 1964.
380. DALCIK H AND PHELPS CJ. Median eminence-afferent vasoactive intestinal peptide (VIP) neurons in the hypothalamus: localization by simultaneous tract tracing and immunocytochemistry. *Peptides* 14: 1059–1066, 1993.
381. DANNIES PS AND TASHJIAN AHJ. Effects of thyrotropin-releasing hormone and hydrocortisone on synthesis and degradation of prolactin in a rat pituitary cell strain. *J Biol Chem* 248: 6174–6179, 1973.
382. DAS R AND VONDERHAAR BK. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. *Oncogene* 13: 1139–1145, 1995.
383. DAS R AND VONDERHAAR BK. Transduction of prolactin's (PRL) growth signal through both long and short forms of the PRL receptor. *Mol Endocrinol* 9: 1750–1759, 1995.
384. DAS R AND VONDERHAAR BK. Activation of raf-1, MEK and MAP kinase in prolactin responsive mammary cells. *Breast Cancer Res Treat* 40: 141–149, 1996.
385. DAVEAU A, MALPAUX B, TILLET Y, ROBLOT G, WYLDE R, AND CHEMINEAU P. Active immunization against melatonin in Ile-de-France ewes and photoperiodic control of prolactin secretion and ovulatory activity. *J Reprod Fertil* 102: 285–292, 1994.
386. DAVIS JA AND LINZER DIH. Expression of multiple forms of the prolactin receptor in mouse liver. *Mol Endocrinol* 3: 674–680, 1989.
387. DAWSON TM, BREIT DS, FOTUHI M, HWANG PM, AND SNYDER SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. *Proc Natl Acad Sci USA* 88: 7797–7801, 1991.
388. DAWSON TM, DAWSON VL, AND SNYDER SH. Molecular mechanisms of nitric oxide actions in the brain. *Ann NY Acad Sci* 738: 76–85, 1994.
389. DAWSON TM AND SNYDER SH. Gases as biological messengers: nitric

- oxide and carbon monoxide in the brain. *J Neurosci* 14: 5147–5159, 1994.
390. DAY R, DONG W, PANETTA R, KRAICER J, GREENWOOD MT, AND PATEL YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. *Endocrinology* 136: 5232–5235, 1995.
 391. DE A, MORGAN TE, SPETH RC, BOYADJEVA N, AND SARKAR DK. Pituitary lactotrope expresses transforming growth factor β (TGF β) type II receptor mRNA and protein and contains 125 I-TGF β 1 binding sites. *J Endocrinol* 149: 19–27, 1996.
 392. DEB S, HAMLIN GP, ROBY KF, KWOK SCM, AND SOARES MJ. Heterologous expression and characterization of prolactin-like protein-A. Identification of serum binding proteins. *J Biol Chem* 268: 3298–3305, 1993.
 393. DEB S, HASHIZUME K, BOONE K, SOUTHARD JN, TALAMANTES F, RAWITCH A, AND SOARES MJ. Antipeptide antibodies reveal structural and functional characteristics of rat placental lactogen-II. *Mol Cell Endocrinol* 63: 45–56, 1989.
 394. DEBELJUK L, DIAZ MD, MAINES VM, AND SEILICOVICH A. Prolonged treatment with gamma-aminobutyric acid (GABA)-mimetic substances in prepubertal male rats. *Arch Androl* 10: 239–243, 1983.
 395. DEBELJUK L, GOLMAN S, SEILICOVICH A, DIAZ MC, AND RETTORI VB. Current concepts. II. Effect of aminooxyacetic acid and bicuculline on prolactin release in castrated male rats. *Life Sci* 27: 2025–2029, 1980.
 396. DEBELJUK L, SEILICOVICH A, AND DIAZ MC. Effect of 3-aminopropane-sulfonic acid and allylglycine on prolactin release in male rats. *Proc Soc Exp Biol Med* 168: 214–217, 1981.
 397. DEBELJUK L AND TORRES A. I. GABA-mimetic compounds block haloperidol-induced hyperprolactinemia in rats. *Adv Biochem Psychopharmacol* 42: 139–144, 1986.
 398. DE CAMILLI P, MACCONI D, AND SPADA A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary tumors. *Nature* 278: 252–254, 1979.
 399. DE CASTRO E SILVA E, NONAKA KO, AND ANTUNES-RODRIGUES J. Effect of a selective epinephrine synthesis inhibitor, SKF 64 1389, on prolactin secretion in the rat. *Braz J Med Biol Res* 19: 389–394, 1986.
 400. DE CASTRO E SILVA EJ AND ANTUNES-RODRIGUES J. Central adrenoceptors and basal prolactin release in the rat. *Horm Metab Res* 21: 179–181, 1989.
 401. DECAVEL C AND VAN DEN POL AN. GABA: a dominant neurotransmitter in the hypothalamus. *J Comp Neurol* 302: 1019–1037, 1990.
 402. DEES WL, SKELLEY CW, AND KOZLOWSKI GP. Central effects of an antagonist and an antiserum to substance P on serum gonadotropin and prolactin secretion. *Life Sci* 37: 1627–1631, 1985.
 403. DE GREFF WJ AND NEILL JD. Dopamine levels in hypophysial stalk plasma of the rat during surges of prolactin secretion induced by cervical stimulation. *Endocrinology* 105: 1093–1099, 1979.
 404. DE GREFF WJ, PLOTSKY PM, AND NEILL JD. Dopamine levels in hypophysial stalk plasma and prolactin levels in peripheral plasma of the lactating rat: effects of a simulated suckling stimulus. *Neuroendocrinology* 32: 229–233, 1981.
 405. DE GREFF WJ, VOOGT JL, VISSER TJ, LAMBERTS WJS, AND VAN DER SHOOT P. Control of prolactin release induced by suckling. *Endocrinology* 121: 316–322, 1987.
 406. DE LEAN A, FERLAND L, DROUIN J, KELLY PA, AND LABRIE F. Modulation of pituitary thyrotropin releasing hormone receptor levels by estrogens and thyroid hormones. *Endocrinology* 100: 1496–1504, 1977.
 407. DEL MAR HERNANDEZ M, FERREIRO REG, GARCIA DE, HERNANDEZ ME, CLAPP C, AND DE LA ESCALERA GM. Potentiation of prolactin secretion following lactotrope escape from dopamine action. I. Dopamine withdrawal augments L-type calcium current. *Neuroendocrinology* 70: 20–30, 1999.
 408. DELIDOW BC, BILLIS WM, AGARWAL P, AND WHITE BA. Inhibition of prolactin gene transcription by transforming growth factor-beta in GH $_3$ cells. *Mol Endocrinol* 5: 1716–1722, 1991.
 409. DEMAREST K, RIEGLE G, AND MOORE K. Prolactin-induced activation of tuberoinfundibular dopaminergic neurons: evidence for both a rapid “tonic” and a delayed “induction” component. *Neuroendocrinology* 38: 467–475, 1984.
 410. DEMAREST KT, DUDA NJ, RIEGLE GD, AND MOORE KE. Placental lactogen mimics prolactin in activating tuberoinfundibular dopaminergic neurons. *Brain Res* 272: 175–178, 1983.
 411. DEMAREST KT, JOHNSTON CA, AND MOORE KE. Biochemical indices of catecholaminergic neuronal activity in the median eminence during the estrous cycle of the rat. *Neuroendocrinology* 32: 24–27, 1981.
 412. DEMAREST KT, MCKAY DW, RIEGLE GD, AND MOORE KE. Sexual differences in tuberoinfundibular dopamine nerve activity induced by neonatal androgen exposure. *Neuroendocrinology* 32: 108–113, 1981.
 413. DEMAREST KT AND MOORE KE. Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons. *J Neural Transm* 46: 263–277, 1979.
 414. DEMAREST KT AND MOORE KE. Sexual differences in the sensitivity of tuberoinfundibular dopamine neurons to the actions of prolactin. *Neuroendocrinology* 33: 230–234, 1981.
 415. DEMAREST KT, MOORE KE, AND RIEGLE GD. Acute restraint stress decreases tuberoinfundibular dopaminergic neuronal activity: evidence for a differential response in male versus female rats. *Neuroendocrinology* 41: 504–511, 1985.
 416. DEMAREST KT, RIEGLE GD, AND MOORE KE. Adenohypophysial dopamine content during physiological changes in prolactin secretion. *Endocrinology* 115: 2091–2097, 1984.
 417. DEMAREST KT, RIEGLE GD, AND MOORE KE. Long-term treatment with estradiol induces reversible alterations in tuberoinfundibular dopaminergic neurons: a decreased responsiveness to prolactin. *Neuroendocrinology* 39: 193–200, 1984.
 418. DEMAREST KT, RIEGLE GD, AND MOORE KE. Hypoprolactinemia induced by hypophysectomy and long-term bromocriptine treatment decreases tuberoinfundibular dopaminergic neuronal activity and the responsiveness of these neurons to prolactin. *Neuroendocrinology* 40: 369–376, 1985.
 419. DEMARIA JE, LERANT AA, AND FREEMAN ME. Prolactin activates all three populations of hypothalamic neuroendocrine dopaminergic neurons in ovariectomized rats. *Brain Res* 837: 236–241, 1999.
 420. DEMARIA JE, LIVINGSTONE JD, AND FREEMAN ME. Characterization of the dopaminergic input to the pituitary gland throughout the estrous cycle of the rat. *Neuroendocrinology* 67: 377–383, 1998.
 421. DEMARIA JE, NAGY GM, LERANT A, FEKETE MIE, LEVENSON CW, AND FREEMAN ME. Dopamine transporters participate in the physiological regulation of prolactin. *Endocrinology* 141: 366–374, 2000.
 422. DEMARIA JE, ZELENKA D, VECSENYÉY M, NAGY GM, AND FREEMAN ME. The effect of neurointermediate lobe denervation on hypothalamic neuroendocrine dopaminergic neurons. *Brain Res* 806: 89–94, 1998.
 423. DEMLING J, FUCHS E, BAUMERT M, AND WUTTKE W. Preoptic catecholamine, GABA, and glutamate release in ovariectomized and ovariectomized estrogen-primed rats utilizing a push-pull cannula technique. *Neuroendocrinology* 31: 212–219, 1985.
 424. DENEFF C. Paracrine mechanisms in the pituitary. In: *The Pituitary Gland*, edited by Imura H. New York: Raven, 1994, p. 351–378.
 425. DENEFF C AND ANDRIES M. Evidence for paracrine interaction between gonadotrophs and lactotrophs in pituitary cell aggregates. *Endocrinology* 112: 813–822, 1983.
 426. DENEFF C, BAES M, AND SCHRAME C. Paracrine interactions in the anterior pituitary: role in the regulation of prolactin and growth hormone secretion. In: *Frontiers in Neuroendocrinology*, edited by Ganong WF and Martini L. New York: Raven, 1986, p. 115.
 427. DENEFF C, MANET D, AND DEWALS R. Dopaminergic stimulation of prolactin release. *Nature* 285: 243–246, 1980.
 428. DEPALATIS LR, KHORRAM O, HO RH, NEGRO-VILAR A, AND MCCANN SM. Partial characterization of immunoreactive substance P in the rat pituitary gland. *Life Sci* 34: 225–238, 1984.
 429. DE PAUL AL, PONS P, AOKI A, AND TORRES AI. Heterogeneity of pituitary lactotrophs: immunocytochemical identification of functional subtypes. *Acta Histochem* 99: 277–289, 1997.
 430. DE QUIDT ME AND EMSON PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system. I. Radioimmunoassay and chromatographic characterization. *Neuroscience* 18: 527–543, 1986.
 - 430a. D'ERAMO JL, SOMOZA GM, KERTESZ E, AND LIBERTUN C. Baclofen, a

- GABA derivative, inhibits stress-induced prolactin release in the rat. *Eur J Pharmacol* 120: 81–85, 1986.
431. DESCHERPER CL, LOTSTRA F, VANDESANDE F, AND VANDERHAEGHEN JJ. Cholecystokinin varies in the posterior pituitary and external median eminence of the rat according to factors affecting vasopressin and oxytocin. *Life Sci* 32: 2571–2577, 1983.
 432. DEVINS SS, MILLER A, HERNDON BL, O'TOOLE L, AND REISZ G. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. *Crit Care Med* 20: 1644–1649, 1992.
 433. DEVITO WJ. Distribution of immunoreactive prolactin in the male and female rat brain: effects of hypophysectomy and intraventricular administration of colchicine. *Neuroendocrinology* 47: 284–289, 1988.
 434. DEVITO WJ. Comparison of brain and pituitary immunoreactive prolactin by peptide mapping and lectin affinity chromatography. *Endocrinology* 125: 2439–2444, 1989.
 435. DEVITO WJ, AVAKIAN C, AND STONE S. Proteolytic modification of prolactin by the female rat brain. *Neuroendocrinology* 56: 597–603, 1992.
 436. DEVITO WJ, AVAKIAN C, STONE S, AND ACE CI. Estradiol increases prolactin synthesis and prolactin messenger ribonucleic acid in selected brain regions in the hypophysectomized female rat. *Endocrinology* 131: 2154–2160, 1992.
 437. DEVITO WJ, STONE S, AND VAKIAN CA. Stimulation of hypothalamic prolactin release by veratridine and angiotensin II in the female rat: effect of ovariectomy and estradiol administration. *Neuroendocrinology* 54: 391–398, 1991.
 438. DE VOS AM, ULTSCH M, AND KOSSIAKOFF AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 255: 306–312, 1992.
 439. DE WELLE JR, FOSSET M, SCHMID A, AND LAZDUNSKI M. Galinin inhibits dopamine secretion and activates a potassium channel in pheochromocytoma cells. *Brain Res* 485: 199, 1989.
 440. DEYO SN, SWIFT RM, AND MILLER RJ. Morphine and endorphins modulate dopamine turnover in rat median eminence. *Proc Natl Acad Sci USA* 76: 3006–3009, 1979.
 441. DIAZ MC, SEILICOVICH A, DUVILANSKI BH, SISELES N, LASAGA M, AND DEBELJUK L. Estriol affects prolactin and LH secretion in rats. *J Endocrinol Invest* 12: 1–7, 1989.
 442. DI CARLO R, BOLE-FEYSOT C, GUALILLO O, MELI R, NAGANO M, AND KELLY PA. Regulation of prolactin receptor mRNA expression in peripheral lymphocytes in rats in response to changes in serum concentrations of prolactin. *Endocrinology* 136: 4713–4716, 1995.
 443. DÍAZ S, SERÓN-FERRÉ M, CÁRDENAS H, SCHIAPPACASSE V, BRANDEIS A, AND CROXATTO HB. Circadian variation of basal plasma prolactin, prolactin response to suckling, and length of amenorrhea in nursing women. *J Clin Endocrinol Metab* 68: 946–955, 1989.
 444. DIEZ-GUERRA FJ, BICKNELL RJ, MANSFIELD S, EMSON PC, AND DYER RG. Effect of neonatal testosterone upon opioid receptors and the content of beta-endorphin, neuropeptide Y and neurotensin in the medial preoptic and the mediobasal hypothalamic areas of the rat brain. *Brain Res* 424: 225–230, 1987.
 445. DIMATTIA GE, GELLERSEN B, BOHNET HG, AND FRIESEN HG. A human B-lymphoblastoid cell line produces prolactin. *Endocrinology* 122: 2508–2517, 1988.
 446. DINGLEDEINE R, MYERS SJ, AND NICHOLAS RA. Molecular biology of mammalian amino acid receptors. *FASEB J* 4: 2636–2645, 1990.
 447. DJANE J, DELOUIS D, AND KELLY PA. Prolactin receptor in explants of pseudopregnant rabbit mammary glands. *Mol Cell Endocrinol* 25: 163–170, 1982.
 448. DOBSON PR AND BROWN BL. Involvement of the hypothalamus in opiate-stimulated prolactin secretion. *Regul Pept* 20: 305–310, 1988.
 449. DOCKERAY GJ. Immunochemical evidence of cholecystokinin-like peptides in brain. *Nature* 264: 568–570, 1976.
 450. DOHANICS J, SMITH MS, BLACKBURN RE, AND VERBALIS JG. Osmotic inhibition of prolactin secretion in rats. *J Neuroendocrinol* 6: 291–298, 1994.
 451. DOHERTY PC, BARTKE A, SMITH MS, AND DAVIS SL. Increased serum prolactin levels mediate the suppressive effects of ectopic pituitary grafts on copulatory behavior in male rats. *Horm Behav* 19: 111–121, 1985.
 452. DOMAE M, YAMADA K, HANABUSA Y, AND FURUKAWA T. Inhibitory effects of endothelin-1 and endothelin-3 on prolactin release: possible involvement of endogenous endothelin isopeptides in the rat anterior pituitary. *Life Sci* 50: 715–722, 1992.
 453. DOMINIC CJ. Observations on the reproductive pheromones of mice. II. Neuroendocrine mechanisms involved in the olfactory block to pregnancy. *J Reprod Fertil* 11: 415–421, 1966.
 454. DOMINIC CJ. Effect of exogenous prolactin on olfactory block to pregnancy in mice exposed to urine of alien males. *Indian J Exp Biol* 5: 47–48, 1967.
 455. DONHAM RS, PALACIO E, AND STETSON MH. Dissociation of the reproductive and prolactin photoperiodic responses in male golden hamsters. *Biol Reprod* 51: 366–372, 1994.
 456. DONOSO AO. Induction of prolactin and luteinizing hormone release by histamine in male and female rats and the influence of brain transmitter antagonists. *J Endocrinol* 76: 193–202, 1978.
 457. DONOSO AO AND BANZAN AM. H1- and H2-histamine receptor antagonists and induced release of prolactin in male rats. *Neuroendocrinology* 30: 11–14, 1980.
 458. DONOSO AO, BANZAN AM, AND BORZINO MI. Prolactin and luteinizing hormone release after intraventricular injection of histamine in rats. *J Endocrinol* 68: 171–172, 1976.
 459. DONOSO AO AND ZARATE MB. Changes in prolactin release caused by GABA and endogenous GABA increase in rats. *Brain Res Bull* 7: 359–364, 1981.
 460. DONOSO AO, ZARATE MB, AND SELTZER A. Histamine-induced prolactin release: pharmacological characterization of receptors in male rats. *Neuroendocrinology* 36: 436–442, 1983.
 461. DORFLINGER LJ AND SCHONBRUNN A. Somatostatin inhibits basal and vasoactive intestinal peptide-stimulated hormone release by different mechanisms in GH pituitary cells. *Endocrinology* 113: 1551–1558, 1983.
 462. DORFLINGER LJ AND SCHONBRUNN A. Somatostatin inhibits vasoactive intestinal peptide-stimulated cyclic adenosine monophosphate accumulation in GH pituitary cells. *Endocrinology* 113: 1541–1550, 1983.
 463. DOURNAUD P, GU YZ, SCHONBRUNN A, MAZELLA J, TANNENBAUM GS, AND BEAUDET A. Localization of somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. *J Neurosci* 16: 4468–4478, 1996.
 464. DRAGO F, D'AGATA V, SPADARO F, GRASSI M, AND VALERIO C. Prolactin as a protective factor in stress-induced gastric ulcers. *Ann NY Acad Sci* 597: 248–251, 1990.
 465. DROUHault R, GUÉRINEAU N-C, MOLLARD P, CADORET M-A, CORCUFF J-B, VACHER A-M, AND VILAYLECK N. Prolactin and growth hormone release and calcium influx are stimulated by galinin within a "window" range of concentrations in pituitary GH₃ B6 cells. *Neuroendocrinology* 60: 179–184, 1994.
 466. DROUIN J, DE LEAN A, RAINVILLE D, LACHANCE R, AND LABRIE F. Characteristics of the interaction between thyrotropin-releasing hormone and somatostatin for thyrotropin and prolactin release. *Endocrinology* 98: 514–521, 1976.
 467. DRUST DS AND MARTIN TF. Thyrotropin-releasing hormone rapidly activates protein phosphorylation in GH₃ pituitary cells by a lipid-linked, protein kinase C-mediated pathway. *J Biol Chem* 259: 14520–14530, 1984.
 468. DUAN WR, LINZER DIH, AND GIBORI G. Cloning and characterization of an ovarian-specific protein that associates with the short form of the prolactin receptor. *J Biol Chem* 271: 15602–15607, 1996.
 469. DUAN WR, FARMER TG, ALBARRACIN CT, ZHONG L, AND GIBORI G. PRAP, a prolactin receptor associated protein: its gene expression and regulation in the corpus luteum. *Endocrinology* 138: 3216–3221, 1997.
 470. DUDLEY CA, JAMISON TS, AND MOSS RL. Inhibition of lordosis behavior in the female rat by intraventricular infusion of prolactin and by chronic hyperprolactinemia. *Endocrinology* 110: 677–679, 1982.
 471. DUNNE MJ, BULLETT MJ, LI GD, AND PETERSEN OH. Galinin activates nucleotide-dependent K⁺ channels in insulin-secreting cells via a pertussis toxin-sensitive G-protein. *EMBO J* 8: 413, 1989.
 472. DUPONT A, BARDEN N, CUSAN L, MERAND Y, LABRIE F, AND VAUDRY H. beta-Endorphin and Met-enkephalins: their distribution, modula-

- tion by estrogens and haloperidol, and role in neuroendocrine control. *Federation Proc* 39: 2544–2550, 1980.
473. DUPONT A, CUSAN L, FERLAND L, LEMAY A, AND LABRIE F. Evidence for a role of endorphins in the control of prolactin secretion. In: *Central Nervous System Effects of Hypothalamic Hormones and Other Peptides*, edited by Collu R. New York: Raven, 1979, p. 283–300.
 474. DURHAM RA, EATON MJ, MOORE KE, AND LOOKINGLAND KJ. Effects of selective activation of dopamine D2 and D3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons. *Eur J Pharmacol* 335: 37–42, 1997.
 475. DURHAM RA, JOHNSON JD, EATON MJ, MOORE KE, AND LOOKINGLAND KJ. Opposing roles for dopamine D1 and D2 receptors in the regulation of hypothalamic tuberoinfundibular dopamine neurons. *Eur J Pharmacol* 355: 141–147, 1998.
 476. DUTT A, KAPLITT MG, KOW L-M, AND PFAFF DW. Prolactin, central nervous system and behavior: a critical review. *Neuroendocrinology* 59: 413–419, 1994.
 477. DUVILANSKI B, MUNOZ MV, AND DEBELJUK L. GABA-related enzymes in the hypothalamus of rats treated with estradiol. *Eur J Pharmacol* 89: 259–264, 1983.
 478. DUVILANSKI BH, SEILICOVICH A, DEL CARMEN M, LASAGA M, AND DEBELJUK L. The effect of prolactin on glutamate decarboxylase activity and GABA concentration in hypothalamic slices. *Psychoneuroendocrinology* 12: 107–116, 1987.
 479. DUVILANSKI BH, SEILICOVICH A, DIAZ MC, LASAGA M, AND DEBELJUK L. GABA-prolactin interactions. *Adv Biochem Psychopharmacol* 42: 119–130, 1986.
 480. DUVILANSKI BH, SEILICOVICH A, LASAGA M, DEL CARMEN D, AND DEBELJUK L. Mechanisms of endogenous GABA release from hypothalamic fragments. Effect of prolactin. *Neuroendocrinology* 46: 504–510, 1987.
 481. DUVILANSKI BH, ZAMBRUNO C, LASAGA M, PISERA D, AND SEILICOVICH A. Role of nitric oxide cyclic GMP pathway in the inhibitory effect of GABA and dopamine on prolactin release. *J Neuroendocrinol* 8: 909–913, 1996.
 482. DUVILANSKI BH, ZAMBRUNO C, SEILICOVICH A, PISERA D, LASAGA M, DIAZ MDC, BELOVA N, RETTORI V, AND MCCANN SM. Role of nitric oxide in control of prolactin release by the adenohypophysis. *Proc Natl Acad Sci USA* 92: 170–174, 1995.
 483. DYMSHITZ J AND BEN-JONATHAN N. Coculture of anterior and posterior pituitary cells: selective stimulation of lactotrophs. *Endocrinology* 128: 2469–2475, 1991.
 484. DYMSHITZ J AND BEN-JONATHAN N. Effects of coculture of anterior and posterior pituitary cells on the responsiveness of lactotrophs to different secretagogues. *Endocrinology* 129: 2535–2540, 1991.
 485. DYMSHITZ J, LAUDON M, AND BEN-JONATHAN N. Endothelin-induced biphasic response of lactotrophs cultured under different conditions. *Neuroendocrinology* 55: 724–729, 1992.
 486. EATON MJ, GOPALAN C, KIM E, LOOKINGLAND KJ, AND MOORE KE. Comparison of the effects of the dopamine D2 agonist quinlorane on tuberoinfundibular dopaminergic neuronal activity in male and female rats. *Brain Res* 629: 53–58, 1993.
 487. EATON MJ, LOOKINGLAND KJ, AND MOORE KE. Effects of the selective dopaminergic D2 agonist quinlorane on the activity of dopaminergic and noradrenergic neurons projecting to the diencephalon of the rat. *J Pharmacol Exp Ther* 268: 645–652, 1994.
 488. EBLING FJP, WOOD RI, SUTTIE JM, ADEL TE, AND FOSTER DL. Prenatal photoperiod influences neonatal prolactin secretion in the sheep. *Endocrinology* 125: 384–391, 1989.
 489. ECKSTEIN N, WEHRENBURG WB, LOUIS K, CARMEL PW, ZIMMERMANN EA, FRANTZ AG, AND FERIN M. Effects of substance P on anterior pituitary secretion in the female rhesus monkey. *Neuroendocrinology* 31: 338–342, 1980.
 490. EDWARDS GM, WILFORD FH, LIU X, HENNIGHAUSEN L, DJIANE J, AND STREULI CH. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. *J Biol Chem* 273: 9495–9500, 1998.
 491. EINHORN LC, FALARDEAU P, CARON M, CIVELLI O, AND OXFORD GS. Both isoforms of the D2 dopamine receptor couple to a G protein-activated K^+ channel when expressed in GH₄ cells. *Soc Neurosci Abstr* 16: 382, 1990.
 492. EINHORN LC, GREGERSON KA, AND OXFORD GS. D₂ dopamine receptor activation of potassium channels in identified rat lactotrophs: whole-cell and single-channel recording. *J Neurosci* 11: 3727–3737, 1991.
 493. EIPPER BA AND MAINS RE. Structure and biosynthesis of proadrenocorticotropin/endorphin and related peptides. *Endocr Rev* 1: 1–27, 1980.
 494. ELIAS KA, WEINER RI, AND MELLON SH. Effect of extracellular matrix on prolactin secretion and mRNA accumulation in GH₃ cells. *DNA Cell Biol* 9: 369–375, 1990.
 495. ELIE C, MOUKHTAR MS, MILHAUD G, AND CRESSENT M. Hypoprolactinemic effect of calcitonin gene-related peptide in the rat. *Neuropeptides* 16: 109–113, 1990.
 496. ELLERKMANN E, NAGY GM, AND FRAWLEY LS. Rapid augmentation of prolactin cell number and secretory capacity by an estrogen-induced factor released from the neurointermediate lobe. *Endocrinology* 129: 838–842, 1991.
 497. ELLERKMANN E, NAGY GM, AND FRAWLEY LS. α -Melanocyte-stimulating hormone is a mammotrophic factor released by neurointermediate lobe cells after estrogen treatment. *Endocrinology* 130: 133–138, 1992.
 498. ELLERKMANN E, PORTER TE, NAGY GM, AND FRAWLEY LS. N-acetylation is required for the lactotrope recruitment activity of α -melanocyte-stimulating hormone and beta-endorphin. *Endocrinology* 131: 566–570, 1992.
 499. ELLIS LA AND PICCIANO MF. Bioactive and immunoreactive prolactin variants in human milk. *Endocrinology* 136: 2711–2720, 1995.
 500. ELMQUIST JK, MARATOS-FLIER E, SAPER CB, AND FLIER JS. Unraveling the central nervous system pathways underlying responses to leptin. *Nature Neurosci* 1: 445–450, 1998.
 501. EMANUELE NV, JURGENS JK, HALLORAN MM, TENTLER JJ, LAWRENCE AM, AND KELLEY MR. The rat prolactin gene is expressed in brain tissue: detection of normal and alternatively spliced prolactin messenger RNA. *Mol Endocrinol* 6: 35–42, 1992.
 502. EMANUELE NV, METCALFE L, WALLOCK L, TENTLER J, HAGEN TC, BEER CT, MARTINSON D, GOUT PW, KIRSTEINS L, AND LAWRENCE AM. Extrahypothalamic brain prolactin: characterization and evidence for independence from pituitary prolactin. *Brain Res* 421: 255–262, 1987.
 503. ENDO TA, MASUHARA M, YOKOUCHI M, SUZUKI R, SAKAMOTO H, MITSUI K, MATSUMOTO A, TANIMURA S, OHTSUBO M, MISAWA H, MIYAZAKI T, LEONOR N, TANIGUCHI T, FUJITA T, KANAKURA Y, KOMIYA S, AND YOSHIMURA A. A new protein containing an SH2 domain that inhibits JAK kinases. *Nature* 387: 921–924, 1997.
 504. ENEROTH P, FUXE K, GUSTAFSSON JA, HOKFELT T, LOFSTROM A, SKETT P, AND AGNATI L. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. II. Inhibitory influence of nicotine on LH, FSH and prolactin secretion in the ovariectomized female rat and its relation to regional changes in dopamine and noradrenaline levels and turnover. *Med Biol* 55: 158–166, 1977.
 505. ENJALBERT A, ARANCIBIA S, PRIAM M, BLUET-PAJOT MT, AND KORDON C. Neurotensin stimulation of prolactin secretion in vitro. *Neuroendocrinology* 34: 95–98, 1982.
 506. ENJALBERT A, BERTRAND P, BOCKAERT J, DROUVA S, AND KORDON C. Multiple coupling of neurohormone receptors with cyclic AMP and inositol phosphate production in anterior pituitary cells. *Biochimie* 69: 271–279, 1987.
 507. ENJALBERT A, BERTRAND P, LE DAFNIET M, EPELBAUM J, HUGUES JN, KORDON C, MOYSE E, PEILLON F, AND SHU C. Somatostatin and regulation of prolactin secretion. *Psychoneuroendocrinology* 11: 155–165, 1986.
 508. ENJALBERT A AND BOCKAERT J. Pharmacological characterization of D2 dopamine receptors negatively coupled with adenylate cyclase in the rat anterior pituitary. *Mol Pharmacol* 23: 576–584, 1983.
 509. ENJALBERT A, EPELBAUM J, ARANCIBIA S, TAPIA-ARANCIBIA L, BLUET-PAJOT MT, AND KORDON C. Reciprocal interactions of somatostatin with thyrotropin-releasing hormone and vasoactive intestinal peptide on prolactin and growth hormone secretion in vitro. *Endocrinology* 111: 42–47, 1982.
 510. ENJALBERT A, GUILLON G, MOUILLAC B, AUDINOT V, RASOLONJANAHARY R, KORDON C, AND BOCKAERT J. Dual mechanisms of inhibition by dopamine of basal and thyrotropin-releasing hormone-stimulated inositol phosphate production in anterior pituitary cells. Evidence

- for an inhibition not mediated by voltage-dependent Ca^{2+} channels. *J Biol Chem* 265: 18816–18822, 1990.
511. ENJALBERT A, RUBERG M, ARANCIBIA S, FIORE L, PRIAM M, AND KORDON C. Independent inhibition of prolactin secretion by dopamine and gamma-aminobutyric acid in vitro. *Endocrinology* 105: 823–826, 1979.
 512. ENJALBERT A, RUBERG M, ARANCIBIA S, PRIAM M, AND KORDON C. Endogenous opiates block dopamine inhibition of prolactin secretion in vitro. *Nature* 280: 595–597, 1979.
 513. ENJALBERT A, SLADECZEK F, GUILLON G, BERTRAND P, SHU C, EPELBAUM J, GARZIA-SAINZ A, JARD S, LOMBARD C, KORDON C, AND BOCKAERT J. Angiotensin II and dopamine modulate both cAMP and inositol phosphate productions in anterior pituitary cells. *J Biol Chem* 261: 4071–4075, 1986.
 514. EPAND RM, STAFFORD AR, AND ORLOWSKI RC. Calcitonin inhibits the rise of intracellular calcium induced by thyrotropin-releasing hormone in GH_3 cells. *Cell Calcium* 10: 145–149, 1989.
 515. EPELBAUM J, ENJALBERT A, KRANTIC S, MUSSET F, BERTRAND P, RASOLONJANAHARY R, SHU C, AND KORDON C. Somatostatin receptors on pituitary somatotrophs, thyrotrophs, and lactotrophs: pharmacological evidence for loose coupling to adenylate cyclase. *Endocrinology* 121: 2177–2185, 1987.
 516. ERSPAMER V, FALCONIERI ERSPAMER G, AND INSELVINI M. Occurrence of bombesin and alanylin in extracts of the skin of three European frogs and pharmacological actions of bombesin on extravascular smooth muscle. *Br J Pharmacol* 45: 333–348, 1972.
 517. ERSPAMER V, MELCHIORRI P, BROCCARDO M, ERSPAMER GF, FALASCHI P, IMPROOTA G, NEGRI L, AND RENDA T. The brain-gut-skin triangle: new peptides. *Peptides* 2 Suppl 2: 7–16, 1981.
 518. ERWIN RA, KIRKEN RA, MALABARBA MG, FARRAR WL, AND RUI H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. *Endocrinology* 136: 3512–3518, 1995.
 519. ESCH F, BOHLEN P, LING N, BENOIT R, BRAZEAU P, AND GUILLEMIN R. Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25. *Proc Natl Acad Sci USA* 77: 6827–6831, 1980.
 520. ESKAY RL, OLIVER C, BEN-JONATHAN N, AND PORTER JC. Hypothalamic hormones in portal and systemic blood. In: *Hypothalamic Hormones: Chemistry, Physiology, Pharmacology and Clinical Uses*, edited by Motta M, Crosighani PG, and Martini L. New York: Academic, 1975, p. 125–137.
 521. EUKER JS, MEITES J, AND RIEGLE GD. Effects of acute stress on serum LH and prolactin in intact, castrate and dexamethasone-treated male rats. *Endocrinology* 96: 85–92, 1975.
 522. EVANS CJ, KEITH DEJ, MORRISON H, MAGENDZO K, AND EDWARDS RH. Cloning of a delta opioid receptor by functional expression. *Science* 258: 1952–1955, 1992.
 523. EVERETT JW. Luteotropic function of autografts of the rat hypophysis. *Endocrinology* 54: 685–690, 1954.
 524. EVERETT JW. Functional corpora lutea maintained for months by autografts of rat hypophysis. *Endocrinology* 58: 786–796, 1956.
 525. EVERITT A AND HOKFELT T. The coexistence of neuropeptide Y with other peptides and amines in the central nervous system. In: *Neuropeptide Y*, edited by Mutt V, Hokfelt T, Fuxe K, and Lundberg JM. New York: Raven, 1989, p. 61–67.
 526. EVERITT A, HOKFELT T, TERENIUS L, TATEMOTO K, MUTT V, AND GOLDSTEIN M. Differential coexistence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. *Neuroscience* 11: 443–462, 1984.
 527. EVERITT BJ, MEISTER B, AND HOKFELT T. The organization of monoaminergic neurons in the hypothalamus in relation to neuroendocrine integration. In: *Neuroendocrinology*, edited by Nemeroff CB. Boca Raton, FL: CRC, 1992, p. 87–128.
 528. EWALD DA, STERNWEIS PC, AND MILLER RJ. Guanine nucleotide-binding protein G_o -induced coupling of neuropeptide Y receptors to Ca^{2+} channels in sensory neurons. *Proc Natl Acad Sci USA* 85: 3633–3637, 1988.
 529. EXTON JH. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. *Annu Rev Pharmacol Toxicol* 36: 481–509, 1996.
 530. FAGIN KD AND NEILL JD. The effect of dopamine on thyrotropin-releasing hormone-induced prolactin secretion in vitro. *Endocrinology* 109: 1835–1840, 1981.
 531. FAHIM A, RETTORI V, AND MCCANN SM. The role of calcitonin gene-related peptide in the control of growth hormone and prolactin release. *Neuroendocrinology* 51: 688–693, 1990.
 532. FAHTI Z, CUNNINGHAM AM, IBEN I, BATTAGLINO PB, WARD SA, NICHOL KA, PINE KA, GOLDSTEIN ME, ISMAA TP, AND ZIMANYI A. Cloning, pharmacological characterization and distribution of a novel galanin receptor. *Mol Brain Res* 51: 49–59, 1997.
 533. FALCK B, HILLARP NA, THIEME G, AND TORP A. Fluorescence of catecholamines and related compounds condensed with formaldehyde. *J Histochem Cytochem* 10: 348–354, 1962.
 534. FALCONER IR, LANGLEY JV, AND VACEK AT. Effect of prolactin on $^{86}\text{Rb}^{+}$ uptake, potassium content and $[\text{G-}^3\text{H}]$ ouabain binding of lactating rabbit mammary tissue. *J Physiol (Lond)* 334: 1–17, 1983.
 535. FALCONER IR AND ROWE JM. Possible mechanism for action of prolactin on mammary cell sodium transport. *Nature* 256: 327–328, 1975.
 536. FAN X AND CHILDS GV. Epidermal growth factor and transforming growth factor- α messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. *Endocrinology* 136: 2284–2293, 1995.
 537. FARIA TN, DEB S, KWOK SCM, TALAMANTES F, AND SOARES MJ. Ontogeny of placental lactogen-I and placental lactogen-II expression in the developing rat placenta. *Dev Biol* 141: 279–291, 1990.
 538. FAURE N, CRONIN MJ, MARTIAL JA, AND WEINER RI. Decreased responsiveness of GH_3 cells to the dopaminergic inhibition of prolactin. *Endocrinology* 107: 1022–1026, 1980.
 539. FEKETE MI, KANYICKA B, AND HERMAN JP. Simultaneous radioenzymatic assay of catecholamines and dihydroxy-phenylacetic acid/DOPAC; comparison of the effects of drugs on the tuberoinfundibular and striatal dopamine metabolism and on plasma prolactin level. *Life Sci* 23: 1549–1556, 1978.
 540. FEKETE MI, KANYICKA B, SZENTENDREI T, SIMONYI A, AND STARK E. Decrease of morphine-induced prolactin release by a procedure causing prolonged stress. *J Endocrinol* 101: 169–172, 1984.
 541. FEKETE MI, KANYICKA B, SZENTENDREI T, AND STARK E. Loss of sensitivity to morphine induced by prolonged ACTH treatment. *Pharmacol Biochem Behav* 20: 879–882, 1984.
 542. FELIX R, MEZA U, AND COTA G. Induction of classical lactotropes by epidermal growth factor in rat pituitary cell cultures. *Endocrinology* 136: 939–946, 1995.
 543. FELMAN K AND TAPPAZ M. GABAergic biochemical parameters of the tuberoinfundibular neurons following chronic hyperprolactinemia. *Neuroendocrinology* 49: 580–585, 1989.
 544. FERGUSON AV AND WASHBURN DLS. Angiotensin II: a peptidergic neurotransmitter in central autonomic pathways. *Prog Neurobiol* 54: 169–192, 1998.
 545. FERIN M. Endogenous opioid peptides and the menstrual cycle. *Trends Neurosci* 7: 194–196, 1984.
 546. FERIN M, VAN VUGT D, AND WARDLAW S. The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides. *Recent Prog Horm Res* 40: 441–485, 1984.
 547. FERLAND L, FUXE K, ENEROTH P, GUSTAFSSON JA, AND SKETT P. Effects of methionine-enkephalin on prolactin release and catecholamine levels and turnover in the median eminence. *Eur J Pharmacol* 43: 89–90, 1977.
 548. FERRAG F, CHIARENZA A, GOFFIN V, AND KELLY PA. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription. *Mol Endocrinol* 10: 451–460, 1996.
 549. FERRAG F, GOFFIN V, BUTEAU H, AND KELLY PA. Immune function of prolactin (PRL) and signal transduction by PRL/GH/cytokine receptors: specificity, redundancy and lessons from chimaeras. *Cytokines Cell Mol Ther* 3: 197–213, 1997.
 550. FERRAG F, PEZET A, CHIARENZA A, BUTEAU H, NELSON BH, GOFFIN V, AND KELLY PA. Homodimerization of IL-2 receptor beta chain is necessary and sufficient to activate Jak2 and downstream signaling pathways. *FEBS Lett* 421: 32–36, 1998.
 551. FESSLER RG, DEYO SN, MELTZER HY, AND MILLER RJ. Evidence that the medial and dorsal raphe nuclei mediate serotonergically-induced increases in prolactin release from the pituitary. *Brain Res* 299: 231–237, 1984.
 552. FINIDORI J AND KELLY PA. Cytokine receptor signalling through two

- novel families of transducer molecules: Janus kinases and signal transducers and activators of transcription. *J Endocrinol* 147: 11–23, 1995.
553. FINK G, KOCH Y, AND BENAROYA N. Release of thyrotropin releasing hormone into hypophyseal portal blood is high relative to other neuropeptides and may be related to prolactin secretion. *Brain Res* 243: 186–189, 1982.
 554. FINK K, SCHLICKER E, AND GOTHERT M. *N*-methyl-D-aspartate-stimulated noradrenaline release in rat brain cortex is modulated by presynaptic H₃-receptors. *Naunyn-Schmiedeberg's Arch Pharmacol* 349: 113–117, 1994.
 555. FINK K, SCHLICKER E, NEISE A, AND GOTHERT M. Involvement of presynaptic H₃ receptors in the inhibitory effect of histamine on serotonin release in the rat brain cortex. *Naunyn-Schmiedeberg's Arch Pharmacol* 342: 513–519, 1990.
 556. FINLEY JCW, MADERDRUT JL, ROGER J, AND PETRUSZ P. The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system. *Neuroscience* 6: 2192, 1981.
 557. FLECKENSTEIN AE, LOOKINGLAND KJ, AND MOORE KE. Evidence that histamine-stimulated prolactin secretion is not mediated by an inhibition of tuberoinfundibular dopaminergic neurons. *Life Sci* 51: 741–746, 1992.
 558. FLECKENSTEIN AE, LOOKINGLAND KJ, AND MOORE KE. Differential role of histamine in mediating stress-induced changes in central dopaminergic neuronal activity in the rat. *Brain Res* 653: 267–272, 1994.
 559. FLIER JS AND MARATOS-FLIER E. Obesity and the hypothalamus: novel peptides for new pathways. *Cell* 92: 437–440, 1999.
 560. FLIETSTRA RJ AND VOOGT JL. Rat placental lactogens initiate and maintain lactation yet inhibit suckling-induced prolactin release. *Endocrine* 5: 103–110, 1996.
 561. FLIETSTRA RJ AND VOOGT JL. Lactogenic hormones of the placenta and pituitary inhibit suckling-induced prolactin (PRL) release but not the ante-partum PRL surge. *Proc Soc Exp Biol Med* 214: 258–264, 1997.
 562. FLUGGE G, OERTEL WH, AND WUTTKE W. Evidence for estrogen-receptive GABAergic neurons in the preoptic/anterior hypothalamic area of the rat brain. *Neuroendocrinology* 43: 1–5, 1986.
 563. FOMINA AF AND LEVITAN ES. Three phases of TRH-induced facilitation of exocytosis by single lactotrophs. *J Neurosci* 15: 4982–4991, 1995.
 564. FOMINA AF AND LEVITAN ES. Control of Ca²⁺ channel current and exocytosis in rat lactotrophs by basally active protein kinase C and calcineurin. *Neuroscience* 78: 523–531, 1997.
 565. FOORD SM, PETERS JR, DIEQUEZ C, SCANLON MF, AND HALL R. Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. *Endocrinology* 112: 1567–1577, 1983.
 566. FORESTA C, DE CARLO E, MIONI R, ZORZI M, AND CANDELLARI CS. Evidence for a dopaminergic involvement in the inhibitory effect of alpha human natriuretic peptide on prolactin in man. *Horm Metab Res* 21: 630–634, 1989.
 567. FORGET H, PAINSON J-C, DREWS RT, LAGACÉ G, AND COLLU R. MMQ cells: a model for evaluating the role of G proteins in the modulation of prolactin release. *Mol Cell Endocrinol* 93: 125–133, 1993.
 568. FORSYTH IA. Comparative aspects of placental lactogens: structure and function. *Exp Clin Endocrinol* 102: 244–251, 1994.
 569. FOSTER DL AND AGATANI SN. Physiological perspectives on leptin as a regulator of reproduction: role in timing puberty. *Biol Reprod* 60: 205–215, 1999.
 570. FOSTER GV, MACINTYRE I, AND PEARSE AGE. Calcitonin production and the mitochondrion-rich cells of the dog thyroid. *Nature* 203: 1029–1030, 1964.
 571. FRANCI CR, ANSELMO-FRANCI JA, AND MCCANN SM. The role of endogenous atrial natriuretic peptide in resting and stress-induced release of corticotropin, prolactin, growth hormone, and thyroid-stimulating hormone. *Proc Natl Acad Sci USA* 89: 11391–11395, 1992.
 572. FRAWLEY LS AND BOOCKFOR FR. Focusing on hormone release. *Nature* 321: 793–793, 1986.
 573. FRAWLEY LS AND BOOCKFOR FR. Mammosomatotropes: presence and functions in normal and neoplastic pituitary tissue. *Endocr Rev* 12: 337–355, 1991.
 574. FRAWLEY LS, BOOCKFOR FR, AND HOEFFLER JP. Identification by plaque assays of a pituitary cell type that secretes both growth hormone and prolactin. *Endocrinology* 116: 734–737, 1985.
 575. FRAWLEY LS, MULCHAHEY JJ, AND NEILL JD. Nursing induces a biphasic release of prolactin in rhesus monkeys. *Endocrinology* 112: 558–561, 1983.
 576. FRAWLEY LS AND NEILL JD. A reverse hemolytic plaque assay for microscopic visualization of growth hormone release from individual cells: evidence for somatotrope heterogeneity. *Neuroendocrinology* 39: 484–487, 1984.
 577. FREEMAN ME. A direct effect of the uterus on the surges of prolactin induced by cervical stimulation in the rat. *Endocrinology* 105: 387–390, 1979.
 578. FREEMAN ME. The nonpregnant uterus as an endocrine organ. *News Physiol Sci* 3: 31–32, 1988.
 579. FREEMAN ME. Neuropeptide Y: a unique member of the constellation of gonadotropin-releasing hormones. *Endocrinology* 133: 2411–2412, 1993.
 580. FREEMAN ME. The neuroendocrine control of the ovarian cycle of the rat. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 613–658.
 581. FREEMAN ME AND BANKS JA. Hypothalamic sites which control the surges of prolactin secretion induced by cervical stimulation. *Endocrinology* 106: 668–673, 1980.
 582. FREEMAN ME AND BURRIS TP. Dopamine as a prolactin-releasing hormone. In: *Molecular and Clinical Advances in Pituitary Disorders-1993*, edited by Melmed S. Beverly Hills, CA: Endocrine Research and Education, 1993, p. 249–253.
 583. FREEMAN ME, DUPKE KC, AND CROTEAU CM. Extinction of the estrogen-induced daily signal for LH release in the rat: a role for the prooestrous surge of progesterone. *Endocrinology* 99: 223–229, 1976.
 584. FREEMAN ME AND NEILL JD. The pattern of prolactin secretion during pseudopregnancy in the rat: a daily nocturnal surge. *Endocrinology* 90: 1292–1294, 1972.
 585. FREEMAN ME AND STERMAN JR. Ovarian steroid modulation of prolactin surges in cervically-stimulated ovariectomized rats. *Endocrinology* 102: 1915–1920, 1978.
 586. FREEMARK M, DRISCOLL P, ANDREWS J, KELLY PA, AND ROYSTER M. Ontogenesis of prolactin receptor gene expression in the rat olfactory system: potential roles for lactogenic hormones in olfactory development. *Endocrinology* 137: 934–942, 1996.
 587. FREEMARK M, NAGANO M, EDERY M, AND KELLY PA. Prolactin receptor gene expression in the fetal rat. *J Endocrinol* 144: 285–292, 1995.
 588. FUCHS E, MANKSY T, STOCK KW, VIJAYAN E, AND WUTTKE W. Involvement of catecholamines and glutamate in GABAergic mechanism regulatory to luteinizing hormone and prolactin secretion. *Neuroendocrinology* 38: 484–489, 1984.
 589. FUJII R, FUKUSUMI S, HOSOYA M, KAWAMATA Y, HABATA Y, HINUMA S, SEKIGUCHI M, KITADA C, KUROKAWA T, NISHIMURA O, ONDA H, SUMINO Y, AND FUJINO M. Tissue distribution of prolactin-releasing peptide (PrRP) and its receptor. *Regul Pept* 83: 1–10, 1999.
 590. FUJIKAWA T, SOYA H, YOSHIZATO H, SAKAGUCHI K, DOH-URA K, TANAKA M, AND NAKASHIMA K. Restraint stress enhances the gene expression of prolactin receptor long form at the choroid plexus. *Endocrinology* 136: 5608–5613, 1995.
 591. FURCHGOTT RF AND ZAWADSKI JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 288: 373–376, 1980.
 592. FUXE H, AGNATI LF, AND HARFSTRAND A. Studies on the neurochemical mechanisms underlying the neuroendocrine actions of neuropeptide Y. In: *Neuropeptide Y*, edited by Mutt V, Hokfelt T, Fuxe K, and Lundberg JM. New York: Raven, 1989, p. 115–136.
 593. FUXE K. Evidence for the existence of monoamine neurons in the central nervous system. *Acta Physiol Scand Suppl* 247: 239, 1965.
 594. FUXE K, HÖKFELT T, ENEROTH P, GUSTAFSSON JA, AND SKETT P. Prolactin-like immunoreactivity: localization in nerve terminals of rat hypothalamus. *Science* 196: 899–900, 1977.
 595. FUXE K, HÖKFELT T, AND NILSSON O. Factors involved in the control of the activity of tubero-infundibular dopamine neurons during pregnancy and lactation. *Neuroendocrinology* 5: 257–270, 1969.
 596. GABRIEL SM, KAPLAN LM, MARTIN JB, AND KOENIG JI. Tissue-specific

- sex differences in galanin-like immunoreactivity and galanin mRNA during development in the rat. *Peptides* 10: 369–374, 1989.
597. GALA RR. The physiology and mechanisms of the stress-induced changes in prolactin secretion in the rat. *Life Sci* 46: 1407–1420, 1990.
598. GALA RR AND HAISENLEDER DJ. Restraint stress decreases afternoon plasma prolactin levels in female rats, influence of neural antagonist and agonists on restraint-induced changes in plasma prolactin and corticosterone. *Neuroendocrinology* 43: 115–123, 1986.
599. GALA RR AND SHEVACH EM. Evidence for the release of a prolactin-like substance by mouse lymphocytes and macrophages. *Proc Soc Exp Biol Med* 205: 12–19, 1994.
600. GALLO RV, RABII J, AND MOBERG GP. Effect of methysergide, a blocker of serotonin receptors, on plasma prolactin levels in lactating and ovariectomized rats. *Endocrinology* 97: 1096–1105, 1975.
601. GANONG WF. Angiotensin II in the brain and pituitary: contrasting roles in the regulation of adenohypophyseal secretion. *Horm Res* 31: 24–31, 1989.
602. GANONG WF, DESCHEPPER CF, STEELE MK, AND INTEBI A. Renin-angiotensin system in the anterior pituitary of the rat. *Am J Hypertens* 2: 320–322, 1989.
603. GARBARO M, TUONG MD, GROS C, AND SCHWARTZ JC. Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. *Eur J Pharmacol* 164: 1–11, 1989.
604. GARCIA DY, LI S, FOURNIER A, ST-PIERRE S, AND PELLETIER G. Involvement of the Y2 receptor subtype in the regulation of prolactin gene expression by neuropeptide Y in the male rat. *Neurosci Lett* 190: 77–80, 1995.
605. GARRIS PA AND BEN-JONATHAN N. Regulation of dopamine release in vitro from the posterior pituitary by opioid peptides. *Neuroendocrinology* 52: 399–404, 1990.
606. GARRIS PA AND BEN-JONATHAN N. Estradiol rapidly stimulates dopamine release from the posterior pituitary in vitro. *Neuroendocrinology* 53: 601–607, 1991.
607. GARRIS PA, BEN-JONATHAN N, AND PESCOVITZ OH. Estradiol acutely stimulates endogenous dopamine release from the posterior pituitary in vitro via an opioidergic mechanism. *Endocrine Society Meeting Atlanta GA 1990*, p. 1192.
608. GAY VL, MIDGLEY ARJ, AND NISWENDER GD. Patterns of gonadotrophin secretion associated with ovulation. *Federation Proc* 29: 1880–1887, 1970.
609. GEISTHOEVEL F, ARANA JB, BALMACEDA JP, ROJAS FJ, AND HASCH R. Prolactin and gonadotrophin dynamics in response to antagonists of LHRH and dopamine in ovariectomized rhesus monkeys: a dissection of their common secretion. *Hum Reprod* 3: 591–596, 1988.
610. GELBAND CH, SUMNERS C, LU D, AND RAIZADA MK. Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. *Regul Pept* 73: 141–147, 1998.
611. GELLERSEN B, BONHOFF A, HUNT N, AND BOHNET HG. Decidual-type prolactin expression by the human myometrium. *Endocrinology* 129: 158–168, 1991.
612. GELLERSEN B, DIMATTIA GE, FRIESEN HG, AND BOHNET HG. Phorbol ester stimulates prolactin release but reduces prolactin mRNA in the human B-lymphoblastoid cell line IM-9-P3. *Mol Cell Endocrinol* 66: 153–161, 1989.
613. GELLERSEN B, DIMATTIA GE, FRIESEN HG, AND BOHNET HG. Regulation of prolactin secretion in the human B-lymphoblastoid cell line IM-9-P3 by dexamethasone but not other regulators of pituitary prolactin secretion. *Endocrinology* 125: 2853–2861, 1989.
614. GERAS E, REBECCHI MJ, AND GERSHENGORN MC. Evidence that stimulation of thyrotropin and prolactin secretion by thyrotropin-releasing hormone occur via different calcium-mediated mechanisms: studies with verapamil. *Endocrinology* 110: 901–906, 1982.
615. GERAS EJ AND GERSHENGORN MC. Evidence that TRH stimulates secretion of TSH by two calcium-mediated mechanisms. *Am J Physiol Endocrinol Metab* 242: E109–E114, 1982.
616. GERSHENGORN MC. Mechanism of thyrotropin releasing hormone stimulation of pituitary hormone secretion. *Annu Rev Physiol* 48: 515–526, 1986.
617. GERSHENGORN MC, GERAS E, PURELLO VS, AND REBECCHI MJ. Inositol triphosphate mediates thyrotropin-releasing hormone mobilization of nonmitochondrial calcium in rat mammatropic pituitary cells. *J Biol Chem* 259: 10675–10681, 1984.
618. GHOSH PK, DEBELJUK L, WAGNER TE, AND BARTKE A. Effect of immunoneutralization of neuropeptide Y on gonadotropin and prolactin secretion in normal mice and in transgenic mice bearing bovine growth hormone gene. *Endocrinology* 129: 597–602, 1991.
619. GIANATTASIO G, DE FERRARI ME, AND SPADA A. Dopamine-inhibited adenylate cyclase in female rat adenohypophysis. *Life Sci* 28: 1605–1612, 1981.
620. GIBBS DM. High concentrations of oxytocin in hypophysial portal plasma. *Endocrinology* 114: 1216–1218, 1984.
621. GIBBS DM AND NEILL JD. Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. *Endocrinology* 102: 1895–1900, 1978.
622. GIBBS DM, PLOTSKY PM, DE GREEF WJ, AND NEILL JD. Effect of histamine and acetylcholine on hypophysial stalk plasma dopamine and peripheral plasma prolactin levels. *Life Sci* 24: 2063–2070, 1979.
623. GIGUERE V, MEUNIER H, VEILLEUX R, AND LABRIE F. Direct effects of sex steroids on prolactin release at the anterior pituitary level: interactions with dopamine, thyrotropin-releasing hormone, and isobutylmethylxanthine. *Endocrinology* 111: 857–862, 1982.
624. GILLESPIE MN, OWASOYO JO, MCMURTY IF, AND O'BRIEN RF. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. *J Pharmacol Exp Ther* 236: 339–343, 1986.
625. GILLIES G. Somatostatin: the neuroendocrine story. *Trends Pharmacol Sci* 18: 87–95, 1997.
626. GIROS B, JABER M, JONES SR, WIGHTMAN RM, AND CARON MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 379: 606–612, 1996.
627. GISS BJ AND WALKER AM. Mammatroph autoregulation: intracellular fate of internalized prolactin. *Mol Cell Endocrinol* 42: 259–267, 1985.
628. GIUSTINA A, LICINI M, SCHETTINO M, DOGA M, PIZZOCOLO G, AND NEGRO-VILAR A. Physiological role of galanin in the regulation of anterior pituitary function in humans. *Am J Physiol Endocrinol Metab* 266: E57–E61, 1994.
629. GLORIA E, REGISFORD C, AND KATZ LS. Effects of bromocriptine treatment on the expression of sexual behavior in male sheep (*Ovis aries*). *J Anim Sci* 72: 591–597, 1994.
630. GOEDERT M, LIGHTMAN SL, NAGY JJ, MARLEY PD, AND EMSON PC. Neurotensin in the rat anterior pituitary gland. *Nature* 298: 163–165, 1982.
631. GOFFIN V, BOUCHARD B, ORMANDY CJ, WEIMANN E, FERRAG F, TOURAINE P, BOLE-FEYSOT C, MAASKANT RA, CLEMENT-LACROIX P, EDERY M, BINART N, AND KELLY PA. Prolactin: a hormone at the crossroads of neuroimmunendocrinology. *Ann NY Acad Sci* 840: 498–509, 1998.
632. GOFFIN V, FERRAG F, AND KELLY PA. Molecular aspects of prolactin and growth hormone receptors. In: *Advances in Molecular and Cellular Endocrinology*, edited by LeRoith D. London: JAI, 1998, p. 1–33.
633. GOFFIN V AND KELLY PA. Prolactin and growth hormone receptors. *Clin Endocrinol* 45: 247–255, 1996.
634. GOFFIN V, KINET S, FERRAG F, BINART N, MARTIAL JA, AND KELLY PA. Antagonistic properties of human prolactin analogues that show paradoxical agonistic activity in the Nb2 bioassay. *J Biol Chem* 271: 16573–16579, 1996.
635. GOFFIN V, MARTIAL JA, AND SUMMERS NL. Use of a model to understand prolactin and growth hormone specificities. *Protein Eng* 8: 1215–1231, 1995.
636. GOFFIN V, TOURAINE P, PICHARD C, BERNICHTEN S, AND KELLY PA. Should prolactin be reconsidered as a therapeutic target in human breast cancer? *Mol Cell Endocrinol* 151: 79–87, 1999.
637. GOLANDER A, BARRETT J, HURLEY T, BARRY S, AND HANDWERGER S. Failure of bromocriptine, dopamine, and thyrotropin-releasing hormone to affect prolactin secretion by human decidual tissue in vitro. *J Clin Endocrinol Metab* 49: 787–789, 1979.
638. GOLANDER A, RICHARDS R, THRAILKILL K, CAPEL D, ROGERS D, AND

- HANDWERGER S. Decidual prolactin (PRL)-releasing factor stimulates the synthesis of PRL from human decidual cells. *Endocrinology* 123: 335–339, 1988.
639. GOLDSMITH PC, CRONIN MJ, AND WEINER RI. Dopamine receptor sites in the anterior pituitary. *J Histochem Cytochem* 27: 1205, 1979.
640. GONZALEZ LC, PINILLA L, TENA-SEMPERE M, AND AGUILAR E. Lep^{tin}_{116–130} stimulates prolactin and luteinizing hormone secretion in fasted adult male rats. *Neuroendocrinology* 70: 213–220, 1998.
641. GONZALEZ MC, LINARES JD, SANTOS M, AND LORENTE EL. Effects of nitric oxide donors sodium nitroprusside and 3-morpholino-sydnonimine on prolactin secretion in conscious rats. *Neurosci Lett* 203: 167–170, 1996.
642. GONZALEZ MC, LLORENTE E, AND ABREU P. Sodium nitroprusside inhibits the tyrosine hydroxylase activity of the median eminence in the rat. *Neurosci Lett* 254: 133–136, 1998.
643. GONZALEZ-PARRA S, CHOWEN JA, GARCIA SL, AND ARGENTE J. Ontogeny of pituitary transcription factor-1 (Pit-1), growth hormone (GH) and prolactin (PRL) mRNA levels in male and female rats and the differential expression of Pit-1 in lactotrophs and somatotrophs. *J Neuroendocr* 8: 211–225, 1996.
644. GOODMAN G, LAWSON DM, AND GALA RR. The effects of neurotransmitter receptor antagonists on ether-induced prolactin release in ovariectomized, estrogen-treated rats. *Proc Soc Exp Biol Med* 153: 225–229, 1976.
645. GOROSPE WC AND FREEMAN ME. An ovarian role in prolonging and terminating the two surges of prolactin in pseudopregnant rats. *Endocrinology* 108: 1293–1298, 1981.
646. GOROSPE WC AND FREEMAN ME. The imprint provided by cervical stimulation for the initiation and maintenance of daily prolactin surges: modulation by the uterus and ovaries. *Endocrinology* 110: 1866–1870, 1982.
647. GOROSPE WC AND FREEMAN ME. Uterus of the rat contains prolactin inhibitory activity. *Am J Physiol Endocrinol Metab* 247: E251–E257, 1984.
648. GOROSPE WC AND FREEMAN ME. Detection of prolactin inhibitory activity in uterine epithelial cell secretions and rat serum. *Endocrinology* 116: 1559–1564, 1985.
649. GOROSPE WC AND FREEMAN ME. Effects of placenta and maternal serum on prolactin secretion in vitro. *Biol Reprod* 32: 279–283, 1985.
650. GOROSPE WC, MICK C, AND FREEMAN ME. The obligatory role of the uterus for termination of prolactin surges initiated by cervical stimulation. *Endocrinology* 109: 1–4, 1981.
651. GOTH MI, LYONS CEJ, ELLWOOD MR, BARRETT JR, AND THORNER MO. Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. *Endocrinology* 137: 274–280, 1996.
652. GOTO A, YAMADA K, ISHI M, YOSHIOKA M, ISHIGURO T, EGUCHI C, AND SUGIMOTO T. Existence of a polar digitalis-like factor in mammalian hypothalamus. *Biochem Biophys Res Commun* 161: 953–958, 1989.
653. GOTTSCHALL PE, TATSUNO I, AND ARIMURA A. Hypothalamic binding sites for pituitary adenylate cyclase activating polypeptide: characterization and molecular identification. *FASEB J* 5: 194–199, 1991.
654. GOTTSCHALL PE, TATSUNO I, MIYATA A, AND ARIMURA A. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. *Endocrinology* 127: 272–277, 1990.
655. GOUDREAU JL, FALLS WM, LOOKINGLAND KJ, AND MOORE KE. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. *Neuroendocrinology* 62: 147–154, 1995.
656. GOUDREAU JL, LINDLEY SE, LOOKINGLAND KJ, AND MOORE KE. Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary. *Neuroendocrinology* 56: 100–105, 1992.
657. GOUDREAU JL, LOOKINGLAND KJ, AND MOORE KE. 5-Hydroxytryptamine₂ receptor-mediated regulation of periventricular-hypophysial dopaminergic neuronal activity and the secretion of alpha-melanocyte-stimulating hormone. *J Pharmacol Exp Ther* 268: 175–179, 1994.
658. GOUILLEUX F, PALLARD C, DUSANTER-FOURT I, WAKAO H, HALDOSEN LA, NORSTEDT G, LEVY D, AND GRONER B. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. *EMBO J* 14: 2005–2013, 1995.
659. GOUILLEUX F, WAKAO H, MUNDT M, AND GRONER B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. *EMBO J* 13: 4361–4369, 1994.
660. GOUPILLE O, DANIEL N, BIGNON C, JOLIVET G, AND DJANE J. Prolactin signal transduction to milk protein genes: carboxy-terminal part of the prolactin receptor and its tyrosine phosphorylation are not obligatory for JAK2 and STAT5 activation. *Mol Cell Endocrinol* 127: 155–169, 1997.
661. GRANDISON L. Actions of benzodiazepines on the neuroendocrine system. *Neuropharmacology* 22: 1505–1510, 1983.
662. GRANDISON L, GELATO M, AND MEITES J. Inhibition of prolactin secretion by cholinergic drugs. *Proc Soc Exp Biol Med* 145: 1236–1239, 1974.
663. GRANDISON L AND GUIDOTTI A. Regulation of prolactin release by endogenous opiates. *Nature* 270: 357–359, 1977.
664. GRANDISON L AND GUIDOTTI A. gamma-Aminobutyric acid receptor function in rat anterior pituitary: evidence for control of prolactin release. *Endocrinology* 105: 754–759, 1979.
665. GRANDISON L AND MEITES J. Evidence for adrenergic mediation of cholinergic inhibition of prolactin release. *Endocrinology* 99: 775–779, 1976.
666. GRANDY DK, MARCHIONNI MA, MAKAM H, STOFKO RE, ALFANO M, FROTHINGHAM L, FISCHER JB, BURKE-HOWIE KJ, BUNZOW JR, SERVER AC, AND CIVELLI O. Cloning of the cDNA and gene for a human D2 dopamine receptor. *Proc Natl Acad Sci USA* 86: 9762–9766, 1989.
667. GRATAN DR AND WAVERILL RL. Intrahypothalamic pituitary grafts elevate prolactin in the cerebrospinal fluid and attenuate prolactin release following ether stress. *Proc Soc Exp Biol Med* 196: 42–46, 1991.
668. GRATAN DR AND WAVERILL RL. Role of the placenta in the control of the ante-partum surge of prolactin in the rat. *J Endocrinol* 130: 401–407, 1991.
669. GRATAN DR AND SELMANOFF M. Prolactin- and testosterone-induced inhibition of LH secretion after orchidectomy: role of preoptic and tuberoinfundibular gamma-aminobutyric acidergic neurons. *J Endocrinol* 143: 165–174, 1994.
670. GREENAN JR, BALDEN E, HO TWC, AND WALKER AM. Biosynthesis of the secreted 24 K isoforms of prolactin. *Endocrinology* 125: 2041–2048, 1989.
671. GREENMAN Y AND MELMED S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in mammosomatotroph lineage. *J Clin Endocrinol Metab* 79: 724–729, 1994.
672. GREENWALD GS. Further observations on the luteotropic complex in the hamster. *Arch Anat* 56: 281–291, 1967.
673. GREER ER, CALDWELL JD, JOHNSON MF, PRANGE AJ, AND PEDERSEN CA. Variations in concentration of oxytocin and vasopressin in the paraventricular nucleus of the hypothalamus during the estrous cycle in rats. *Life Sci* 38: 3211–3218, 1986.
674. GREGERSON KA, CHUKNYSKA R, AND GOLESORKHI N. Stimulation of prolactin release by dopamine withdrawal: role of calcium influx. *Am J Physiol Endocrinol Metab* 267: E789–E794, 1994.
675. GREGERSON KA, GOLESORKHI N, AND CHUKNYSKA R. Stimulation of prolactin release by dopamine withdrawal: role of membrane hyperpolarization. *Am J Physiol Endocrinol Metab* 267: E781–E788, 1994.
676. GRIFFOND B, COLARD C, DERAY A, FELLMANN D, AND BUGNON C. Evidence for the expression of dynorphin gene in the prolactin-immunoreactive neurons of the rat lateral hypothalamus. *Neurosci Lett* 165: 89–92, 1994.
677. GRIFFOND B, DERAY A, FELLMANN D, CIOFI P, CROIX D, AND BUGNON C. Colocalization of prolactin- and dynorphin-like substances in a neuronal population of the rat lateral hypothalamus. *Neurosci Lett* 156: 91–95, 1993.
678. GRIFFOND B, DERAY A, JACQUEMARD C, FELLMANN D, AND BUGNON C. Prolactin immunoreactive neurons of the rat lateral hypothala-

- mus: immunocytochemical and ultrastructural studies. *Brain Res* 635: 179–186, 1994.
679. GROSSMAN A, DELITALA G, YEO T, AND BESSER GM. GABA and muscimol inhibit the release of prolactin from dispersed rat anterior pituitary cells. *Neuroendocrinology* 32: 145–149, 1981.
 680. GROSVENOR CE AND KEENAN TW. Hormones and growth factors in milk. *Endocr Rev* 14: 710–728, 1992.
 681. GROSVENOR CE AND MENA F. Evidence that thyrotropin-releasing hormone and a hypothalamic prolactin-releasing factor may function in the release of prolactin in the lactating rat. *Endocrinology* 107: 863–868, 1980.
 682. GROSVENOR CE, MENA F, AND WHITWORTH N. Sensory stimuli from pups involved in inhibition of milk secretion in rats during late lactation. *Horm Behav* 8: 287–296, 1977.
 683. GROSVENOR CE, MENA F, AND WHITWORTH NS. The secretion rate of prolactin in the rat during suckling and its metabolic clearance rate after increasing intervals of nonsuckling. *Endocrinology* 104: 372–376, 1979.
 684. GROSVENOR CE AND WHITWORTH N. Evidence for a steady rate of secretion of prolactin following suckling in the rat. *J Dairy Sci* 57: 900–904, 1974.
 685. GROSVENOR CE AND WHITWORTH NS. Incorporation of rat prolactin into rat milk in vivo and in vitro. *J Endocrinol* 70: 1–9, 1976.
 686. GROSVENOR CE AND WHITWORTH NS. Accumulation of prolactin by maternal milk and its transfer to circulation of neonatal rat: a review. *Endocrinol Exp* 17: 271–282, 1983.
 687. GROVE DS, BOUR B, KACSOH B, AND MASTRO AM. Effect of neonatal milk-prolactin deprivation on the ontogeny of the immune system of the rat. *Endocr Regul* 25: 111–119, 1991.
 688. GU Y, SOARES MJ, SRIVASTAVA RK, AND GIBORI G. Expression of decidual prolactin-related protein in the rat decidua. *Endocrinology* 135: 1422–1427, 1994.
 689. GU Y, SRIVASTAVA RK, CLARKE DL, LINZER DIH, AND GIBORI G. The decidual prolactin receptor and its regulation by decidua-derived factors. *Endocrinology* 137: 4878–4885, 1996.
 690. GUALILLO O, LAGO F, GARCIA M, MENENDEZ C, SENARIS R, CASANUEVA FF, AND DIEGUEZ C. Prolactin stimulates leptin secretion by rat white adipose tissue. *Endocrinology* 140: 5149–5153, 1999.
 691. GUDELSKY GA, APUD JA, MASOTTO C, LOCATELLI V, COCCHI D, RACAGNI G, AND MULLER EE. Ethanolamine-O-sulfate enhances gamma-aminobutyric acid secretion into hypophyseal portal blood and lowers serum prolactin concentrations. *Neuroendocrinology* 37: 397–399, 1983.
 692. GUDELSKY GA, BERRY SA, AND MELTZER HY. Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat. *Neuroendocrinology* 49: 604–609, 1989.
 693. GUDELSKY GA AND PORTER JC. Morphine- and opioid peptide-induced inhibition of the release of dopamine from tuberoinfundibular neurons. *Life Sci* 25: 1697–1702, 1979.
 694. GUDELSKY GA AND PORTER JC. Release of newly synthesized dopamine into the hypophyseal portal vasculature of the rat. *Endocrinology* 104: 583–587, 1979.
 695. GUDELSKY GA AND PORTER JC. Release of dopamine from tuberoinfundibular neurons into pituitary stalk blood after prolactin or haloperidol administration. *Endocrinology* 106: 526–529, 1980.
 696. GUDELSKY GA AND PORTER JC. Sex-related difference in the release of dopamine into hypophyseal portal blood. *Endocrinology* 109: 1394–1398, 1981.
 697. GUERINEAU N, DROUHAILT R, CORCUFF B, VACHER AM, VILAYLECK N, AND MOLLARD P. Galanin evokes a cytosolic calcium bursting mode and hormone release in GH₃/B6 pituitary cells. *FEBS Lett* 276: 111–114, 1990.
 698. GUERRA MJ, LISTE I, AND LABANDEIRA-GARCIA JL. Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. *Synapse* 28: 71–82, 1998.
 699. GUIVARCH D, VINCENT JD, AND VERNIER P. Alternative splicing of the D₂ dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. *Endocrinology* 139: 4213–4221, 1998.
 700. GULLNER HG AND YAJIMA H. Gastrin releasing peptide: endocrine functions in the rat. *Pharmacol Res Commun* 15: 247–252, 1983.
 701. GULLNER HG, YAJIMA H, HERBERT D, AND WOWEN W. Growth hormone, prolactin and FSH release by the tachykinin dodecapeptide kassinin in the rat. *Arch Int Pharmacodyn Ther* 256: 4–9, 1982.
 702. GUNES H, GROVE DS, BOUR B, ZAWILLA S, AND MASTRO AM. The expression of forms of prolactin receptors in splenocytes and thymocytes of neonatal rats: the effect of milk ingestion. *Endocr Regul* 27: 193–200, 1993.
 703. GUNES H AND MASTRO AM. Prolactin receptor gene expression in rat splenocytes and thymocytes from birth to adulthood. *Mol Cell Endocrinol* 117: 41–52, 1996.
 704. GUNES H AND MASTRO AM. Prolactin receptor gene expression in rat splenocytes and thymocytes during oestrous cycle, pregnancy and lactation. *Cell Prolif* 30: 219–235, 1997.
 705. GUNNET JW AND FREEMAN ME. The mating-induced release of prolactin: a unique neuroendocrine response. *Endocr Rev* 4: 44–60, 1983.
 706. GUNNET JW AND FREEMAN ME. Hypothalamic regulation of mating-induced prolactin release: effect of electrical stimulation of the medial preoptic area in conscious females. *Neuroendocrinology* 38: 12–16, 1984.
 707. GUNNET JW AND FREEMAN ME. The interaction of the medial preoptic area and the dorsomedial-ventromedial nuclei of the hypothalamus in the regulation of the mating-induced release of prolactin. *Neuroendocrinology* 40: 232–237, 1985.
 708. GUNNET JW, LOOKINGLAND KJ, AND MOORE KE. Comparison of the effects of castration and steroid replacement on incertohypothalamic dopaminergic neurons on male and female rats. *Neuroendocrinology* 44: 269–275, 1986.
 709. GUNNET JW, LOOKINGLAND KJ, AND MOORE KE. Effects of gonadal steroids on tuberoinfundibular and tuberohypophyseal dopaminergic neuronal activity in male and female rats. *Proc Soc Exp Biol Med* 183: 49–98, 1986.
 710. GUNNET JW, MICK C, AND FREEMAN ME. The role of the dorsomedial-ventromedial area of the hypothalamus in control of prolactin secretion induced by cervical stimulation. *Endocrinology* 109: 1846–1850, 1981.
 711. GUO DF AND INAGAMI T. The genomic organization of the rat angiotensin II receptor AT_{1B}. *Biochim Biophys Acta* 1218: 91–94, 1994.
 712. GUSHCHIN GV, CHENEY C, GLASER R, AND MALARKEY WB. Temporal relationships and IL-2 dependency of prolactin-induced lymphocyte proliferation. *J Neuroimmunol* 60: 93–98, 1995.
 713. GUTKOWSKA J, ANTUNES-RODRIGUES J, AND MCCANN SM. Atrial natriuretic peptides in brain and pituitary gland. *Physiol Rev* 77: 466–515, 1997.
 714. GUY J AND PELLETIER G. Neuronal interactions between neuropeptide Y (NPY) and catecholaminergic systems in the rat arcuate nucleus as shown by dual immunocytochemistry. *Peptides* 9: 567–570, 1988.
 715. HAGEN TC, ARNAOUT MA, SCHERZER WJ, MARTINSON DR, AND GARTH-WAITE AL. Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells. *Neuroendocrinology* 43: 641–645, 1986.
 716. HAIENLEDER DJ, GALA RR, AND LAWSON DM. Comparison of the effects of suckling or transient dopamine antagonism on thyrotropin-releasing hormone and suckling induced prolactin release in lactating rats. *Life Sci* 39: 659–664, 1986.
 717. HAIENLEDER DJ, GALA RR, AND LAWSON DM. The effect of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in female rats during the estrous cycle. *Life Sci* 48: 1911–1918, 1991.
 718. HAIENLEDER DJ, MOY JA, GALA RR, AND LAWSON DM. Effect of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in ovariectomized rats treated with estradiol and/or progesterone. *Endocrinology* 119: 1996–2003, 1986.
 719. HAIENLEDER DJ, MOY JA, GALA RR, AND LAWSON DM. Effect of transient dopamine antagonism on thyrotropin-releasing hormone-induced prolactin release in pregnant rats. *Endocrinology* 119: 1980–1988, 1986.
 720. HAIENLEDER DJ, MOY JA, GALA RR, AND LAWSON DM. Effects of transient dopamine antagonism on thyrotropin-releasing hor-

- mone-induced prolactin release in pseudopregnant rats. *Endocrinology* 119: 1989–1995, 1986.
721. HAISENLEDER DJ, MOY JA, GALA RR, AND LAWSON DM. The effect of dopamine antagonists and/or VIP on TRH- or VIP-induced prolactin release in estrogen- and progesterone-treated ovariectomized rats. *Proc Soc Exp Biol Med* 187: 341–349, 1988.
 722. HAISENLEDER DJ, YASIN M, AND MARSHALL JC. Regulation of gonadotropin, thyrotropin subunit, and prolactin messenger ribonucleic acid expression by pulsatile or continuous protein kinase-C stimulation. *Endocrinology* 136: 13–19, 1995.
 723. HAKANSSON M-L, DE LECEA L, SUTCLIFFE JG, YANAGISAWA M, AND MEISTER B. Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. *J Neuroendocrinol* 11: 653–663, 1999.
 724. HALASZ B. Hypothalamo-anterior pituitary system and pituitary portal vessels. In: *The Pituitary Gland*, edited by Imura H. New York: Raven, 1994, p. 1–28.
 725. HALMI NS, PARSONS JA, ERLANDSEN SL, AND DUELLO T. Prolactin and growth hormone cells in the human hypophysis: a study with immunoenzyme histochemistry and differential staining. *Cell Tissue Res* 158: 497–507, 1975.
 726. HAMMOND PJ, KHANDAN-NIA N, WITHERS DJ, JONES PM, GHATEI MA, AND BLOOM SR. Regulation of anterior pituitary galanin and vasoactive intestinal peptide by oestrogen and prolactin status. *J Endocrinol* 152: 211–219, 1997.
 727. HAMMOND PJ, SMITH DM, AKINSANYA KO, MUFTI WA, WYNICK D, AND BLOOM SR. Signalling pathways mediating secretory and mitogenic responses to galanin and pituitary adenylate cyclase-activating polypeptide in the 235-1 clonal rat lactotroph cell line. *J Neuroendocrinol* 8: 457–464, 1996.
 728. HANDWERGER S. Clinical counterpoint: the physiology of placental lactogen in human pregnancy. *Endocr Rev* 12: 329–336, 1991.
 729. HANDWERGER S, BARRY S, MARKOFF E, BARRETT J, AND CONN PM. Stimulation of the synthesis and release of decidual prolactin by a placental polypeptide. *Endocrinology* 112: 1370–1374, 1983.
 730. HANDWERGER S, CAPEL D, KORNER G, AND RICHARDS R. Purification of decidual prolactin-releasing factor, a placental protein that stimulates prolactin release from human decidual tissue. *Biochem Biophys Res Commun* 147: 452–459, 1987.
 731. HANDWERGER S, RICHARDS R, AND MARKOFF E. Autocrine/paracrine regulation of prolactin release from human decidual cells. *Ann NY Acad Sci* 622: 111–119, 1991.
 732. HANDWERGER S, RICHARDS RG, AND MARKOFF E. The physiology of decidual prolactin and other decidual protein hormones. *Trends Endocrinol Metab* 3: 91–95, 1992.
 733. HANEW K AND RENNELS EG. Effects of culture age on PRL and GH responses to bromocriptine and somatostatin from primary cultures of rat anterior pituitary cells. *Proc Soc Exp Biol Med* 171: 12–18, 1982.
 734. HANEW K, SHIINO M, AND RENNELS EG. Effects of indoles, AVT, oxytocin and AVP on prolactin secretion in rat pituitary clonal (2B8) cells. *Proc Soc Exp Biol Med* 164: 257–261, 1980.
 735. HANSEN BL, HANSEN GN, AND HAGEN C. Immunoreactive material resembling ovine prolactin in perikarya and nerve terminals of the rat hypothalamus. *Cell Tissue Res* 226: 121–131, 1982.
 736. HANSSON LO, WATERS N, HOLM S, AND SONESSON C. On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D₂ autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression. *J Med Chem* 38: 3121–3131, 1995.
 737. HARLAN RE, SHIVERS BD, FOX SR, KAPLOVE KA, SCHACHTER BS, AND PFAFF SW. Distribution and partial characterization of immunoreactive prolactin in the rat brain. *Neuroendocrinology* 49: 7–22, 1989.
 738. HARLAN RE, SHIVERS BD, AND PFAFF DW. Midbrain microinfusions of prolactin increase the estrogen-dependent behavior, lordosis. *Science* 219: 1451–1453, 1983.
 739. HARMS PG, LANGLIER P, AND MCCANN SM. Modification of stress-induced prolactin release by dexamethasone or adrenalectomy. *Endocrinology* 96: 475–478, 1975.
 740. HARO LS, LEE DW, SINGH RNP, BEE G, MARKOFF E, AND LEWIS UJ. Glycosylated human prolactin: alterations in glycosylation pattern modify affinity for lactogen receptor and values in prolactin radioimmunoassay. *J Clin Endocrinol Metab* 71: 379–383, 1990.
 741. HARTMANN DP, HOLADAY JW, AND BERNTON EW. Inhibition of lymphocyte proliferation by antibodies to prolactin. *FASEB J* 3: 2194–2202, 1989.
 742. HASKINS JT, GUDELSKY GA, MOSS RL, AND PORTER JC. Iontophoresis of morphine into the arcuate nucleus: effects on dopamine concentrations in hypophysial portal plasma and serum prolactin concentrations. *Endocrinology* 108: 767–771, 1981.
 743. HASKINS JT AND MOSS RL. Differential effects of morphine, dopamine and prolactin administered iontophoretically on arcuate-ventromedial hypothalamic neurons. *Brain Res* 268: 185–188, 1983.
 744. HATTORI N, WAKIMASU M, TAKAHASHI M, HIROSAWA M, SHIOTA K, AND OGAWA T. Characterization of rat placental lactogen- α (PL- α) with an antipeptide antibody directed against rat PLs. *Endocr J* 40: 727–735, 1993.
 745. HAUG E AND GAUTVIK KM. Effects of sex steroids on prolactin secreting rat pituitary cells in culture. *Endocrinology* 99: 1482–1489, 1976.
 746. HAUGER RL, AGUILERA G, BAUKAL AJ, AND CATT KJ. Characterization of angiotensin II receptors in the anterior pituitary gland. *Mol Cell Endocrinol* 25: 203–212, 1982.
 747. HAYMES AA AND HINKLE PM. Activation of protein kinase C increases Ca²⁺ sensitivity of secretory response of GH₃ pituitary cells. *Am J Physiol Cell Physiol* 264: C1020–C1028, 1993.
 748. HEIMAN ML AND BEN-JONATHAN N. Dopaminergic receptors in the rat anterior pituitary change during the estrous cycle. *Endocrinology* 111: 37–41, 1982.
 749. HEMMER A AND HYDE JF. Regulation of galanin secretion from pituitary cells in vitro by estradiol and GHRH. *Peptides* 13: 1201–1206, 1992.
 750. HENNIGHAUSEN L, ROBINSON GW, WAGNER KU, AND LIU XW. Prolactin signaling in mammary gland development. *J Biol Chem* 272: 7567–7569, 1997.
 751. HENTSCHEL K, CHEUNG S, MOORE KE, AND LOOKINGLAND KJ. Pharmacological evidence that neurotensin mediates prolactin-induced activation of tuberoinfundibular dopamine neurons. *Neuroendocrinology* 68: 71–76, 1998.
 752. HERBISON AE AND THEODOSIS DT. Localization of oestrogen receptors in preoptic neurons containing neurotensin but not tyrosine hydroxylase, cholecystokinin or luteinizing hormone-releasing hormone in the male and female rat. *Neuroscience* 50: 283–298, 1992.
 753. HERLANT M. The cells of the adenohypophysis and their functional significance. *Int Rev Cytol* 17: 299–382, 1964.
 754. HERNANDEZ ME, DEL MAR HERNANDEZ M, DIAZ-MUNOZ M, CLAPP C, AND DE LA ESCALERA GM. Potentiation of prolactin secretion following lactotrope escape from dopamine action. II. Phosphorylation of the α_1 subunit of L-type, voltage-dependent calcium channels. *Neuroendocrinology* 70: 31–42, 1999.
 755. HERZ Z, KHAN I, JAYATILAK PG, AND GIBORI G. Evidence for the secretion of decidual luteotropin: a prolactin-like hormone produced by rat decidual cells. *Endocrinology* 118: 2203–2210, 1986.
 756. HICKEY KA, RUBANYI G, PAUL RJ, AND HIGSMITH RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. *Am J Physiol Cell Physiol* 248: C550–C556, 1985.
 757. HIESTAND PC, MEKLER P, NORDMANN R, GRIEDER A, AND PERMMONGKOL C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. *Proc Natl Acad Sci USA* 83: 2599–2603, 1986.
 758. HIESTAND PC, NORDMANN R, GRIEDER A, AND PERMMONGKOL C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. *Proc Natl Acad Sci USA* 83: 2599–2603, 1986.
 759. HIGUCHI T, HONDA K, TAKANO S, AND NEGORO H. Estrogen fails to reduce tuberoinfundibular dopaminergic neuronal activity and to cause a prolactin surge in lactating, ovariectomized rats. *Brain Res* 576: 143–146, 1992.
 760. HILL JB, LACY ER, NAGY GM, GÖRCS TJ, AND FRAWLEY LS. Does α -melanocyte-stimulating hormone from the pars intermedia regulate suckling-induced prolactin release? Supportive evidence

- from morphological and functional studies. *Endocrinology* 133: 2991–2997, 1993.
761. HILL JB, NAGY GM, AND FRAWLEY LS. Suckling unmasks the stimulatory effect of dopamine on prolactin release: possible role for α -melanocyte-stimulating hormone as a mammatrope responsiveness factor. *Endocrinology* 129: 843–847, 1991.
 762. HILTON DJ, RICHARDSON RT, ALEXANDER WS, VINEY EM, WILLSON TA, SPRIGG NS, STARR R, NICHOLSON SE, METCALF D, AND NICOLA NA. Twenty proteins containing a C-terminal SOCS box form five structural classes. *Proc Natl Acad Sci USA* 95: 114–119, 1998.
 763. HINKLE PM AND TASHIAN AHJ. Receptors for thyrotropin-releasing hormone in prolactin producing rat pituitary cells in culture. *J Biol Chem* 248: 6180–6186, 1973.
 764. HINTERBERGER-FISCHER M, KIER P, SPONA J, SEBESTA C, TIEFENGRABER E, HABERTHEUER KH, RUCKSER R, SCHMID A, KALHS P, LECHNER K, AND HINTERBERGER W. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans. *Bone Marrow Transplant* 14: 403–406, 1994.
 765. HINUMA S, HABATA Y, FUJII R, KAWAMATA Y, HOSOYA N, FUKUSUMI S, KITADA C, MASUO Y, ASANO T, MATSUMOTO H, SEKIGUCHI M, KUROKAWA T, NISHIMURA O, ONDA H, AND FUJINO M. A prolactin-releasing peptide in the brain. *Nature* 393: 272–276, 1998.
 766. HNASKO R, KHURANA S, SHACKLEFORD N, STEINMETZ R, LOW MJ, AND BEN-JONATHAN N. Two distinct pituitary cell lines from mouse intermediate lobe tumors: a cell that produces prolactin-regulating factor and a melanotroph. *Endocrinology* 138: 5589–5596, 1997.
 767. HO MY, KAO JPY, AND GREGERSON KA. Dopamine withdrawal elicits prolonged calcium rise to support prolactin rebound release. *Endocrinology* 137: 3513–3521, 1996.
 768. HO TWC, GREENAN JR, AND WALKER AM. Mammatroph autoregulation: the differential roles of the 24K isoforms of prolactin. *Endocrinology* 124: 1507–1514, 1989.
 769. HO TWC, LEONG FS, OLASO CH, AND WALKER AM. Secretion of specific nonphosphorylated and phosphorylated rat prolactin isoforms at different stages of the estrous cycle. *Neuroendocrinology* 58: 160–165, 1993.
 770. HOFFFLER JP, BOOCKFOR FR, AND FRAWLEY LS. Ontogeny of prolactin cells in neonatal rats: initial prolactin secretors also release growth hormone. *Endocrinology* 117: 187–195, 1985.
 771. HOFFFLER JP AND FRAWLEY LS. Hypothalamic factors differentially affect the proportions of cells that secrete growth hormone or prolactin. *Endocrinology* 120: 791–795, 1987.
 772. HOFFMAN JC AND CULLIN AM. Effects of pinealectomy and constant light on the estrous cycles of female rats. *Neuroendocrinology* 17: 167–174, 1975.
 773. HOFLAND LJ, VAN KOETSVELD PM, AND LAMBERTS SW. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201–995. *Eur J Cancer* 26: 37–44, 1990.
 - 773a. HÖKFELT T AND FUXE K. Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. *Neuroendocrinology* 9: 100–122, 1972.
 774. HOKFELT T, FUXE K, JOHANSSON O, JEFFCOATE S, AND WHITE N. Distribution of thyrotropin-releasing hormone (TRH) in the central nervous system as revealed with immunohistochemistry. *Eur J Pharmacol* 34: 389–392, 1975.
 775. HOKFELT T, GOLDSTEIN M, AND JOHANSSON O. Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain. *Brain Res* 66: 235–251, 1974.
 776. HOKFELT T, JOHANSSON O, AND GOLDSTEIN M. Chemical neuroanatomy of the brain. *Science* 225: 1326–1334, 1984.
 777. HOKFELT T, PERNOW B, NILSSON G, WETTERBERG L, GOLDSTEIN M, AND JEFFCOATE SL. Dense plexus of substance P immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus. *Proc Natl Acad Sci USA* 75: 1013–1015, 1978.
 778. HOKFELT T, REHFELD JF, SKIRBOLL L, IVEMARK B, GOLDSTEIN M, AND MARKEY K. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. *Nature* 285: 476–478, 1980.
 779. HOKFELT T, SKIRBOLL L, EVERITT B, MEISTER B, BROWNSTEIN M, JACOBS T, FADEN A, KUGA S, GOLDSTEIN M, MARKSTEIN R, DOCKRAY G, AND REHFELD J. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. *Ann NY Acad Sci* 448: 255–274, 1985.
 780. HOKFELT T, SKIRBOLL L, REHFELD JF, GOLDSTEIN M, MARKEY K, AND DANN O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. *Neuroscience* 5: 2093–2124, 1980.
 781. HOKFELT T, TSURUO Y, MEISTER B, MELANDER T, SCHALLING M, AND EVERITT B. Localization of neuroactive substances in the hypothalamus with special reference to coexistence of messenger molecules. In: *Regulation of Ovarian and Testicular Function*, edited by Mahesh VB, Dhindsa DS, Anderson E, and Kalra SP. New York: Plenum, 1987, p. 21–46.
 782. HOLMES MC, ANTONI FA, AGUILERA G, AND CATT KJ. Magnocellular axons in passage through the median eminence release vasopressin. *Nature* 319: 326–329, 1986.
 783. HOLZBAUER M AND RACKE K. The dopaminergic innervation of the intermediate lobe and of the neural lobe of the pituitary gland. *Med Biol* 63: 97–116, 1985.
 784. HOLZBAUER M, SHARMAN DF, AND GODDEN U. Observations on the function of the dopaminergic nerves innervating the pituitary gland. *Neuroscience* 3: 1251–1262, 1978.
 785. HOLZBAUER M, SHARMAN DF, GODDEN U, MANN SP, AND STEPHENS DB. Effect of water and salt intake on pituitary catecholamines in the rat and domestic pig. *Neuroscience* 5: 1959–1968, 1980.
 786. HONMA K AND WUTTKE W. Norepinephrine and dopamine turnover rates in the medial preoptic area and the mediobasal hypothalamus of the rat brain after various endocrinological manipulations. *Endocrinology* 106: 1848–1853, 1980.
 787. HORI S, KOMATSU Y, SHIGEMOTO R, MIZUNO N, AND NAKANISHI S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. *Endocrinology* 130: 1885–1895, 1992.
 788. HORN AM, FRASER HM, AND FINK G. Effects of antiserum to thyrotrophin-releasing hormone on the concentrations of plasma prolactin, thyrotrophin and LH in the pro-oestrous rat. *J Endocrinol* 104: 205–209, 1985.
 789. HORN AM, ROBINSON ICAF, AND FINK G. Oxytocin and vasopressin in rat hypophysial portal blood: experimental studies in normal and Brattleboro rats. *J Endocrinol* 104: 211–224, 1985.
 790. HORSEMAN N, ZHAO W, MONTECINO-RODRIGUEZ E, TANAKA M, NAKASHIMA K, ENGLE SJ, SMITH F, MARKOFF E, AND DORSHKIND K. Defective mammapoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. *EMBO J* 16: 6926–6935, 1997.
 791. HORSEMAN ND AND YU-LEE LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. *Endocr Rev* 15: 627–649, 1994.
 792. HORVATH E, KOVACS K, AND EZRIN C. Functional contact between lactotrophs and gonadotrophs in rat pituitary. *ICRS Med Sci* 5: 511, 1977.
 793. HORVATH TL, KALRA SP, NAFTOLIN F, AND LERANTH C. Morphological evidence for a galanin-opiate interaction in the rat mediobasal hypothalamus. *J Neuroendocr* 7: 579–588, 1995.
 794. HORWITZ MJ, BLOCH KD, KIM NB, AND AMICO JA. Expression of the endothelin-1 and oxytocin genes in the hypothalamus of the pregnant rat. *Brain Res* 648: 59–64, 1994.
 795. HOSOKAWA H AND WYCHE JH. Prolactin control of growth and prolactin autoregulation in cultured human pituitary cells. *Horm Res* 21: 240–245, 1985.
 796. HOUBEN H, ANDRIES M, AND DENEFF C. Autoradiographic demonstration of ¹²⁵I-Tyr4-bombesin binding sites on rat anterior pituitary cells. *Peptides* 15: 1289–1295, 1994.
 797. HOUBEN H AND DENEFF C. Stimulation of growth hormone and prolactin release from rat pituitary cell aggregates by bombesin- and ranatensin-like peptides is potentiated by estradiol, 5 α -dihydrotestosterone, and dexamethasone. *Endocrinology* 126: 2257–2266, 1990.
 798. HOUBEN H AND DENEFF C. Effect of the bombesin receptor blockers [Leu13, psi CH₂NH-Leu14]bombesin and N-pivaloyl GRP(20–25) alkylamide (L 686,095–001C002) on basal and neuromedin C-

- stimulated PRL and GH release in pituitary cell aggregates. *Peptides* 12: 371–374, 1991.
799. HOUBEN H AND DENEFF C. Negative regulation by dexamethasone of the potentiation of neuromedin C-induced growth hormone and prolactin release by estradiol in anterior pituitary cell aggregates. *Life Sci* 50: 775–780, 1992.
 800. HOUBEN H AND DENEFF C. Bioactive peptides in anterior pituitary cells. *Peptides* 15: 547–582, 1994.
 801. HOUGHTON DC, YOUNG IR, AND McMILLEN IC. Photoperiodic history and hypothalamic control of prolactin secretion before birth. *Endocrinology* 138: 1506–1511, 1997.
 802. HOUSEKNECHT KL, BAILE CA, MATTERI RL, AND SPURLOCK ME. The biology of leptin: a review. *J Anim Sci* 76: 1405–1420, 1998.
 803. HOWARD G, PENG L, AND HYDE JF. An estrogen receptor binding site within the human galanin gene. *Endocrinology* 138: 4649–4656, 1997.
 805. HRABOVSKY E AND LIPOSITS Z. Adrenergic innervation of dopamine neurons in the hypothalamic arcuate nucleus of the rat. *Neurosci Lett* 182: 143–146, 1994.
 806. HRABOVSKY E AND LIPOSITS Z. Galanin-containing axons synapse on tyrosine hydroxylase-immunoreactive neurons in the hypothalamic arcuate nucleus of the rat. *Brain Res* 652: 49–55, 1994.
 807. HSIEH K-P AND MARTIN TFJ. Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins G_q and G_{11} . *Mol Endocrinol* 6: 1673–1681, 1992.
 808. HSU DW, HOOI SC, HEDLEY-WHITE ET, STRAUSS RM, AND KAPLAN LM. Coexpression of galanin and adrenocorticotropin hormone in human pituitary and pituitary adenomas. *Am J Physiol* 138: 897–909, 1991.
 809. HU Z AND DUFAU ML. Multiple and differential regulation of ovarian prolactin receptor messenger RNAs and their expression. *Biochem Biophys Res Commun* 181: 219–225, 1991.
 810. HU Z, ZHUANG L, AND DUFAU ML. Multiple and tissue-specific promoter control of gonadal and nongonadal prolactin receptor gene expression. *J Biol Chem* 271: 10242–10246, 1996.
 811. HU Z, ZHUANG L, GUAN X, MENG J, AND DUFAU ML. Steroidogenic factor-1 is an essential transcriptional activator for gonad-specific expression of promoter I of the rat prolactin receptor gene. *J Biol Chem* 272: 14263–14271, 1997.
 812. HU ZZ, ZHUANG L, MENG J, AND DUFAU ML. Transcriptional regulation of the generic promoter III of the rat prolactin receptor gene by C/EBP β and Sp1. *J Biol Chem* 273: 26225–26235, 1998.
 813. HUANG SK AND PAN JT. Stimulatory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide on tuberoinfundibular dopaminergic neuron activity in estrogen-treated ovariectomized rats and their correlation with prolactin secretion. *Neuroendocrinology* 64: 208–214, 1996.
 814. HUGGINS JP, PELTON JT, AND MILLER RC. The structure and specificity of endothelin receptors: their importance in physiology and medicine. *Pharmacol Ther* 59: 55–123, 1994.
 815. HUGHES J, SMITH TW, KOSTERLITZ HW, FOTHERGILL LA, MORGAN BA, AND MORRIS HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature* 258: 577–579, 1975.
 816. HUGHES JS. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. *Brain Res* 88: 295–308, 1975.
 817. HUHMAN KL, MOUGEY EH, MOORE TO, AND MEYERHOFF JL. Stressors, including social conflict, decrease plasma prolactin in male golden hamsters. *Horm Behav* 29: 581–592, 1995.
 818. HULTING AL, LAND T, BERTHOLD M, LANGE U, HOKFELT T, AND BARTFAI T. Galanin receptors from human pituitary tumors assayed with human galanin as ligand. *Brain Res* 625: 173–176, 1993.
 819. HULTING AL, MEISTER B, GRIMMELIUS L, WERSALL J, ANGARD A, AND HOKFELT T. Production of a galanin-like peptide by a human pituitary adenoma: immunohistochemical evidence. *Acta Physiol Scand* 137: 561–562, 1989.
 820. HULTING AL, MEISTER L, CARLSSON L, HILDING A, AND ISAKSON O. On the role of the peptide galanin in the regulation of growth hormone secretion. *Acta Endocrinol* 125: 518–525, 1991.
 821. HYDE JF AND BEN-JONATHAN N. Characterization of prolactin-releasing factor in the rat posterior pituitary. *Endocrinology* 122: 2533–2539, 1988.
 822. HYDE JF AND BEN-JONATHAN N. The posterior pituitary contains a potent prolactin-releasing factor: in vivo studies. *Endocrinology* 125: 736–741, 1989.
 823. HYDE JF, ENGLE MG, AND MALEY BE. Colocalization of galanin and prolactin within secretory granules of anterior pituitary cells in estrogen-treated Fischer 344 rats. *Endocrinology* 129: 270–276, 1991.
 824. HYDE JF AND KELLER BK. Galanin secretion from anterior pituitary cells in vitro is regulated by dopamine, somatostatin, and thyrotropin-releasing hormone. *Endocrinology* 128: 917–922, 1991.
 825. HYDE JF, MOORE JPJ, AND CAI A. Galanin in normal and hyperplastic anterior pituitary cells. From pituitary tumor cell lines to transgenic mice. *Ann NY Acad Sci* 863: 48–55, 1998.
 826. HYDE JF, MORRISON DG, MOORE JPJ, AND HOWARD G. MtTW-10 pituitary tumor cells: galanin gene expression and peptide secretion. *Endocrinology* 133: 2588–2593, 1993.
 827. HYDE JF, MURAI I, AND BEN-JONATHAN N. The rat posterior pituitary contains a potent prolactin-releasing factor: studies with perfused anterior pituitary cells. *Endocrinology* 121: 1531–1539, 1987.
 828. HYDE JF, MURAI I, AND BEN-JONATHAN N. Differential effects of pituitary stalk-section on posterior pituitary and hypothalamic contents of prolactin-releasing factor, oxytocin, dopamine and beta-endorphin. *Neuroendocrinology* 48: 314–319, 1988.
 829. HYDE JF, NORTH WG, AND BEN-JONATHAN N. The vasopressin-associated glycopeptide is not a prolactin-releasing factor: studies with lactating Brattleboro rats. *Endocrinology* 125: 35–40, 1989.
 830. HYMER WC AND MOTTER KA. Heterogeneity in mammothrophs prepared from diethylstilbestrol-induced prolactinomas. *Endocrinology* 122: 2324–2338, 1988.
 831. IBATA Y, FUKUI K, OKAMURA H, KAWAKAMI T, TANAKA M, OBATA HL, TSUTO T, TERUBAYASHI H, YANAIHARA C, AND YANAIHARA N. Coexistence of dopamine and neurotensin in hypothalamic arcuate and periventricular neurons. *Brain Res* 269: 177–179, 1983.
 832. ICHIKI T AND INAGAMI T. Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene. *Circ Res* 76: 693–700, 1995.
 833. IEIRI T, CHEN HT, CAMPBELL GA, AND MEITES J. Effects of naloxone and morphine on the proestrous surge of prolactin and gonadotropins in the rat. *Endocrinology* 106: 1568–1570, 1980.
 834. IHLE JN, WITTHUHN BA, QUELLE FW, YAMAMOTO K, THIERFELDER WE, KREIDER B, AND SILVENNOINEN O. Signalling by the cytokine receptor superfamily: Jaks and Stats. *Trends Biochem Sci* 19: 222–227, 1994.
 835. IJIMA N, KATAOKA Y, KAKIHARA K, BAMBA H, TAMADA Y, HAYASHI S, MATSUDA T, TANAKA M, HONJO H, HOSoya W, HINUMA S, AND IBATA Y. Cytochemical study of prolactin-releasing peptide (PrRP) in the rat brain. *Neuroreport* 10: 1713–1716, 1999.
 836. IKEGAMI H, JIKIHARA H, KOIKE K, MORISHIGE K, KURACHI H, YAMAMOTO N, HIROTA K, MIYAKE A, AND TANIZAWA O. Intraventricular administration of thyrotropin-releasing hormone (TRH) suppresses prolactin secretion and synthesis: a possible involvement of dopamine release by TRH from rat hypothalamus. *J Endocrinol* 133: 59–66, 1992.
 837. IMAGAWA W, YANG J, GUZMAN RC, AND NANDI S. Control of mammary gland growth and development. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 1033–1063.
 838. INAGAKI N, YAMATODANI A, YAMAMOTO M, TOHYAMA M, WATANABE T, AND WADA H. Organization of histaminergic fibers in the rat brain. *J Comp Neurol* 273: 283–300, 1988.
 839. INAGAMI T, NARUSE M, AND HOOVER R. Endothelium as an endocrine organ. *Annu Rev Physiol* 57: 171–189, 1995.
 840. INENAGA K AND MASON WT. Chloride channels activated by γ -aminobutyric acid in normal bovine lactotrophs. *Brain Res* 405: 159–164, 1987.
 841. INENAGA K AND MASON WT. Gamma-aminobutyric acid modulates chloride channel activity in cultured primary bovine lactotrophs. *Neuroscience* 23: 649–660, 1987.
 842. INGRAM CD, CIOBANU R, COCULESCU IL, TANASESCU R, COCULESCU M, AND MIHAI R. Vasopressin neurotransmission and the control of

- circadian rhythms in the suprachiasmatic nucleus. *Prog Brain Res* 119: 351–364, 1998.
843. INOUE A, YANAGISAWA M, KIMURA S, KASUYA Y, MIYAUCHI T, GOTO K, AND MASAKI T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci USA* 86: 2863–2867, 1989.
 844. INOUE T, KATO Y, KOSHIYAMA H, YANAIHARA N, AND IMURA H. Galanin stimulates the release of vasoactive intestinal polypeptide from perfused hypothalamic fragments in vitro and from periventricular structures into the cerebrospinal fluid in vivo in the rat. *Neurosci Lett* 85: 95–100, 1988.
 845. INOUE ST. Horizontal knife cuts either ventral or dorsal to the hypothalamic paraventricular nucleus block testicular regression in golden hamsters maintained in short days. *Brain Res* 370: 102–107, 1986.
 846. ISRAEL JM, DUFY B, GOURDJ D, AND VINCENT JD. Effects of GABA on electrical properties of cultured rat pituitary tumor cells: an intracellular recording study. *Life Sci* 29: 351–359, 1981.
 847. ISRAEL JM, KIRK C, AND VINCENT JD. Electrophysiological responses to dopamine of rat hypophysial cells in lactotroph-enriched primary cultures. *J Physiol (Lond)* 390: 1–22, 1987.
 848. ITOH N, OBATA K, YANAIHARA N, AND OKAMOTO N. Human prepro-vasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. *Nature* 304: 547–549, 1983.
 849. ITOH S, KATSUURA G, AND TAKASHIMA A. Effects of vasoactive intestinal peptide on dopaminergic system in the rat brain. *Peptides* 9: 315–317, 1988.
 850. IWAI N AND INAGAMI. Identification of two subtypes in the rat type I angiotensin II receptor. *FEBS Lett* 298: 257–260, 1992.
 851. IWATSUKI K, SHINOZAKI M, HATTORI N, HIRASAWA K, ITAGAKI SI, SHIOTA K, AND OGAWA T. Molecular cloning and characterization of a new member of the rat placental prolactin (PRL) family, PRL-like protein D (PLP-D). *Endocrinology* 137: 3849–3855, 1996.
 852. JABBOUR HN, CRITCHLEY HO, AND BODDY SC. Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin. *J Clin Endocrinol Metab* 83: 2545–2553, 1998.
 853. JACOBS JW, GOODMAN RH, CHIN WW, DEE PC, HABENER JF, BELL NH, AND POTTS JT JR. Calcitonin messenger RNA encodes multiple polypeptides in a single precursor. *Science* 213: 457–459, 1981.
 854. JAHN GA, DANIEL N, JOLIVET G, BELAIR L, BOLE-FEYSOT C, KELLY PA, AND DUJANE J. In vivo study of prolactin (PRL) intracellular signaling during lactogenesis in the rat: JAK/STAT pathway is activated by PRL in the mammary gland but not in the liver. *Biol Reprod* 57: 894–900, 1997.
 855. JAHN GA AND DIES RP. Stress-induced prolactin release in female, male and androgenized rats: influence of progesterone treatment. *J Endocrinol* 110: 423–428, 1986.
 856. JANG YC, KAO LS, AND WANG FF. Involvement of Ca^{2+} signalling in the vasoactive intestinal peptide and 8-Br-cAMP induction of *c-fos* mRNA expression. *Cell Signal* 10: 27–34, 1998.
 857. JARD S, BARBERIS C, AUDIGIER S, AND TRIBOLLET E. Neurohypophyseal hormone receptor systems in the brain and in the periphery. *Prog Brain Res* 72: 173–187, 1987.
 858. JARRY H, LEONHARDT S, SCHMIDT WE, CREUTZFELDT W, AND WUTTKE W. Contrasting effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vivo and in vitro prolactin and growth hormone release in male rats. *Life Sci* 51: 823–830, 1992.
 859. JARRY H, SPRENGER M, AND WUTTKE W. Rates of release of GABA and catecholamines in the mediobasal hypothalamus of ovariectomized and ovariectomized estrogen-treated rats: correlation with blood prolactin levels. *Neuroendocrinology* 44: 422–428, 1986.
 860. JAYATILAK PG AND GIBORI G. Ontogeny of prolactin receptors in rat decidual tissue: binding by a locally produced prolactin-like hormone. *J Endocrinol* 110: 115–121, 1986.
 861. JESSOP DS, CHOWDREY HS, LARSEN PJ, AND LIGHTMAN SL. Substance P: multifunctional peptide in the hypothalamo-pituitary system? *J Endocrinol* 132: 331–337, 1992.
 862. JIA L-G, CANNY BJ, ORTH DN, AND LEONG DA. Distinct classes of corticotropes mediate corticotropin-releasing hormone- and arginine vasopressin-stimulated adrenocorticotropin release. *Endocrinology* 128: 197–203, 1991.
 863. JIMENEZ-ANGUANO A, BAEZ-SALDANA A, AND DRUCKER-COLIN R. Cerebrospinal fluid (CSF) extracted immediately after REM sleep deprivation prevents REM rebound and contains vasoactive intestinal peptide (VIP). *Brain Res* 631: 345–348, 1993.
 864. JOHNSON JW, TYSON JE, MITZNER W, BECK JC, ANDREASSEN B, LONDON WT, AND VILLAR J. Amniotic fluid prolactin and fetal lung maturation. *Am J Obstet Gynecol* 153: 372–380, 1985.
 865. JOHNSTON CA, DEMAREST KT, AND MOORE KE. 5-Hydroxytryptamine synthesis and metabolism in discrete nuclei of the rat brain during surges of prolactin associated with restraint stress or suckling. *Neuroendocrinology* 38: 117–122, 1984.
 866. JOHNSTON CA AND NEGRO-VILAR A. Maturation of the prolactin and proopiomelanocortin-derived peptide responses to ether stress and morphine: neurochemical analysis. *Endocrinology* 118: 797–805, 1986.
 867. JOHNSTON CA AND NEGRO-VILAR A. Role of oxytocin on prolactin secretion during proestrus and in different physiological or pharmacological paradigms. *Endocrinology* 122: 341–350, 1988.
 868. JOHNSTON CA, SPINEDI EJ, AND NEGRO-VILAR A. Effect of acute ether stress on monoamine metabolism in median eminence and discrete hypothalamic nuclei of the rat brain and on anterior pituitary hormone secretion. *Neuroendocrinology* 41: 83–88, 1985.
 869. JOHREN O, INAGAMI T, AND SAAVEDRA JM. AT_{1A} , AT_{1B} , and AT_2 angiotensin II receptor subtype gene expression in rat brain. *Neuroreport* 6: 2549–2552, 1995.
 870. JOHREN O, INAGAMI T, AND SAAVEDRA JM. Localization of AT_2 angiotensin II receptor gene expression in rat brain by in situ hybridization histochemistry. *Mol Brain Res* 37: 192–200, 1996.
 871. JOHREN O AND SAAVEDRA JM. Expression of AT_{1A} and AT_{1B} angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats. *Am J Physiol Endocrinol Metab* 271: E104–E112, 1996.
 - 871a. JOHREN O, SANVITTO GL, EGIDY G, AND SAAVEDRA JM. Angiotensin II AT_{1A} receptor mRNA expression is induced by estrogen-progesterone in dopaminergic neurons of the female rat arcuate nucleus. *J Neurosci* 17: 8283–8292, 1997.
 872. JONASSEN JA, MULLIKIN-KILPATRICK D, MCADAM A, AND LEEMAN SE. Thyroid hormone status regulates preprotachykinin-A gene expression in male rat anterior pituitary. *Endocrinology* 121: 1555–1561, 1987.
 873. JONES EE AND NAFTOLIN F. Estrogen effects on the tuberoinfundibular dopaminergic system in the female rat brain. *Brain Res* 510: 84–91, 1990.
 874. JONES MA AND RENEGAR RH. Temporal and regional expression of placental lactogen-II messenger ribonucleic acid and protein in the hamster placenta. *Biol Reprod* 50: 581–592, 1994.
 875. JORGENSEN H, KNIGGE U, KIAER A, AND WARBERG J. Interactions of histaminergic and serotonergic neurons in the hypothalamic regulation of prolactin and ACTH secretion. *Neuroendocrinology* 64: 329–336, 1996.
 876. JORGENSEN H, KNIGGE U, AND WARBERG J. Effect of serotonin 5-HT₁, 5-HT₂, and 5-HT₃ receptor antagonists on the prolactin response to restraint and ether stress. *Neuroendocrinology* 56: 371–377, 1992.
 877. JOSEFSBERG Z, POSNER BI, PATEL B, AND BERGERON JJM. The uptake of prolactin in the female rat liver: concentration of intact hormone in the Golgi apparatus. *J Biol Chem* 254: 209–214, 1979.
 879. JUANEDA C, DUBOURG P, CIOFI P, CORIO M, AND TRAMU G. Ultrastructural colocalization of vesicular cholecystokinin and corticoliberin in the periportal nerve terminals of the rat median eminence. *J Neuroendocrinol* 11: 203–209, 1999.
 880. JUDD AM, KUBOTA T, KUAN SI, JARVIS WD, SPANGELO BL, AND MACLEOD RM. Calcitonin decreases thyrotropin-releasing hormone-stimulated prolactin release through a mechanism that involves inhibition of inositol phosphate production. *Endocrinology* 127: 191–199, 1990.
 881. JUDD AM, LOGIN IS, KOVACS K, ROSS PC, SPANGELO BL, JARVIS WD, AND MACLEOD RM. Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. *Endocrinology* 123: 2341–2350, 1988.
 882. JURCOVICOVÁ J, DAY RN, AND MACLEOD RM. Expression of prolactin

- in rat lymphocytes. *Prog Neuroendocrinimmunol* 5: 256–263, 1993.
883. JURCOVICOVA J, KVETANSKY R, DOBRAKOVOVA M, JEZOVA D, KISS A, AND MAKARA GB. Prolactin response to immobilization stress and hemorrhage: the effect of hypothalamic deafferentations and posterior pituitary denervation. *Endocrinology* 126: 2527–2533, 1990.
 884. JURCOVICOVA J, LE T, AND KRULICH L. The paradox of α_2 adrenergic regulation of prolactin (PRL) secretion. I. The PRL-releasing action of the α_2 receptor agonists. *Brain Res Bull* 23: 417–424, 1989.
 885. JURCOVICOVA J, LE T, AND KRULICH L. The paradox of α_2 adrenergic regulation of prolactin (PRL) secretion. II. PRL-releasing action of the α_2 receptor antagonists. *Brain Res Bull* 23: 425–432, 1989.
 886. KABAYAMA Y, KATO Y, SHIMATSU A, YANAIHARA N, AND IMURA H. Stimulation by gastrin-releasing peptide, neurotensin and DN1417, a novel TRH analog, of dopamine and norepinephrine release from perfused rat hypothalamic fragments in vitro. *Brain Res* 372: 394–399, 1986.
 887. KACSOH B AND NAGY GY. Circadian rhythms in plasma prolactin, luteinizing hormone and hypophyseal prolactin levels in lactating rats. *Endocrinol Exp* 17: 301–310, 1983.
 888. KACSOH B, TÓTH BE, AVERY LM, YAMAMURO Y, AND GROSVENOR CE. Molecular heterogeneity of prolactin in lactating rats and their pups: biological and immunological activities in pituitary gland, serum and milk. *Endocr Regul* 25: 98–110, 1991.
 889. KACSOH B, VERESS Z, TÓTH BE, AVERY LM, AND GROSVENOR CE. Bioactive and immunoreactive variants of prolactin in milk and serum of lactating rats and their pups. *J Endocrinol* 138: 242–257, 1993.
 890. KADOWAKI J, KU N, OETTING WS, AND WALKER AM. Mammothroph autoregulation: uptake of secreted prolactin and inhibition of secretion. *Endocrinology* 114: 2060–2067, 1984.
 891. KAJI H, CHIHARA K, ABE H, KITA T, KASHIO Y, OKIMURA Y, AND FUJITA T. Effect of passive immunization with antisera to vasoactive intestinal polypeptide and peptide histidine isoleucine amide on 5-hydroxy-L-tryptophan-induced prolactin release in rats. *Endocrinology* 117: 1914–1920, 1985.
 892. KAJI H, CHIHARA K, ABE H, MINAMITANI N, KODAMA H, KITA T, FUJITA T, AND TATEMOTO K. Stimulatory effect of peptide histidine isoleucine amide 1–27 on prolactin release in the rat. *Life Sci* 35: 641–648, 1984.
 893. KAJI H, CHIHARA K, KITA T, KASHIO Y, OKIMURA Y, AND FUJITA T. Administration of antisera to vasoactive intestinal polypeptide and peptide histidine isoleucine attenuates ether-induced prolactin secretion in rats. *Neuroendocrinology* 41: 529–531, 1985.
 894. KAKAR SS, SELLERS JC, DEVOR DC, MUSGROVE LC, AND NEILL JD. Angiotensin type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. *Biochem Biophys Res Commun* 183: 1090–1096, 1992.
 895. KAKUSKA I, TAPPAZ ML, GAAL G, STOECKEL ME, AND MAKARA GB. GABAergic innervation of somatostatin-containing neurosecretory cells of the anterior periventricular hypothalamic area: a light and electron microscopy double immunolabelling study. *Neuroscience* 25: 585–593, 1988.
 896. KALRA PS, SIMPKINS JW, LUTTGE WG, AND KALRA SP. Effects on male sex behavior and preoptic dopamine neurons of hyperprolactinemia induced by MtTw15 pituitary tumors. *Endocrinology* 113: 2065–2071, 1983.
 897. KALRA SP AND CROWLEY WR. Neuropeptide Y: a novel neuroendocrine peptide in the control of pituitary hormone secretion, and its relation to luteinizing hormone. In: *Frontiers in Neuroendocrinology*, edited by Ganong WF and Martini L. New York: Raven, 1992, p. 1–46.
 898. KANEDA H, TANIMOTO K, SHINTANI T, KAKIGI T, AND MAEDA K. The effect of intracerebroventricular administration of somatostatin on prolactin and TSH release in rats. *Jpn J Psychiatry Neurol* 45: 903–907, 1991.
 899. KANEMATSU S AND SAWYER CH. Elevation of plasma prolactin after hypophysial stalk section in the rat. *Endocrinology* 93: 238–241, 1973.
 900. KANGAWA K AND MATSUI H. Purification and complete amino acid sequence of α -human atrial natriuretic polypeptide. *Biochem Biophys Res Commun* 118: 131–139, 1984.
 901. KANUKA H, MATSUYAMA S, OHNISHI M, MATSUMOTO Y, NISHIHARA M, AND TAKAHASHI M. Prolactin expresses differential effects on apoptotic cell death of luteal cells in vivo and in vitro. *Endocr J* 44: 11–22, 1997.
 902. KANYICSKA B, BURRIS TP, AND FREEMAN ME. Endothelin-3 inhibits prolactin and stimulates LH, FSH and TSH secretion from pituitary cell culture. *Biochem Biophys Res Commun* 174: 338–343, 1991.
 903. KANYICSKA B, BURRIS TP, AND FREEMAN ME. The effects of endothelins on the secretion of prolactin, luteinizing hormone, and follicle-stimulating hormone are mediated by different guanine nucleotide-binding proteins. *Endocrinology* 129: 2607–2613, 1991.
 904. KANYICSKA B AND FREEMAN ME. Characterization of endothelin receptors in the anterior pituitary gland. *Am J Physiol Endocrinol Metab* 265: E601–E608, 1993.
 905. KANYICSKA B, LERANT A, AND FREEMAN ME. Endothelin is an autocrine regulator of prolactin secretion. *Endocrinology* 139: 5164–5173, 1998.
 906. KANYICSKA B, LIVINGSTONE JD, AND FREEMAN ME. Long term exposure to dopamine reverses the inhibitory effect of endothelin-1 on prolactin secretion. *Endocrinology* 136: 990–994, 1995.
 907. KANYICSKA B, NGUYEN DN, AREY BJ, AND FREEMAN ME. Hysterectomy-induced alterations in prolactin secretion of lactating rats. *Endocrinology* 126: 2021–2026, 1990.
 908. KANYICSKA B, STARK E, HORVATH G, SIMONYI A, AND FEKETE MI. Long-term ACTH induced diminished responsiveness of prolactin secretion to morphine. *Life Sci* 33: 55–63, 1983.
 909. KAPLAN LM, GABRIEL SM, KOENIG JI, SUNDAY ME, SPINDEL ER, MARTIN JB, AND CHIN WW. Galanin is an estrogen-inducible, secretory product of the rat anterior pituitary. *Proc Natl Acad Sci USA* 85: 7408–7412, 1988.
 910. KAPLAN LM, HOOI SC, ABRACZINSKAS DR, STRAUSS RM, DAVIDSON MB, HSU DW, AND KOENIG J. Neuroendocrine regulation of galanin gene expression. In: *Galanin: A Multifunctional Peptide in the Neuroendocrine System*, edited by Hokfelt T. New York: Macmillan, 1991, p. 43–65.
 911. KAPOOR R, CHAPMAN IM, AND WILLOUGHBY JO. α_2 and β adrenoceptors in the mediobasal hypothalamus and α_2 adrenoceptors in the preoptic-anterior hypothalamus stimulate prolactin secretion in the conscious male rat. *J Neuroendocrinol* 5: 189–193, 1993.
 912. KARASHIMA T, OKAJIMA T, KATO K, AND IBAYASHI H. Suppressive effects of cholecystokinin and bombesin on growth hormone and prolactin secretion in urethane-anesthetized rats. *Endocrinol Jpn* 31: 539–547, 1984.
 913. KARASHIMA T AND SCHALLY AV. Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol. *Proc Soc Exp Biol Med* 185: 69–75, 1987.
 914. KASK K, BERTHOLD M, AND BARTFAI T. Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. *Life Sci* 60: 1523–1533, 1997.
 915. KASK K, LANGE U, AND BARTFAI T. Galanin: a neuropeptide with inhibitory actions. *Cell Mol Neurobiol* 15: 653–673, 1995.
 916. KATO Y, CHIHARA K, OHGO S, IWASAKI Y, ABE H, AND IMURA H. Growth hormone and prolactin release by substance P. *Life Sci* 19: 441, 1976.
 917. KATO Y, IWASAKI Y, IWASAKI J, ABE H, YANAIHARA N, AND IMURA H. Prolactin release by vasoactive intestinal polypeptide in rats. *Endocrinology* 103: 554–558, 1978.
 918. KATO Y, MATSUSHITA N, KATAKAMI H, SHIMATSU A, AND IMURA H. Stimulation by dynorphin of prolactin and growth hormone secretion in the rat. *Eur J Pharmacol* 73: 353, 1981.
 919. KATO Y, NAKAI Y, IMURA H, CHIHARA K, AND OGO S. Effect of 5-hydroxytryptophan (5-HTP) on plasma prolactin levels in man. *J Clin Endocrinol Metab* 38: 695–697, 1974.
 920. KAWAKAMI M AND ARITA J. Midbrain pathways for the initiation and maintenance of the nocturnal prolactin surge in pseudopregnant rats. *Endocrinology* 110: 1977–1982, 1982.
 921. KAWAKAMI M, ARITA J, AND YOSHIOKA E. Loss of estrogen-induced daily surges of prolactin and gonadotropins by suprachiasmatic nucleus lesions in ovariectomized rats. *Endocrinology* 106: 1087–1092, 1980.
 922. KAWANO H AND DAIKOKU S. Functional topography of the rat hypothalamic dopamine neuron systems: retrograde tracing and immunohistochemical study. *J Comp Neurol* 265: 242–253, 1987.

923. KEHOE L, JANIK J, AND CALLAHAN P. Effects of immobilization stress on tuberoinfundibular dopaminergic (TIDA) neuronal activity and prolactin levels in lactating and non-lactating female rats. *Life Sci* 50: 55–63, 1991.
924. KEITH LD, TAM B, IKADA H, OPSAHL Z, AND GREER MA. Dynamics of thyrotropin-releasing hormone-induced thyrotropin and prolactin secretion by acutely dispersed rat adenohypophyseal. *Neuroendocrinology* 43: 445–452, 1986.
925. KELLY MA, RUBINSTEIN M, ASA SL, ZHANG G, SAEZ C, BUNZOW JR, ALLEN RG, HNASKO R, BEN-JONATHAN N, GRANDY DK, AND LOW MJ. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. *Neuron* 19: 103–113, 1997.
926. KELLY PA, DJIANE J, POSTEL-VINAY M-C, AND EDERY M. The prolactin/growth hormone receptor family. *Endocr Rev* 12: 235–251, 1991.
927. KENNAWAY DJ, DUNSTAN EA, GILMORE TA, AND SEAMARK RF. Effects of shortened daylength and melatonin treatment on plasma prolactin and melatonin levels in pinealectomized and sham-operated ewes. *Anim Reprod Sci* 5: 287–294, 1982.
928. KENTROTI S, DEES WL, AND MCCANN SM. Evidence for a physiological role of hypothalamic gastrin-releasing peptide to suppress growth hormone and prolactin release in the rat. *Proc Natl Acad Sci USA* 85: 953–957, 1988.
929. KENTROTI S AND MCCANN SM. Role of dopamine in the inhibitory control of growth hormone and prolactin release by gastrin-releasing peptide. *Brain Res Bull* 39: 201–204, 1996.
930. KERDELHUE B, TARTAR A, LENOIR V, EL ABDED A, HUBLAU P, AND MILLAR R. Binding studies of substance P anterior pituitary binding sites: changes in substance P binding-sites during the rat estrous cycle. *Regul Pept* 10: 133–143, 1985.
931. KHACHATURIAN H, LEWIS ME, SCHAFER MK, AND WATSON SJ. Anatomy of the CNS opioid systems. *Trends Neurosci* 8: 111–119, 1985.
932. KHAWAJA AM AND ROGERS DF. Tachykinins: receptor to effector. *Int J Biochem Cell Biol* 28: 721–738, 1996.
933. KHORRAM O, BEDRAN DECASTRO JC, AND MCCANN SM. Influence of suckling on the hypothalamic and pituitary secretion of immunoreactive α -melanocyte stimulating hormone. *Brain Res* 398: 361–361, 1986.
934. KIEFFER BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. *Cell Mol Neurobiol* 15: 615–635, 1995.
935. KIEFFER BL, BEFORT K, GAVERIAUX-RUFF C, AND HIRTH CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. *Proc Natl Acad Sci USA* 89: 12048–12052, 1992.
936. KIEM DT, FEKETE MI, BARTHA L, NAGY G, AND MAKARA GB. Prolactin response to morphine in intact and adrenalectomized lactating rats. *Brain Res* 563: 171–174, 1991.
937. KIEM DT, KANYICSKA B, STARK E, AND FEKETE MI. Prolactin release induced by opiate agonists, effect of glucocorticoid pretreatment in intact and adrenalectomized rats. *Neuroendocrinology* 48: 174–179, 1988.
938. KIM BG AND BROOKS CL. Isolation and characterization of phosphorylated bovine prolactin. *Biochem J* 296: 41–47, 1993.
939. KIMURA F AND KAWAKAMI M. Reanalysis of the preoptic afferents involved in the surge of LH, FSH and prolactin release in the proestrous rat. *Neuroendocrinology* 27: 74–85, 1978.
940. KIMURA F, MITSUGI N, ARITA J, AKEMA T, AND YOSHIDA K. Effects of preoptic injections of gastrin, cholecystokinin secretion, vasoactive intestinal peptide and PHI on the secretion of luteinizing hormone and prolactin on ovariectomized estrogen-primed rats. *Brain Res* 410: 315–322, 1987.
941. KIMURA N AND HAYAFUJI C. Characterization of 17-beta-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary. *J Biol Chem* 264: 7033–7040, 1989.
942. KIMURA N, HAYAFUJI C, KONAGAYA H, AND TAKAHASHI K. 17 β -Estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. *Endocrinology* 119: 1028–1036, 1986.
943. KINEMAN RD, GETTYS TW, AND FRAWLEY LS. Role of guanine nucleotide-binding proteins, G₁₀₃ and G_{sa}, in dopamine and thyrotropin-releasing hormone signal transduction: evidence for competition and commonality. *J Endocrinol* 148: 447–455, 1996.
944. KINSLEY CH, MANN PE, AND BRIDGES RS. Alterations in stress-induced prolactin release in adult female and male rats exposed to stress, in utero. *Physiol Behav* 45: 1073–1076, 1989.
945. KIRKEN RA, MALABARBA MG, XU J, LIU X, FARRAR WL, HENNIGHAUSEN L, LARNER AC, GRIMLEY PM, AND RUI H. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. *J Biol Chem* 272: 14098–14103, 1997.
946. KISS A, PALKOVITS M, ANTONI FA, ESKAY RL, AND SKIRBOLL LR. Neurotensin in the rat median eminence: the possible sources of neurotensin-like fibers and varicosities in the external layer. *Brain Res* 416: 129–135, 1987.
947. KISS JZ. Anatomical studies of cholecystokinin in neurons and pathways involved in neuroendocrine regulation. *Ann NY Acad Sci* 448: 144–151, 1985.
948. KISS JZ, KANYICSKA B, AND NAGY GM. The hypothalamic paraventricular nucleus has a pivotal role in regulation of prolactin release in lactating rats. *Endocrinology* 119: 870–873, 1986.
949. KISS JZ, WILLIAMS TH, AND PALKOVITS M. Distribution and projections of cholecystokinin-immunoreactive neurons in the hypothalamic paraventricular nucleus of rat. *J Comp Neurol* 227: 173–181, 1984.
950. KITAMURA K, MINAMINO N, HAYASHI Y, KANAGAWA K, AND MATSUO H. Regional distribution of a-neoendorphin in rat brain and pituitary. *Biochem Biophys Res Commun* 109: 966, 1990.
951. KIZER JS, ZIVIN JA, JACOBOWITZ DM, AND KOPIN IJ. The nyctohemeral rhythm of plasma prolactin: effects of ganglionectomy, pinealectomy, constant light, constant darkness or 6-OH-dopamine administration. *Endocrinology* 96: 1230–1240, 1975.
952. KJAER A. Vasopressin as a neuroendocrine regulator of anterior pituitary hormone secretion. *Acta Endocrinol* 129: 489–496, 1993.
953. KJAER A, KNIGGE U, OLSEN L, VILHARDT H, AND WARBERG J. Mediation of the stress-induced prolactin release by hypothalamic histaminergic neurons and the possible involvement of vasopressin in this response. *Endocrinology* 128: 103–110, 1991.
954. KJAER A, KNIGGE U, VILHARDT H, AND WARBERG J. Involvement of vasopressin in histamine- and stress-induced prolactin release: permissive, mediating or potentiating role? *Neuroendocrinology* 57: 314–321, 1993.
955. KJAER A, KNIGGE U, AND WARBERG J. Histamine- and stress-induced prolactin secretion: importance of vasopressin V1- and V2-receptors. *Eur J Endocrinol* 131: 391–397, 1994.
956. KJAER A, KNIGGE U, AND WARBERG J. Involvement of oxytocin in histamine- and stress-induced ACTH and prolactin secretion. *Neuroendocrinology* 61: 704–713, 1995.
957. KNEPEL W, GOTZ D, AND FAHRENHOLTZ F. Interaction of rat adenohypophyseal vasopressin analogues substituted at positions 7 and 1: dissimilarity from the V1 vasopressin receptor. *Neuroendocrinology* 44: 390–396, 1986.
958. KNIGGE U, BACH FW, MATZEN S, BANG P, AND WARBERG J. Effect of histamine on the secretion of pro-opiomelanocortin-derived peptides in rats. *Acta Endocrinol* 119: 312–319, 1988.
959. KNIGGE U, HOLST JJ, KNUHTSEN S, BACH FW, AND BANG P. Corticotropin-releasing activity of gastrin-releasing peptide in normal men. *J Clin Endocrinol Metab* 65: 1291–1295, 1987.
960. KNIGGE U, MATZEN S, AND WARBERG J. Histaminergic mediation of the stress-induced release of prolactin in male rats. *Neuroendocrinology* 47: 68–74, 1988.
961. KNIGGE U, SOE-JENSEN P, JORGENSEN H, KJAER A, MOLLER M, AND WARBERG J. Stress-induced release of anterior pituitary hormones: effect of H₃ receptor-mediated inhibition of histaminergic activity or posterior hypothalamic lesion. *Neuroendocrinology* 69: 44–53, 1999.
962. KNIGGE U AND WARBERG J. The role of histamine in the neuroendocrine regulation of pituitary hormone secretion. *Acta Endocrinol* 124: 609–619, 1991.
963. KOCH Y, GOLDBABER G, FIREMAN I, ZOR U, AND SHANI J. Suppression of prolactin and thyrotropin secretion in the rat by antiserum to thyrotropin-releasing hormone. *Endocrinology* 100: 1476–1478, 1977.
964. KOENIG JI, MAYFIELD MA, MCCANN SM, AND KRULICH L. On the prolactin-inhibiting effect of neurotensin. The role of dopamine. *Neuroendocrinology* 35: 277–281, 1982.

965. KOENIG JI, MAYFIELD MA, MCCANN SM, AND KRULICH L. Differential role of the opioid mu and delta receptors in the activation of prolactin (PRL) and growth hormone (GH) secretion by morphine in the male rat. *Life Sci* 34: 1829–1837, 1984.
966. KOENIG JI, MELTZER HY, DEVANE GD, AND GUDELSKY GA. The concentration of arginine vasopressin in pituitary stalk plasma of the rat after adrenalectomy or morphine. *Endocrinology* 118: 2534, 1986.
967. KOHAMA SG, FREESH F, AND BETHEA CL. Immunocytochemical colocalization of hypothalamic progesterin receptors and tyrosine hydroxylase in steroid-treated monkeys. *Endocrinology* 131: 509–517, 1992.
968. KOHMOTO K, TSUNASAWA S, AND SAKIYAMA F. Complete amino acid sequence of mouse prolactin. *Eur J Biochem* 138: 227–237, 1984.
969. KOHSAKA A, WATANOBÉ H, KAKIZAKI Y, HABU S, AND SUDA T. A significant role of leptin in the generation of steroid-induced luteinizing hormone and prolactin surges in female rats. *Biochem Biophys Res Commun* 254: 578–581, 1999.
970. KOLBINGER W, BEYER C, FOHR K, REISERT I, AND PILGRIM C. Diencephalic GABAergic neurons in vitro respond to prolactin with a rapid increase in intracellular free calcium. *Neuroendocrinology* 56: 148–152, 1992.
971. KOLESNICK RN AND GERSHENGORN MC. Thyrotropin-releasing hormone stimulation of prolactin secretion is coordinately but not synergistically regulated by an elevation of cytoplasmic calcium and 1,2-diacylglycerol. *Endocrinology* 119: 2461–2466, 1986.
972. KORDON C, BLAKE CA, TERKEL J, AND SAWYER CH. Participation of serotonin-containing neurons in the suckling-induced rise in plasma prolactin levels in lactating rats. *Neuroendocrinology* 13: 213–223, 1973.
973. KOSHIYAMA H, KATO Y, INOUE T, MURAKAMI Y, ISHIKAWA Y, YANAIHARA N, AND IMURA H. Central galanin stimulates pituitary prolactin secretion in rats: possible involvement of hypothalamic vasoactive intestinal polypeptide. *Neurosci Lett* 75: 49–54, 1987.
974. KOSHIYAMA H, KATO Y, ISHIKAWA Y, MURAKAMI Y, INOUE T, AND IMURA H. Stimulation of prolactin secretion by L-3,4-dihydroxyphenylserine (L-DOPS) via central norepinephrine in the rat. *Life Sci* 41: 983–988, 1987.
975. KOSHIYAMA H, SHIMATSU A, ASSADIAN H, HATTORI N, ISHIKAWA Y, TANO H, YANAIHARA N, KATO Y, AND IMURA H. Galanin interacts with serotonin in stimulating prolactin secretion in the rat. *J Neuroendocrinol* 2: 217–220, 1990.
976. KOSHIYAMA H, SHIMATSU A, KATO Y, ASSADIAN H, HATTORI N, ISHIKAWA Y, TANO H, YANAIHARA N, AND IMURA H. Galanin-induced prolactin release in rats: pharmacological evidence for the involvement of α -adrenergic and opioidergic mechanisms. *Brain Res* 507: 321–324, 1990.
977. KOVES K, ARIMURA A, GORCS TG, AND SOMOGYVARI-VIGH A. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. *Neuroendocrinology* 54: 159–169, 1991.
978. KOVES K, GOTTSCHALL PE, GORCS T, SCAMMELL JG, AND ARIMURA A. Presence of immunoreactive vasoactive intestinal polypeptide in anterior pituitary of normal male and long term estrogen-treated female rats: a light microscopic immunohistochemical study. *Endocrinology* 126: 1756–1763, 1990.
979. KRAMER IM AND HOPKINS CR. Studies on the kinetics of dopamine-regulated prolactin secretion. *Mol Cell Endocrinol* 28: 191–198, 1982.
980. KROWN KA, WANG Y-F, HO TWC, KELLY PA, AND WALKER AM. Prolactin isoform 2 as an autocrine growth factor for GH₃ cells. *Endocrinology* 131: 595–602, 1992.
981. KRUEGER JM, FANG J, HANSEN MK, ZHANG J, AND OBAL F JR. Humoral regulation of sleep. *News Physiol Sci* 13: 189–194, 1998.
982. KRULICH L, DHARIWAL AP, AND MCCANN SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. *Endocrinology* 83: 783–790, 1968.
983. KRULICH L, JURCOVICOVA J, AND LE T. Prolactin (PRL) release-inhibiting properties of the alpha 2 adrenergic receptor antagonist idazoxan: comparison with yohimbine. *Life Sci* 44: 809–818, 1989.
984. KRULICH L, KOENIG JI, CONWAY S, MCCANN SM, AND MAYFIELD MA. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine. *Neuroendocrinology* 42: 75–81, 1986.
985. KRULICH L, KOENIG JI, CONWAY S, MCCANN SM, AND MAYFIELD MA. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488. *Neuroendocrinology* 42: 82–87, 1986.
986. KRULICH L, MCCANN SM, AND MAYFIELD MA. On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide, and cyproheptadine. *Endocrinology* 108: 1115–1124, 1981.
987. KUBOTA T AND ASO T. Role of angiotensin on paracrine prolactin release in the pituitary gland and its possible effects on ovarian function. *Horm Res* 35 Suppl 1: 13–20, 1991.
988. KUDLOW JE AND KOBRIN MS. Secretion of epidermal growth factor-like mitogens by cultured cells from bovine anterior pituitary glands. *Endocrinology* 115: 911–917, 1984.
989. KURANAGA E, KANUKA H, BANNAI M, SUZUKI M, NISHIHARA M, AND TAKAHASHI M. Fas/Fas ligand system in prolactin-induced apoptosis in rat corpus luteum: possible role of luteal immune cells. *Biochem Biophys Res Commun* 260: 167–173, 1999.
990. KUROKAWA K, YAMADA H, AND OCHI J. Topographical distribution of neurons containing endothelin type A receptor in the rat brain. *J Comp Neurol* 389: 348–360, 1997.
991. KURONO C. Intercellular communication within the rat pituitary gland. VI. Development of gap junctions between folliculostellate cells under the influence of ovariectomy and sex steroids in the female rats. *Anat Rec* 224: 366–373, 1998.
992. KURTZ A, BRISTOL LA, TÓTH BE, LAZAR-WESLEY E, TAKÁCS L, AND KACSÓH B. Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. *Biol Reprod* 48: 1095–1103, 1993.
993. KVVITNITSKAYA-RYZHOVA T, SHINKAI T, OOKA H, AND OHTSUBO K. Immunocytochemical demonstration of prolactin interaction with choroid plexus in aging and acute hyperprolactinemia. *Mech Ageing Dev* 76: 65–72, 1994.
994. LABRIE F, DROUIN J, FERLAND L, LAGACE L, BEAULIEU M, DE LEAN A, KELLY PA, CARON MG, AND RAYMOND V. Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. *Recent Prog Horm Res* 34: 25–93, 1978.
995. LAFLAMME N, NAPPI RE, DROLET G, LABRIE C, AND RIVEST S. Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. *J Neurobiol* 36: 357–378, 1998.
996. LAGNY-POURMIR I, AMIRANOFF B, LORINET AM, TATEMOTO K, AND LABURTHE M. Characterization of galanin receptors in the insulin-secreting cell line RinnSF: evidence for coupling with a pertussis toxin-sensitive guanosine triphosphate regulatory protein. *Endocrinology* 124: 2635, 1989.
997. LAI HL, YANG TH, MESSING RO, CHING YH, LIN SC, AND CHERN YJ. Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A_{2A}-adenosine receptor-mediated cAMP response. *J Biol Chem* 272: 4970–4977, 1997.
998. LAMBERTS R, VIJAYAN E, GRAF M, MANSKY T, AND WUTTKE W. Involvement of preoptic-anterior hypothalamic GABA neurons in the regulation of pituitary LH and prolactin release. *Exp Brain Res* 52: 356–362, 1983.
999. LAMBERTS SW AND MACLEOD RM. The interaction of the serotonergic and dopaminergic systems on prolactin secretion in the rat. The mechanism of action of the “specific” serotonin receptor antagonist, methysergide. *Endocrinology* 103: 287–295, 1978.
1000. LAMBERTS SW AND MACLEOD RM. Metergoline and other peripheral serotonin antagonists inhibit prolactin secretion through mechanisms unrelated to serotonin. *Proc Soc Exp Biol Med* 162: 75–79, 1979.
1001. LAMBERTS SW, ZUYDERWIJK J, DEN HOLDER F, VAN KOETSVELD P, AND HOFLAND L. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thy-

- rotropin release by cultured rat pituitary cells. *Neuroendocrinology* 50: 44–50, 1989.
1002. LAMBERTS SWJ AND MACLEOD RM. Regulation of prolactin secretion at the level of the lactotroph. *Physiol Rev* 70: 279–318, 1990.
1003. LANGELEIR P AND MCCANN SM. The effects of interruption of the ventral noradrenergic pathway on the proestrous discharge of prolactin in the rat. *Proc Soc Exp Biol Med* 154: 553–557, 1977.
1004. LANGER G, FERIN M, AND SACHAR E. Effect of haloperidol and L-dopa on plasma prolactin in stalk-sectioned and intact monkeys. *Endocrinology* 102: 367–370, 1973.
1005. LANGEVIN H AND EMSON PC. Distribution of substance P, somatostatin and neurotensin in the human hypothalamus. *Brain Res* 246: 65–69, 1982.
1006. LARSEN P, MIKKELSEN JD, MAU SE, AND SOERMARK T. Binding and internalization of an iodinated substance P analog by cultured anterior pituitary cells. *Mol Cell Endocrinol* 65: 91–101, 1989.
1007. LARSEN P, MIKKELSEN JD, AND SOERMARK T. Efferent projections from the periventricular and medial parvocellular subnuclei of the hypothalamic paraventricular nucleus to circumventricular organs of the rat: a phaseolus vulgaris-leucoagglutinin (PHA-L) tracing study. *Endocrinology* 124: 2548–2557, 1989.
1008. LARSEN PJ, SAERMARK T, AND EMAU S. Binding of an iodinated substance P analogue to cultured anterior pituitary prolactin- and luteinizing hormone-containing cells. *J Histochem Cytochem* 40: 487–493, 1992.
1009. LARSON GH AND WISE PM. Constitutive and regulated prolactin secretion: effects of estradiol. *Biol Reprod* 50: 357–362, 1994.
1010. LARSON LI, FAHRENKRUG J, SCHAFFALLISTSKY DE MUCKADELL OB, SUNDLER F, HAKANSON R, AND REHFELD JF. Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral nerves. *Proc Natl Acad Sci USA* 73: 3197–3200, 1976.
1011. LAUDON M, GROSSMAN DA, AND BEN-JONATHAN N. Prolactin-releasing factor: cellular origin in the intermediate lobe of the pituitary. *Endocrinology* 126: 3185–3192, 1990.
1012. LAWSON DM AND GALA RR. The influence of adrenergic, dopaminergic, cholinergic and serotonergic drugs on plasma prolactin levels in ovariectomized, estrogen-treated rats. *Endocrinology* 96: 313–318, 1975.
1013. LEBRUN J-J, ALI S, SOFER L, ULLRICH A, AND KELLY PA. Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. *J Biol Chem* 269: 14021–14026, 1994.
1014. LEBRUN J-J, ALI S, ULLRICH A, AND KELLY PA. Proline-rich sequence-mediated JAK2 association to the prolactin receptor is required but not sufficient for signal transduction. *J Biol Chem* 270: 10664–10670, 1995.
1015. LECHAN RM AND JACKSON IMD. Immunohistochemical localization of thyrotropin-releasing hormone in the rat hypothalamus and pituitary. *Endocrinology* 111: 55–65, 1982.
1016. LEE LR, HAISENLEDER DJ, MARSHALL JC, AND SMITH MS. The role of the suckling stimulus in regulating pituitary prolactin mRNA in the rat. *Mol Cell Endocrinol* 64: 243–249, 1989.
1017. LEE MS, BEN-RAFAEL Z, MELONI F, MASTROIANNI LJ, AND FLICKINGER GL. Effects of prolactin on steroidogenesis by human luteinized granulosa cells. *Fertil Steril* 46: 32–36, 1986.
1018. LEE SC AND SHIN SH. Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cells. *J Endocrinol* 148: 69–76, 1996.
1019. LEFCOURT AM, AKERS RM, WOOD DL, AND BITMAN J. Circadian and ultradian rhythms of peripheral prolactin concentrations in lactating dairy cows. *Am J Physiol Regulatory Integrative Comp Physiol* 267: R1461–R1466, 1994.
1020. LEITE DMM, TOURAINE P, GAGNERAULT MC, SAVINO W, KELLY PA, AND DARDENNE M. Prolactin receptors and the immune system. *Ann Endocrinol* 56: 567–570, 1995.
1021. LENKEI Z, PALKOVITS M, CORVOL P, AND LORENS-CORTES CL. Distribution of angiotensin II type-2 receptor (AT2) mRNA expression in the adult rat brain. *J Comp Neurol* 373: 322–339, 1996.
1022. LENKEI Z, PALKOVITS M, CORVOL P, AND LORENS-CORTES CL. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. *Front Neuroendocrinol* 18: 383–439, 1997.
1023. LENKEI Z, PALKOVITS M, CORVOL P, AND LORENS-CORTES CL. Distribution of angiotensin type-1 receptor messenger RNA expression in the adult rat brain. *Neuroscience* 82: 827–841, 1998.
1024. LEONG DA, FRAWLEY LS, AND NEILL JD. Neuroendocrine control of prolactin secretion. *Annu Rev Physiol* 45: 109–127, 1983.
1025. LEONHARDT S, JARRY H, KREIPE A, WERSTLER K, AND WUTTKE W. Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates pituitary hormone release in male rats. *Neuroendocrinol Lett* 14: 319–327, 1992.
1026. LEONTIC EA AND TYSON JE. Prolactin and fetal osmoregulation: water transport across isolated human amnion. *Am J Physiol Regulatory Integrative Comp Physiol* 232: R124–R127, 1977.
1027. LERANT A AND FREEMAN ME. Dopaminergic neurons in periventricular and arcuate nuclei of proestrous and ovariectomized rats: endogenous diurnal rhythm of Fos-related antigens expression. *Neuroendocrinology* 65: 436–445, 1997.
1028. LERANT A AND FREEMAN ME. Ovarian steroids differentially regulate the expression of PRL-R in neuroendocrine dopaminergic neuron populations: a double label confocal microscopic study. *Brain Res* 802: 141–154, 1998.
1029. LERANT A, HERMAN ME, AND FREEMAN ME. Dopaminergic neurons of periventricular and arcuate nuclei of pseudopregnant rats: semicircadian rhythm in fos-related antigens immunoreactivities and in dopamine concentration. *Endocrinology* 137: 3621–3628, 1996.
1030. LERANT A AND NAGY GM. Analysis of autocrine and paracrine interactions in the pituitary gland by the reverse hemolytic plaque assay. *Neuroprotocols* 5: 198–208, 1994.
1031. LESUEUR L, EDERY M, ALI S, PALLY J, KELLY PA, AND DJIANE J. Comparison of long and short forms of the prolactin receptor on prolactin-induced milk protein gene transcription. *Proc Natl Acad Sci USA* 88: 824–828, 1991.
1032. LEUNG FC, CHEN HT, VERKAIK SJ, STEGER RW, PELUSO JJ, CAMPBELL GA, AND MEITES J. Mechanism(s) by which adrenalectomy and corticosterone influence prolactin release in the rat. *J Endocrinol* 87: 131–140, 1980.
1033. LEVIN MC, SAWCHENKO PE, HOWE JR, BLOOM FE, AND POLAK JM. Organization of galanin-immunopositive inputs to the paraventricular nucleus with special reference to their relationship to catecholaminergic afferents. *J Comp Neurol* 261: 562–582, 1987.
1034. LEWIS ME, KHACHATURIAN H, AND WATSON SJ. Visualization of opiate receptors and opioid peptides in sequential brain sections. *Life Sci* 31: 1347–1350, 1982.
1035. LI CH. Studies on pituitary lactogenic hormone: the primary structure of the porcine hormone. *Int J Pept Protein Res* 8: 205–224, 1976.
1036. LI CH, DIXON JS, LO TB, SCHMIDT KD, AND PANKOV YA. Studies on pituitary lactogenic hormone. 30. The primary structure of the sheep hormone. *Arch Biochem Biophys* 141: 705–737, 1970.
1037. LI CS, KABA H, SAITO H, AND SETO K. Excitatory influence of the accessory olfactory bulb on tuberoinfundibular arcuate neurons of female mice and its modulation by oestrogen. *Neuroscience* 29: 201–208, 1989.
1038. LI CS, KABA H, SAITO H, AND SETO K. Neural mechanisms underlying the action of primer pheromones in mice. *Neuroscience* 36: 773–778, 1990.
1039. LI H-Y, BLAUSTEIN JD, DE VRIES GJ, AND WADE GN. Estrogen-receptor immunoreactivity in hamster brain: preoptic area, hypothalamus and amygdala. *Brain Res* 631: 304–312, 1993.
1040. LI Q, MURAKAMI S, STALL S, LEVY MS, BROWNFIELD DE, NICHOLS DE, AND VAN DE KAR LD. Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminindan (MMAI), and p-methylthioamphetamine (MTA). *J Pharmacol Exp Ther* 279: 1261–1267, 1996.
1041. LI S, ZHU J, CHEN C, CHEN YW, DERIEL JK, ASHBY B, AND LIU-CHEN LY. Molecular cloning and expression of a rat kappa opioid receptor. *Biochem J* 295: 629–633, 1993.
1042. LIANG P AND PARDEE AB. Recent advances in differential display. *Curr Opin Immunol* 7: 274–280, 1995.
1043. LIBERTUN C AND MCCANN SM. Further evidence for cholinergic control of gonadotropin and prolactin secretion. *Proc Soc Exp Biol Med* 147: 498–504, 1974.

1044. LIBERTUN C AND McCANN SM. The possible role of histamine in the control of prolactin and gonadotropin release. *Neuroendocrinology* 20: 110–120, 1976.
1045. LIEBERMAN ME, MAURER RA, CLAUDE P, WIKLUND J, WERTZ N, AND GORSKI J. Regulation of pituitary growth and prolactin gene expression by estrogen. *Adv Exp Med Biol* 138: 151–163, 1981.
1046. LIEN EL, FENICHEL RL, GARSKY V, SARANTAKIS D, AND GRANT NH. Enkephalin-stimulated prolactin release. *Life Sci* 19: 837, 1976.
1047. LIEN EL, MORRISON A, KASSARICH J, AND SULLIVAN D. Alpha-2-adrenergic control of prolactin release. *Neuroendocrinology* 44: 184–189, 1986.
1048. LIGHTMAN SL. Alterations of hypothalamic-pituitary responsiveness during lactation. *Ann NY Acad Sci* 652: 340–346, 1992.
1049. LIN JY, LI CS, AND PAN JT. Effects of various neuroactive substances on single-unit activities of hypothalamic arcuate neurons in brain slices. *Brain Res Bull* 31: 587–594, 1993.
1050. LINCOLN GA AND CLARKE IJ. Photoperiodically-induced cycles in the secretion of prolactin in hypothalamo-pituitary disconnected rams: evidence for translation of the melatonin signal in the pituitary gland. *J Neuroendocrinol* 6: 251–260, 1994.
1051. LINCOLN GA AND CLARKE IJ. Evidence that melatonin acts in the pituitary gland through a dopamine-independent mechanism to mediate effects of daylength on the secretion of prolactin in the ram. *J Neuroendocrinol* 7: 637–643, 1995.
1052. LINCOLN GA, McNEILLY AS, AND CAMERON CL. The effects of a sudden decrease or increase in daylength on prolactin secretion in the ram. *J Reprod Fertil* 52: 305–311, 1978.
1053. LINCOLN GA AND TORTONESE DJ. Does melatonin act on dopaminergic pathways in the mediobasal hypothalamus to mediate effects of photoperiod on prolactin secretion in the ram? *Neuroendocrinology* 62: 425–433, 1995.
1054. LINDLEY SE, GUNNET JW, LOOKINGLAND KJ, AND MOORE KE. Effects of alterations in the activity of tuberohypophyseal dopaminergic neurons on the secretion of alpha-melanocyte stimulating hormone. *Proc Soc Exp Biol Med* 188: 282–286, 1988.
1055. LINKOWSKI P, SPIEGEL K, KERKHOF M, L'HERMITE-BALÉRIAUX M, VAN ONDERBERGEN A, LEPROULT R, MENDLEWICZ J, AND VANCAUTER E. Genetic and environmental influences on prolactin secretion during wake and during sleep. *Am J Physiol Endocrinol Metab* 274: E909–E919, 1998.
1056. LINZER DI, LEE SJ, OGREN L, TALAMANTES F, AND NATHANS D. Identification of proliferin mRNA and protein in mouse placenta. *Proc Natl Acad Sci USA* 82: 4356–4359, 1985.
1057. LINZER DI AND NATHANS D. A new member of the prolactin-growth hormone gene family expressed in mouse placenta. *EMBO J* 4: 1419–1423, 1985.
1058. LINZER DIH AND FISHER SJ. The placenta and the prolactin family of hormones: regulation of the physiology of pregnancy. *Mol Endocrinol* 13: 837–840, 1999.
1059. LIU J-W AND BEN-JONATHAN N. Prolactin-releasing activity of neurohypophyseal hormones: structure-function relationship. *Endocrinology* 134: 114–118, 1994.
1060. LIU X, ROBINSON GW, WAGNER KU, GARRETT L, WYNshaw-BORIS A, AND HENNIGHAUSEN L. Sta5a is mandatory for adult mammary gland development and lactogenesis. *Genes Dev* 11: 179–186, 1997.
1061. LIU YY AND JU G. Galanin-like immunoreactive nerve fibres in the anterior pituitary of the normal and adrenalectomized rat. *Acta Histochem* 100: 149–156, 1998.
1062. LJUNGDAHL A, HOKFELT T, AND NILSSON G. Distribution of substance P-like immunoreactivity in the central nervous system of the rat. I. Cell bodies and nerve terminals. *Neuroscience* 3: 861–943, 1978.
1063. LKHIDER M, DELPAL S, AND BOUSQUET MO. Rat prolactin in serum, milk, and mammary tissue: characterization and intracellular localization. *Endocrinology* 137: 4969–4979, 1996.
1064. LKHIDER M, DELPAL S, LE PROVOST F, AND OLLIVIER-BOUSQUET M. Rat prolactin synthesis by lactating mammary epithelial cells. *FEBS Lett* 401: 117–122, 1997.
1065. LLEDO PM, HOMBURGER V, BOCKAERT J, AND VINCENT J-D. Differential G protein-mediated coupling of D2 dopamine receptors to K^+ and Ca^{2+} currents in rat anterior pituitary cells. *Neuron* 8: 455–463, 1992.
1066. LLEDO P-M, ISRAEL J-M, AND VINCENT J-D. A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium currents by dopamine in rat lactotrophs. *Brain Res* 528: 143–147, 1990.
1067. LLEDO P-M, ISRAEL JM, AND VINCENT J-D. Chronic stimulation of D₂ dopamine receptors specifically inhibits calcium but not potassium currents in rat lactotrophs. *Brain Res* 558: 231–238, 1991.
1068. LLEDO P-M, LEGENDRE P, ISRAEL J-M, AND VINCENT J-D. Dopamine inhibits two characterized voltage-dependent calcium currents in identified rat lactotroph cells. *Endocrinology* 127: 990–1001, 1990.
1069. LLEDO P-M, LEGENDRE P, ZHANG J, ISRAEL J-M, AND VINCENT J-D. Effects of dopamine on voltage-dependent potassium currents in identified rat lactotroph cells. *Neuroendocrinology* 52: 545–555, 1990.
1070. LLEDO PM, VERNIER P, VINCENT JD, MASON WT, AND ZOREC R. New approaches in the study of stimulus-secretion coupling in anterior pituitary cells. *Ann NY Acad Sci* 710: 301–318, 1994.
1071. LOCATELLI V, APUD JA, GUDELSKY GA, COCCHI D, MASOTTO C, CASENUEVA F, RACAGNI G, AND MULLER EE. Prolactin in cerebrospinal fluid increases the synthesis and release of hypothalamic gamma-aminobutyric acid. *J Endocrinol* 106: 323–328, 1985.
1072. LOEFFLER JP, KLEY N, PITTIUS CW, ALMEIDA OF, AND HOLLT V. In vivo and in vitro studies of GABAergic inhibition of prolactin biosynthesis. *Neuroendocrinology* 43: 504–510, 1986.
1073. LOEFFLER JP, KLEY N, PITTIUS CW, AND HOLLT V. gamma-Aminobutyric acid decreases levels of messenger ribonucleic acid encoding prolactin in the rat pituitary. *Neurosci Lett* 53: 121–125, 1985.
1074. LOGIN IS. Direct stimulation of pituitary prolactin release by glutamate. *Life Sci* 47: 2269–2275, 1990.
1075. LOGIN IS, JUDD AM, KUAN SI, AND MACLEOD RM. Role of calcium in dopaminergic regulation of TRH- and angiotensin II-stimulated prolactin release. *Am J Physiol Endocrinol Metab* 260: E553–E560, 1991.
1076. LOOKINGLAND KJ, GUNNET JW, AND MOORE KE. Stress-induced secretion of alpha-melanocyte-stimulating hormone is accompanied by a decrease in the activity of tuberohypophyseal dopaminergic neurons. *Neuroendocrinology* 53: 91–96, 1991.
1077. LOOKINGLAND KJ, GUNNET JW, TONEY TW, AND MOORE KE. Comparison of the effects of ether and restraint stress on the activity of tuberoinfundibular dopaminergic neurons in female and male rats. *Neuroendocrinology* 52: 99–105, 1990.
1078. LOPEZ FJ, MEADE EHJ, AND NEGRO-VILAR A. Development and characterization of a specific and sensitive radioimmunoassay for rat galanin: measurement in brain tissue, hypophyseal portal and peripheral serum. *Brain Res Bull* 24: 395–399, 1990.
1079. LOPEZ FJ, MEADE EHJ, AND NEGRO-VILAR A. Endogenous galanin modulates the gonadotropin and prolactin preovulatory surges in the rat. *Endocrinology* 132: 795–800, 1993.
1080. LOPEZ FJ, MERCHENTHALER I, CHING M, WISNIEWSKI MG, AND NEGRO-VILAR A. Galanin: a hypothalamic-hypophysiotropic hormone modulating reproductive functions. *Proc Natl Acad Sci USA* 88: 4508–4512, 1991.
1081. LOPEZ PR, EHLERDING A, LEONHARDT S, JARRY H, AND WUTTKE W. Effects of angiotensin II and atrial natriuretic peptide on LH release are exerted in the preoptic area: possible involvement of gamma-aminobutyric acid (GABA). *Exp Clin Endocrinol* 101: 350–355, 1993.
1082. LORSIGNOL A, TAUPIGNON A, AND DUFY B. Short applications of gamma-aminobutyric acid increase intracellular calcium concentrations in single identified rat lactotrophs. *Neuroendocrinology* 60: 389–399, 1994.
1083. LOWENSTEIN CJ AND SNYDER SH. Nitric oxide, a novel biologic messenger. *Cell* 70: 705–707, 1992.
1084. LU CC, TSAI SC, HUANG WJ, TSAI CL, AND WANG PS. Effects of hyperprolactinemia on calcitonin secretion in male rats. *Metabolism* 48: 221–226, 1999.
1085. LU KH AND MEITES J. Effects of serotonin precursors and melatonin on serum prolactin release in rats. *Endocrinology* 93: 152–155, 1973.
1086. LUCAS BK, ORMANDY CJ, BINART N, BRIDGES RS, AND KELLY PA. Null mutation of the prolactin receptor gene produces a defect in maternal behavior. *Endocrinology* 139: 4102–4107, 1998.
1087. LUMPKIN MD, SAMSON WK, AND McCANN SM. Hypothalamic and pituitary sites of action of oxytocin to alter prolactin secretion in the rat. *Endocrinology* 112: 1711–1718, 1983.

1088. LUO G AND YU-LEE L. Transcriptional inhibition by Stat5. Differential activities at growth-related versus differentiation-specific promoters. *J Biol Chem* 272: 26841–26849, 1997.
1089. LUO X, IKEDA Y, AND PARKER KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. *Cell* 77: 481–490, 1994.
1090. LUQUE EH, MONOZ DE TORO M, SMITH PF, AND NEILL JD. Subpopulation of lactotropes detected with the reverse hemolytic plaque assay show differential responsiveness to dopamine. *Endocrinology* 118: 2120–2124, 1986.
1091. LUX-LANTOS V, REY E, AND LIBERTUN C. Activation of GABA B receptors in the anterior pituitary inhibits prolactin and luteinizing hormone secretion. *Neuroendocrinology* 56: 687–693, 1992.
1092. LUX-LANTOS V, SOMOZA G, REY E, AND LIBERTUN C. Further evidence for the inhibitory action of baclofen on a prolactin-releasing factor. *Proc Soc Exp Biol Med* 197: 337–341, 1991.
1093. LYONS WR. The direct mammatrophic action of lactogenic hormone. *Proc Soc Exp Biol Med* 51: 308–311, 1942.
1094. LYONS WR. Hormonal synergism in mammary growth. *Proc R Soc Lond B Biol Sci* 149: 303–325, 1958.
1095. LYSON K AND MCCANN SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. *Neuroendocrinology* 54: 262–266, 1991.
1096. MACLEOD RM. Influence of norepinephrine and catecholamine-depleting agents on the synthesis and release of prolactin and growth hormone. *Endocrinology* 85: 916–923, 1969.
1097. MACLEOD RM. Regulation of prolactin secretion. In: *Frontiers in Neuroendocrinology*, edited by Martini L and Ganong WF. New York: Raven, 1976, p. 169.
1098. MACLEOD RM, FONTAM EH, AND LEHMEYER JE. Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines. *Neuroendocrinology* 6: 283–294, 1970.
1099. MAI LM AND PAN JT. Central administration of bombesin blocks the estrogen-induced afternoon prolactin surge. *Neuroendocrinology* 57: 40–44, 1993.
1100. MAI LM AND PAN JT. Bombesin acts in the suprachiasmatic nucleus to affect circadian changes in tuberoinfundibular dopaminergic neuron activity and prolactin secretion. *Endocrinology* 136: 4163–4167, 1995.
1101. MAI L-M, SHIEH K-R, AND PAN J-T. Circadian changes of serum prolactin levels and tuberoinfundibular dopaminergic neuron activities in ovariectomized rats treated with or without estrogen: the role of the suprachiasmatic nuclei. *Neuroendocrinology* 60: 520–526, 1994.
1102. MAINOYA JR. Analysis of the role of endogenous prolactin on fluid and sodium chloride absorption by the rat jejunum. *J Endocrinol* 67: 343–349, 1975.
1103. MAINOYA JR. Effects of bovine growth hormone, human placental lactogen and ovine prolactin on intestinal fluid and ion transport in the rat. *Endocrinology* 96: 1165–1170, 1975.
1104. MAINOYA JR. Further studies on the action of prolactin on fluid and ion absorption by the rat jejunum. *Endocrinology* 96: 1158–1164, 1975.
1105. MAKARA GB AND KOVACS KJ. Lesioning of the hypothalamic paraventricular nucleus inhibits ether-induced ACTH but not prolactin release. *Neurobiology* 5: 403–411, 1997.
1106. MAKINEN M, AHTEE L, ROSENQVIST K, TUOMINEN RK, AND MANNISTO P. Effects of intraventricular taurine, homotaurine and GABA on serum prolactin and thyrotropin levels in female and in male rats. *J Neural Transm Gen Sect* 94: 155–163, 1993.
1107. MALABU UH, KILPATRICK A, WARE M, VERNON RG, AND WILLIAMS G. Increased neuropeptide Y concentrations in specific hypothalamic regions of lactating rats: possible relationship to hyperphagia and adaptive changes in energy balance. *Peptides* 15: 83–87, 1994.
1108. MALARKEY WB, HALL JC, PEARL DK, KIECOLT-GLASER JK, AND GLASER R. The influence of academic stress and season on 24-h concentrations of growth hormone and prolactin. *J Clin Endocrinol Metab* 73: 1089–1092, 1991.
1109. MALARKEY WB, O'DORISIO TM, KENNEDY M, AND CATALAND S. The influence of vasoactive intestinal polypeptide and cholecystokinin on prolactin release in rat and human monolayer cultures. *Life Sci* 28: 2489–2495, 1981.
1110. MALGAROLI A, VALLAR L, ELAHI FR, POZZAN T, SPADA A, AND MELDOESI J. Dopamine inhibits cytosolic Ca^{2+} increases in rat lactotroph cells. *J Biol Chem* 262: 13920–13927, 1987.
1111. MALVEN PV AND SAWYER CH. A luteolytic action of prolactin in hypophysectomized rats. *Endocrinology* 79: 268–274, 1966.
1112. MANGURIAN LP, JURJUS AR, AND WALSH RJ. Prolactin receptor localization to the area postrema. *Brain Res* 836: 218–220, 1999.
1113. MANGURIAN LP, WALSH RJ, AND POSNER BI. Prolactin enhancement of its own uptake at the choroid plexus. *Endocrinology* 131: 698–702, 1992.
1114. MANKU MS, MTABAJI JP, AND HORROBIN DF. Effect of cortisol, prolactin and ADH on the amniotic membrane. *Nature* 258: 78–80, 1975.
1115. MANNISTO PT, LANG A, HARRO J, PEURANEN E, BRADWEIN J, AND VASAR E. Opposite effects mediated by CKA and CKB receptors in behavioural and hormonal studies in rats. *Naunyn-Schmiedeberg's Arch Pharmacol* 349: 478–484, 1994.
1116. MANNISTO PT, PEURANEN E, HARRO J, AND VASAR E. Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats. *Neuropeptides* 23: 251–258, 1992.
1117. MANSKY T, DUKER E, AND WUTTKE W. Hypothalamic and limbic GABA concentrations and turnover rates and glutamate concentrations following induction of hyperprolactinemia in ovariectomized rats. *Neurosci Lett* 39: 267–272, 1983.
1118. MANSKY T, MESTRES-VENTURA P, AND WUTTKE W. Involvement of GABA in the feedback action of estradiol on gonadotropin and prolactin release: hypothalamic GABA and catecholamine turnover rates. *Brain Res* 231: 353–364, 1982.
1119. MANSOUR A, FOX CA, AKIL H, AND WATSON SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. *Trends Neurosci* 18: 22–29, 1995.
1120. MANTYH P, GATES T, AND MAGGIO J. Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. *J Neurosci* 9: 258–279, 1989.
1121. MANZANARES J, DURHAM RA, LOOKINGLAND KJ, AND MOORE KE. δ -Opioid receptor-mediated regulation of central dopaminergic neurons in the rat. *Eur J Pharmacol* 249: 107–112, 1993.
1122. MANZANARES J, TONEY TW, LOOKINGLAND KJ, AND MOORE KE. Activation of tuberoinfundibular and tuberohypophysial dopamine neurons following intracerebroventricular administration of bombesin. *Brain Res* 565: 142–147, 1991.
1123. MANZANARES J, WAGNER EJ, LAVIGNE SD, LOOKINGLAND KJ, AND MOORE KE. Sexual differences in kappa opioid receptor-mediated regulation of tuberoinfundibular dopaminergic neurons. *Neuroendocrinology* 55: 301–307, 1992.
1124. MANZANARES J, WAGNER EJ, LOOKINGLAND KJ, AND MOORE KE. Effects of immunoneutralization of dynorphin 1–17 and dynorphin 1–8 on the activity of central dopaminergic neurons in the male rat. *Brain Res* 587: 301–305, 1992.
1125. MARAGOS WF, PENNEY JB, AND YOUNG AB. Anatomic correlation of NMDA and 3H -TCP-labelled receptors in the rat brain. *J Neurosci* 8: 493–501, 1988.
1126. MARCOS P, CORIO M, COVENAS R, AND TRAMU G. Neurotensin and tyrosine hydroxylase in the tuberoinfundibular system of the guinea pig hypothalamus with special emphasis to lactation status. *Peptides* 17: 139–146, 1996.
1127. MARKOFF E, SIGEL MB, LACOUR N, SEAVEY BK, FRIESEN HG, AND LEWIS UJ. Glycosylation selectively alters the biological activity of prolactin. *Endocrinology* 123: 1303–1306, 1988.
1128. MARTIN R, GEIS R, HOLL R, SCHAFER M, AND VOIGHT KH. Co-existence of unrelated peptides in oxytocin and vasopressin terminals of rat neuropeptides: immunoreactive methionin⁵-enkephalin-, leucine⁵-enkephalin-, and cholecystokinin-like substances. *Neuroscience* 8: 213–227, 1983.
1129. MARTIN TFJ AND TASHJIAN AH. Cell culture studies of thyrotropin-releasing hormone action. In: *Biochemical Action of Hormones*, edited by Litwack G. New York: Academic, 1977, p. 270.
1130. MARTIN WR, EADES CG, THOMPSON JA, HUPPLER RE, AND GILBERT PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. *J Pharmacol Exp Ther* 197: 517–532, 1976.
1131. MARTINELLI GP, LIU H, CLARKE WP, HEISENLEDER DJ, AND KNIGHT RJ. Prolactin suppression enhances the effects of perioperative do-

- nor-specific blood transfusions on graft survival. *J Surg Res* 64: 190–197, 1996.
1132. MARTINEZ DE LA ESCALERA G, GUTHRIE J, AND WEINER RI. Transient removal of dopamine potentiates the stimulation of prolactin release by TRH but not VIP: stimulation by Ca^{2+} /protein kinase C pathway 1. *Neuroendocrinology* 47: 38–45, 1988.
 1133. MARTINEZ DE LA ESCALERA G, MARTIN TFJ, AND WEINER RI. Phosphoinositide hydrolysis in response to the withdrawal of dopamine inhibition in enriched lactotrophs in culture. *Neuroendocrinology* 46: 545–548, 1987.
 1134. MARTINEZ DE LA ESCALERA G, PORTER BW, MARTIN TFJ, AND WEINER RI. Dopamine withdrawal and addition of thyrotropin-releasing hormone stimulate membrane translocation of protein kinase-C and phosphorylation of an endogenous 80K substrate in enriched lactotrophs. *Endocrinology* 125: 1168–1173, 1989.
 1135. MARTINEZ DE LA ESCALERA G AND WEINER RI. Effect of dopamine withdrawal on activation of adenylate cyclase and phospholipase C in enriched lactotrophs. *Endocrinology* 123: 1682–1687, 1988.
 1136. MARTINEZ DE LA ESCALERA G AND WEINER RI. Mechanism(s) by which the transient removal of dopamine regulation potentiates the prolactin-releasing action of thyrotropin-releasing hormone. *Neuroendocrinology* 47: 186–193, 1988.
 1137. MARTINEZ DE LA ESCALERA G AND WEINER RI. Transient dopamine withdrawal differentially potentiates thyrotropin releasing hormone-induced release of prolactin of various ages. *Neuroendocrinology* 51: 694–699, 1990.
 1138. MARTINEZ DE LA ESCALERA G AND WEINER RI. Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. *Endocr Rev* 13: 241–255, 1992.
 1139. MARUYAMA M, MATSUMOTO H, FUJIWARA K, KITADA C, HINUMA S, ONDA H, FUJINO M, AND INOUE K. Immunocytochemical localization of prolactin-releasing peptide in the rat brain. *Endocrinology* 140: 2326–2333, 1999.
 1140. MASAKI T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. *Endocr Rev* 14: 256–268, 1993.
 1141. MASAKI T. Endothelin in vascular biology. *Ann NY Acad Sci* 714: 101–108, 1994.
 1142. MASAKI T, KIMURA S, YANAGISAWA M, AND GOTO K. Molecular and cellular mechanism of endothelin regulation: implications for vascular function. *Circulation* 84: 1457–1468, 1991.
 1143. MASLAR IA AND ANSBACHER R. Effects of progesterone on decidual prolactin production by organ cultures of human endometrium. *Endocrinology* 118: 2102–2108, 1986.
 1144. MASUHARA M, SAKAMOTO H, MATSUMOTO A, SUZUKI R, YASUKAWA H, MITSUI K, WAKIOKA T, TANIMURA S, SASAKI A, MISAWA H, YOKOUCHI M, OHTSUBO M, AND YOSHIMURA A. Cloning and characterization of novel CIS family genes. *Biochem Biophys Res Commun* 239: 439–446, 1997.
 1145. MATERA L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. *Life Sci* 59: 599–614, 1996.
 1146. MATHIASSEN JR, TOMOGANE H, AND VOGGT JL. Serotonin-induced decrease in hypothalamic tyrosine hydroxylase activity and corresponding increase in prolactin release are abolished at midpregnancy and by transplants of rat choriocarcinoma cells. *Endocrinology* 131: 2527–2532, 1992.
 1147. MATSUMOTO H, MURAKAMI Y, HORIKOSHI Y, NOGUCHI J, HABATA Y, KITADA C, HINUMA S, ONDA H, AND FUJINO M. Distribution and characterization of immunoreactive prolactin-releasing peptide (PrRP) in rat tissue and plasma. *Biochem Biophys Res Commun* 257: 264–268, 1999.
 1148. MATSUMOTO H, NOGUCHI J, HORIKOSHI Y, KAWAMATA Y, KITADA C, HINUMA S, ONDA H, NISHIMURA O, AND FUJINO M. Stimulation of prolactin release by prolactin-releasing peptide in rats. *Biochem Biophys Res Commun* 259: 321–324, 1999.
 1149. MATSUMOTO H, SUZUKI N, SHIOTA K, INOUE K, TSUDA M, AND FUJINO M. Insulin-like growth factor-I stimulates endothelin-3 secretion from rat anterior pituitary cells in primary culture. *Biochem Biophys Res Commun* 172: 661–668, 1990.
 1150. MATSUMURA M, YAMANAI A, YAMAMOTO S, MORI H, AND SAITO. In vivo and in vitro effects of cholecystokinin octapeptide on the release of prolactin in rats. *Horm Metab Res* 17: 293–297, 1985.
 1151. MATSUO H AND MINAMINO N. Natriuretic peptides. In: *Progress in Endocrinology. The Proceedings of the Ninth International Congress of Endocrinology Nice 1992*, edited by Mornex R, Jaffiol C, and Leclère J. New York: Parthenon, 1993, p. 131–135.
 1152. MATSUSHITA N, KATO Y, KATAKAMI H, SHIMATSU A, AND IMURA H. Inhibition of naloxone of prolactin release induced by L-5-hydroxytryptophan in rats. *Proc Soc Exp Biol Med* 168: 282–285, 1981.
 1153. MATSUSHITA N, KATO Y, KATAKAMI H, SHIMATSU A, YANAIHARA N, AND IMURA H. Inhibition of prolactin secretion by gastrin releasing peptide (GRP) in the rat. *Proc Soc Exp Biol Med* 172: 118–121, 1983.
 1154. MATSUSHITA N, KATO Y, SHIMATSU A, KATAKAMI H, FUJINO M, MATSUO H, AND IMURA H. Stimulation of prolactin secretion in the rat by alpha-neo-endorphin, beta-neo-endorphin and dynorphin. *Biochem Biophys Res Commun* 107: 735–741, 1982.
 1155. MATSUSHITA N, KATO Y, SHIMATSU A, KATAKAMI H, YANAIHARA N, AND IMURA H. Effects of VIP, TRH, GABA and dopamine on prolactin release from superfused rat anterior pituitary cells. *Life Sci* 32: 1263–1269, 1983.
 1156. MATSUYAMA S, CHANG KT, KANUKA H, OHNISHI M, IKEDA A, NISHIHARA M, AND TAKAHASHI M. Occurrence of deoxyribonucleic acid fragmentation during prolactin-induced structural luteolysis in cycling rats. *Biol Reprod* 54: 1245–1251, 1996.
 1157. MATTON A, BOLLENGIER F, FINNE E, AND VANHAELST L. Effect of N^{ω} -nitro-L-arginine methyl ester, a nitric oxide synthesis inhibitor, on stress- and morphine-induced prolactin release in male rats. *Br J Pharmacol* 120: 268–272, 1997.
 1158. MAU SE, SAERMARK T, AND VILHARDT H. Translocation of protein kinase C isozymes in lactotroph-enriched anterior pituitary cell cultures: differential effects of substance P and phorbol ester. *J Mol Endocrinol* 12: 293–203, 1994.
 1159. MAURER RA. Estradiol regulates the transcription of the prolactin gene. *J Biol Chem* 257: 2133–2136, 1982.
 1160. MAY PC, KOHAMA SG, AND FINCH CE. N-methyl-aspartic lesions of the arcuate nucleus in adult C57BL/6J mice: a new model for age related lengthening of the estrous cycle. *Neuroendocrinology* 50: 605–612, 1989.
 1161. MCCANN S. The role of nitric oxide in the action of glutamatergic neurons to control the release of hypothalamic releasing and inhibiting hormones. In: *Excitatory Amino Acids: Their Role in Neuroendocrine Function*, edited by Brann DW and Mahesh VB. Boca Raton, FL: CRC, 1996, p. 205–222.
 1162. MCCANN SM, KARANTH S, KIMURA M, YU WH, AND RETTORI V. The role of nitric oxide (NO) in control of hypothalamic-pituitary function. *Rev Bras Biol* 56 Su 1 Pt 1: 105–112, 1996.
 1163. MCCANN SM, KIMURA M, KARANTH S, YU WH, AND RETTORI V. Nitric oxide controls the hypothalamic-pituitary response to cytokines. *Neuroimmunomodulation* 4: 98–106, 1997.
 1164. MCCANN SM, KIMURA M, KARANTH S, YU WH, AND RETTORI V. Role of nitric oxide in the neuroendocrine responses to cytokines. *Ann NY Acad Sci* 840: 174–184, 1998.
 1165. MCCANN SM, KIMURA M, WALCZEWSKA A, KARANTH S, RETTORI V, AND YU WH. Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. *Neuroimmunomodulation* 5: 193–202, 1998.
 1166. MCCANN SM AND VIJAYAN E. Control of anterior pituitary hormone secretion by neurotensin. *Ann NY Acad Sci* 668: 287–297, 1992.
 1167. MCCANN SM, VIJAYAN E, KOENIG J, AND KRULICH L. The effects of neurotensin on anterior pituitary hormone secretion. *Ann NY Acad Sci* 400: 160–171, 1982.
 1168. MCCANN SM, VIJAYAN E, NEGRO-VILAR A, MIZUNUMA H, AND MANGAT H. Gamma aminobutyric acid (GABA), a modulator of anterior pituitary hormone secretion by hypothalamic and pituitary action. *Psychoneuroendocrinology* 9: 97–106, 1984.
 1169. McDONALD JK, KOENIG JI, GIBBS DM, COLLINS P, AND NOE BD. High concentrations of neuropeptide Y in pituitary portal blood of rats. *Neuroendocrinology* 46: 538–541, 1987.
 1170. MCNEILLY AS, GLASIER A, JONASSEN J, AND HOWIE PW. Evidence for direct inhibition of ovarian function by prolactin. *J Reprod Fertil* 65: 559–569, 1982.
 1171. MEADOR-WOODRUFF JH, MANSOUR A, BUNZOW JR, VAN TOL HHM, WATSON SJ JR, AND CIVELLI O. Distribution of D₂ dopamine receptor mRNA in rat brain. *Proc Natl Acad Sci USA* 86: 7625–7628, 1989.

1172. MEISTER B, CECCATELLI S, HÖKFELT T, ANDÉN N-E, ANDÉN M, AND THEODORSSON E. Neurotransmitters, neuropeptides and binding sites in the rat mediobasal hypothalamus: effects of monosodium glutamate (MSG) lesions. *Exp Brain Res* 76: 343–368, 1989.
1173. MEISTER B AND HÖKFELT T. Peptide- and transmitter-containing neurons in the mediobasal hypothalamus and their relation to GABAergic systems: possible roles in control of prolactin and growth hormone secretion. *Synapse* 2: 585–605, 1988.
1174. MEISTER B, HÖKFELT T, GEFFARD M, AND ERTEL WO. Glutamic acid decarboxylase- and gamma-aminobutyric acid-like immunoreactivities in corticotropin-releasing factor-containing parvocellular neurons of the hypothalamic paraventricular nucleus. *Neuroendocrinology* 48: 516–526, 1988.
1175. MEITES J. Evidence that underfeeding acts via the neuroendocrine system to influence aging processes. *Prog Clin Biol Res* 287: 169–180, 1989.
1176. MELAMPY RM AND ANDERSON LL. Role of the uterus in corpus luteum function. *J Anim Sci* 27 Suppl 1: 77–96, 1968.
1177. MELANDER T, FUXE K, HARFSTRAND A, ENEROTH P, AND HÖKFELT T. Effects of intraventricular injections of galanin on neuroendocrine functions in the male rat. Possible involvement of hypothalamic catecholamine neuronal systems. *Acta Physiol Scand* 131: 25–32, 1987.
1178. MELLER E, PUZA T, DIAMOND J, LIEU HD, AND BOHMAKER K. Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro. *J Pharmacol Exp Ther* 263: 462–469, 1992.
1179. MEMO M, CARBONI E, TRABUCCHI M, CARRUBA MO, AND SPANO PF. Dopamine inhibition of neurotensin-induced increase in Ca^{2+} influx into rat pituitary cells. *Brain Res* 347: 253–257, 1985.
1180. MEMO M, CASTELETTI L, VALERIO A, MISSALE C, AND SPANO PF. Identification of neurotensin receptors associated with calcium channels and prolactin release in rat pituitary. *J Neurochem* 47: 1682–1688, 1986.
1181. MENA F, ENJALBERT A, CARBONELL L, PRIAM M, AND KORDON C. Effects of suckling on plasma and hypothalamic monoamine levels in the rat. *Endocrinology* 99: 445–451, 1976.
1182. MENA F AND GROSVENOR CE. Effect of number of pups upon suckling-induced fall in pituitary prolactin concentration and milk ejection in the rat. *Endocrinology* 82: 623–626, 1968.
1183. MENA F AND GROSVENOR CE. Release of prolactin in rats by exteroceptive stimulation: sensory stimuli involved. *Horm Behav* 2: 107–116, 1971.
1184. MENA F AND GROSVENOR CE. Effect of suckling and of exteroceptive stimulation upon prolactin release in the rat during late lactation. *J Endocrinol* 52: 11–22, 1972.
1185. MERCHENTHALER I. Induction of enkephalin in tuberoinfundibular dopaminergic neurons of pregnant, pseudopregnant, lactating and aged female rats. *Neuroendocrinology* 60: 185–193, 1994.
1186. MERCHENTHALER I, CSERNUS V, AND CSONTOS C. New data on the immunocytochemical localization of thyrotropin-releasing hormone in the rat central nervous system. *Am J Anat* 181: 359–376, 1988.
1187. MERCHENTHALER I, LENNARD DE, CIANCHETTA P, MERCHENTHALER A, AND BRONSTEIN D. Induction of proenkephalin in tuberoinfundibular dopaminergic neurons by hyperprolactinemia: the role of sex steroids. *Endocrinology* 136: 2442–2450, 1995.
1188. MERCHENTHALER I AND NEGRO-VILAR A. Anatomy and physiology of central galanin-containing pathways. *Prog Neurobiol* 40: 711–769, 1993.
1189. MEUNIER JC, MOLLEURAU C, TOLL L, SAUAUDEAU C, MOISAND C, ALVIERIE P, BUTOUR JL, GUILLEMOT JG, FERRARA P, MONSARRAT B, MAZARAGUIL H, VASSART G, PARMENTIER M, AND COSTENTIN J. Isolation and structure of the endogenous agonist of the opioid receptor-like ORL1 receptor. *Nature* 377: 532–535, 1995.
1190. MEZEY E, HUNYADY B, MITRA S, HAYES E, LIU QS, SCHAEFFER J, AND SCHONBRUNN A. Cell specific expression of the SST2A and SST5 somatostatin receptors in the rat anterior pituitary. *Endocrinology* 139: 414–419, 1998.
1191. MEZEY E AND KISS JZ. Vasoactive intestinal peptide-containing neurons in the paraventricular nucleus may participate in regulating prolactin secretion. *Proc Natl Acad Sci USA* 82: 245–247, 1985.
1192. MEZEY E AND PALKOVITS M. Two-way transport in the hypothalamo-hypophyseal system. In: *Frontiers in Neuroendocrinology*, edited by Ganong WF and Martini L. New York: Raven, 1982, p. 1–29.
1193. MEZEY E, REISINE TD, SKIRBOLL L, BEINFELD M, AND KISS JZ. Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus. Co-existence with corticotropin-releasing hormone. *Ann NY Acad Sci* 448: 152–154, 1985.
1194. MILENKOVIC L, PARLOW AF, AND MCCANN SM. Physiological significance of the negative short-loop feedback of prolactin. *Neuroendocrinology* 52: 389–392, 1990.
1195. MILLER GM, ALEXANDER JM, BIKKAL HA, KATZNELSON L, ZERVAS NT, AND LIBANSKI AK. Somatostatin receptor subtype gene expression in pituitary adenomas. *J Clin Endocrinol Metab* 80: 1386–1392, 1999.
1196. MINAMI M AND SATOH M. Molecular biology of the opioid receptors: structures, functions and distributions. *Neurosci Res* 23: 121–145, 1995.
1197. MINAMI S, NAKATA T, TOKITA R, ONODERA H, AND IMAKI J. Cellular localization of prolactin-releasing peptide messenger RNA in the rat brain. *Neurosci Lett* 266: 73–75, 1999.
1198. MINAMI S AND SARKAR DK. Transforming growth factor- β 1 inhibits prolactin secretion and lactotropic cell proliferation in the pituitary of oestrogen-treated Fischer 344 rats. *Neurochem Int* 30: 499–506, 1997.
1199. MINAMINO N, KANGAWA K, AND MATSUO H. Neuromedin B and neuromedin C: two mammalian bombesin-like peptides identified in porcine spinal cord and brain. *Ann NY Acad Sci* 547: 373–390, 1988.
1200. MINAMITANI N, MINAMITANI T, LECHAN RM, BOLLINGER-GRUBER J, AND REICHLIN S. Paraventricular nucleus mediates prolactin secretory responses to restraint stress, ether stress, and 5-hydroxy-L-tryptophan injection in the rat. *Endocrinology* 120: 860–867, 1987.
1201. MISSALE C, BORONI F, FRASSINE M, CARUSO A, AND SPANO P. Nerve growth factor promotes the differentiation of pituitary mammothroph cells in vitro. *Endocrinology* 136: 1205–1213, 1995.
1202. MISSALE C, BORONI F, SIGALA S, BURIANI A, FABRIS M, LEON A, DAL TOSO R, AND SPANO PF. Nerve growth factor in the anterior pituitary: localization in mammothrophs and cosecretion with prolactin by a dopamine-regulated mechanism. *Proc Natl Acad Sci USA* 93: 4240–4245, 1996.
1203. MISSALE C, BORONI F, SIGALA S, ZANELLATO A, DAL TOSO R, BALSARI A, AND SPANO P. Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammothroph phenotype. *Endocrinology* 135: 290–298, 1994.
1204. MISSALE C, CASTELLETTI L, BORONI F, MEMO M, AND SPANO P. Epidermal growth factor induces the functional expression of dopamine receptors in the GH₃ cell line. *Endocrinology* 128: 13–20, 1991.
1205. MISSALE C AND SPANO P. Nerve growth factor in pituitary development and pituitary tumors. *Front Neuroendocrinol* 19: 128–150, 1998.
1206. MITCHELL R, GRIEVE G, DOW R, AND FINK G. Endogenous GABA receptor ligands in hypophysial portal blood. *Neuroendocrinology* 37: 169–176, 1983.
1207. MITTRA I. A novel cleaved prolactin in the rat pituitary. I. Biosynthesis, characterization and regulatory control. *Biochem Biophys Res Commun* 95: 1750–1759, 1980.
1208. MIYATA A, ARIMURA A, DAHL RR, MINAMINO N, UEHARA A, JIANG L, CULLER MD, AND COY DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. *Biochem Biophys Res Commun* 164: 567–574, 1989.
1209. MOGG RJ AND SAMSON WK. Interactions of dopaminergic and peptidergic factors in the control of prolactin release. *Endocrinology* 126: 728–735, 1990.
1210. MOGULEVSKY JA, CARBONE S, AND SZWARCFARB B. Changes in the effect of gamma-aminobutyric acid on prolactin secretion during sexual maturation in female rats. *Endocrinology* 131: 458–462, 1992.
1211. MOLINARO GA AND DRAY S. Antibody coated erythrocytes as a manifold probe for antigens. *Nature* 248: 515–517, 1974.
1212. MONCADA S, PALMER RM, AND HIGGS EA. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication. *Biochem Pharmacol* 38: 1709–1715, 1989.
1213. MONCADA S, PALMER RMJ, AND HIGGS EA. Nitric oxide: physiology,

- pathophysiology, and pharmacology. *Pharmacol Rev* 43: 109–142, 1991.
1214. MONTGOMERY DW, LEFEVRE JA, ULRICH ED, ADAMSON CR, AND ZUKOSKI CF. Identification of prolactin-like proteins synthesized by normal murine lymphocytes. *Endocrinology* 127: 2601–2603, 1990.
 1215. MONTGOMERY DW, SHEN GK, ULRICH ED, STEINER LL, PARRISH PR, AND ZUKOSKI CF. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. *Endocrinology* 131: 3019–3026, 1992.
 1216. MONTGOMERY DW, ZUKOSKI CT, SHAH GN, BUCKLEY AR, PACHOLCZYK T, AND RUSSELL DH. Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoactivity. *Biochem Biophys Res Commun* 145: 692–698, 1987.
 1217. MOODY TW, GETZ R, AND O'DONOHUE TL. Localization of receptors for bombesin-like peptides in the rat brain. *Ann NY Acad Sci* 547: 114–130, 1988.
 1218. MOORE KE. Interactions between prolactin and dopaminergic neurons. *Biol Reprod* 36: 47–58, 1987.
 1219. MOORE KE AND DEMAREST KT. Tuberoinfundibular and tuberohypophyseal dopaminergic neurons. In: *Frontiers in Neuroendocrinology*, edited by Ganong WF and Martini L. New York: Raven, 1982, p. 161–190.
 1220. MOORE KE, DEMAREST KT, AND JOHNSTON CA. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. *Federation Proc* 39: 2912–2916, 1980.
 1221. MOREHEAD MH AND GALA RR. Restraint stress depresses prolactin surges in pseudopregnant rats and adrenalectomy does not alter the response. *Life Sci* 41: 1491–1498, 1987.
 1222. MOREHEAD MH AND GALA RR. The lack of a physiologic effect of the stress-induced decrease of the proestrous prolactin surge in the rat. *Life Sci* 41: 2355–2362, 1987.
 1223. MOREHEAD MH AND GALA RR. The restraint stress-induced decrease of the nocturnal prolactin surge and the physiology of pseudopregnancy and pregnancy in the rat. *Life Sci* 45: 207–215, 1989.
 1224. MOREHEAD MH, LOOKINGLAND KJ, AND GALA RR. Stress-induced suppression of the prolactin afternoon surge in ovariectomized, estrogen-treated rats and the nocturnal surge in pseudopregnant rats are accompanied by an increase in median eminence dihydroxyphenylacetic acid concentrations. *Neuroendocrinology* 51: 208–212, 1990.
 1225. MOREL G, CHABOT JG, ENJALBERT A, PRIAM M, AND DUBOIS PM. Evidence for direct action of calcitonin in the rat pituitary gland. *Acta Endocrinol* 120: 682–688, 1989.
 1226. MOREL G, CHAYVIALLE JA, KERDELHUE B, AND DUBOIS PM. Ultrastructural evidence for endogenous substance-P-like immunoreactivity in the rat pituitary gland. *Neuroendocrinology* 35: 86–92, 1982.
 1227. MOREL G AND DUBOIS PM. Immunocytochemical evidence for gonadoliberein in rat anterior pituitary gland. *Neuroendocrinology* 34: 197–206, 1982.
 1228. MOREL G, HEMMING F, TONON MC, VAUDRY H, DUBOIS MP, COY D, AND DUBOIS PM. Ultrastructural evidence for corticotropin-releasing factor (CRF)-like immunoreactivity in the rat pituitary gland. *Biol Cell* 44: 89, 1982.
 1229. MOREL G, MESGUICH P, DUBOIS MP, AND DUBOIS PM. Ultrastructural evidence for endogenous somatostatin-like immunoreactivity in the pituitary gland. *Neuroendocrinology* 36: 291–299, 1983.
 1230. MOREL G, MESGUICH P, DUBOIS MP, AND DUBOIS PM. Ultrastructural evidence for endogenous growth hormone-releasing factor-like immunoreactivity in the monkey pituitary gland. *Neuroendocrinology* 38: 123–133, 1984.
 1231. MORISHIGE WK AND ROTHCHILD I. A paradoxical inhibiting effect of ether on prolactin release in the rat: comparison with effect of ether on LH and FSH. *Neuroendocrinology* 16: 95–107, 1974.
 1232. MORISHIGE WK AND ROTHCHILD I. Temporal aspects of the regulation of corpus luteum function by luteinizing hormone, prolactin and placental luteotrophin during the first half of pregnancy in the rat. *Endocrinology* 95: 260–274, 1974.
 1233. MORITA A, NOMIZU M, OKITSU M, HORIE K, YOKOGOSHI H, AND PROLLER P. D-Val22 containing human big endothelin-1 analog, [D-Val22]big ET-1[16–38], inhibits the endothelin converting enzyme. *FEBS Lett* 353: 84–88, 1994.
 1234. MORLEY JE, VARNER AA, MODLIN IM, CARLSON HE, BRAUNSTEIN GD, WALSH JH, AND HERSHMAN JM. Failure of bombesin to alter anterior pituitary hormone secretion in man. *Clin Endocrinol* 13: 369–373, 1980.
 1235. MORMEDE P, VINCENT J-D, AND KERDELHUE B. Vasopressin and oxytocin reduce plasma prolactin levels of conscious rats in basal and stress conditions. Study of the characteristics of the receptor involved. *Life Sci* 39: 1737–1745, 1986.
 1236. MORRELL JI, ROSENTHAL MF, MCCABE JT, HARRINGTON CA, CHIKARASHI DM, AND PFAFF DW. Tyrosine hydroxylase mRNA in the neurons of the tuberoinfundibular region and zona incerta examined after gonadal steroid hormone treatment. *Mol Endocrinol* 3: 1426–1433, 1989.
 1237. MOUHATE A AND LESTAGE J. Epidermal growth factor: a potential paracrine and autocrine system within the pituitary. *Neuroreport* 6: 1401–1404, 1995.
 1238. MOUHATE A AND LESTAGE J. Estrogen increases the release of epidermal growth factor from individual pituitary cells in female rats. *J Endocrinol* 146: 495–500, 1995.
 1239. MOUHATE A, VERRIER D, AND LESTAGE J. Identification of epidermal growth factor-secreting cells in the anterior pituitary of lactating female rats. *J Endocrinol* 148: 319–324, 1996.
 1240. MOYER JA, O'DONOHUE TL, HERRENKOHL LR, GALA RR, AND JACOBOWITZ DM. Effects of suckling on serum prolactin levels and catecholamine concentrations and turnover in discrete brain regions. *Brain Res* 176: 125–133, 1979.
 1241. MUCCIOLI G AND DICARLO R. S-adenosyl-L-methionine restores prolactin receptors in the aged rabbit brain. *Eur J Pharmacol* 166: 223–230, 1989.
 1242. MUCCIOLI G, PAPOTTI M, DICARLO R, AND GENAZZANI E. Prolactin receptors in the choroid plexus of non-mammalian and mammalian species. *Pharmacol Res* 21: 95–96, 1989.
 1243. MUIR JL AND PFISTER HP. Influence of exogenously administered oxytocin on the corticosterone and prolactin response to psychologic stress. *Pharmacol Biochem Behav* 29: 699–703, 1988.
 1244. MUKHERJEE A, KULKARNI P, MCCANN SM, AND NEGRO-VILAR A. Evidence for the presence and characterization of angiotensin II receptors in rat anterior pituitary membranes. *Endocrinology* 110: 665–667, 1982.
 1245. MUKHERJEE A, SNYDER G, AND MCCANN SM. Characterization of muscarinic cholinergic receptors on intact rat anterior pituitary cells. *Life Sci* 27: 475–482, 1980.
 1246. MUKHERJEE P, SALADA T, AND HYMER WC. Function of prolactin cells in the individual rat pituitary gland is location dependent. *Mol Cell Endocrinol* 76: 35–44, 1991.
 1247. MULCHAHEY JJ AND NEILL JD. Gamma aminobutyric acid (GABA) levels in hypophyseal stalk plasma of rats. *Life Sci* 31: 453–456, 1982.
 1248. MULCHAHEY JJ AND NEILL JD. Dopamine levels in the anterior pituitary gland monitored by in vivo electrochemistry. *Brain Res* 386: 332–340, 1986.
 1249. MULLER EE. Some aspects of the neurotransmitter control of anterior pituitary function. *Pharmacol Res* 21: 75–85, 1989.
 1250. MULLER EE, LOCATELLI V, CELLA S, PENALVA A, NOVELLI A, AND COCCHI D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. *Drugs* 25: 399–432, 1983.
 1251. MULLER EE, LOCATELLI V, AND COCCHI D. Neuroendocrine control of growth hormone secretion. *Physiol Rev* 79: 511–607, 1999.
 1252. MULLER JE, STRAUS E, AND YALOW RS. Cholecystokinin and its COOH-terminal octapeptide in the pig brain. *Proc Natl Acad Sci USA* 74: 3035–3037, 1977.
 1253. MULLOY AL AND MALVEN PV. Relationships between concentrations of porcine prolactin in blood serum and milk of lactating sows. *J Anim Sci* 48: 876–881, 1979.
 1254. MURAD F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? *Recent Prog Horm Res* 53: 43–60, 1998.
 1255. MURAI I AND BEN-JONATHAN N. Chronic posterior pituitary lobectomy: prolonged elevation of plasma prolactin and interruption of cyclicity. *Neuroendocrinology* 43: 453–458, 1986.
 1256. MURAI I AND BEN-JONATHAN N. Posterior pituitary lobectomy abolishes the suckling-induced rise in prolactin (PRL): evidence for a PRL-releasing factor in the posterior pituitary. *Endocrinology* 121: 205–211, 1987.

1257. MURAI I AND BEN-JONATHAN N. Prolactin secretion in posterior pituitary lobectomized rats: differential effects of 5-hydroxytryptophan and ether. *Brain Res* 420: 227–232, 1987.
1258. MURAI I, GARRIS PA, AND BEN-JONATHAN N. Time-dependent increase in plasma prolactin after pituitary stalk section: role of posterior pituitary dopamine. *Endocrinology* 124: 2343–2349, 1989.
1259. MURAI I, REICHLIN S, AND BEN-JONATHAN N. The peak phase of the proestrous prolactin surge is blocked by either posterior pituitary lobectomy or antisera to vasoactive intestinal peptide. *Endocrinology* 124: 1050–1055, 1989.
1260. MURAKAMI M, NARAZAKI M, HIBI M, YAWATA H, YASUKAWA K, HAMAGUCHI M, TAGA T, AND ISHIMOTO TK. Critical cytoplasmic region of the interleukin-6 signal transducer, gp130, is conserved in the cytokine receptor family. *Proc Natl Acad Sci USA* 88: 11349–11353, 1991.
1261. MURAKI T, TOKUNAGA Y, NAKADATE T, AND KATO R. Inhibition of prolactin release by cholinergic agonists of the prolactin release induced by morphine. *Naunyn-Schmiedeberg Arch Pharmacol* 308: 249–254, 1979.
1262. MURATA T AND YING S-Y. Transforming growth factor- β and activin inhibit basal secretion of prolactin in a pituitary monolayer culture system. *Proc Soc Exp Biol Med* 198: 599–605, 1991.
1263. MURDOCH GH, POTTER E, NICOLAISEN AK, EVANS RM, AND ROSENFELD MG. Epidermal growth factor rapidly stimulates prolactin gene transcription. *Nature* 300: 192–194, 1982.
1264. MUSTAFA A, NYBERG F, BOGDANOVIC N, ISLAM A, SULIMAN I, LINDGREN U, ROOS P, AND ADEM A. Prolactin binding sites in rat brain and liver: effects of long-term ovariectomy and ovarian steroids. *Neurosci Lett* 200: 179–182, 1995.
1265. MYERS LS AND STEELE MK. The brain renin-angiotensin system and the regulation of prolactin secretion in female rats: influence of ovarian hormones. *J Neuroendocrinol* 1: 299–303, 1989.
1266. MYERS LS AND STEELE MK. The brain renin-angiotensin system and prolactin secretion in the male rat. *Endocrinology* 129: 1744–1748, 1991.
1267. NAGANO M AND KELLY PA. Absence of a putative ATP/GTP binding site in the rat prolactin receptor. *Biochem Biophys Res Commun* 183: 610–618, 1992.
1268. NAGANO M AND KELLY PA. Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. *J Biol Chem* 269: 13337–13345, 1994.
1269. NAGY E AND BERCZI I. Immunodeficiency in hypophysectomized rats. *Acta Endocrinol* 89: 530–537, 1978.
1270. NAGY E AND BERCZI I. Prolactin and contact sensitivity. *Allergy* 36: 429–431, 1981.
1271. NAGY E AND BERCZI I. Hypophysectomized rats depend on residual prolactin for survival. *Endocrinology* 128: 2776–2784, 1991.
1272. NAGY E, BERCZI I, AND RIESEN HF. Regulation of immunity in rats by lactogenic and growth hormones. *Acta Endocrinol* 102: 351–357, 1983.
1273. NAGY E, BERCZI I, WREN E, ASA SL, AND KOVACS K. Immunomodulation by bromocryptine. *Immunopharmacology* 6: 231–243, 1978.
1274. NAGY G AND HALASZ B. Time course of the litter removal-induced depletion in plasma prolactin levels of lactating rats. *Neuroendocrinology* 37: 459–462, 1983.
1275. NAGY G, MULCHAHEY JJ, AND NEILL JD. Autocrine control of prolactin secretion by vasoactive intestinal peptide. *Endocrinology* 122: 364–366, 1988.
1276. NAGY G, MULCHAHEY JJ, SMYTH DG, AND NEILL JD. The glycopeptide moiety of vasopressin-neurophysin precursor is neurohypophysial prolactin releasing factor. *Biochem Biophys Res Commun* 151: 524–529, 1988.
1277. NAGY G, NEILL JD, MAKARA GB, AND HALÁSZ B. Lack of the suckling-induced prolactin release in homozygous Brattleboro rats: the vasopressin-neurophysin-glycopeptide precursor may play a role in prolactin release. *Brain Res* 504: 165–167, 1989.
1278. NAGY G, TAKACS L, AND HALASZ B. (D-Met²,Pro⁵) enkephalinamide causes a decrease in plasma prolactin levels of lactating rats continuously suckled and an increase in those deprived of their litter. *Regul Pept* 8: 321–326, 1984.
1279. NAGY GM, ARENDT A, BÁNKY Z, AND HALÁSZ B. Dehydration attenuates plasma prolactin response to suckling through a dopaminergic mechanism. *Endocrinology* 130: 819–824, 1992.
1280. NAGY GM, BOOKFOR FR, AND FRAWLEY LS. The suckling stimulus increases the responsiveness of mammatropes located exclusively within the central region of the adenohypophysis. *Endocrinology* 128: 761–764, 1991.
1281. NAGY GM, DEMARIA JE, AND FREEMAN ME. Changes in the local metabolism of dopamine in the anterior and neural lobes but not in the intermediate lobe of the pituitary gland during nursing. *Brain Res* 790: 315–317, 1998.
1282. NAGY GM AND FRAWLEY LS. Suckling increases the proportions of mammatropes responsive to various prolactin-releasing stimuli. *Endocrinology* 127: 2079–2084, 1990.
1283. NAGY GM, GORCS TJ, AND HALASZ B. Attenuation of the suckling-induced prolactin release and the high afternoon oscillations of plasma prolactin secretion of lactating rats by antiserum to vasopressin. *Neuroendocrinology* 54: 566–570, 1991.
1284. NAGY GM, KACSOH B, AND HALASZ B. Episodic and pulsatile secretion of prolactin in the lactating rat. In: *Prolactin: Basic and Clinical Correlates*, edited by MacLeod RA, Thorner MO, and Scapagnini U. Padova: Liviana, 1985, p. 123–130.
1285. NAIR NP, LAL S, EUGENIO H, LIZONDO E, THAVUNDAYIL JX, WOOD PL, ETIENNE P, AND GUYDA H. CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects. *Horm Metab Res* 18: 53–55, 1986.
1286. NAKAGAWA Y, SHISAKA S, EMSON PC, AND TOHYAMA M. Distribution of neuropeptide Y in the forebrain and diencephalon: an immunohistochemical analysis. *Brain Res* 361: 52–60, 1985.
1287. NAKANE PK. Classifications of anterior pituitary cell types with immunoenzyme histochemistry. *J Histochem Cytochem* 18: 9–21, 1970.
1288. NAMBA M, GHATEI MA, BISHOP AE, GIBSON SJ, MANN DJ, POLAK JM, AND BLOOM SR. Presence of neuromedin B-like immunoreactivity in the brain and gut of rat and guinea-pig. *Peptides* 6 Suppl 3: 257–263, 1985.
1289. NARAZAKI M, FUJIMOTO M, MATSUMOTO T, MORITA Y, SAITO H, KAJITA T, YOSHIZAKI K, NAKA T, AND KISHIMOTO T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. *Proc Natl Acad Sci USA* 95: 13130–13134, 1998.
1290. NARUSE K, TAKII Y, AND INAGAMI T. Immunohistochemical localization of renin in luteinizing hormone-producing cells of rat pituitary. *Proc Natl Acad Sci USA* 78: 7579, 1981.
1291. NARUSE M, NARUSE K, AND DEMURA H. Recent advances in endothelin research on cardiovascular and endocrine system. *Endocr J* 41: 491–507, 1994.
1292. NARUSE M, NARUSE K, NISHIKAWA T, YOSHIHARA I, OHSUMI K, SUZUKI N, DEMURA R, AND DEMURA H. Endothelin-3 immunoreactivity in gonadotrophs of the human anterior pituitary. *J Clin Endocrinol Metab* 74: 968–972, 1992.
1293. NATHAN C. Nitric oxide as a secretory product of mammalian cells. *FASEB J* 6: 3051–3064, 1992.
1294. NEIDHART M. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. *Biomed Pharmacother* 51: 118–125, 1997.
1295. NEIDHART M. Prolactin in autoimmune diseases. *Proc Soc Exp Biol Med* 217: 408–419, 1998.
1296. NEILL JD. Effect of “stress” on serum prolactin and luteinizing hormone levels during the estrous cycle of the rat. *Endocrinology* 87: 1192–1197, 1970.
1297. NEILL JD. Sexual differences in the hypothalamic regulation of prolactin secretion. *Endocrinology* 90: 1154–1159, 1972.
1298. NEILL JD. Prolactin: its secretion and control. In: *Handbook of Physiology. Endocrinology. The Pituitary Gland and Its Neuroendocrine Control*. Washington, DC: Am. Physiol. Soc., 1974, sect. 7, vol. IV, p. 469–488.
1299. NEILL JD. Neuroendocrine regulation of prolactin secretion. In: *Frontiers in Neuroendocrinology*, edited by Martini L and Ganong WF. New York: Raven, 1980, p. 129–155.
1300. NEILL JD AND FRAWLEY LS. Detection of hormone release from individual cells in mixed populations using a reverse hemolytic plaque assay. *Endocrinology* 112: 1135–1137, 1983.

1301. NEILL JD, FRAWLEY LS, PLOTSKY PM, PECK JD, AND LEONG D. Hypothalamic regulation of prolactin secretion. In: *Pituitary Hormones and Related Peptides*, edited by Motta M, Zanisi M, and Piva F. New York: Academic, 1982, p. 223–241.
1302. NEILL JD, FREEMAN ME, AND TILLSON SA. Control of the proestrus surge of prolactin and luteinizing hormone secretion by estrogens in the rat. *Endocrinology* 89: 1148–1453, 1971.
1303. NEILL JD AND NAGY GM. Prolactin secretion and its control. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 1833–1860.
1304. NEILL JD AND REICHERT LE JR. Development of a radioimmunoassay for rat prolactin and evaluation of the NIAMDD rat prolactin radioimmunoassay. *Endocrinology* 88: 548–555, 1970.
1305. NEILL JD AND SMITH MS. Pituitary-ovarian interrelationships in the rat. In: *Current Topics in Experimental Endocrinology*, edited by James VHT and Martini L. New York: Academic, 1974, p. 73–106.
1306. NELSON WO AND GAUNT R. Initiation of lactation in the hypophysectomized guinea pig. *Proc Soc Exp Biol Med* 34: 671–673, 1936.
1307. NEMETH E, BOLE-FEYSOT C, AND TASHIMA LS. Suppression subtractive hybridization (SSH) identifies prolactin stimulation of p38 MAP kinase gene expression in Nb2 T lymphoma cells: molecular cloning of rat p38 MAP kinase. *J Mol Endocrinol* 20: 151–156, 1998.
1308. NETTI C, GUIDOBONO F, SIBILIA V, PAGANI F, BRAGA PC, AND PECILE A. Evidence of a central inhibition of growth hormone secretion by calcitonin gene-related peptide. *Neuroendocrinology* 49: 242–247, 1989.
1309. NEUMANN I, KREMARK P, AND PITTMAN QJ. Acute, sequence-specific effects of oxytocin and vasopressin antisense oligonucleotides on neuronal responses. *Neuroscience* 69: 997–1003, 1995.
1310. NEUMANN I, LUDWIG M, ENGELMANN M, PITTMAN QJ, AND LANDGRAF R. Simultaneous microdialysis in blood and brain: oxytocin and vasopressin release in response to central and peripheral osmotic stimulation and suckling in the rat. *Neuroendocrinology* 58: 637–645, 1993.
1311. NIALL HD, HOGAN ML, SAUER R, ROSENBLUM IY, AND GREENWOOD FC. Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication. *Proc Natl Acad Sci USA* 68: 866–870, 1971.
1312. NICHOLSON SE AND HILTON DJ. The SOCS proteins: a new family of negative regulators of signal transduction. *J Leukoc Biol* 63: 665–668, 1998.
1313. NICOSIA S, OLIVA D, GIANNATTASIO G, AND SPADA A. The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone. *J Endocrinol Invest* 6: 235–242, 1983.
1314. NICOSIA S, SPADA A, BORGHI C, CORTELAZZI L, AND GIANATTASIO G. Effects of vasoactive intestinal polypeptide (VIP) in human prolactin (PRL) secreting adenomas. *FEBS Lett* 122: 159–162, 1980.
1315. NICOT A, ROSTÈNE W, AND BÉROD A. Hypercorticism induces neurotensin mRNA in rat periventricular hypothalamus. *Neuroreport* 6: 2158–2160, 1995.
1316. NIEUWENHUIS R. *Chemoarchitecture of the Brain*. New York: Springer-Verlag, 1985.
1317. NIIGAWA H, YAMATODANI A, NISHIMURA T, WADA H, AND CACABELOS R. Effect of neurotoxic lesions in the mammillary bodies on the distribution of brain histamine. *Brain Res* 459: 183–186, 1988.
1318. NISHIHARA M AND KIMURA F. Roles of gamma-aminobutyric acid and serotonin in the arcuate nucleus in the control of prolactin and luteinizing hormone secretion. *Jpn J Physiol* 37: 955–961, 1987.
1319. NISHIMURA O, MORIYA T, SUENAGA M, TANAKA Y, ITOH T, KOYAMA N, FUJII R, HINUMA S, KITADA C, AND FUJINO M. Synthesis of new peptides with prolactin-releasing activity by a combination of recombinant DNA technology and a cysteine-specific cyanilation reaction. *Chem Pharm Bull* 46: 1490–1492, 1998.
1320. NISHINO H. Intracerebral grafting of catecholamine producing cells and reconstruction of disturbed brain function. *Neurosci Res* 16: 157–172, 1993.
1321. NISHIZUKA M, SHIVERS BD, LERANTH C, AND PFAFF DW. Ultrastructural characterization of prolactin-like immunoreactivity in rat medial basal hypothalamus. *Neuroendocrinology* 51: 249–254, 1990.
1322. NISWENDER GD AND NETT TM. Corpus luteum and its control in infraprimate species. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 781–816.
1323. NOHARA A, OHMICHU M, KOIKE K, JIKIHARA H, KIMURA A, MASUHARA K, IKEGAMI H, INOUE M, MIYAKE A, AND MURATA Y. Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. *Biochem Biophys Res Commun* 238: 473–477, 1997.
1324. NOKELAINEN P, PELTOKETO H, VIHKO R, AND VIHKO P. Expression cloning of a novel estrogenic mouse 17 beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat. *Mol Endocrinol* 12: 1048–1059, 1998.
1325. NOLIN JM. Molecular homology between prolactin and ovarian peptides: evidence for physiologic modification of the parent molecule by the target. *Peptides* 3: 823–831, 1982.
1326. NOLIN JM AND WITORSCH RJ. Detection of endogenous immunoreactive prolactin in rat mammary epithelial cells during lactation. *Endocrinology* 99: 949–958, 1976.
1327. NORDSTROM O, MELANDER T, HOKFELT T, BARTFAI T, AND GOLDSTEIN M. Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence. *Neurosci Lett* 73: 21–26, 1987.
1328. NOUËL D, FAURE MP, ST PIERRE JA, ALONSO R, QUIRION R, AND BEAUDET A. Differential binding profile and internalization process of neurotensin via neuronal and glial receptors. *J Neurosci* 17: 1795–1803, 1997.
1329. NUMAN M. Maternal behavior. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 221–302.
1330. NUNEZ L AND FRAWLEY LS. alpha-MSH potentiates the responsiveness of mammatropes by increasing Ca^{2+} entry. *Am J Physiol Endocrinol Metab* 274: E971–E977, 1998.
1331. OBAL FJ, PAYNE L, KACSOH B, OPP M, KAPAS L, GROSVENOR CE, AND KRUEGER JM. Involvement of prolactin in the REM sleep-promoting activity of systemic vasoactive intestinal peptide (VIP). *Brain Res* 645: 143–149, 1994.
1332. OBÁL F JR, KACSOH B, BREDOW S, GUHA-THAKURTA N, AND KRUEGER JM. Sleep in rats rendered chronically hyperprolactinemic with anterior pituitary grafts. *Brain Res* 755: 130–136, 1997.
1333. OBAL F JR, OPP M, CADY AB, JOHANNSEN L, AND KRUEGER JM. Prolactin, vasoactive intestinal peptide, and peptide histidine methionine elicit selective increases in REM sleep in rabbits. *Brain Res* 490: 292–300, 1989.
1334. O'CARROLL AM AND KREMPELS K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. *Endocrinology* 136: 5224–5227, 1995.
1335. O'DONOHUE TL, CHARLTON CG, MILLER RL, BODEN G, AND JACOBOWITZ DM. Identification, characterization, and distribution of secretin immunoreactivity in rat and pig brain. *Proc Natl Acad Sci USA* 78: 5221, 1981.
1336. O'DONOHUE TL, CHRONWALL BM, PRUSS RM, MEZEY E, KISS JZ, EIDEN LE, MASSARI VJ, TESSEL RE, PICKEL VM, AND DIMAGGIO DA. Neuropeptide Y and peptide YY neuronal and endocrine systems. *Peptides* 6: 755–768, 1985.
1337. OETTING WS, TAUZON PT, TRAUGH JA, AND WALKER AM. Phosphorylation of prolactin. *J Biol Chem* 261: 1649–1652, 1986.
1338. O'HALLORAN DJ, JONES PM, GHATEI MA, AND BLOOM SR. Rat anterior pituitary neuropeptides following chronic prolactin manipulation: a combined radioimmunoassay and mRNA study. *J Endocrinol* 131: 411–419, 1991.
1339. O'HALLORAN DJ, JONES PM, STEEL JH, GON G, GIAID A, GHATEI MA, POLAK JM, AND BLOOM SR. Effect of endocrine manipulation on anterior pituitary galanin in the rat. *Endocrinology* 127: 467–475, 1990.
1341. OHGO S, KATO Y, CHIHARA K, IMURA H, AND MAEDA K. Effect of hypothalamic surgery on prolactin release induced by 5-hydroxytryptophan (5-HTP) in rats. *Endocrinol Jpn* 23: 485–491, 1976.
1342. OHTA H, KATO Y, MATSUSHITA N, SHIMATSU A, KABAYAMA Y, AND IMURA H. Central inhibitory action of TRH on prolactin secretion in the rat. *Proc Soc Exp Biol Med* 179: 9–12, 1985.
1343. OHTA H, KATO Y, TOJO K, SHIMATSU A, INOUE T, KABAYAMA Y, AND IMURA H. Further evidence that peptide histidine isoleucine (PHI)

- may function as a prolactin releasing factor in rats. *Peptides* 6: 709–713, 1985.
1344. OHTAKI T, WATANABE T, ISHIBASHI Y, KITADA C, TSUDA M, GOTTSCHALL PE, ARIMURA A, AND FUJINO M. Molecular identification of receptor for pituitary adenylate cyclase activating polypeptide. *Biochem Biophys Res Commun* 171: 838–844, 1990.
 1345. OHYAMA Y, MIYAMOTO K, AND SAITO Y. Cloning and characterization of two forms of C-type natriuretic peptide receptor in rat brain. *Biochem Biophys Res Commun* 183: 743–749, 1992.
 1346. OJEDA SR, HARMS PG, AND MCCANN SM. Possible role of cyclic AMP and prostaglandin E_1 in the dopaminergic control of prolactin release. *Endocrinology* 95: 1694–1703, 1974.
 1347. OLGATI VR, GUIDOBONO F, LUISETTO G, NETTI C, BIANCHI C, AND PECILE A. Calcitonin inhibition of physiological and stimulated prolactin secretion in rats. *Life Sci* 29: 585–594, 1981.
 1348. OLGATI VR, NETTI C, GUIDOBONO F, AND PECILE A. High sensitivity to calcitonin of prolactin-secreting control in lactating rats. *Endocrinology* 111: 641–644, 1982.
 1349. OLIVA D, VALLAR L, GIANNATTASIO G, SPADA A, AND NICOSIA S. Combined effects of vasoactive intestinal peptide and dopamine on adenylate cyclase in prolactin-secreting cells. *Peptides* 5: 1067–1070, 1984.
 1350. OLIVE DL, SCHENKEN RS, SABELLA V, MORENO A, AND RIEHL RM. Gonadotropin-releasing hormone antagonists attenuate estrogen/progesterone-induced hyperprolactinemia in monkeys. *Fertil Steril* 51: 1040–1045, 1989.
 1351. OLIVER C, MICAL RS, AND PORTER JC. Hypothalamic-pituitary vasculature: evidence for retrograde blood flow in the pituitary stalk. *Endocrinology* 101: 598–604, 1977.
 1352. OLLIVIER-BOUSQUET M, KANN G, AND DURAND G. Prolactin transit through mammary epithelial cells and appearance in milk. *Endocr Regul* 27: 115–124, 1993.
 1353. OLSON L, FUXE K, AND HÖKFELT T. The effect of pituitary transplants on the tubero-infundibular dopamine neurons in various endocrine states. *Acta Endocrinol* 71: 233–244, 1972.
 1354. ONALI P, EVA C, OLIANAS MC, SCHWARTZ JP, AND COSTA E. In GH_3 cells, acetylcholine and vasoactive intestinal polypeptide antagonistically modulate adenylate cyclase, cyclic AMP content, and prolactin secretion. *Mol Pharmacol* 24: 189–194, 1983.
 1355. ONALI P, SCHWARTZ JP, AND COSTA E. Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal polypeptide in anterior pituitary. *Proc Natl Acad Sci USA* 78: 6531–6534, 1981.
 1356. ONDO JG AND DOM R. Arcuate nucleus: a site for γ -aminobutyric acid regulation of prolactin secretion. *Brain Res* 381: 43–48, 1986.
 1357. ONDO JG AND PASS KA. The effects of neurally active amino acids on prolactin secretion. *Endocrinology* 98: 1248–1252, 1976.
 - 1357a. O'NEAL KD, CHARI MV, McDONALD CH, COOK RG, YU-LEE L-Y, MORRISSETT JD, AND SHEARER WT. Multiple *cis-trans* conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse phase HPLC, CD and NMR. *Biochem J* 315: 833–844, 1996.
 1358. ORMANDY CJ, CAMUS A, BARRA J, DAMOTTE JD, LUCAS B, BUTEAU H, EDERY M, BROUSSE N, BABINET C, BINART N, AND KELLY PA. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. *Genes Dev* 11: 167–178, 1997.
 1359. OTSUKA M AND YOSHIOKA K. Neurotransmitter functions of mammalian tachykinins. *Physiol Rev* 73: 229–308, 1993.
 1360. OTTLECH A, SNYDER GD, AND MCCANN SM. Regulatory role of galanin in control of hypothalamic-anterior pituitary function. *Proc Natl Acad Sci USA* 85: 9861–9865, 1988.
 1361. OVADIA H AND ABRAMSKY O. Dopamine receptors on isolated membranes of rat lymphocytes. *J Neurosci Res* 18: 70–74, 1987.
 1362. OWENS DF, BOYCE LH, DAVIS MBE, AND KRIEGSTEIN AR. Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recording and calcium imaging. *J Neurosci* 16: 6414–6423, 1996.
 1363. OWEBACH D, RUTTER WJ, COOKE NE, MARTIAL JA, AND SHOWS TB. The prolactin gene is located on chromosome 6 in humans. *Science* 212: 815–816, 1981.
 1364. PAGLIN S, STUKENBROK H, AND JAMIESON JD. Interaction of angiotensin II with dispersed cells from the anterior pituitary of the male rat. *Endocrinology* 114: 2284–2292, 1984.
 1365. PAHUJA DN AND DELUCA HF. Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. *Science* 214: 1038–1039, 1981.
 1366. PALAZZI E, FISONE G, HOKFELT T, AND BARTFAI T. Galanin inhibits the muscarinic stimulation of phosphoinositide turnover in rat ventral hippocampus. *Eur J Pharmacol* 148: 479, 1988.
 1367. PALKOVITS M, KISS JZ, BEINFELD MC, AND BROWNSTEIN MJ. Cholecystokinin in the hypothalamo-hypophyseal system. *Brain Res* 299: 186–189, 1984.
 1368. PAN J-T. Neuroendocrine functions of dopamine. In: *Neurotransmitters and Neuromodulators*, edited by Stone T. Boca Raton, FL: CRC, 1996, p. 213–232.
 1369. PAN J-T AND GALA RR. Central nervous system regions involved in the estrogen-induced afternoon prolactin surge. I. Lesion studies. *Endocrinology* 117: 382–387, 1985.
 1370. PAN J-T AND GALA RR. Central nervous system regions involved in the estrogen-induced afternoon prolactin surge. II. Implantation studies. *Endocrinology* 117: 388–395, 1985.
 1371. PAN JT, KOW LM, AND PFAFF DW. Single-unit activity of hypothalamic arcuate neurons in brain tissue slices. Effects of anterior pituitary hormones, cholecystokinin-octapeptide, and neurotransmitters. *Neuroendocrinology* 43: 189–196, 1986.
 1372. PAN J-T AND MAI L-M. Dopamine antagonism does not potentiate the effects of oxytocin and vasopressin on prolactin secretion. *Life Sci* 47: 2443–2450, 1990.
 1373. PAN J-T, TIAN Y, LOOKINGLAND KJ, AND MOORE KE. Neurotensin-induced activation of hypothalamic dopaminergic neurons is accompanied by a decrease in pituitary secretion of prolactin and α -melanocyte-stimulating hormone. *Life Sci* 50: 2011–2017, 1992.
 1375. PANETTA R AND PATEL YC. Expression of all five somatostatin receptors (hSSTR1–5) in pituitary tumors. *Life Sci* 56: 333–342, 1995.
 1376. PANULA P, PIRVOLA U, AUVINEN S, AND SAIRAKSINEN M. Histamine-immunoreactive nerve fibres in the rat brain. *Neuroscience* 28: 585–610, 1989.
 1377. PANULA P, YANG H-YT, AND COSTA E. Comparative distribution of bombesin/GRP- and substance P-like immunoreactivities in rat hypothalamus. *J Comp Neurol* 224: 606–617, 1984.
 1378. PANULA-LEHTO E, AHTEE L, TUOMINEN RK, AND MANNISTO PT. Comparison of the effects of intraventricular taurine, GABA and homotaurine on serum prolactin levels in male rats. *Pharmacol Toxicol* 65: 152–156, 1989.
 1379. PAPE JR AND TRAMU G. Suckling-induced changes in neuropeptide Y and proopiomelanocortin gene expression in the arcuate nucleus of the rat: evaluation of a putative intervention of prolactin. *Neuroendocrinology* 63: 540–549, 1996.
 1380. PARKER DC, ROSSMAN LG, AND VAN DER LAAN EF. Relation of sleep-entrained human prolactin release to REM-nonREM cycles. *J Clin Endocrinol Metab* 38: 646–651, 1974.
 1381. PARKER SL, CARROLL BL, KALRA SP, ST-PIERRE S, FOURNIER A, AND CROWLEY WR. Neuropeptide Y Y2 receptors in hypothalamic neuroendocrine areas are upregulated by estradiol and decreased by progesterone cotreatment in the ovariectomized rat. *Endocrinology* 137: 2896–2900, 1996.
 1382. PARKS JS, ADESS ME, AND BROWN MR. Genes regulating hypothalamic and pituitary development. *Acta Paediatr* 86: 28–32, 1997.
 1383. PARRAGUEZ VH, VALENZUELA GJ, VERGARA M, DUCSAY CA, YELLON SM, AND SERÓN-FERRÉ M. Effect of constant light on fetal and maternal prolactin rhythms in sheep. *Endocrinology* 137: 2355–2361, 1996.
 1384. PASQUALINI C, LENOIR V, ABED AE, AND KERDELHUE B. Anterior pituitary dopamine receptors during the rat estrous cycle. *Neuroendocrinology* 38: 39–44, 1984.
 1385. PASQUALINI C, LEVIEL V, GUIBERT B, FAUCON BIGUET N, AND KERDELHUE B. Inhibitory actions of acute estradiol treatment on the activity and quantity of tyrosine hydroxylase in the median eminence of ovariectomized rats. *J Neuroendocrinol* 3: 575–580, 1991.
 1386. PASS KA AND GONDO J. The effects of gamma-aminobutyric acid on prolactin and gonadotropin secretion in the unanesthetized rat. *Endocrinology* 100: 1437–1442, 1977.
 1387. PASTEELS JL, GAUSSER P, DANGUY A, ECTORS F, AND NICOLL CS. Morphology of the lactotropes and somatotropes of man and rhesus monkey. *J Clin Endocrinol Metab* 34: 959–967, 1972.
 1388. PASTERKAMP RJ, YURI K, MORITA N, AND KAWATA M. Differential

- expression of estrogen receptor mRNA and protein in the female rat preoptic area. *Neurosci Lett* 239: 81–84, 1997.
1389. PASTORCIC M, DE A, BOYADJEVA N, VALE W, AND SARKAR DK. Reduction in the expression and action of transforming growth factor beta 1 on lactotrophs during estrogen-induced tumorigenesis in the anterior pituitary. *Cancer Res* 55: 4892–4898, 1995.
 1390. PATEL YC. General aspects of the biology and function of somatostatin. In: *The Role of Somatostatin. Basic and Clinical Aspects of Neuroscience*, edited by Weil C, Muller EE, and Thorner MO. Berlin: Springer-Verlag, 1992, p. 1–16.
 1391. PATEL YC. Molecular pharmacology of somatostatin receptor subtypes. *J Endocrinol Invest* 20: 348–367, 1997.
 1392. PATEL YC, GREENWOOD M, PANETTA R, HUKOVIC N, GRIGORAKIS S, ROBERTSON LA, AND SRIKANT CB. Molecular biology of somatostatin receptor subtypes. *Metabolism* 45: 31–38, 1996.
 1393. PATEL YC, GREENWOOD MT, PANETTA R, DEMCHYSHYN L, NIZNIK HB, AND SRIKANT CB. Mini review: the somatostatin receptor family. *Life Sci* 57: 1249–1265, 1995.
 1394. PATEL YC AND SRIKANT CB. Somatostatin mediation of adenylyl cyclase secretion. *Annu Rev Physiol* 48: 551–567, 1986.
 1395. PATTERSON JC AND CHILDS GV. Nerve growth factor and its receptor in the anterior pituitary. *Endocrinology* 135: 1689–1696, 1994.
 1396. PATTERSON JC AND CHILDS GV. Nerve growth factor in the anterior pituitary: regulation of secretion. *Endocrinology* 135: 1697–1704, 1994.
 1397. PAULSEN RH, PAULSEN EJ, GAUTVIK KM, AND GORDELADZE JO. Modulation of G proteins and second messenger responsiveness by steroid hormones in GH₃ rat pituitary tumour cells. *Acta Physiol Scand* 146: 511–518, 1992.
 1398. PELLEGRINI I, LEBRUN J-J, ALI S, AND KELLY PA. Expression of prolactin and its receptor in human lymphoid cells. *Mol Endocrinol* 6: 1023–1031, 1992.
 1399. PELLETIER G, LECLERC R, PUVIANI R, AND POLAK JM. Electron immuno-cytochemistry of vasoactive intestinal peptide (VIP) in the rat brain. *Brain Res* 210: 356–360, 1981.
 1400. PELLETIER G AND TONG Y. Lactation but not prolactin increases the levels of pre-proNPY messenger RNA in the rat arcuate nucleus. *Mol Cell Neurosci* 3: 286–290, 1992.
 1401. PENIT-SORIA J, DURAND C, BESSON MJ, AND HERVE D. Levels of stimulatory G protein are increased in the rat striatum after neonatal lesion of dopamine neurons. *Neuroreport* 8: 829–833, 1997.
 1402. PENKE B, KOVACS GL, ZSIGO J, KADAR T, SZABO G, KOVACS K, AND TELEGDY G. In vivo sulfation of cholecystokinin octapeptide. Possible interactions of the two forms of cholecystokinin with dopamine in the brain. *Ann NY Acad Sci* 448: 293–305, 1985.
 1403. PERKINS KL AND WONG RKS. The depolarizing GABA response. *Can J Physiol Pharmacol* 75: 516–519, 1997.
 1404. PERROT-APPLANAT M, GUALILLO O, BUTEAU H, EDERY M, AND KELLY PA. Internalization of prolactin receptor and prolactin in transfected cells does not involve nuclear translocation. *J Cell Sci* 110: 1123–1132, 1997.
 1405. PERT CB AND SNYDER SH. Opiate receptor: demonstration in nervous tissue. *Science* 179: 1011–1014, 1973.
 1406. PETERS LL, HOEFER MT, AND BEN-JONATHAN N. The posterior pituitary: regulation of anterior pituitary prolactin secretion. *Science* 213: 659–661, 1981.
 1407. PETRAGLIA F, VALE W, AND RIVIER C. Beta-endorphin and dynorphin participate in the stress-induced release of prolactin in the rat. *Neuroendocrinology* 45: 338–342, 1987.
 1408. PETRAGLIA F, VAUGHAN J, AND VALE W. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. *Proc Natl Acad Sci USA* 86: 5114–5117, 1989.
 1409. PETRALIA RS AND WENTHOLD RJ. Types of excitatory amino acid receptors and their localization in the nervous system and hypothalamus. In: *Excitatory Amino Acids: Their Role in Neuroendocrine Function*, edited by Brann DW and Mahesh VB. Boca Raton, FL: CRC, 1996, p. 56–101.
 1410. PEURANEN E, VASAR E, KOKS S, VOLKE V, LANG A, RAUHALA P, AND MANNISTO PT. Further studies on the role of cholecystokinin-A and -B receptors in secretion of anterior pituitary hormones in male rats. *Neuropeptides* 28: 1–11, 1995.
 1411. PEZET A, FAVRE H, KELLY PA, AND EDERY M. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. *J Biol Chem* 274: 24497–24502, 1999.
 1412. PEZET A, FERRAG F, KELLY PA, AND EDERY M. Tyrosine docking sites of the rat prolactin receptor required for association and activation of Stat5. *J Biol Chem* 272: 25043–25050, 1997.
 1413. PHELPS CJ, CARLSON SW, VACCARELLA MY, AND FELTEN SY. Developmental assessment of hypothalamic tuberoinfundibular dopamine in prolactin-deficient dwarf mice. *Endocrinology* 132: 2715–2722, 1993.
 1414. PHELPS CJ, VACCARELLA MY, ROMERO MI, AND HURLEY DL. Postnatal reduction in number of hypothalamic tuberoinfundibular dopaminergic neurons in prolactin-deficient dwarf mice. *Neuroendocrinology* 59: 189–196, 1994.
 1415. PI XJ AND GRATAN DR. Distribution of prolactin receptor immunoreactivity in the brain of estrogen-treated, ovariectomized rats. *J Comp Neurol* 394: 462–474, 1998.
 1416. PICANCO-DINIZ DL, VALENCA MM, FRANCI CR, AND ANTUNES-RODRIGUES J. Role of substance P in the medial preoptic area in the regulation of gonadotropin and prolactin secretion in normal or orchidectomized rats. *Neuroendocrinology* 51: 675–682, 1990.
 1417. PICCOLETTI R, MARONI P, BENDINELLI P, AND BERNELLI-ZAZZERA A. Rapid stimulation of mitogen-activated protein kinase of rat liver by prolactin. *Biochem J* 303: 429–433, 1994.
 1418. PIEPER DR AND GALA RR. The effect of light on the prolactin surges of pseudopregnant and ovariectomized, estrogenized rats. *Biol Reprod* 20: 727–732, 1979.
 1419. PIERCY M AND SHIN SH. Comparative studies of prolactin secretion in estradiol-primed and normal male rats induced by ether stress, pimozide and TRH. *Neuroendocrinology* 31: 270–275, 1980.
 1420. PILOTTE NS AND PORTER JC. Dopamine in hypophysial portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine. *Endocrinology* 108: 2137–2141, 1981.
 1421. PLOTSKY PM, DE GREEF WJ, AND NEILL JD. In situ voltammetric microelectrodes: application to the measurement of median eminence catecholamine release during simulated suckling. *Brain Res* 250: 251–262, 1982.
 1422. PLOTSKY PM, GIBBS DM, AND NEILL JD. Liquid chromatographic-electrochemical measurement of dopamine in hypophysial stalk blood of rats. *Endocrinology* 102: 1887–1894, 1978.
 1423. PLOTSKY PM AND NEILL JD. The decrease in hypothalamic dopamine secretion induced by suckling: comparison of voltammetric and radioisotopic methods of measurement. *Endocrinology* 110: 691–696, 1982.
 1424. PLOTSKY PM AND SAWCHENKO PE. Hypophysial-portal plasma levels, median eminence content, and immunohistochemical staining of corticotropin-releasing factor arginine vasopressin, and oxytocin after pharmacological adrenalectomy. *Endocrinology* 120: 1361–1369, 1987.
 1425. PONTIROLI AE, ALBERETTO M, RESTELLI L, AND FACCHINETTI A. Effect of bombesin and ceruletide on prolactin, growth hormone, luteinizing hormone, and parathyroid hormone release in normal human males. *J Clin Endocrinol Metab* 51: 1303–1305, 1980.
 1426. PONTIROLI AE AND SCARPIGNATO C. Effect of bombesin on basal and stimulated secretion of some pituitary hormones in humans. *Horm Res* 23: 129–135, 1986.
 1427. PORTER TE, CHAPMAN LE, VAN DOLAH FM, AND FRAWLEY LS. Normal differentiation of prolactin cells in neonatal rats requires a maternal signal specific to early lactation. *Endocrinology* 128: 792–796, 1991.
 1428. PORTER TE, ELLERKMANN E, AND FRAWLEY LS. Acute recruitment of prolactin-secreting cells is regulated posttranscriptionally. *Mol Cell Endocrinol* 84: 23–31, 1992.
 1429. PORTER TE AND FRAWLEY LS. Stimulation of prolactin cell differentiation in vitro by a milk-borne peptide. *Endocrinology* 129: 2707–2713, 1991.
 1430. POSTEL-VINAY M-C, BELAIR L, KAYSER C, KELLY PA, AND DJIANE J. Identification of prolactin and growth hormone binding proteins in rabbit milk. *Proc Natl Acad Sci USA* 88: 6687–6690, 1991.
 1431. POULTON AL, ENGLISH J, SYMONS AM, AND ARENDT J. Effects of various melatonin treatments on plasma prolactin concentrations in the ewe. *J Endocrinol* 108: 287–292, 1986.
 1432. POULTON AL, ENGLISH J, SYMONS AM, AND ARENDT J. Plasma prolactin concentrations in pinealectomized ewes receiving melatonin

- treatment and in pineal intact ewes maintained under a non-24-hour photoperiod. *J Pineal Res* 6: 243–252, 1989.
1433. POWERS CA. Anterior pituitary glandular kallikrein: a putative prolactin processing protease. *Mol Cell Endocrinol* 90: C15–C20, 1993.
1434. PRAYDAYROL L, JORNWALL H, MUTT V, AND RIBERT A. N-terminally extended somatostatin: the primary structure of somatostatin-28. *FEBS Lett* 109: 55–58, 1980.
1435. PREVARSKAYA NB, SKRYMA RN, VACHER P, DANIEL N, DJIANE J, AND DUFY B. Role of tyrosine phosphorylation in potassium channel activation. Functional association with prolactin receptor and JAK2 tyrosine kinase. *J Biol Chem* 270: 24292–24299, 1995.
1436. PREZIOSI P, MARTIRE M, NAVARRA P, PISTRITTO G, AND VACCA M. Prolactin-lowering ability of (+/–)-idazoxan may be linked to a central noradrenergic-serotonergic interplay. *J Pharmacol Exp Ther* 249: 256–263, 1989.
1437. PROESMANS M, VAN BAELE A, ANDRIES M, AND DENEFF C. Mitogenic effects of nerve growth factor on different cell types in reaggregate cell cultures of immature rat pituitary. *Mol Cell Endocrinol* 134: 119–127, 1997.
1438. PUTNAM CD, BRANN DW, AND MAHESH VB. Acute activation of the adrenocorticotropin-adrenal axis: effect on gonadotropin and prolactin secretion in the female rat. *Endocrinology* 128: 2558–2566, 1991.
1439. RACAGNI G, APUD JA, COCCHI D, LOCATELLI V, IULIANO E, CASANUEVA F, AND MULLER EE. Regulation of prolactin secretion during suckling: involvement of the hypothalamo-pituitary GABAergic system. *J Endocrinol Invest* 7: 481–487, 1984.
1440. RACAGNI G, APUD JA, COCCHI D, LOCATELLI V, AND MULLER EE. GABAergic control of anterior pituitary hormone secretion. *Life Sci* 31: 823–838, 1982.
1441. RACAGNI G, APUD JA, LOCATELLI V, COCCHI D, NISTICO G, DI GIORGIO RM, AND MULLER EE. GABA of CNS origin in the rat anterior pituitary inhibits prolactin secretion. *Nature* 281: 575–578, 1979.
1442. RACAGNI G, APUD JA, MASOTTO C, ROVESCILLI AC, COCCHI D, LOCATELLI V, AND MULLER EE. The hypothalamo-pituitary GABAergic regulation of prolactin release in the rat. *Adv Biochem Psychopharmacol* 42: 103–117, 1986.
1443. RACKE K, HOLZBAUER M, COOPER TR, AND SHARMAN DF. Dehydration increases the electrically evoked dopamine release from the neural and intermediate lobes of the rat hypophysis. *Neuroendocrinology* 43: 6–11, 1986.
1444. RALL LB, SCOTT J, BELL GI, CRAWFORD RJ, PENSCHOW JD, NIALL HD, AND COGHLAN JP. Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. *Nature* 313: 228–231, 1985.
1445. RAM PA AND WAXMAN DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear Jak2 tyrosine kinase. *J Biol Chem* 272: 17694–17702, 1997.
1446. RAMALHO MJ, REIS LC, ANTUNES-RODRIGUES J, NONAKA KO, AND DE C. Reduced prolactin release during immobilization stress in thyrotoxic rats: role of the central serotonergic system. *Horm Metab Res* 27: 121–125, 1995.
1447. RAMSEY DH AND BERN HA. Stimulation by ovine prolactin of fluid transfer in everted sacs of rat small intestine. *J Endocrinol* 53: 453–459, 1972.
1448. RANCE N, WISE PM, SELMANOFF MK, AND BARRACLOUGH CA. Catecholamine turnover rates in discrete hypothalamic areas and associated changes in median eminence luteinizing hormone-releasing hormone and serum gonadotropins on proestrus and diestrous day 1. *Endocrinology* 108: 1795–1802, 1981.
1449. RAO Y-P, BUCKLEY DJ, OLSON MD, AND BUCKLEY AR. Nuclear translocation of prolactin: collaboration of tyrosine kinase and protein kinase C activation in rat Nb2 node lymphoma cells. *J Cell Physiol* 163: 266–276, 1995.
1450. RAO Y, OLSON MD, BUCKLEY DJ, AND BUCKLEY AR. Nuclear colocalization of prolactin and the prolactin receptor in rat Nb2 node lymphoma cells. *Endocrinology* 133: 3062–3065, 1993.
1451. RAO YP, BUCKLEY DJ, AND BUCKLEY AR. The nuclear prolactin receptor: a 62-kDa chromatin-associated protein in rat Nb2 lymphoma cells. *Arch Biochem Biophys* 322: 506–515, 1995.
1452. RATOVONDRAHONA D, FAHMI M, FOURNIER B, ODESSA MF, SKRYMA R, PREVARSKAYA N, DJIANE J, AND DUFY B. Prolactin induces an inward current through voltage-independent Ca^{2+} channels in Chinese hamster ovary cells stably expressing prolactin receptor. *J Mol Endocrinol* 21: 85–95, 1998.
1453. RATOVONDRAHONA D, FOURNIER B, ODESSA MF, AND DUFY B. Prolactin stimulation of phosphoinositide metabolism in CHO cells stably expressing the PRL receptor. *Biochem Biophys Res Commun* 243: 127–130, 1998.
1454. RAYMOND V, BEAULIEU M, LABRIE F, AND BOISSIER J. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. *Science* 200: 1173–1175, 1978.
1455. REDEN J. Molsidomine. *Blood Vessels* 27: 282–294, 1990.
1456. REGOLI D, BOUDON A, AND FAUCHERE JL. Receptors and antagonists for substance P and related peptides. *Pharmacol Rev* 46: 551–599, 1994.
1457. REHFELD J, HANSEN HF, AND MARLEY PD. Molecular forms of cholecystokinin in the brain and the relationship to neuronal gastrins. *Ann NY Acad Sci* 448: 11–23, 1985.
1458. REHFELD JF. Localization of gastrins to neuro- and adenohypophysis. *Nature* 271: 771, 1978.
1459. REHFELD JF, LINDHOLM J, ANDERSEN BN, BARDRAM L, CANTOR P, FENGER M, AND LUDECKE DK. Pituitary tumors containing cholecystokinin. *N Engl J Med* 316: 1244–1247, 1987.
1460. REICHLIN S. Somatostatin. *N Engl J Med* 309: 910, 1984.
1461. REICHLIN S. Prolactin and growth hormone secretion in stress. *Adv Exp Med Biol* 245: 353–376, 1988.
1462. REISINE T. Somatostatin. *Cell Mol Neurobiol* 15: 597–614, 1995.
1463. REISINE T AND BELL GI. Molecular biology of somatostatin receptors. *Endocr Rev* 16: 427–442, 1995.
1464. REN R, MAYER BJ, CICCHETTI P, AND BALTIMORE D. Identification of ten amino acid proline-rich SH3 binding site. *Science* 259: 1157–1161, 1993.
1465. RETTORI V, MILENKOVIC L, RIEDEL M, AND MCCANN SM. Physiological role of neuropeptide Y (NPY) in control of anterior pituitary hormone release in the rat. *Endocrinol Exp* 24: 37–45, 1990.
1466. RETTORI V, MILENKOVIC L, RIEDEL M, AND MCCANN SM. The role of neuropeptide Y (NPY) in control of gonadotropin and prolactin release in the rat. *Gynecol Endocrinol* 4: 169–179, 1990.
1467. REYMOND MJ, KAUR C, AND PORTER JC. An inhibitory role for morphine on the release of dopamine into hypophysial portal blood and on the synthesis of dopamine in tuberoinfundibular neurons. *Brain Res* 262: 253–258, 1983.
1468. REYNOLDS LR, RUBEL AM, AND NIKITOVITCH-WINER MB. Cimetidine inhibits the histamine-induced prolactin release in male rats. *Proc Soc Exp Biol Med* 163: 322–325, 1980.
1469. REY-ROLDAN EB, LUX-LANTOS V, CHAMSON-REIG A, AND LIBERTUN C. In vivo interaction of baclofen, TRH and serotonin on PRL and TSH secretion in the developing and adult male and female rats. *Life Sci* 61: 2283–2290, 1997.
1470. RICCI A AND AMENTA F. Dopamine D_5 receptors in human peripheral blood lymphocytes: a radioligand binding study. *J Neuroimmunol* 53: 1–7, 1994.
1471. RICHARDS JS AND WILLIAMS JL. Luteal cell receptor content for prolactin (PRL) and luteinizing hormone (LH). Regulation by LH and PRL. *Endocrinology* 99: 1571–1581, 1976.
1472. RICHARDSON DW, GOLDSMITH LT, POHL CR, SCHALLENBERGER E, AND KNOBIL E. The role of prolactin in the regulation of the primate corpus luteum. *J Clin Endocrinol Metab* 60: 501–504, 1985.
1473. RIDDICK DH AND DALY DC. Decidual prolactin production in human gestation. *Semin Perinatol* 6: 229–237, 1982.
1474. RIDDICK DH, DALY DC, AND WALTERS CA. The uterus as an endocrine compartment. *Clin Perinatol* 10: 627–639, 1983.
1475. RIDDICK DH, LUCIANO AA, KUSMIK WF, AND MASLAR IA. De novo synthesis of prolactin by human decidua. *Life Sci* 23: 1913–1921, 1978.
1476. RIDDICK DH AND MASLAR IA. The transport of prolactin by human fetal membranes. *J Clin Endocrinol Metab* 52: 220–224, 1981.
1477. RIDDLE O, BATES RW, AND DYKSHORN SW. The preparation, identification and assay of prolactin—a hormone of anterior pituitary. *Am J Physiol* 105: 191–216, 1933.
1478. RIDGWAY EC, KLIBANSKI A, LANDENSON PW, CLEMMONS D, MCARTHUR IZ, MARTORANA MA, AND ZERVAS NT. Pure alpha-secreting pituitary adenomas. *N Engl J Med* 304: 1254–1259, 1981.
1479. RILLEMA JA, CAMPBELL GS, LAWSON DM, AND CARTER-SU C. Evidence

- for a rapid stimulation of tyrosine kinase activity by prolactin in Nb₂ rat lymphoma cells. *Endocrinology* 131: 973–975, 1992.
1480. RILLEMA JA, GOLDEN K, AND JENKINS MA. Effect of prolactin on alpha-aminoisobutyric acid uptake in mouse mammary gland explants. *Am J Physiol Endocrinol Metab* 262: E402–E405, 1992.
 1481. RISKIND PN, MILLARD WJ, AND MARTIN JB. Evidence that thyrotropin-releasing hormone is not a major prolactin-releasing factor during suckling in the rat. *Endocrinology* 115: 312–316, 1984.
 1482. RIVIER C, BROWN M, AND VALE W. Effect of neurotensin, substance P and morphine sulfate on the secretion of prolactin and growth hormone in the rat. *Endocrinology* 100: 751–754, 1977.
 1483. RIVIER C, RIVIER J, AND VALE W. The effect of bombesin and related peptides on prolactin and growth hormone secretion in the rat. *Endocrinology* 102: 519–522, 1978.
 1484. RIVIER C AND VALE W. Effects of gamma-aminobutyric acid and histamine on prolactin secretion in the rat. *Endocrinology* 101: 506–511, 1977.
 1485. RIVIER C, VALE W, LING N, BROWN M, AND GUILLEMIN R. Stimulation in vivo of the secretion of prolactin and growth hormone by β -endorphin. *Endocrinology* 100: 238–241, 1977.
 1486. ROBBERECHT W, ANDRIES M, AND DENEFF C. Angiotensin II is retained in gonadotrophs of pituitary cell aggregates cultured in serum-free medium but does not mimic the effects of exogenous angiotensins and luteinizing-hormone-releasing hormone on growth hormone release. *Neuroendocrinology* 56: 550–560, 1992.
 1487. ROBERTSON MC, COSBY H, FRESNOZA A, CATTINI PA, SHIU RPC, AND FRIESEN HG. Expression, purification, and characterization of recombinant rat placental lactogen-I: a comparison with the native hormone. *Endocrinology* 134: 393–400, 1994.
 1488. ROBERTSON MC, COSBY H, AND SHIU RPC. Rat placental lactogen-I variant (rPL-I_v), product of a unique gene, is biologically different from rPL-I. *Endocrinology* 137: 5242–5249, 1996.
 1489. ROBERTSON MC, CROZE F, SCHROEDTER IC, AND FRIESEN HG. Molecular cloning and expression of rat placental lactogen-I complementary deoxyribonucleic acid. *Endocrinology* 127: 702–710, 1990.
 1490. ROBERTSON MC, GILLESPIE B, AND FRIESEN HG. Characterization of the two forms of rat placental lactogen (rPL): rPL-I and rPL-II. *Endocrinology* 111: 1862–1866, 1982.
 1491. ROBERTSON MC, SCHROEDTER IC, AND FRIESEN HG. Molecular cloning and expression of rat placental lactogen-I_v, a variant of rPL-I present in late pregnant rat placenta. *Endocrinology* 129: 2746–2756, 1991.
 1492. ROBERTSON MT, BAYAJIAN MJ, PATTERSON K, AND ROBERTSON WVB. Modulation of the chloride concentration of human sweat by prolactin. *Endocrinology* 119: 2439–2444, 1986.
 1493. ROBINSON AG, ROBERTS MM, EVRON WA, JANOCKO LE, AND HOFFMAN GE. Total translation of vasopressin and oxytocin in neurohypophysis of rats. *Am J Physiol Regulatory Integrative Comp Physiol* 257: R109–R117, 1989.
 1494. ROHRER SP, BIRZIN ET, MOSLEY RT, BERK SC, HUTCHINS SM, SHEN DM, XIONG Y, HAYES EC, PARMAR RM, FOOR F, MITRA SW, DEGRADO SJ, SHU M, KLOPP JM, CAI SJ, BLAKE A, CHAN WW, PASTERNAK A, YANG L, PATCHETT AA, SMITH RG, CHAPMAN KT, AND SCHAEFFER JM. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. *Science* 282: 737–740, 1998.
 1495. ROKY R, PAUT-PAGANO L, GOFFIN V, KITAHAMA K, VALATX JL, KELLY PA, AND JOUVET M. Distribution of prolactin receptors in the rat forebrain. Immunohistochemical study. *Neuroendocrinology* 63: 422–429, 1996.
 1496. ROKY R, VALATX J-L, AND JOUVET M. Effect of prolactin on the sleep-wake cycle in the rat. *Neurosci Lett* 156: 117–120, 1993.
 1497. ROLAND BL, SUTTON SW, WILSON SJ, LUO L, PYATI J, HUVAR R, ERLANDER MG, AND LOVENBERG TW. Anatomical distribution of prolactin-releasing peptide and its receptor suggests additional functions in the central nervous system and periphery. *Endocrinology* 140: 5736–5745, 1999.
 1498. ROMERO MI AND PHELPS CJ. Prolactin replacement during development prevents the dopaminergic deficit in hypothalamic arcuate nucleus in prolactin-deficient Ames dwarf mice. *Endocrinology* 133: 1860–1870, 1993.
 1499. RONDEEL JM, DE GREEF WJ, VISSER TJ, AND VOOGT JL. Effect of suckling on the in vivo release of thyrotropin-releasing hormone, dopamine and adrenaline in the lactating rat. *Neuroendocrinology* 48: 93–96, 1988.
 1500. RONNEKLEIV OK, KELLY MJ, AND ESKAY RL. Distribution of immunoreactive substance P neurons in the hypothalamus and pituitary of the rhesus monkey. *J Comp Neurol* 224: 51–59, 1984.
 1501. ROSENBERG SM, MASLAR IA, AND RIDDICK DH. Decidual production of prolactin in late gestation: further evidence for a decidual source of amniotic fluid prolactin. *Am J Obstet Gynecol* 138: 681–685, 1980.
 1502. ROSENFELD MG, MERMOD JJ, AMARA SG, SWANSON LW, SAWCHENKO PE, RIVIER J, VALE WW, AND EVANS RM. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. *Nature* 304: 129–135, 1983.
 1503. ROSSER AE, REMFRY CJ, AND KEVERNE EB. Restricted exposure of mice to primer pheromones coincident with prolactin surges blocks pregnancy by changing hypothalamic dopamine release. *J Reprod Fertil* 87: 553–559, 1989.
 1504. ROSSIER J, FRENCH E, RIVIER C, SHIBASAKI T, GUILLEMIN R, AND BLOOM FE. Stress-induced release of prolactin: blockade by dexamethasone and naloxone may indicate beta-endorphin mediation. *Proc Natl Acad Sci USA* 77: 666–669, 1980.
 1505. ROSSO DI SAN SECONDO VEM, FITCH CA, ANIASI A, CLOSE FT, SIRCHIA G, AND FREEMAN ME. Bromocryptine prevents the immunosuppression induced in mice by anti-lymphocytic serum. *Transplant Proc* 28: 3193–3195, 1996.
 1506. ROSTENE WH. Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (VIP). *Prog Neurobiol* 22: 103–129, 1984.
 1507. ROSTENE WH AND ALEXANDER MJ. Neurotensin and neuroendocrine regulation. *Front Neuroendocrinol* 18: 115–173, 1997.
 1508. ROTHCHILD I. The regulation of the mammalian corpus luteum. *Rec Prog Horm Res* 37: 183–298, 1981.
 1509. ROWE DW AND ERSKINE MS. c-Fos proto-oncogene activity induced by mating in the preoptic area, hypothalamus and amygdala in the female rat: role of afferent input via the pelvic nerve. *Brain Res* 621: 25–34, 1993.
 1510. RUBANYI G AND VANHOUTTE PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. *J Physiol (Lond)* 364: 45–56, 1985.
 1511. RUBERG M, ENJALBERT A, ARANCIBIA S, AND KORDON C. Regulation of prolactin secretion at the pituitary level. *Exp Brain Res Suppl* 3: 182–199, 1981.
 1512. RUBERG M, ROTSZTEJN WH, ARANCIBIA S, BESSON J, AND ENJALBERT A. Stimulation of prolactin release by vasoactive intestinal peptide (VIP). *Eur J Pharmacol* 51: 319–320, 1978.
 1513. RUDNICK MS AND DANNIES PS. Muscarinic inhibition of prolactin production in cultures of rat pituitary cells. *Biochem Biophys Res Commun* 101: 689–696, 1981.
 1514. RUI H, DJEU JY, EVANS GA, KELLY PA, AND FARRAR WL. Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation. *J Biol Chem* 267: 24076–24081, 1992.
 1515. RUI H, KIRKEN RA, AND FARRAR WL. Activation of receptor-associated tyrosine kinase Jak2 by prolactin. *J Biol Chem* 269: 5364–5368, 1994.
 1516. RUSSELL DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase-C activation. *Trends Pharmacol Sci* 10: 40–44, 1989.
 1517. RUSSELL DH, KIBLER R, MATRISIAN L, LARSON DF, POULOS B, AND MAGUN BE. Prolactin receptors on rat lymphoid tissues and on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. In: *Prolactin. Basic and Clinical Correlates*, edited by MacLeod RM, Thorner MO, and Scapagnini U. Padova: Liviana, 1985, p. 375–384.
 1518. RUSSELL DH, MATRISIAN L, KIBLER R, LARSON DF, POULOS B, AND MAGUN BE. Prolactin receptors on human lymphocytes and their modulation by cyclosporine. *Biochem Biophys Res Commun* 121: 899–906, 1984.
 1519. RUSSELL DH, MATRISIAN L, KIBLER R, LARSON DF, POULOS B, AND MAGUN BE. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. *J Immunol* 134: 3027–3031, 1985.

1520. RUSSELL FD AND DAVENPORT AP. Secretory pathways in endothelin synthesis. *Br J Pharmacol* 126: 391–398, 1999.
1521. SAAVEDRA JM. Brain and pituitary angiotensin. *Endocr Rev* 13: 329–380, 1992.
1522. SAAVEDRA JM. Localization of atrial natriuretic peptide B and C receptors in rat brain. In: *Neuropeptide Receptors in the CNS*, edited by Bjorklund A, Hokfelt T, and Kuhar MJ. Amsterdam: Elsevier, 1992, p. 39–54.
1523. SABHARWAL P, GLASER R, LAFUSE W, VARMA S, LIU Q, ARKINS S, KOOLJMAN R, KUTZ L, KELLEY KW, AND MALARKEY WB. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. *Proc Natl Acad Sci USA* 89: 7713–7716, 1992.
1524. SAGRILLO CA AND SELMANOFF M. Effects of prolactin on expression of the mRNAs encoding the immediate early genes *zif/268* (NGF1-A), *nur/77* (NGF1-B), *c-fos* and *c-jun* in the hypothalamus. *Mol Brain Res* 61: 62–68, 1998.
1525. SAGRILLO CA AND VOOGT JL. Endogenous opioids mediate the nocturnal prolactin surge in the pregnant rat. *Endocrinology* 129: 925–930, 1991.
1526. SAIARDI A, BOZZI Y, BAIK JH, AND BORRELLI E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. *Neuron* 19: 115–126, 1997.
1527. SAID SI AND MUTT V. Polypeptide with broad biological activity in the porcine small intestine. *Science* 169: 1217–1218, 1970.
1528. SAID SI AND PORTER JC. Vasoactive intestinal polypeptide: release into hypophyseal portal blood. *Life Sci* 24: 227–230, 1979.
1529. SAINT-ANDRE JP, ROHMER V, ALHENC-GELAS F, MENARD J, BIGORGNE JC, AND CORVOL P. Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas. *J Clin Endocrinol Metab* 63: 231–237, 1986.
1530. SAKAGUCHI K, TANAKA M, OHKUBO T, DOH-URA K, FUJIKAWA T, SUDO S, AND NAKASHIMA K. Induction of brain prolactin receptor long-form mRNA expression and maternal behavior in pup-contacted male rats: promotion by prolactin administration and suppression by female contact. *Neuroendocrinology* 63: 559–568, 1996.
1531. SAMSON WK. Central nervous system actions of atrial natriuretic factor. *Brain Res Bull* 20: 831–837, 1988.
1532. SAMSON WK. The endothelin-A receptor subtype transduces the effects of the endothelins in the anterior pituitary gland. *Biochem Biophys Res Commun* 187: 590–595, 1992.
1533. SAMSON WK AND BIANCHI R. Further evidence for a hypothalamic site of action of atrial natriuretic factor: inhibition of prolactin secretion in the conscious rat. *Can J Physiol Pharmacol* 66: 301–305, 1988.
1534. SAMSON WK, BIANCHI R, AND MOGG R. Evidence for a dopaminergic mechanism for the prolactin inhibitory effect of atrial natriuretic factor. *Neuroendocrinology* 47: 268–271, 1988.
1535. SAMSON WK AND FREEMAN ME. Vasoactive intestinal peptide: a neural modulator of endocrine function. In: *Brain-Gut Peptides and Reproductive Function*, edited by Johnston CA and Barnes CD. Boca Raton, FL: CRC, 1991, p. 85–103.
1536. SAMSON WK, HUANG WL, AND FULTON RJ. Opposing neuroendocrine actions of the natriuretic peptides: C-type and A-type natriuretic peptides do not interact with the same hypothalamic cells controlling prolactin secretion. *J Neuroendocrinol* 7: 759–763, 1995.
1537. SAMSON WK, LUMPKIN MD, AND MCCANN SM. Evidence for a physiological role for oxytocin in the control of prolactin. *Endocrinology* 119: 554–561, 1986.
1538. SAMSON WK, LUMPKIN MD, McDONALD JK, AND MCCANN SM. Prolactin-releasing activity of porcine intestinal peptide (PHI-27). *Peptides* 4: 817–819, 1983.
1539. SAMSON WK, MARTIN L, MOGG RJ, AND FULTON RJ. A nonoxytocinergic prolactin releasing factor and a nondopaminergic prolactin inhibiting factor in bovine neurointermediate lobe extracts: in vitro and in vivo studies. *Endocrinology* 126: 1610–1617, 1990.
1540. SAMSON WK, McDONALD JK, AND LUMPKIN MD. Naloxone-induced dissociation of oxytocin and prolactin releases. *Neuroendocrinology* 40: 68–71, 1985.
1541. SAMSON WK, RESCH ZT, MURPHY TC, AND CHANG J-K. Gender-biased activity of the novel prolactin releasing peptides: comparison with thyrotropin releasing hormone reveals only pharmacological effects. *Endocrine* 9: 289–291, 1998.
1542. SAMSON WK AND SCHELL DA. Oxytocin and the anterior pituitary gland. *Adv Exp Med Biol* 395: 355–364, 1995.
1543. SAMSON WK AND SKALA KD. Comparison of the pituitary effects of the mammalian endothelins: vasoactive intestinal contractor (endothelin- β , rat endothelin-2) is a potent inhibitor of prolactin secretion. *Endocrinology* 130: 2964–2970, 1992.
1544. SAMSON WK, SKALA KD, ALEXANDER BD, AND SHUANG F-L. Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro. *Biochem Biophys Res Commun* 169: 737–743, 1990.
1545. SANTAMBROGIO L, LIPARTITI M, BRUNI A, AND DALTOSO R. Dopamine receptors on human T- and B-lymphocytes. *J Neuroimmunol* 45: 113–120, 1993.
1546. SANTOLAYA RC AND WINIK B. Morphological correlates of prolactin release and brain GABA increase. *Adv Biochem Psychopharmacol* 42: 131–137, 1986.
1547. SANYAL S AND VANTOL HH. Dopamine D4 receptor-mediated inhibition of cyclic adenosine 3',5'-monophosphate production does not affect prolactin regulation. *Endocrinology* 138: 1871–1878, 1997.
1548. SAR M. Estradiol is concentrated in tyrosine hydroxylase-containing neurons of the hypothalamus. *Science* 223: 938–940, 1984.
1549. SAR M. Distribution of progesterin-concentrating cells in rat brain: colocalization of [3 H]ORG.2058, a synthetic progesterin, and antibodies to tyrosine hydroxylase in hypothalamus by combined autoradiography and immunocytochemistry. *Endocrinology* 123: 1110–1118, 1988.
1550. SAR M AND MEITES J. Effects of progesterone, testosterone, and cortisol on hypothalamic prolactin-inhibiting factor and pituitary prolactin content. *Proc Soc Exp Biol Med* 127: 426–429, 1968.
1551. SARKAR DK AND GIBBS DM. Cyclic variation of oxytocin in the blood of pituitary portal vessels of rats. *Neuroendocrinology* 39: 481–483, 1984.
1552. SARKAR DK, HEE KIM K, AND INAMI SM. Transforming growth factor- β 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. *Mol Endocrinol* 6: 1825–1833, 1992.
1553. SARKAR DK, PASTORCIC M, DE A, ENGEL M, MOSES H, AND GHASEMZA-DEH MB. Role of transforming growth factor (TGF)- β type I and TGF- β type II receptors in the TGF- β 1-regulated gene expression in pituitary prolactin-secreting lactotropes. *Endocrinology* 139: 3620–3628, 1998.
1554. SARKAR DK AND CYEN SS. Changes in beta-endorphin-like immunoreactivity in pituitary portal blood during the estrous cycle and after ovariectomy in rats. *Endocrinology* 116: 2075–2079, 1985.
1555. SASSIN JF, FRANTZ AG, KAPEN S, AND WEITZMAN ED. The nocturnal rise of human prolactin is dependent on sleep. *J Clin Endocrinol Metab* 37: 436–440, 1973.
1556. SASSIN JF, FRANTZ AG, WEITZMAN ED, AND KAPEN S. Human prolactin: 24-hour pattern with increased release during sleep. *Science* 177: 1205–1207, 1972.
1557. SATO K AND WATANABE YG. Corticosteroids stimulate the differentiation of growth hormone cells but suppress that of prolactin cells in the fetal rat pituitary. *Arch Histol Cytol* 61: 75–81, 1998.
1558. SATO N, WANG X, AND GREER MA. An acute release of Ca^{2+} from sequestered intracellular pools is not the primary transduction mechanism causing the initial burst of PRL and TSH secretion induced by TRH in normal rat pituitary cells. *Cell Calcium* 13: 173–182, 1992.
1559. SATO S. Postnatal development, sexual difference and sexual cycle variation of prolactin cells in rats: special reference to the topographic affinity to a gonadotroph. *Endocrinol Jpn* 27: 573, 1998.
1560. SAWANGJAROEN K AND CURLEWIS JD. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on prolactin, luteinizing hormone and growth hormone secretion in the ewe. *J Neuroendocrinol* 6: 549–555, 1994.
1561. SAWCHENKO P, SWANSON LW, GRZANNA R, HOWER PRC, BLOOM SR, AND POLAK JM. Colocalization of neuropeptide Y in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. *J Comp Neurol* 241: 138–153, 1985.
1562. SCARBROUGH K, WEILAND NG, LARSON GH, SORTINO MA, CHIU SF, HIRSHFIELD AN, AND WISE PM. Measurement of peptide secretion and gene expression in the same cell. *Mol Endocrinol* 5: 134–142, 1991.

1563. SCARPIGNATO C, PEZZETTA A, AND TARDITI E. Effect of caerulein on pituitary response to TRH in humans. *Horm Res* 24: 295–301, 1986.
1564. SCHAEFFER JM AND HSUEH AJ. Acetylcholine receptors in the rat anterior pituitary gland. *Endocrinology* 106: 1377–1381, 1980.
1565. SCHAFER R, WULFSEN I, BEHRENS S, WEINSBERG F, BAUER CK, AND SCHWARZ JR. The erg-like potassium current in rat lactotrophs. *J Physiol (Lond)* 518: 401–416, 1999.
1566. SCHALLY AV, BOWERS CY, REDDING TW, AND BARETT JF. Isolation of thyrotropin releasing factor (TRF) from porcine hypothalamus. *Biochem Biophys Res Commun* 25: 165–169, 1966.
1567. SCHALLY AV, GUOTH JG, REDDING TW, GROOT K, RODRIGUEZ H, SZONYI E, STULTS J, AND NIKOLICS K. Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalamus. *Proc Natl Acad Sci USA* 88: 3540–3544, 1991.
1568. SCHALLY AV, HUANG WY, CHANG RC, ARIMURA A, REDDING TW, MILLAR RP, HUNKAPILLER MW, AND HOOD LE. Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. *Proc Natl Acad Sci USA* 77: 4489–4493, 1980.
1569. SCHALLY AV, REDDING TW, ARIMURA A, DUPONT A, AND LINTHICUM GL. Isolation of gamma-amino butyric acid from pig hypothalamus and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro. *Endocrinology* 100: 681–691, 1977.
1570. SCHIMCHOWITSCH S, VUILLEZ P, TAPPAZ ML, KLEIN MJ, AND STOECKEL ME. Systematic presence of GABA-immunoreactivity in the tubero-infundibular and tubero-hypophyseal dopaminergic axonal systems: an ultrastructural immunogold study on several mammals. *Exp Brain Res* 83: 575–586, 1991.
1571. SCHLICKEER E, FINK K, DETZNER M, AND GOTHERT M. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. *J Neural Transm Gen Sect* 93: 1–10, 1993.
1572. SCHMITZ U AND BERK BC. Angiotensin II signal transduction. Stimulation of multiple mitogen-activated protein kinase pathways. *Trends Endocrinol Metab* 8: 261–266, 1997.
1573. SCHONBRUNN A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. *Endocrinology* 110: 1147–1154, 1982.
1574. SCHRADIN C AND ANZENBERGER G. Prolactin, the hormone of paternity. *News Physiol Sci* 14: 223–231, 1999.
1575. SCHRAMME C AND DENEFF C. Stimulation of prolactin release by angiotensin II in superfused rat anterior pituitary cell aggregates. *Neuroendocrinology* 36: 483–485, 1983.
1576. SCHUMAN EM AND MADISON DV. Nitric oxide and synaptic function. *Annu Rev Neurosci* 17: 153–183, 1994.
1577. SCHWARTZ J AND CHERNY R. Intercellular communication within the anterior pituitary influencing the secretion of hypophysial hormones. *Endocr Rev* 13: 453–475, 1992.
1578. SCHWARTZ J AND PEREZ FM. Intercellular interactions in the anterior pituitary. *J Endocrinol Invest* 17: 459–470, 1994.
1579. SCHWARTZ J, VAN DE PAVERT S, CLARKE I, RAO A, RAY D, AND VRANA K. Paracrine interactions within the pituitary gland. *Ann NY Acad Sci* 839: 239–243, 1998.
1580. SCHWARTZ JC, ARRANG JM, AND GARBARG M. Histaminergic transmission in the mammalian brain. *Physiol Rev* 71: 1–51, 1991.
1581. SCHWINN G, VON ZUR MAKLEN A, AND WARNECKE U. Effects of dexamethasone on thyrotropin and prolactin plasma levels in rats. *Acta Endocrinol* 82: 486–492, 1976.
1582. SCOTT CJ, JANSEN HT, KAO C-C, KUEHL DE, AND JACKSON GL. Disruption of reproductive rhythms and patterns of melatonin and prolactin secretion following bilateral lesions of the suprachiasmatic nuclei in the ewe. *J Neuroendocrinol* 7: 429–443, 1995.
1583. SEDDIKI T AND OLLIVIER-BOUSQUET M. Temperature dependence of prolactin endocytosis and casein exocytosis in epithelial mammary cells. *Eur J Cell Biol* 55: 60–70, 1991.
1584. SELMANOFF M. Rapid effects of hyperprolactinemia on basal prolactin secretion and dopamine turnover in the medial and lateral median eminence. *Endocrinology* 116: 1943–1952, 1985.
1585. SELMANOFF M AND WISE PM. Decreased dopamine turnover in the median eminence in response to suckling in the lactating rat. *Brain Res* 212: 101–115, 1981.
1586. SELTZER A, TSUTSUMI K, SHIGEMATSU K, AND SAAVEDRA JM. Reproductive hormones modulate angiotensin II AT₁ receptors in the dorsomedial arcuate nucleus of the female rat. *Endocrinology* 133: 939–941, 1993.
1587. SELYE H, COLLIP JB, AND THOMSON DL. Effect of hypophysectomy upon pregnancy and lactation. *Proc Soc Exp Biol Med* 30: 589–590, 1933.
1588. SENARIS RM, HUMPHREY PP, AND CEMSON P. Distribution of somatostatin receptors 1, 2 and 3 mRNA in rat brain and pituitary. *Eur J Neurosci* 6: 1883–1896, 1994.
1589. SEROOGY K, TSURUO Y, HÖKFELT T, WALSH J, FAHRENKRUG J, EMSON PC, AND GOLDSTEIN M. Further analysis of presence of peptides in dopamine neurons: cholecystokinin, peptide histidine-isoleucine/vasoactive intestinal polypeptide and substance P in rat supramammillary region and mesencephalon. *Exp Brain Res* 72: 523–534, 1988.
1590. SHAAR CJ AND CLEMENS JA. The role of catecholamines in the release of anterior pituitary prolactin in vitro. *Endocrinology* 95: 1202, 1974.
1591. SHAAR CJ, CLEMENS JA, AND DININGER NB. Effect of vasoactive intestinal polypeptide on prolactin release in vitro. *Life Sci* 25: 2071–2074, 1979.
1592. SHAH GN, LAIRD HE, AND RUSSELL DH. Identification and characterization of a prolactin-like polypeptide synthesized by mitogen-stimulated murine lymphocytes. *Int Immunol* 3: 297–304, 1991.
1593. SHAH GV, DEFTOS LJ, AND CROWLEY WR. Synthesis and release of calcitonin-like immunoreactivity by anterior pituitary cells: evidence for a role in paracrine regulation of prolactin secretion. *Endocrinology* 132: 1367–1372, 1993.
1594. SHAH GV, EPAND RM, AND ORLOWSKI RC. Calcitonin inhibition of prolactin secretion in isolated rat pituitary cells. *J Endocrinol* 116: 279–286, 1988.
1595. SHAH GV, PEDCHENKO V, STANLEY S, LI ZA, AND SAMSON WK. Calcitonin is a physiological inhibitor of prolactin secretion in ovariectomized female rats. *Endocrinology* 137: 1814–1822, 1996.
1596. SHAH GV, SHYR SW, GROSVENOR CE, AND CROWLEY WR. Hyperprolactinemia after neonatal prolactin (PRL) deficiency in rats: evidence for altered anterior pituitary regulation of PRL secretion. *Endocrinology* 122: 1883–1889, 1988.
1597. SHAH GV, WANG W, GROSVENOR CE, AND CROWLEY WR. Calcitonin inhibits basal and thyrotropin-releasing hormone-induced release of prolactin from anterior pituitary cells: evidence for a selective action exerted proximal to secretagogue-induced increases in cytosolic Ca²⁺. *Endocrinology* 127: 621–628, 1990.
1598. SHAMGOCHIAN MD, AVAKIAN C, TRUONG NH, STONE S, TANG KT, AND DEVITO WJ. Regulation of prolactin receptor expression by estradiol in the female rat brain. *Neuroreport* 6: 2537–2541, 1995.
1599. SHARP ZD. Rat Pit-1 stimulates transcription in vitro by influencing preinitiation complex assembly. *Biochem Biophys Res Commun* 206: 40–45, 1995.
1600. SHAW D AND GOLDMAN BD. Gender differences in influence of prenatal photoperiods on postnatal pineal melatonin rhythms and serum prolactin and follicle-stimulating hormone in the Siberian hamster (*Phodopus sungorus*). *Endocrinology* 136: 4237–4246, 1995.
1601. SHEN GK, MONTGOMERY DW, ULRICH ED, MAHONEY KR, AND ZUKOSKI CF. Up-regulation of prolactin gene expression and feedback modulation of lymphocyte proliferation during acute allograft rejection. *Surgery* 112: 387–394, 1992.
1602. SHENNAN DB. Regulation of water and solute transport across mammalian plasma cell membranes by prolactin. *J Dairy Res* 61: 155–166, 1994.
1603. SHEWARD WJ, FRASER HM, AND FINK G. Effect of immunoneutralization of thyrotrophin-releasing hormone on the release of thyrotrophin and prolactin during suckling or in response to electrical stimulation of the hypothalamus in the anaesthetized rat. *J Endocrinol* 106: 113–119, 1985.
1604. SHEWARD WJ, LIM A, ALDER B, COPOLOV D, DOW RC, AND FINK G. Hypothalamic release of atrial natriuretic factor and beta-endorphin into rat hypophysial portal plasma: relationship to oestrous cycle and effects of hypophysectomy. *J Endocrinol* 131: 113–125, 1991.
1605. SHIDA MM, JACKSON-GRUSBY LL, ROSS SR, AND LINZER DIH. Placental-specific expression from the mouse placental lactogen II gene promoter. *Proc Natl Acad Sci* 89: 3864–3868, 1992.
1606. SHIEH KR, CHU YS, AND PAN JT. Circadian change of dopaminergic

- neuron activity: effects of constant light and melatonin. *Neuroreport* 8: 2283–2287, 1997.
1607. SHIEH KR AND PAN JT. Sexual differences in the diurnal changes of tuberoinfundibular dopaminergic neuron activity in the rat: role of cholinergic control. *Biol Reprod* 54: 987–992, 1996.
 1608. SHIMATSU A, KATO Y, INOUE T, CHRISTOFIDES ND, BLOOM SR, AND IMURA H. Peptide histidine isoleucine- and vasoactive intestinal polypeptide-like immunoreactivity coexist in rat hypophyseal portal blood. *Neurosci Lett* 43: 259–262, 1983.
 1609. SHIMATSU A, KATO Y, MATSUSHITA N, KATAKAMI H, YANAIHARA N, AND IMURA H. Immunoreactive vasoactive intestinal polypeptide in rat hypophyseal portal blood. *Endocrinology* 108: 395–398, 1981.
 1610. SHIMATSU A, KATO Y, MATSUSHITA N, KATAKAMI H, YANAIHARA N, AND IMURA H. Stimulation by serotonin of vasoactive intestinal polypeptide release into rat hypophyseal portal blood. *Endocrinology* 111: 338–340, 1982.
 1611. SHIMATSU A, KATO Y, OHTA H, TOYO K, KABAYAMA Y, INOUE T, YANAIHARA N, AND IMURA H. Involvement of hypothalamic vasoactive intestinal polypeptide (VIP) in prolactin secretion induces by serotonin in rats. *Proc Soc Exp Biol Med* 175: 414–416, 1984.
 1612. SHIMOMURA K AND BREMEL RD. Characterization of bovine placental lactogen as a glycoprotein with N-linked and O-linked carbohydrate side chains. *Mol Endocrinol* 2: 845–853, 1988.
 1613. SHIMON I, TAYLOR JE, DONG JZ, BITONTE RA, KIM S, MORGAN B, COY DH, CULLER MD, AND MELMED S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid stimulating hormone, and prolactin regulation. *J Clin Invest* 99: 789–798, 1997.
 1614. SHIN SH. Dopamine-induced inhibition of prolactin release from cultured adenohypophyseal cells: spare receptors for dopamine. *Life Sci* 22: 67–74, 1978.
 1615. SHIN SH. Thyrotropin releasing hormone (TRH) is not the physiological prolactin releasing factor (PRF) in the male rat. *Life Sci* 23: 1813–1818, 1978.
 1616. SHIN SH. Vasopressin has a direct effect on prolactin release in male rats. *Neuroendocrinology* 34: 55–58, 1982.
 1617. SHIN SH, HANNA SF, HONG M, AND HAMANDAS KJ. Reexamination of dopamine as the prolactin-release inhibiting factor (PIF): supplementary agent may be required for dopamine to function as the physiological PIF. *Can J Physiol Pharmacol* 68: 1226–1230, 1990.
 1618. SHIN SH AND OBONSAWIN MC. Bovine neurophysin II has prolactin-releasing activity in the estradiol-primed male rat. *Neuroendocrinology* 41: 276–283, 1985.
 1619. SHIN SH, OBONSAWIN MC, AND BATES L. Gamma-aminobutyric acid is not likely a physiological prolactin-inhibiting factor. *Horm Res* 19: 33–42, 1984.
 1620. SHIN SH AND STIRLING R. Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release in primary cultured rat pituitary cells. *J Endocrinol* 118: 287–294, 1988.
 1621. SHIROTA M, BANVILLE D, ALI S, JOLICOEUR C, BOUTIN JM, EDERY M, DJANE J, AND KELLY PA. Expression of two forms of prolactin receptor in rat ovary and liver. *Mol Endocrinol* 4: 1136–1142, 1990.
 1622. SHIU RPC, ELSHOLTZ HP, TANAKA T, FRIESEN HG, GOUT PW, GEER CT, AND NOBLE RL. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. *Endocrinology* 113: 159–165, 1983.
 1623. SHIVERS BD, GÖRCS TJ, GOTTSCHALL PE, AND ARIMURA A. Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. *Endocrinology* 128: 3055–3065, 1991.
 1624. SHOME B AND PARLOW AF. Human pituitary prolactin (hPRL): the entire linear amino acid sequence. *J Clin Endocrinol Metab* 45: 1112–1115, 1977.
 1625. SHOUPPE D, MONTZ FJ, KLETZKY OA, AND DIZEREGA GS. Prolactin molecular heterogeneity: response to thyrotropin-releasing hormone stimulation of concanavalin A-bound and -unbound immunoassayable prolactin during human pregnancy. *Am J Obstet Gynecol* 147: 482–487, 1983.
 1626. SHUGHRUE PJ, STUMPF WE, SAR M, ELGER W, AND SCHULZE P-E. Progesterin receptors in brain and pituitary of 20-day-old fetal mice: an autoradiographic study using [¹²⁵I]progesterin. *Endocrinology* 124: 333–338, 1989.
 1627. SHULL JD AND GORSKI J. Estrogen stimulates prolactin gene transcription by a mechanism independent of pituitary protein synthesis. *Endocrinology* 114: 1550–1557, 1984.
 1628. SHULL JD AND GORSKI J. Estrogen regulation of prolactin gene transcription in vivo: paradoxical effects of 17 β -estradiol dose. *Endocrinology* 124: 279–285, 1989.
 1629. SHYR SW, CROWLEY WR, AND GROSVENOR CE. Effect of neonatal prolactin deficiency on prepubertal tuberoinfundibular and tuberohypophyseal dopaminergic neuronal activity. *Endocrinology* 119: 1217–1221, 1986.
 1630. SIAUD P, MANZONI O, BALMEFREZOL M, BARBANEL G, ASSENMACHER I, AND ALONSO G. The organization of prolactin-like-immunoreactive neurons in the rat central nervous system. Light- and electron-microscopic immunocytochemical studies. *Cell Tissue Res* 255: 107–115, 1989.
 1631. SIBILIA V, NETTI C, GUIDOBONO F, CAZZAMALLI E, AND PECILE A. Effect of calcitonin gene-related peptide on prolactin secretion. *Pharmacol Res* 21: 97–98, 1989.
 1632. SIBILIA V, NETTI C, GUIDOBONO F, PAGANI F, AND PECILE A. Cimetidine-induced prolactin release: possible involvement of the GABA-ergic system. *Neuroendocrinology* 40: 189–192, 1985.
 1633. SIBILIA V, NETTI C, GUIDOBONO F, VILLA I, AND PECILE A. Inhibitory effects of centrally administered ASU1-7-eel calcitonin on basal and stimulated prolactin release in rats. *J Endocrinol Invest* 13: 507–511, 1990.
 1634. SIEGEL RA, CHOWERS J, CONFORTI N, AND WEIDENFELD J. Effects of naloxone on basal and stress-induced prolactin secretion, in intact, hypothalamic deafferented, adrenalectomized, and dexamethasone pretreated male rats. *Life Sci* 30: 1691–1699, 1982.
 1635. SIMMONDS SH. Inhibition of inositol phospholipid breakdown by D2 dopamine receptors in dissociated bovine anterior pituitary cells. *Neurosci Lett* 60: 267–272, 1985.
 1636. SIMON EJ, HILLER JM, AND EDELMAN I. Stereospecific binding of the potent narcotic analgesic [³H]etorphine to rat-brain homogenate. *Proc Natl Acad Sci USA* 70: 1947–1949, 1973.
 1637. SIMPSON J, WILLIAMSON LJ, AND FINK G. Choline acetyltransferase activity in the pars distalis, preoptic area and striatum during the rat estrous cycle. *Neuroendocrinology* 40: 444–449, 1985.
 1638. SIMS KB, HOFFMAN DL, SAID SI, AND ZIMMERMAN EA. Vasoactive intestinal polypeptide (VIP) in mouse and rat brain: an immunohistochemical study. *Brain Res* 186: 165–183, 1980.
 1639. SINHA YN. Structural variants of prolactin. In: *Pars Distalis of the Pituitary Gland—Structure, Function and Regulation*, edited by Yoshimura F and Gorbman A. Amsterdam: Elsevier Science, 1986, p. 399–412.
 1640. SINHA YN. Structural variants of prolactin: occurrence and physiological significance. *Endocr Rev* 16: 354–369, 1995.
 1641. SINHA YN, DEPAOLO LV, HARO LS, SINGH RNP, JACOBSEN BP, SCOTT KE, AND LEWIS UJ. Isolation and biochemical properties of four forms of glycosylated porcine prolactin. *Mol Cell Endocrinol* 80: 203–213, 1991.
 1642. SINHA YN AND GILLIGAN TA. A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. *Endocrinology* 114: 2046–2053, 1984.
 1643. SINHA YN, GILLIGAN TA, LEE DW, HOLLINGSWORTH D, AND MARKOFF E. Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. *J Clin Endocrinol Metab* 60: 239–243, 1985.
 1644. SKOFITSCH G AND JACOBOWITZ DM. Calcitonin- and calcitonin gene-related peptide: receptor binding sites in the central nervous system. In: *Neuropeptide Receptors in the CNS*, edited by Bjorklund A, Hokfelt T, and Kuhar MJ. New York: Elsevier, 1992, p. 97–144.
 1645. SLAMA A, VIDEAU C, KORDON C, AND EPELBAUM J. Estradiol regulation of somatostatin receptors in the arcuate nucleus of the female rat. *Neuroendocrinology* 56: 240–245, 1992.
 1646. SMITH MS. Lactation alters neuropeptide-Y and proopiomelanocortin gene expression in the arcuate nucleus of lactating rats. *Endocrinology* 133: 1258–1265, 1993.
 1647. SMITH MS, FREEMAN ME, AND NEILL JD. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. *Endocrinology* 96: 219–226, 1975.

1648. SMITH MS AND NEILL JD. Termination at midpregnancy of the two daily surges of plasma prolactin initiated by mating in the rat. *Endocrinology* 98: 696–706, 1976.
1649. SMITH SW AND GALA RR. Influence of restraint on plasma prolactin and corticosterone in female rats. *J Endocrinol* 74: 303–314, 1977.
1650. SNYDER JM, WILFINGER WW, AND HYMER WC. Maintenance of separated rat pituitary mammatrophs in cell culture. *Endocrinology* 98: 25–32, 1976.
1651. SOARES MJ, COLOSI P, OGREN L, AND TALAMANTES F. Identification and partial characterization of a lactogen from the midpregnant mouse conceptus. *Endocrinology* 112: 1313–1317, 1983.
1652. SOARES MJ, MÜLLER H, ORWIG KE, PETERS TJ, AND DAI GL. The uteroplacental prolactin family and pregnancy. *Biol Reprod* 58: 273–284, 1998.
1653. SOBRINHO LG. The psychogenic effects of prolactin. *Acta Endocrinol* 129 Suppl 1: 38–40, 1993.
1654. SODERSTEN P, HANSEN S, AND ENEROTH P. Evidence that prolactin does not affect the induction of sexual behavior by oestradiol and progesterone in ovariectomized rats. *J Endocrinol* 99: 181–187, 1983.
1655. SODERSTEN P, HANSEN S, AND ENEROTH P. Inhibition of sexual behavior in lactating rats. *J Endocrinol* 99: 189–197, 1983.
1656. SOE-JENSEN P, KNIGGE U, GARBARG M, KJAER A, ROULEAU A, BACH FW, SCHWARTZ JC, AND WARBERG J. Responses of anterior pituitary hormones and hypothalamic histamine to blockade of histamine synthesis and to selective activation or inactivation of presynaptic histamine H3 receptors in stressed rats. *Neuroendocrinology* 57: 532–540, 1993.
1657. SOFRONIEW MV. Vasopressin, oxytocin, and their related neuropeptides. In: *GABA and Neuropeptides in the CNS, Part I*, edited by Bjorklund A and Hokfelt T. Amsterdam: Elsevier, 1985, p. 93–165.
1658. SORENSEN P AND SHEFFIELD LG. Involvement of c-src in beta-casein expression by mammary epithelial cells. *Biochem Biophys Res Commun* 241: 710–713, 1997.
1659. SORIN B, GOUPILLE O, VACHER AM, PALLY J, DJIANE J, AND VACHER P. Distinct cytoplasmic regions of the prolactin receptor are required for prolactin-induced calcium entry. *J Biol Chem* 273: 28461–28469, 1998.
1660. SORTINO MA, ALEPPO G, SCAPAGNINI U, AND CANONICO PL. Comparative effects of eel calcitonin, salmon calcitonin and [Asu1,7]eel calcitonin on hypophyseal and osteoblastic function. *Gynecol Endocrinol* 7: 89–96, 1993.
1661. SORTINO MA, CANONICO PL, AND CLEMENTI G. Bimodal action of [Asu1,7]eel-calcitonin on phosphoinositide hydrolysis in cultured anterior pituitary cells. *Eur J Pharmacol* 207: 345–350, 1991.
1662. SOUTHARD JN, CAMPBELL GT, AND TALAMANTES F. Hamster placental lactogens: gestational profiles and high molecular weight forms. *Endocrinology* 121: 900–906, 1987.
1663. SOUTHARD JN, DO L, SMITH WC, AND TALAMANTES F. Hamster placental lactogen-II contains a structural feature unique among the growth hormone-prolactin-placental lactogen family. *Mol Endocrinol* 3: 1710–1713, 1989.
1664. SOUTHARD JN, THORDARSON G, AND TALAMANTES F. Purification and partial characterization of hamster placental lactogen. *Endocrinology* 119: 508–515, 1986.
1665. SPANGELO BL, ISAKSON PC, AND MACLEOD RM. Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3',5'-monophosphate and vasoactive intestinal peptide. *Endocrinology* 127: 403–409, 1990.
1666. SPANGELO BL, JARVIS WD, JUDD AM, AND MACLEOD RM. Induction of interleukin-6 release by interleukin-1 in rat anterior pituitary cells in vitro: evidence for an eicosanoid-dependent mechanism. *Endocrinology* 129: 2886–2894, 1991.
1667. SPANGELO BL, JUDD AM, ISAKSON PC, AND MACLEOD RM. Interleukin-6 stimulates anterior pituitary hormone release in vitro. *Endocrinology* 125: 575–577, 1989.
1668. SPANGELO BL, JUDD AM, ISAKSON PC, AND MACLEOD RM. Interleukin-1 stimulates interleukin-6 release from rat anterior pituitary cells in vitro. *Endocrinology* 128: 2685–2692, 1991.
1669. SPANGELO BL, MACLEOD RM, AND ISAKSON PC. Production of interleukin-6 by anterior pituitary cells in vitro. *Endocrinology* 126: 582–586, 1990.
1670. SPANSWICK D, SMITH MA, GROPPA VE, LOGAN SD, AND ASHFORD MLJ. Lepin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. *Nature* 390: 521–525, 1997.
1671. SPINDEL ER, GILADI E, SEGERSON TP, AND NAGALLA S. Bombesin-like peptides: of ligands and receptors. *Recent Prog Horm Res* 48: 365–391, 1993.
1672. STARR R AND HILTON DJ. SOCS: suppressors of cytokine signalling. *Int J Biochem Cell Biol* 30: 1081–1085, 1998.
1673. STEELE MK. The role of brain angiotensin II in the regulation of luteinizing hormone and prolactin secretion. *Trends Endocrinol Metab* 3: 295–301, 1992.
1674. STEELE MK, BROWNFIELD MS, AND GANONG WF. Immunocytochemical localization of angiotensin immunoreactivity in gonadotropes and lactotropes of the rat anterior pituitary gland. *Neuroendocrinology* 35: 155–158, 1982.
1675. STEELE MK, MCCANN SM, AND NEGRO-VILAR A. Modulation by dopamine and estradiol of the central effects of angiotensin II on anterior pituitary hormone release. *Endocrinology* 111: 722–729, 1982.
1676. STEELE MK AND MYERS LS. Angiotensin II and prolactin secretion in the male rat. *Soc Neurosci Abstr* 16: 95, 1990.
1677. STEELE MK AND MYERS LS. In vivo studies on paracrine actions of pituitary angiotensin II in stimulating prolactin release in rats. *Am J Physiol Endocrinol Metab* 258: E619–E624, 1990.
1678. STEELE MK, NEGRO-VILAR A, AND MCCANN SM. Effect of angiotensin II on in vivo and in vitro release of anterior pituitary hormones in the female rat. *Endocrinology* 109: 893–899, 1981.
1679. STEFANEANU L. Calcitonin as a neuromodulator. *Endocrinologie* 24: 49–50, 1986.
1680. STEGER RW, CHANDRASHEKAR V, ZHAO W, BARTKE A, AND HORSEMAN ND. Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. *Endocrinology* 139: 3691–3695, 1998.
1681. STEINMETZ R, LIU J, AND BEN-JONATHAN N. Posterior pituitary cells: isolation of subpopulations producing prolactin releasing factor. *Endocr J* 1: 373–379, 1993.
1682. STEINMETZ RW, GRANT AL, AND MALVEN PV. Transcription of prolactin gene in milk secretory cells of the rat mammary gland. *J Endocrinol* 136: 271–276, 1993.
1683. STERN JM AND REICHLIN S. Prolactin circadian rhythm persists throughout lactation in women. *Neuroendocrinology* 51: 31–37, 1990.
1684. STERNWEIS PC AND SMRCKA AV. Regulation of phospholipase C by G proteins. *Trends Biochem Sci* 17: 502–506, 1992.
1685. STIER CT, COWDEN EA, FRIESEN HG, AND ALLISON MEM. Prolactin and the rat kidney: a clearance and micropuncture study. *Endocrinology* 115: 362–367, 1984.
1686. STOECKEL ME, HINDELANG C, KLEIN M-J, POISSONNIER M, AND FELIX J-M. Early expression of the glycoprotein α -subunit in the pars tuberalis of the rat pituitary gland during ontogenesis. *Neuroendocrinology* 58: 616–624, 1993.
1687. STOECKLIN E, WISSLER M, GOUILLEUX F, AND GRONER B. Functional interactions between Stat5 and the glucocorticoid receptor. *Nature* 383: 726–728, 1996.
1688. STOECKLIN E, WISSLER M, MORIGGL R, AND GRONER B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. *Mol Cell Biol* 17: 6708–6716, 1997.
1689. STOJILKOVIC SS AND CATT KJ. Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. *Front Neuroendocrinol* 17: 327–369, 1996.
1690. STOJILKOVIC SS, MERELLI F, IIDA T, KRSMANOVIC LZ, AND CATT KJ. Endothelin stimulation of cytosolic calcium and gonadotropin secretion in anterior pituitary cells. *Science* 248: 1663–1666, 1990.
1691. STRAND FL. Gut and brain neuropeptides. I. Neuropeptide families: gastrin/CCK, VIP/secretin/glucagon, PP/PYY/NTY, bombesin/GRP. In: *Neuropeptides: Regulators of Physiological Processes*, edited by Strand FL. Cambridge, MA: MIT Press, 1999, p. 383–430.
1692. STRAUS E, MULLER JE, CHOI H, PARONETTO F, AND YALOW RS. Immunohistochemical localization in rabbit brain of a peptide resembling the COOH-terminal octapeptide of cholecystokinin. *Proc Natl Acad Sci USA* 74: 3033–3034, 1977.
1693. STRAUS E AND YALOW RS. Species specificity of cholecystokinin in

- gut and brain of several mammalian species. *Proc Natl Acad Sci USA* 75: 486–489, 1978.
1694. STRICKER P AND GRUETER R. Action du lobe anterieur de l'hypophyse sur la montee laiteuse. *CR Soc Biol (Paris)* 99: 1978–1980, 1928.
 1695. STRUMAN I, BENTZIE F, LEE HY, MAINFROID V, D'ANGELO G, GOFFIN V, WEINER RI, AND MARTIAL JA. Opposing actions of intact and N-terminal fragments of the human prolactin growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. *Proc Natl Acad Sci USA* 96: 1246–1251, 1999.
 1696. SUBRAMANIAN MG AND GALA RR. The influence of cholinergic, adrenergic, and serotonergic drugs on the afternoon surge of plasma prolactin in ovariectomized, estrogen-treated rats. *Endocrinology* 98: 842–848, 1976.
 1697. SUDOH T, KANGAWA K, AND MINAMINO N. A new natriuretic peptide in porcine brain. *Nature* 332: 78–81, 1988.
 1698. SUDOH T, KANGAWA K, AND MINAMINO N. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. *Biochem Biophys Res Commun* 168: 863–870, 1990.
 1699. SUGITA S, JOHNSON SW, AND NORTH RA. Synaptic inputs to GABA-A and GABA-B receptors originate from discrete afferent neurons. *Neurosci Lett* 134: 207–211, 1992.
 1700. SUGIYAMA T, MINOURA H, KAWABE N, TANAKA M, AND NAKASHIMA K. Preferential expression of long form prolactin receptor mRNA in the rat brain during the oestrous cycle, pregnancy and lactation: hormones involved in its gene expression. *J Endocrinol* 141: 325–333, 1994.
 1701. SUGIYAMA T, MINOURA H, TOYODA N, SAKAGUCHI K, TANAKA M, SUDO S, AND NAKASHIMA K. Pup contact induces the expression of long form prolactin receptor mRNA in the brain of female rats: effects of ovariectomy and hypophysectomy on receptor gene expression. *J Endocrinol* 149: 335–340, 1996.
 1702. SUN PQ, LOU LM, AND MAURER RA. Regulation of activating transcription factor-1 and the cAMP response element-binding protein by Ca^{2+} /calmodulin-dependent protein kinases type I, II, and IV. *J Biol Chem* 271: 3066–3073, 1996.
 1703. SUTTON CA AND MARTIN TF. Thyrotropin-releasing hormone (TRH) selectively and rapidly stimulates phosphatidylinositol turnover in GH pituitary cells: a possible second step of TRH action. *Endocrinology* 110: 1273–1280, 1982.
 1704. SZABO M AND FROHMAN LA. Dissociation of prolactin-releasing activity from thyrotropin-releasing hormone in porcine stalk median eminence. *Endocrinology* 98: 1451–1459, 1976.
 1705. TACHE Y, BROWN M, AND COLLU R. Effects of neuropeptides on adenohypophyseal hormone response to acute stress in male rats. *Endocrinology* 105: 220–224, 1979.
 1706. TAKAHARA J, YUNOKI S, YAMAUCHI J, YAKUSHIJI W, HASHIMOTO K, AND FUJI TO. Inhibitory effects of substance P on the gamma-aminobutyric acid and gamma-hydroxybutyric acid-induced growth hormone and prolactin release in male rats. *Life Sci* 29: 1229–1231, 1981.
 1707. TAKAHASHI H, NABESHIMA Y, OGATA K, AND TAKEUCHI S. Molecular cloning and nucleotide sequence of DNA complementary to human decidal prolactin mRNA. *J Biochem* 95: 1491–1499, 1984.
 1708. TAKAHASHI S. Development and heterogeneity of prolactin cells. *Int Rev Cytol* 157: 33–98, 1995.
 1709. TAKEDA Y, MIYAMORI I, FURUKAWA K, INABA S, AND MABUCHI H. Mechanisms of FK 506-induced hypertension in the rat. *Hypertension* 33: 130–136, 1999.
 1710. TAKEUCHI K, ALEXANDER RW, NAKAMURA Y, TSUJINO T, AND MURPHY TJ. Molecular structure and transcriptional function of the rat vascular AT_{1A} angiotensin receptor gene. *Circ Res* 73: 612–621, 1993.
 1711. TALEISNIK S. Control of melanocyte-stimulating hormone (MSH) secretion. In: *The Endocrine Hypothalamus*, edited by Jeffcoate SL and Hutchinson JSM. London: Academic, 1978, p. 421–439.
 1712. TAN SK, WANG FF, PU HF, AND LIU TC. Differential effect of age on transforming growth factor-beta 1 inhibition of prolactin gene expression versus secretion in rat anterior pituitary cells. *Endocrinology* 138: 878–885, 1997.
 1713. TANAKA T, SHIU RP, GOUT PW, BEER CT, NOBLE RL, AND FRIESEN HG. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. *J Clin Endocrinol Metab* 51: 1058–1063, 1980.
 1714. TANIMOTO K, TAMMINGA T, CHASE N, AND NILAVER G. Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide. *Endocrinology* 121: 127–132, 1987.
 1715. TAPIA-ARANCIBIA L, ARANCIBIA S, BLUET-PAJOT MT, ENJALBERT A, EPELBAUM J, PRIAM M, AND KORDON C. Effect of vasoactive intestinal peptide (VIP) on somatostatin inhibition of pituitary growth hormone secretion in vitro. *Eur J Pharmacol* 63: 235–236, 1980.
 1716. TAPPAZ ML. GABA and anterior pituitary function: anatomical data. *Psychoneuroendocrinology* 9: 85–95, 1984.
 1717. TAPPAZ ML, BOSLER O, PAUT L, AND BEROD A. Glutamate decarboxylase-immunoreactive boutons in synaptic contacts with hypothalamic dopaminergic cells: a light and electron microscopy study combining immunocytochemistry and radioautography. *Neuroscience* 16: 111–122, 1985.
 1718. TAPPAZ ML, BROWNSTEIN MJ, AND PALKOVITS M. Distribution of glutamate decarboxylase in discrete brain nuclei. *Brain Res* 108: 371–379, 1976.
 1719. TAPPAZ ML, WASSEF M, OERTEL WH, PAUT L, AND PUJOL JF. Light- and electron-microscopic immunocytochemistry of glutamic acid decarboxylase (GAD) in the basal hypothalamus: morphological evidence for neuroendocrine γ -aminobutyrate (GABA). *Neuroscience* 9: 271–287, 1983.
 1720. TARTAGLIA ME, DEMBSKI M, WENG X, DENG N, CULPEPPER J, DEVOS R, RICHARDS GJ, CAMPFIELD LA, CLARK FT, DEEDS J, MUIR C, SANKER S, MORIARTY A, MOORE KJ, SMUTKO JS, MAYS GG, WOOLF EA, MONROE CA, AND TEPPER RI. Identification and expression cloning of a leptin receptor, OB-R. *Neuron* 83: 1263–1271, 1995.
 1721. TASHJIAN AHJ. Clonal strains of hormone-producing pituitary cells. *Methods Enzymol* 58: 527–535, 1979.
 1722. TASHJIAN AHJ, BANCROFT FC, AND LEVINE L. Production of both prolactin and growth hormone by clonal strains of rat pituitary tumor cells. Differential effects of hydrocortisone and tissue extracts. *J Cell Biol* 47: 61–70, 1970.
 1723. TASHJIAN AHJ, BAROWSKY NJ, AND JENSEN DK. Thyrotropin releasing hormone: direct evidence for stimulation of prolactin production by pituitary cells in culture. *Biochem Biophys Res Commun* 43: 516–523, 1971.
 1724. TASHJIAN AHJ, YASUMURA Y, LEVINE L, SATO GH, AND PARKER ML. Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. *Endocrinology* 82: 342–352, 1968.
 1725. TATEMOTO K. Neuropeptide Y: complete amino acid sequence of the brain peptide. *Proc Natl Acad Sci USA* 79: 2514–2518, 1982.
 1726. TATEMOTO K, CARLQUIST M, AND MUTT V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. *Nature* 296: 659–660, 1982.
 1727. TATEMOTO K AND MUTT V. Isolation and characterization of porcine intestinal peptide PHI (PHI-27), a new member of glucagon-secretin family. *Proc Natl Acad Sci USA* 78: 6603–6607, 1981.
 1728. TATEMOTO K, ROKAELUS A, JORNWALL H, McDONALD TJ, AND MUTT V. Galanin—a novel biologically active peptide from porcine intestine. *FEBS Lett* 164: 124–128, 1983.
 1729. TAYLOR RL AND BURT DR. Pituitary cell cultures contain muscarinic receptors. *Eur J Pharmacol* 65: 305–308, 1980.
 1730. TELLERIA CM, PARMER TG, ZHONG L, CLARKE DL, ALBARRACIN CT, DUAN WR, LINZER DI, AND GIBORI G. The different forms of the prolactin receptor in the rat corpus luteum: developmental expression and hormonal regulation in pregnancy. *Endocrinology* 138: 4812–4820, 1997.
 1731. TERENIUS L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. *Acta Pharmacol Toxicol* 32: 317–320, 1973.
 1732. TERKEL J, BLAKE CA, AND SAWYER CH. Serum prolactin levels in lactating rats after suckling or exposure to ether. *Endocrinology* 91: 49–53, 1972.
 1733. TERKEL J, DAMASSA DA, AND SAWYER CH. Ultrasonic cries from infant rats stimulate prolactin release in lactating mothers. *Horm Behav* 12: 95–102, 1979.
 1734. TERRY LC, CROWLEY WR, LYNCH C, LONGSERRE C, AND JOHNSON MD.

- Role of central epinephrine in regulation of anterior pituitary hormone secretion. *Peptides* 3: 311–318, 1982.
1735. TERRY LC, EPELBAUM J, AND MARTIN JB. Monosodium glutamate: acute and chronic effects on rhythmic growth hormone and prolactin secretion, and somatostatin in the undisturbed male rat. *Brain Res* 217: 129–142, 1981.
 1736. TERRY LC AND MARTIN JB. Evidence for alpha-adrenergic regulation of episodic growth hormone and prolactin secretion in the undisturbed male rat. *Endocrinology* 108: 1869–1873, 1981.
 1737. THEODOSIS DT, PAUT L, AND TAPPAZ ML. Immunocytochemical analysis of the GABAergic innervation of oxytocin- and vasopressin-secreting neurons in the rat supraoptic nucleus. *Neuroscience* 19: 207–222, 1986.
 1738. THIERY J-C. Monoamine content of the stalk median eminence and hypothalamus in adult sheep as affected by daylength. *J Neuroendocrinol* 3: 407–411, 1991.
 1739. THOMAS G, CUMMINGS JT, GRIFFIN N, AND CLARKE IJ. Effect and site of action of hypothalamic neuropeptides on prolactin release in sheep. *Neuroendocrinology* 48: 252–257, 1988.
 1740. THOMAS P, WONG JG, AND ALMERS W. Millisecond studies of secretion in single rat pituitary cells stimulated by flash photolysis of caged Ca^{2+} . *EMBO J* 12: 303–306, 1993.
 1741. THOMPSON SA. Localization of immunoreactive prolactin in ependyma and circumventricular organs of rat brain. *Cell Tissue Res* 225: 79–93, 1982.
 1742. THONG FS AND GRAHAM TE. Leptin and reproduction: is it a critical link between adipose tissue, nutrition, and reproduction? *Can J Appl Physiol* 24: 317–336, 1999.
 1743. THORNTON JE, CHEUNG CC, CLIFTON DK, AND STEINER RA. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in *ob/ob* mice. *Endocrinology* 138: 5063–5066, 1997.
 1744. THOSS VS, PEREZ J, PROBST A, AND HOYER D. Expression of five somatostatin receptor mRNAs in the human brain and pituitary. *Naunyn-Schmiedeberg's Arch Pharmacol* 354: 411–419, 1996.
 1745. THRAILKILL KM, GOLANDER A, UNDERWOOD LE, AND HANDWERGER S. Insulin-like growth factor I stimulates the synthesis and release of prolactin from human decidual cells. *Endocrinology* 123: 2930–2934, 1988.
 1746. THRAILKILL KM, GOLANDER A, UNDERWOOD LE, RICHARDS RG, AND HANDWERGER S. Insulin stimulates the synthesis and release of prolactin from human decidual cells. *Endocrinology* 124: 3010–3014, 1989.
 1747. TILDERS FJH, BERKENBOSCH F, AND MELIK S. Control of secretion of peptides related to adrenocorticotropin, melanocyte-stimulating hormone and endorphin. In: *Frontiers in Hormone Research*, edited by van Wimersma Griedanus TJB. Basel: Karger, 1985, p. 161–196.
 1748. TILEMANS D, ANDRIES M, DENEFF C, AND STRAETEMANS L. Luteinizing hormone-releasing hormone and neuropeptide Y influence deoxyribonucleic acid replication in three anterior pituitary cell types. Evidence for mediation by growth factors released from gonadotrophs. *Endocrinology* 130: 882–894, 1992.
 1749. TILEMANS D, ANDRIES M, PROOST P, DEVREESE B, VAN BEEUMEN J, AND DENEFF C. In vitro evidence that an 11-kilodalton N-terminal fragment of proopiomelanocortin is a growth factor specifically stimulating the development of lactotrophs in rat pituitary during postnatal life. *Endocrinology* 135: 168–174, 1994.
 1750. TILEMANS D, RAMAEKERS M, AND DENEFF C. Effect of POMC1–76, its C-terminal fragment γ 3-MSH and anti-POMC1–76 antibodies on DNA replication in lactotrophs in aggregate cell cultures of immature rat pituitary. *J Neuroendocrinol* 9: 627–637, 1997.
 1751. TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF, BENFIELD P, CARINI DJ, LEE RJ, WEXLER RR, SAYE JM, AND MITH RD. Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 45: 205–251, 1993.
 1752. TOFT DJ AND LINZER DI. Prolactin (PRL)-like protein J, a novel member of the PRL/growth hormone family, is exclusively expressed in maternal decidua. *Endocrinology* 140: 5095–5101, 1999.
 1753. TOJO K, KATO Y, KABAYAMA Y, OHTA H, INOUE T, AND IMURA H. Further evidence that central neurotensin inhibits pituitary prolactin secretion by stimulating dopamine release from the hypothalamus. *Proc Soc Exp Biol Med* 181: 517–522, 1986.
 1754. TOJO K, KATO Y, OHTA H, SHIMATSU A, MATSUSHITA N, KABAYAMA Y, INOUE T, YANAIHARA N, AND IMURA H. Potent stimulatory effect of leuromorphin on prolactin secretion from the pituitary in rats. In: *Prolactin: Basic and Clinical Correlates*, edited by MacLeod RM, Thorner MO, and Scapagnini U. Padova: Liviana, 1985, p. 552.
 1755. TOMOGANE H, ARBOGAST LA, SOARES MJ, ROBERTSON MC, AND VOOGT JL. A factor(s) from a rat trophoblast cell line inhibits prolactin secretion in vitro and in vivo. *Biol Reprod* 48: 325–332, 1993.
 1756. TOMOGANE H, MISTRY AM, AND VOOGT JL. Late pregnancy and rat choriocarcinoma cells inhibit nocturnal prolactin surges and serotonin-induced prolactin release. *Endocrinology* 130: 23–28, 1992.
 1757. TONEY TW, MANZANARES J, MOORE KE, AND LOOKINGLAND KJ. Sexual differences in the stimulatory effects of bombesin on tuberoinfundibular dopaminergic neurons. *Brain Res* 598: 279–285, 1992.
 1758. TONEY TW, PAWSAT DE, FLECKENSTEIN AE, LOOKINGLAND KJ, AND MOORE KE. Evidence that prolactin mediates the stimulatory effects of estrogen on tuberoinfundibular dopamine neurons in female rats. *Neuroendocrinology* 55: 282–289, 1992.
 1759. TONG Y, SIMARD J, LABRIE C, ZHAO HF, LABRIE F, AND PELLETIER G. Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland. *Endocrinology* 125: 1821–1828, 1989.
 1760. TONKOWICZ P, ROBERTSON M, AND VOOGT J. Secretion of rat placental lactogen by the fetal placenta and its inhibitory effect on prolactin surges. *Biol Reprod* 28: 707–716, 1983.
 1761. TONKOWICZ PA AND VOOGT JL. Examination of rat placental lactogen and prolactin at 6-hr intervals during midpregnancy (41691). *Proc Soc Exp Biol Med* 173: 583–587, 1983.
 1762. TONKOWICZ PA AND VOOGT JL. Termination of prolactin surges with development of placental lactogen secretion in the pregnant rat. *Endocrinology* 113: 1314–1318, 1983.
 1763. TONKOWICZ PA AND VOOGT JL. Ovarian and fetal control of rat placental lactogen and prolactin secretion at midpregnancy. *Endocrinology* 114: 254–259, 1984.
 1764. TORDA T, LICHARDUS B, KVETNANSKY R, AND PONEC J. Posterior pituitary dopamine and noradrenaline content: effect of thirst, ethanol and saline load. *Endokrinologie* 72: 334–338, 1978.
 1765. TORNER L, MEJÍA S, LÓPEZ-GÓMEZ FJ, QUINTANAR A, DE LA ESCALERA GM, AND CLAPP C. A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. *Endocrinology* 136: 5454–5460, 1995.
 1766. TORNQUIST K. 1,25-Dihydroxycholecalciferol enhances both the bombesin-induced transient in intracellular free Ca^{2+} and the bombesin-induced secretion of prolactin in GH_4C_1 pituitary cells. *Endocrinology* 128: 2175–2182, 1991.
 1767. TORRES G, LEE S, AND RIVIER C. Ontogeny of the rat nitric oxide synthase and colocalization with neuropeptides. *Mol Cell Neurosci* 4: 155–163, 1993.
 1768. TOUGARD C AND TIXIER-VIDAL A. Lactotropes and gonadotropes. In: *The Physiology of Reproduction*, edited by Knobil E and Neill J. New York: Raven, 1994, p. 1711–1747.
 1769. TOURAINE P, LEITE DMM, DARDENNE M, AND KELLY PA. Expression of short and long forms of prolactin receptor in murine lymphoid tissues. *Mol Cell Endocrinol* 104: 183–190, 1994.
 1770. TOURKINE N, SCHINDLER C, LAROSE M, AND HOUEBINE LM. Activation of STAT factors by prolactin, interferon-gamma, growth hormones, and a tyrosine phosphatase inhibitor in rabbit primary mammary epithelial cells. *J Biol Chem* 270: 20952–20961, 1995.
 1771. TRAMU G AND LEONARDELLI J. Immunohistochemical localization of enkephalins in median eminence and adenohypophysis. *Brain Res* 168: 457, 1979.
 1772. TRUONG AT, DUEZ C, BELAYEW A, RENARD A, PICTET R, BELL GI, AND MARTIAL JA. Isolation and characterization of the human prolactin gene. *EMBO J* 3: 429–437, 1984.
 1773. TSAI SJ, JUENGEL JL, AND WILTBANK MC. Hormonal regulation of monocyte chemoattractant protein-1 messenger ribonucleic acid expression in corpora lutea. *Endocrinology* 138: 4517–4520, 1997.
 1774. TSUDA K, YOKOO H, AND GOLDSTEIN M. Neuropeptide Y and galanin in norepinephrine release in hypothalamic slices. *Hypertension* 14: 81–86, 1989.
 1775. TSURUO Y, KAWANO H, HISANO S, KAGOTANI Y, DAIKOKU S, ZHANG T, AND YANAIHARA N. Substance P-containing neurons innervating

- LHRH-containing neurons in the septopreoptic area. *Neuroendocrinology* 53: 236–245, 1999.
1776. TSURUO Y, KAWANO H, NISHIYAMA T, HISANO S, AND DAIKOKU S. Substance P-like immunoreactive neurons in the tuberoinfundibular area of rat hypothalamus. Light and electronmicroscopy. *Brain Res* 289: 1–9, 1983.
 1777. TSUTSUMI K AND SAAVEDRA JM. Angiotensin II receptor subtypes in median eminence and basal forebrain areas involved in regulation of pituitary function. *Endocrinology* 129: 3001–3008, 1991.
 1778. TSUTSUMI K AND SAAVEDRA JM. Characterization and development of angiotensin II receptor subtypes (AT₁ and AT₂) in rat brain. *Am J Physiol Regulatory Integrative Comp Physiol* 261: R206–R216, 1991.
 1779. TUCKER HA. Lactation and its hormonal control. In: *The Physiology of Reproduction*, edited by Knobil E and Neill JD. New York: Raven, 1994, p. 1065–1098.
 1780. TUOMISTO J AND MANNISTO. Neurotransmitter regulation of anterior pituitary hormones. *Pharmacol Rev* 37: 249–332, 1985.
 1781. TYSON JE. The evolutionary role of prolactin in mammalian osmoregulation: effects on fetoplacental hydromineral transport. *Semin Perinatol* 6: 216–228, 1982.
 1782. UNNERSTALL JR AND WAMSLEY JK. Autoradiographic localization of high-affinity [³H]kainic acid binding sites in the rat forebrain. *Eur J Pharmacol* 86: 361–371, 1983.
 - 1782a. VÄHÄ-ESKELI K, ERKKOLA R, IRJALA K, AND VIINAMÄKI O. Effect of thermal stress on serum prolactin, cortisol and plasma arginine vasopressin concentration in the pregnant and non-pregnant state. *Eur J Obstet Gynecol Reprod Biol* 42: 1–8, 1991.
 1783. VALE W, RIVIER C, BRAZEAU P, AND GUILLEMIN R. Effects of somatostatin on the secretion of thyrotropin and prolactin. *Endocrinology* 95: 968–977, 1974.
 1784. VALLAR L, MUCA C, MAGNI M, ALBERT P, BUNZOW J, MELDOLESI J, AND CIVELLI O. Differential coupling of dopaminergic D₂ receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in Ltk⁺ fibroblasts, hyperpolarization, and cytosolic-free Ca²⁺ concentration decrease in GH₄C₁ cells. *J Biol Chem* 265: 10320–10326, 1990.
 1785. VALVERDE RC, CHIEFFO V, AND REICHLIN S. Prolactin releasing factor in porcine and rat hypothalamic tissue. *Endocrinology* 91: 982–993, 1972.
 1786. VAN BAELE A AND DENEUF C. Evidence for a trophic action of the glycoprotein hormone α -subunit in rat pituitary. *J Neuroendocrinol* 8: 99–102, 1996.
 1787. VAN BAELE A, HUYGEN R, HIMPENS B, AND DENEUF C. In vitro evidence that LHRH stimulates the recruitment of prolactin mRNA-expressing cells during the postnatal period in the rat. *J Mol Endocrinol* 12: 107–118, 1994.
 1788. VAN DE KAR LD AND BETHEA CL. Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. *Neuroendocrinology* 35: 225–230, 1982.
 1789. VAN DE KAR LD, S A LORENS SA, URBAN JH, RICHARDSON KD, PARIS J, AND BETHEA CL. Pharmacological studies on stress-induced renin and prolactin secretion: effects of benzodiazepines, naloxone, propranolol and diisopropyl fluorophosphate. *Brain Res* 345: 257–263, 1985.
 1790. VAN DEN BUUSE M. Effects of endothelins on the nervous system. In: *Endothelins in Biology and Medicine*, edited by Huggins JP and Pelton JT. Boca Raton, FL: CRC, 1996, p. 223–255.
 1791. VAN DEN POL AN AND TROMBLEY PQ. Glutamate neurons in hypothalamus regulate excitatory transmission. *J Neurosci* 13: 2829–2836, 1993.
 1792. VAN DEN POL AN AND TSUJIMOTO KL. Neurotransmitters of the hypothalamic suprachiasmatic nucleus: immunocytochemical analysis of 25 neuronal antigens. *Neuroscience* 15: 1049–1086, 1985.
 1793. VAN DEN POL AN, WUARIN J-P, AND DUDEK FE. Glutamate neurotransmission in the neuroendocrine hypothalamus. In: *Excitatory Amino Acids: Their Role in Neuroendocrine Function*, edited by Brann DW and Mahesh VB. Boca Raton, FL: CRC, 1996, p. 1–54.
 1794. VAN DER BEEK EM, SWARTS HJM, AND WIEGANT VM. Central administration of antiserum to vasoactive intestinal polypeptide delays and reduces luteinizing hormone and prolactin surges in ovariectomized, estrogen-treated rats. *Neuroendocrinology* 69: 227–237, 1999.
 1795. VANDERHAEGHEN J-J, GOLDMAN S, LOTSTRA F, VAN REETH O, DESCHÉPER CF, ROSSIER J, AND SCHIFFMANN S. Co-existence of cholecystokinin- or gastrin-like peptides with other peptides in the hypophysis and the hypothalamus. *Ann NY Acad Sci* 448: 334–343, 1985.
 1796. VANDERHAEGHEN JJ, LOTSTRA F, DE MEY J, AND GILLES C. Immunocytochemical localization of cholecystokinin- and gastrin-like peptides in the brain and hypophysis of the rat. *Proc Natl Acad Sci USA* 77: 1190–1194, 1980.
 1797. VANDERHAEGHEN JJ, SIGNEAU JC, AND GEPTS W. New peptide in the vertebrate CNS reacting with antigestrin antibodies. *Nature* 257: 604–605, 1975.
 1798. VAN DER SCHOOT P AND DE GREEF WJ. Effect of adrenalectomy on the regulation of the secretion of gonadotrophins and prolactin in the lactating rat. *J Endocrinol* 98: 227–232, 1983.
 1799. VAN DER SCHOOT P, UILENBROEK JT, AND SLAPPENDEL EJ. Effect of the progesterone antagonist mifepristone on the hypothalamo-hypophysial-ovarian axis in rats. *J Endocrinol* 124: 425–432, 1990.
 1800. VAN ELICK CH, SLOOTER GD, HOFLAND LJ, KORT W, JEEKEL J, LAMBERTS SW, AND MARQUET RL. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. *Br J Surg* 81: 1333–1337, 1994.
 1801. VANKELECOM H, CARMELIET P, VAN DAMME J, BILLIAU A, AND DENEUF C. Production of interleukin-6 by folliculostellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. *Neuroendocrinology* 49: 102–106, 1989.
 1802. VANKELECOM H AND DENEUF C. Paracrine communication in the anterior pituitary as studied in reaggregate cell cultures. *Microsc Res Tech* 39: 150–156, 1997.
 1803. VANKELECOM H, MATTHYS P, AND DENEUF C. Involvement of nitric oxide in the interferon-gamma-induced inhibition of growth hormone and prolactin secretion in anterior pituitary cell cultures. *Mol Cell Endocrinol* 129: 157–167, 1997.
 1804. VAN LOON GR, DE SOUZA EB, HO D, AND SHIN SH. β -Endorphin-induced prolactin secretion is mediated by suppression of release of newly synthesized hypothalamic dopamine. *Can J Physiol Pharmacol* 58: 436–439, 1980.
 1805. VAN LOON GR, DE SOUZA EB, AND SHIN SH. Dopaminergic mediation of beta-endorphin-induced prolactin secretion. *Neuroendocrinology* 31: 293–296, 1980.
 1806. VAN LOON GR, HO D, AND KIM C. β -Endorphin-induced decrease in hypothalamic dopamine turnover. *Endocrinology* 106: 76–80, 1980.
 1807. VAN TOL HHM, BUNZOW JR, GUAN H, SUNAHARA K, SEEMAN P, NIZNIK HB, AND CIVELLI O. Cloning of the gene for a human dopamine D₄ receptor with high affinity for the antipsychotic clozapine. *Nature* 350: 610–614, 1991.
 1808. VAN VUGT DA, BRUNI JF, AND MEITES J. Naloxone inhibition of stress-induced increase in prolactin secretion. *Life Sci* 22: 85–89, 1978.
 1809. VAUGHAN MK, LITTLE JC, JOHNSON LY, BLASK DE, VAUGHAN GM, AND REITER RJ. Effects of melatonin and natural and synthetic analogues of arginine vasotocin on plasma prolactin levels in adult male rats. *Horm Res* 9: 236–246, 1978.
 1811. VECSENYÉS M, KREMPELS K, TOTTH BE, JULESZ J, MAKARA GB, AND NAGY GM. Effect of posterior pituitary denervation (PPD) on prolactin (PRL) and α -melanocyte-stimulating hormone (α -MSH) secretion of lactating rats. *Brain Res Bull* 43: 313–319, 1997.
 1812. VEKEMANS M, DELVOYE P, L'HERMITE M, AND ROBYN C. Serum prolactin levels during the menstrual cycle. *J Clin Endocrinol Metab* 44: 989–993, 1977.
 1813. VELKENIERS B, HOOGHE-PETERS EL, HOOGHE R, BELAYEW A, SMETS G, CLAEYS A, ROBBERECHT P, AND VANHAELST L. Prolactin cell subpopulations separated on discontinuous percoll gradient: an immunocytochemical, biochemical and physiological characterization. *Endocrinology* 123: 1619–1630, 1988.
 1814. VELKENIERS B, KAZEMZADEH M, VANHAELST L, AND HOOGHE-PETERS EL. Functional heterogeneity with respect to oestrogen treatment in prolactin cell subpopulations separated by Percoll gradient centrifugation. *J Endocrinol* 141: 251–258, 1994.
 1815. VELKENIERS B, ZHENG L, KAZEMZADEH M, ROBBERECHT P, VANHAELST L, AND HOOGHE-PETERS EL. Effect of pituitary adenylate cyclase-

- activating polypeptide 38 on growth hormone and prolactin expression. *J Endocrinol* 143: 1–11, 1994.
1816. VIGUË C, THIBAUT J, THIERY JC, TILLET Y, AND MALPAUX B. Photoperiodic modulation of monoamines and amino-acids involved in the control of prolactin and LH secretion in the ewe: evidence for a regulation of tyrosine hydroxylase activity. *J Neuroendocrinol* 8: 465–474, 1996.
 1817. VIGUË C, THIBAUT J, THIERY JC, TILLET Y, AND MALPAUX B. Characterization of the short day-induced decrease in median eminence tyrosine hydroxylase activity in the ewe: temporal relationship to the changes in luteinizing hormone and prolactin secretion and short day-like effect of melatonin. *Endocrinology* 138: 499–506, 1997.
 1818. VLIJAN E AND McCANN SM. Re-evaluation of the role of catecholamines in control of gonadotropin and prolactin release. *Neuroendocrinology* 25: 150–165, 1978.
 1819. VLIJAN E AND McCANN SM. Effects of substance P and neurotensin on growth hormone and thyrotropin release in vivo and in vitro. *Life Sci* 26: 312–327, 1979.
 1820. VLIJAN E AND McCANN SM. In vivo and in vitro effects of substance P and neurotensin on gonadotropin and prolactin release. *Endocrinology* 105: 64–68, 1979.
 1821. VLIJAN E AND McCANN SM. The effects of the cholecystokinin antagonist, proglumide, on prolactin secretion in the rat. *Life Sci* 40: 629–634, 1987.
 1822. VLIJAN E, SAMSON WK, AND McCANN SM. In vivo and in vitro effects of cholecystokinin on gonadotropin, prolactin, growth hormone and thyrotropin release in the rat. *Brain Res* 172: 295–302, 1979.
 1823. VLIJAN E, SAMSON WK, SAID SI, AND McCANN SM. Vasoactive intestinal peptide: evidence for a hypothalamic site of action to release growth hormone, luteinizing hormone, and prolactin in conscious ovariectomized rats. *Endocrinology* 104: 53–57, 1979.
 1824. VILE JM AND STRANGE PG. D₂-like dopamine receptors are not detectable on human peripheral blood lymphocytes. *Biol Psychol* 40: 881–885, 1996.
 1825. VINA J, PUERTES IR, SAEZ GT, AND VINA JR. Role of prolactin in amino acid uptake by the lactating mammary gland of the rat. *FEBS Lett* 126: 250–252, 1981.
 1826. VINCENS M, ENJALBERT A, LLOYD KG, PAILLARD JJ, THURET F, KORDON C, AND LECHAT P. Evidence that clomethiazole interacts with the macromolecular GABA A-receptor complex in the central nervous system and in the anterior pituitary gland. *Naunyn-Schmiedeberg Arch Pharmacol* 339: 397–402, 1989.
 1827. VINCENT SR, HOKFELT T, AND WU JY. GABA neuron systems in hypothalamus and the pituitary gland. Immunohistochemical demonstration using antibodies against glutamate decarboxylase. *Neuroendocrinology* 34: 117–125, 1982.
 1828. VISELLI SM, STANEK EM, MUKHERJEE P, HYMER WC, AND MASTRO AM. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. *Endocrinology* 129: 983–990, 1991.
 1829. VISSER-WISSELAAR HA, HOFLAND LJ, VAN UFFELEN CJC, VAN KOETSVELD PM, AND LAMBERTS SWJ. Somatostatin receptor manipulation. *Digestion* 57: 7–10, 1996.
 1830. VISSER-WISSELAAR HA, VAN UFFELEN CJ, VAN KOETSVELD PM, LICHTENAUER-KALIGIS EG, WAALJERS AM, UITTERLINDEN P, MOOY DM, LAMBERTS SW, AND HOFLAND LJ. 17-Beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. *Endocrinology* 138: 1180–1189, 1997.
 1831. VOLOSCHIN LM AND TRAMEZZANI HH. Relationship of prolactin release in lactating rats to milk ejection, sleep state, and ultrasonic vocalization by the pups. *Endocrinology* 114: 618–623, 1984.
 1832. VOOGT J AND DEGREEF WJ. Inhibition of nocturnal prolactin surges in the pregnant rat by incubation medium containing placental lactogen. *Proc Soc Exp Biol Med* 191: 403–407, 1989.
 1833. VOOGT J, ROBERTSON M, AND RIESEN HF. Inverse relationship of prolactin and rat placental lactogen during pregnancy. *Biol Reprod* 26: 800–805, 1982.
 1834. VOOGT JL. Evidence for an inhibitory influence of rat placental lactogen on prolactin release in vitro. *Biol Reprod* 31: 141–147, 1984.
 1835. VOOGT JL AND CARR LA. Plasma prolactin levels and hypothalamic catecholamine synthesis during suckling. *Neuroendocrinology* 16: 108–118, 1974.
 1836. VOOGT JL, RESCH G, AND TURKINGTON S. Arcuate nucleus and pre-optic area involvement in beta-endorphin-induced release of prolactin in conscious ovariectomized rats. *J Neuroendocrinol* 1: 449–453, 1989.
 1837. VOOGT JL AND SALAMON A. Failure of injection of rat placental lactogen to inhibit prolactin in vivo. *Proc Soc Exp Biol Med* 178: 531–535, 1985.
 1838. VOOGT JL, SOARES MJ, ROBERTSON MC, AND ARBOGAST LA. Rat placental lactogen-I abolishes nocturnal prolactin surges in the pregnant rat. *Endocrine* 4: 233–238, 1996.
 1839. VRONTAKIS ME, PEDEN LM, DUCKWORTH ML, AND FRIESEN HG. Isolation and characterization of a complementary DNA (galanin) clone from estrogen-induced pituitary tumor messenger RNA. *J Biol Chem* 262: 16755–16758, 1987.
 1840. VRONTAKIS ME, SANO T, KOVACS K, AND FRIESEN HG. Presence of galanin-like immunoreactivity in nontumorous corticotrophs and corticotroph adenomas of the human pituitary. *J Clin Endocrinol Metab* 70: 747–751, 1990.
 1841. VRONTAKIS ME, SCHROEDTER IC, COSBY H, AND FRIESEN HG. Expression and secretion of galanin during pregnancy in the rat. *Endocrinology* 130: 458–464, 1992.
 1842. VRONTAKIS ME, TORSSELLO A, AND FRIESEN HG. Galanin. *J Endocrinol Invest* 14: 785–794, 1991.
 1843. VRONTAKIS ME, YAMAMOTO T, SCHROEDTER IC, NAGY JI, AND FRIESEN HG. Estrogen induction of galanin synthesis in the rat anterior pituitary gland demonstrated by in situ hybridization and immunohistochemistry. *Neurosci Lett* 100: 59–64, 1989.
 1844. WADA E, WAY J, LEBACQ-VERHEYDEN AM, AND BATTEY JF. Neuromedin B and gastrin-releasing peptide mRNAs are differentially distributed in the rat nervous system. *J Neurosci* 10: 2917–2930, 1990.
 1845. WADA E, WAY J, SHAPIRA H, KUSANO K, LEBACQ-VERHEYDEN AM, COY D, JENSEN R, AND BATTERY J. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. *Neuron* 6: 421–430, 1991.
 1846. WAGNER EJ, GOUDREAU JL, MOORE KE, AND LOOKINGLAND KJ. GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat. *Brain Res* 659: 194–200, 1994.
 1847. WAGNER S, CASTEL M, GAINER H, AND YAROM Y. GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity. *Nature* 387: 598–603, 1997.
 1848. WALDSTREICHER J, DUFFY JF, BROWN EN, ROGACZ S, ALLAN JS, AND CZEISLER CA. Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels—a clinical research center study. *J Clin Endocrinol Metab* 81: 1483–1487, 1996.
 1849. WALKER MW, EWALD DA, PERNEY TM, AND MILLER RJ. Neuropeptide Y modulates neurotransmitter release and Ca²⁺ currents in rat sensory neurons. *J Neurosci* 8: 2438–2446, 1988.
 1850. WALKER SE, ALLEN SH, AND McMURRAY RW. Prolactin and autoimmune disease. *Trends Endocrinol Metab* 4: 147–151, 1993.
 1851. WALLIS M. The primary structure of bovine prolactin. *FEBS Lett* 44: 205–208, 1974.
 1852. WALSH JH, WONG HC, AND DOCKRAY GJ. Bombesin-like peptides in mammals. *Federation Proc* 38: 219–225, 1979.
 1853. WALSH RJ, MANGURIAN LP, AND POSNER BI. The distribution of lactogen receptors in the mammalian hypothalamus: an in vitro autoradiographic analysis of the rabbit and rat. *Brain Res* 530: 1–11, 1990.
 1854. WALSH RJ, POSNER BI, AND PATEL B. Binding and uptake of (125-I) iodoprolactin by epithelial cells of the rat choroid plexus: an in vivo autoradiographic analysis. *Endocrinology* 114: 1496–1505, 1984.
 1855. WALTERS CA, DALY DC, CHAPITIS J, KUSLIS ST, PRIOR JC, KUSMIK WF, AND RIDDICK DH. Human myometrium: a new potential source of prolactin. *Am J Obstet Gynecol* 147: 639–644, 1983.
 1856. WANG HL AND WU T. α_{q11} mediates neurotensin excitation of substantia nigra dopaminergic neurons. *Mol Brain Res* 36: 29–36, 1996.
 1857. WANG J, CIOFI P, AND CROWLEY WR. Neuropeptide Y suppresses prolactin secretion from rat anterior pituitary cells: evidence for

- interactions with dopamine through inhibitory coupling to calcium entry. *Endocrinology* 137: 587–594, 1996.
1858. WANG PS, LIU J-Y, HWANG C-Y, HWANG C, DAY CH, CHANG C-H, PU H-F, AND PAN J-T. Age-related differences in the spontaneous and thyrotropin-releasing hormone-stimulated release of prolactin and thyrotropin in ovariectomized rats. *Neuroendocrinology* 49: 592–596, 1989.
1859. WANG Y-F AND WALKER AM. Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb₂ cell proliferation. *Endocrinology* 133: 2156–2160, 1993.
1860. WANK SA, PISEGNA JR, AND DEWEERTH A. Cholecystokinin receptor family. *Ann NY Acad Sci* 713: 49–66, 1994.
1861. WAREMBOURG M, JOLIVET A, AND MILGROM E. Immunohistochemical evidence of the presence of estrogen and progesterone receptors in the same neurons of the guinea pig hypothalamus and preoptic area. *Brain Res* 480: 1–15, 1989.
1862. WARNET A, PORSOVA-DUTIOT I, LAHLOU N, SERET-BEGUE D, LAJENUIE E, CHANSON F, WOIMANT G, LOT PJ, GUILLAUSSEAU PJ, AND ROGER M. Glycoprotein hormone α -subunit secretion in prolactinomas and in non-functioning adenomas: relation with the tumor size. *Clin Endocrinol* 41: 177–184, 1994.
1863. WASS JAH. Somatostatin. In: *Endocrinology*, edited by De Groot LJ. Philadelphia, PA: Saunders, 1995, p. 266–279.
1864. WATANOBE H, SCHIOTH HB, WIKBERG JES, AND SUDA T. The melanocortin 4 receptor mediates leptin stimulation of luteinizing hormone and prolactin surges in steroid-primed ovariectomized rats. *Biochem Biophys Res Commun* 257: 860–864, 1999.
1865. WATANOBE H, SUDA T, WIKBERG JES, AND SCHIOTH HB. Evidence that physiological levels of circulating leptin exert a stimulatory effect on luteinizing hormone and prolactin surges in rats. *Biochem Biophys Res Commun* 263: 162–165, 1999.
1866. WATANOBE H AND TAKEBE K. In vivo release of neurotensin from the median eminence of ovariectomized estrogen-primed rats as estimated by push-pull perfusion: correlation with luteinizing hormone and prolactin surges. *Neuroendocrinology* 57: 760–764, 1993.
1867. WATERMAN ML, ADLER S, NELSON C, GREENE GL, EVANS RM, AND ROSENFELD MG. A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. *Mol Endocrinol* 2: 14–21, 1988.
1868. WATERS MJ, DANIEL N, BIGNON C, AND DJIANE J. The rabbit mammary gland prolactin receptor is tyrosine-phosphorylated in response to prolactin in vivo and in vitro. *J Biol Chem* 270: 5136–5143, 1995.
1869. WATSON RE JR, HUTCHINSON RK, LANGUB MC JR, LANDIS JW, SEKSARIA S, RAINEY DM, AND KEIL LC. Colocalization of natriuretic peptide and estrogen receptor immunoreactivities in preoptic nuclei in the female rat. *J Neuroendocrinol* 6: 79–87, 1994.
1870. WEBER E, VOIGT KH, AND MARTIN R. Pituitary somatotropes contain [Met]enkephalin-like immunoreactivity. *Proc Natl Acad Sci USA* 75: 6134, 1978.
1871. WEIGENT DA. Immunoregulatory properties of growth hormone and prolactin. *Pharmacol Ther* 69: 237–257, 1996.
1872. WELLS JA AND DEVOS AM. Hematopoietic receptor complexes. *Annu Rev Biochem* 65: 609–634, 1996.
1873. WERNER S, HULTING AL, HODFELT T, ENEROTH P, TATEMOTO K, MUTT V, MARODER L, AND WUNSCH E. Effect of the peptide PHI-27 on prolactin release in vitro. *Neuroendocrinology* 37: 476–476, 1983.
1874. WERSINGER SR, BAUM MJ, AND ERSKINE MS. Mating-induced FOS-like immunoreactivity in the rat forebrain: a sex comparison and a dimorphic effect of pelvic nerve transection. *J Neuroendocrinol* 5: 557–568, 1993.
1875. WEST B AND DANNIES PS. Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. *Endocrinology* 106: 1108–1113, 1980.
1876. WESTENDORF JM AND SCHONBRUNN A. Bombesin stimulates prolactin and growth hormone release by pituitary cells in culture. *Endocrinology* 110: 352–358, 1982.
1877. WESTENDORF JM AND SCHONBRUNN A. Characterization of bombesin receptors in a rat pituitary cell line. *J Biol Chem* 258: 7527–7535, 1983.
1878. WHITE RE, SCHONBRUNN A, AND ARMSTRONG DL. Somatostatin stimulates Ca activated K channels through protein dephosphorylation. *Nature* 351: 570–573, 1991.
1879. WICKS JR AND BROOKS CL. Prolactin kinase activity in bovine anterior pituitary sub-cellular fractions. *Mol Cell Endocrinol* 147: 125–132, 1999.
1880. WIESNER JB, KOENIG JI, KRULICH L, AND MOSS RL. Site of action for β -endorphin-induced changes in plasma luteinizing hormone and prolactin in the ovariectomized rats. *Life Sci* 34: 1463–1473, 1984.
1881. WILLOUGHBY JO, JERVOIS PM, MENADUE MF, AND BLESSING WW. Activation of GABA receptors in the hypothalamus stimulates secretion of growth hormone and prolactin. *Brain Res* 374: 119–125, 1986.
1882. WILSON DM, EMANUELE NV III, JURGENS JK, AND KELLEY MR. Prolactin message in brain and pituitary of adult male rats is identical: PCR cloning and sequencing of hypothalamic prolactin cDNA from intact and hypophysectomized adult male rats. *Endocrinology* 131: 2488–2490, 1992.
1883. WINDLE JJ, WEINER RI, AND MELLON PL. Cell lines of the pituitary gonadotrope lineage derived by targeted oncogenesis in transgenic mice. *Mol Endocrinol* 4: 597–603, 1990.
1884. WITCHER JA AND FREEMAN ME. The proestrous surge of prolactin enhances sexual receptivity in the rat. *Biol Reprod* 32: 834–839, 1985.
1885. WOJCIKIEWICZ RJH, DOBSON PR, AND BRON BL. Muscarinic acetylcholine receptor activation causes inhibition of cyclic AMP accumulation, prolactin, and growth hormone secretion in GH₃ rat anterior pituitary tumor cells. *Biochim Biophys Acta* 805: 25–29, 1984.
1886. WU H, DEVI R, AND MALARKEY WB. Expression and localization of prolactin messenger ribonucleic acid in the human immune system. *Endocrinology* 137: 349–353, 1996.
1887. WUTTKE W AND MEITES J. Luteolytic role of prolactin during the estrous cycle of the rat. *Proc Soc Exp Biol Med* 137: 988–991, 1971.
1888. WYNICK D, HAMMOND PJ, AKINSANYA KO, AND BLOOM SR. Galanin regulates basal and oestrogen-stimulated lactotroph function. *Nature* 364: 529–532, 1993.
1889. WYNICK D, SMALL CJ, BACON A, HOLMES FE, NORMAN M, ORMANDY CJ, KILIC E, KERR NCH, GHATEI M, TALAMANTES F, BLOOM SR, AND PACHNIS V. Galanin regulates prolactin release and lactotroph proliferation. *Proc Natl Acad Sci USA* 95: 12671–12676, 1998.
1890. WYNICK D, SMITH DM, GHATEI M, AKINSANYA K, BHOGAL R, PURKISS P, BYFIELD P, YANAIHARA N, AND BLOOM SR. Characterization of a high-affinity galanin receptor in the rat anterior pituitary: absence of biological effect and reduced membrane binding of the antagonist M15 differentiate it from the brain/gut receptor. *Proc Natl Acad Sci USA* 90: 4231–4235, 1993.
1891. XU RK AND MCCANN SM. Differential effects of naloxone on basal and stress-induced release of ACTH and prolactin in the male rat. *Life Sci* 45: 1591–1599, 1989.
1892. XU Y, BERELOWITZ M, AND BRUNO DJF. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH₄C₁ cells. *Endocrinology* 136: 5070–5075, 1995.
1893. XU ZQ, PIERIBONE VA, ZHANG X, GRILLNER S, AND HÖKFELT T. A functional role for nitric oxide in locus coeruleus: immunohistochemical and electrophysiological studies. *Exp Brain Res* 98: 75–83, 1994.
1894. XUE-ZHANG Q, STANLEY SM, AND SHAH GV. Calcitonin inhibits prolactin gene transcription in rat pituitary cells. *Endocrine* 3: 445–451, 1995.
1895. YAMADA H AND KUROKAWA K. Histochemical studies on endothelin and the endothelin-A receptor in the hypothalamus. *J Cardiovasc Pharmacol* 31 Suppl 1: S215–S218, 1998.
1896. YAMAGUCHI M, OGREN L, ENDO H, SOARES MJ, AND TALAMANTES F. Co-localization of placental lactogen-I, placental lactogen-II, and prolactin in the mouse placenta at midpregnancy. *Biol Reprod* 51: 1188–1192, 1994.
1897. YAMAKAWA K, KUDO K, KANBA S, AND ARITA J. Distribution of prolactin-releasing peptide-immunoreactive neurons in the rat hypothalamus. *Neurosci Lett* 267: 113–116, 1999.

1898. YAMAMOTO S, MORIMOTO I, KAI K, ARAO T, FUJIHARA T, MORITA E, KANNAN H, AND ETO S. Centrally administered murine leptin stimulates plasma arginin-vasopressin secretion and increases the level of mRNA expression in the supraoptic nucleus of conscious rats. *Neuroendocrinology* 70: 207–212, 1999.
1899. YAMASHITA S, TAKAYANAGI A, AND SHIMIZU N. Temporal and cell-type specific expression of *c-fos* and *c-jun* protooncogenes in the mouse uterus after estrogen stimulation. *Endocrinology* 137: 5468–5475, 1996.
1900. YAMAUCHI K, MURAKAMI Y, NISHIKI M, TANAKA J, KOSHIMURA K, AND KATO Y. Possible involvement of vasoactive intestinal polypeptide in the central stimulating action of pituitary adenylate cyclase-activating polypeptide on prolactin secretion in the rat. *Neurosci Lett* 189: 131–134, 1995.
1901. YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, AND MASAKI TM. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332: 411–415, 1988.
1902. YANG H, LU D, AND RAIZADA MK. Regulation of neuromodulatory actions of angiotensin II in the rat brain neurons by the Ras-dependent mitogen-activated protein kinase pathways. *J Neurosci* 16: 4047–4058, 1996.
1903. YANG J-Y AND PAN J-T. Enhanced tuberoinfundibular dopaminergic neuron activity in thyroidectomized, ovariectomized and estrogen-treated rats with hyperprolactinemia. *Neuroendocrinology* 59: 520–527, 1994.
1904. YANG L, BERK SC, ROHRER SP, MOSLEY RT, GUO L, UNDERWOOD DJ, ARISON BH, BIRZIN ET, HAYES EC, MITRA SW, PARMAR RM, CHENG K, WU TJ, BUTLER BS, FOOR F, PASTERNAK A, PAN Y, SILVA M, FREIDINGER RM, SMITH RG, CHAPMAN K, SCHAEFFER JM, AND PATCHETT AA. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. *Proc Natl Acad Sci USA* 95: 10836–10841, 1998.
1905. YANG MY, PU HF, JENG FS, WANG SW, HO LL, AND WANG PS. Effect of thyroidectomy on the release of prolactin in vitro response to calcitonin. *Chin J Physiol* 31: 105–112, 1988.
1906. YAO XQ, LIU Y, TUNG F, AND DESIR GV. Genomic structure and regulation of Kcn1, a cGMP-gated potassium channel. *Am J Physiol Renal Physiol* 271: F37–F41, 1996.
1907. YASAMURA Y, TASHJIAN AHJ, AND SATO GH. Establishment of four functional, clonal strains of animal cells in culture. *Science* 154: 1186–1189, 1966.
1908. YELLON SM AND LONGO LD. Melatonin rhythms in fetal and maternal circulation during pregnancy in sheep. *Am J Physiol Endocrinol Metab* 252: E799–E802, 1987.
1909. YELLON SM AND LONGO LD. Effect of maternal pinealectomy and reverse photoperiod on the circadian melatonin rhythm in the sheep and fetus during the last trimester of pregnancy. *Biol Reprod* 39: 1093–1099, 1988.
1910. YEN SCC, HOFF JD, LASLEY BL, CASPER RJ, AND SHEEHAN K. Induction of prolactin release by LRF and LRF agonist. *Life Sci* 26: 1963, 1980.
1911. YEN SH AND PAN JT. Progesterone advances the diurnal rhythm of tuberoinfundibular dopaminergic neuronal activity and the prolactin surge in ovariectomized, estrogen-primed rats and in intact proestrous rats. *Endocrinology* 139: 1602–1609, 1998.
1912. YEN SH AND PAN JT. Nitric oxide plays an important role in the diurnal change of tuberoinfundibular dopaminergic neuronal activity and prolactin secretion in ovariectomized, estrogen/progesterone-treated rats. *Endocrinology* 140: 286–291, 1999.
1913. YOGEV L, YAVETZ H, GOTTFREICH A, OPPENHEIM D, HOMONNAI ZT, AND PAZ G. Serum prolactin response to ether stress in diabetic rats: opiate system contribution. *Proc Soc Exp Biol Med* 205: 248–252, 1994.
1914. YOSHIMURA A, OHKUBO T, KIGUCHI T, JENKINS NA, GILBERT DJ, COPELAND NG, HARA T, AND MIYAJIMA A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. *EMBO J* 14: 2816–2826, 1995.
1915. YOSHIZAWA T, SHINMI W, GIAID A, YANAGISAWA M, GIBSON SJ, KIMURA S, UCHIYAMA Y, POLAK JM, MASAKI T, AND KANAZAWA I. Endothelin: a novel peptide in the posterior pituitary system. *Science* 247: 462–464, 1990.
1916. YU K, LU D, ROWLAND NE, AND RAIZADA MK. Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. *Endocrinology* 137: 3566–3576, 1996.
1917. YU R, ASHWORTH R, AND HINKLE PM. Receptors for thyrotropin-releasing hormone on rat lactotropes and thyrotropes. *Thyroid* 8: 887–894, 1998.
1918. YU WH, KIMURA M, WALCZEWSKA A, KARANTH S, AND MCCANN SM. Role of leptin in hypothalamic-pituitary function. *Proc Natl Acad Sci USA* 94: 1023–1028, 1997.
1919. YUAN ZF AND PAN JT. Stimulatory effect of central oxytocin on tuberoinfundibular dopaminergic neuron activity and inhibition on prolactin secretion: neurochemical and electrophysiological studies. *Endocrinology* 137: 4120–4125, 1996.
1920. YU-LEE LY. Molecular actions of prolactin in the immune system. *Proc Soc Exp Biol Med* 215: 35–52, 1997.
1921. ZHANG J, CHEN C, KUKSTAS LA, VINCENT J-D, AND ISRAEL J-M. Functional lactotroph heterogeneity in lactating rats and in vitro modification by 17 β -estradiol. *J Neuroendocrinol* 2: 815–823, 1990.
1922. ZHANG J AND SNYDER SH. Nitric oxide in the nervous system. *Annu Rev Pharmacol Toxicol* 35: 213–233, 1995.
1923. ZHENG T, VILLALOBOS C, NUSSE KD, GETTYS TW, FAUGHT WJ, CASTAÑO JP, AND FRAWLEY LS. Phenotypic characterization and functional correlation of α -MSH binding to pituitary cells. *Am J Physiol Endocrinol Metab* 272: E282–E287, 1997.
1924. ZHOU Q-Y, GRANDY DK, THAMBI L, KUSHNER JA, VAN TOL HHM, CONE R, PRIBNOW D, SALON J, BUNZOW JR, AND CIVELLI O. Cloning and expression of human and rat D₁ dopamine receptors. *Nature* 347: 76–80, 1990.
1925. ZHOU Y, SHUGHRUE PJ, AND DORSA DM. Estrogen receptor protein is differentially regulated in the preoptic area of the brain and in the uterus during the rat estrous cycle. *Neuroendocrinology* 61: 276–283, 1995.
1926. ZIMMERMAN EA, CARMEL PW, HUSAIN MK, FERIN M, TANNENBAUM M, FRANTZ AG, AND ROBINSONS AG. Vasopressin and neurophysin: high concentrations in monkey hypophyseal portal blood. *Science* 182: 925–927, 1973.